

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78341 A1

- (51) International Patent Classification⁷: **A61K 38/30**, 17/06, 17/02 (74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, Level 3, 303 Coronation Drive, Milton, QLD 4064 (AU).
- (21) International Application Number: PCT/AU00/00693
- (22) International Filing Date: 21 June 2000 (21.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/140,345 21 June 1999 (21.06.1999) US
- (71) Applicant (for all designated States except US): MURDOCH CHILDRENS RESEARCH INSTITUTE [AU/AU]; Royal Children's Hospital, Flemington Road, Parkville, VIC 3052 (AU).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): WRIGHT, Christopher, John [AU/AU]; 6 Maple Street, Blackburn, VIC 3130 (AU). WERTHER, George, Arthur [AU/AU]; 65 Bellett Street, Camberwell, VIC 3124 (AU). EDMONDSON, Stephanie, Ruth [AU/AU]; 2 Koonalda Avenue, Glen Waverley, VIC 3150 (AU).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A METHOD FOR THE PROPHYLAXIS AND/OR TREATMENT OF MEDICAL DISORDERS

(57) Abstract: The present invention relates generally to a method for the prophylaxis and/or treatment of skin disorders, and in particular proliferative and/or inflammatory skin disorders, and to genetic molecules useful for same. The present invention is particularly directed to genetic molecules capable of modulating growth factor interaction with its receptor on epidermal keratinocytes to inhibit, reduce or otherwise decrease stimulation of this layer of cells. The present invention contemplates, in a most preferred embodiment, a method for the prophylaxis and/or treatment of psoriasis.

WO 00/78341 A1

- 1 -

A METHOD FOR THE PROPHYLAXIS AND/OR TREATMENT OF MEDICAL DISORDERS

5 FIELD OF THE INVENTION

The present invention relates generally to a method for the prophylaxis and/or treatment of medical disorders, and in particular proliferative and/or inflammatory skin disorders, and to genetic molecules useful for same. The present invention is particularly directed to genetic
10 molecules capable of modulating growth factor interaction with its receptor on cells such as epidermal keratinocytes to inhibit, reduce or otherwise decrease stimulation of this layer of cells. The present invention contemplates, in a particularly preferred embodiment, a method for the prophylaxis and/or treatment of psoriasis or neovascularization conditions such as neovascularization of the retina. The present invention is further directed to the subject genetic
15 molecules in adjunctive therapy for epidermal hyperplasia, such as in combination with UV treatment, and to facilitate apoptosis of cancer cells and in particular cancer cells comprising keratinocytes.

BACKGROUND OF THE INVENTION

20

Bibliographic details of the publications numerically referred to in this specification are collected at the end of the description.

The reference to any prior art in this specification is not, and should not be taken as, an
25 acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia or any other country.

Psoriasis and other similar conditions are common and often distressing proliferative and/or inflammatory skin disorders affecting or having the potential to affect a significant proportion
30 of the population. The condition arises from over proliferation of basal keratinocytes in the epidermal layer of the skin associated with inflammation in the underlying dermis. Whilst a

- 2 -

range of treatments have been developed, none is completely effective and free of adverse side effects. Although the underlying cause of psoriasis remains elusive, there is some consensus of opinion that the condition arises at least in part from over expression of local growth factors and their interaction with their receptors supporting keratinocyte proliferation *via* keratinocyte
5 receptors which appear to be more abundant during psoriasis.

One important group of growth factors are the dermally-derived insulin-like growth factors (IGFs) which support keratinocyte proliferation. In particular, IGF-I and IGF-II are ubiquitous peptides each with potent mitogenic effects on a broad range of cells. Molecules of the IGF type
10 are also known as "progression factors" promoting "competent" cells through DNA synthesis. The IGFs act through a common receptor known as the Type I or IGF-I receptor, which is tyrosine kinase linked. They are synthesised in mesenchymal tissues, including the dermis, and act on adjacent cells of mesodermal, endodermal or ectodermal origin. The regulation of their synthesis involves growth hormone (GH) in the liver, but is poorly defined in most tissues [1].

15

Particular proteins, referred to as IGF binding proteins (IGFBPs), appear to be involved in autocrine/paracrine regulation of tissue IGF availability [2]. Six IGFBPs have so far been identified. The exact effects of the IGFBPs is not clear and observed effects *in vitro* have been inhibitory or stimulatory depending on the experimental method employed [3]. There is some
20 evidence, however, that certain IGFBPs are involved in targeting IGF-I to its cell surface receptor.

Skin, comprising epidermis and underlying dermis, has GH receptors on dermal fibroblasts [4]. Fibroblasts synthesize IGF-I as well as IGFBPs-3, -4, -5 and -6 [5] which may be involved in
25 targeting IGF-I to adjacent cells as well as to the overlaying epidermis. The major epidermal cell type, the keratinocyte, does not synthesize IGF-I, but possesses IGF-I receptors and is responsive to IGF-I [6].

It is apparent, therefore, that IGF-I and other growth promoting molecules, are responsible for
30 or at least participate in a range of skin cell activities. In accordance with the present invention, the inventors have established that aberrations in the normal functioning of these molecules or

- 3 -

aberrations in their interaction with their receptors is an important factor in a variety of medical disorders such as proliferative and/or inflammatory skin disorders. It is proposed, therefore, to target these molecules or other molecules which facilitate their functioning or interaction with their receptors to thereby ameliorate the effects of aberrant activity during or leading to skin
5 disease conditions and other medical conditions such as those involving neovascularization. Furthermore, these molecules may also be used to facilitate apoptosis of target cells and may be useful as adjunctive therapy for epidermal hyperplasia.

SUMMARY OF THE INVENTION

10

Nucleotide and amino acid sequences are referred to by a sequence identifier, i.e. (<400>1), (<400>2), etc. A sequence listing is provided after the claims.

Throughout this specification, unless the context requires otherwise, the word "comprise", or
15 variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Accordingly, one aspect of the present invention contemplates a method for ameliorating the
20 effects of a medical disorder such as a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation or a cell otherwise involved in the said medical disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing a growth factor mediated cell proliferation and/or
25 inflammation and/or other medical disorder.

According to this preferred embodiment, there is provided a method for ameliorating the effects of a medical disorder such as a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin or skin
30 capable of proliferation and/or inflammation or a cell otherwise involved with said medical disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof

- 4 -

capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation and/or inflammation and/or other medical disorder.

According to this embodiment, there is provided a method for ameliorating the effects of a
5 proliferative and/or inflammatory skin disorder such as psoriasis said method comprising
contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or
inflammation with effective amounts of UV treatment and a nucleic acid molecule or chemical
analogue thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation
and/or inflammation.

10

According to this embodiment, there is provided in a particularly preferred aspect a ribozyme
comprising a hybridising region and a catalytic region wherein the hybridising region is capable
of hybridising to at least part of a target mRNA sequence transcribed from a genomic gene
corresponding to <400>1 or <400>2 wherein said catalytic domain is capable of cleaving said
15 target mRNA sequence to reduce or inhibit IGF-I mediated cell proliferation and/or
inflammation and/or other medical disorders.

Yet another aspect of the present invention contemplates co-suppression to reduce expression
or to inhibit translation of an endogenous gene encoding, for example, IGF-I, its receptor, or
20 IGFBPs such as IGFBP-2 and/or -3. In co-suppression, a second copy of an endogenous gene
or a substantially similar copy or analogue of an endogenous gene is introduced into a cell
following topical administration. As with antisense molecules, nucleic acid molecules defining
a ribozyme or nucleic acid molecules useful in co-suppression may first be protected such as by
using a nonionic backbone.

25

Another aspect of the present invention contemplates a pharmaceutical composition for topical
administration which comprises a nucleic acid molecule capable of inhibiting or otherwise
reducing IGF-I mediated cell proliferation such as psoriasis and one or more pharmaceutically
acceptable carriers and/or diluents.

30

- 5 -

Yet another aspect of the present invention contemplates the use of a nucleic acid molecule in the manufacture of a medicament for the treatment of proliferative and/or inflammatory skin disorders or other medical disorders mediated by a growth factor.

- 5 Still a further aspect of the present invention contemplates an agent comprising a nucleic acid molecule as hereinbefore defined useful in the treatment of proliferative and/or inflammatory skin disorders, such as psoriasis or other medical disorder..

The present invention further contemplates the use of the genetic molecules and in particular
10 the antisense molecules to inhibit the anti-apoptotic activity of IGF-I receptor.

- 6 -

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a representation of the nucleotide sequence of IGFBP-2.

```

LOCUS      HSIGFBP2      1433 bp      RNA      PRI      31-JAN-1990
5  DEFINITION Human mRNA for insulin-like growth factor binding protein (IGFBP-2)
   ACCESSION X16302
   KEYWORDS  insulin-like growth factor binding protein.
   SOURCE    human
      ORGANISM Homo sapiens
10  Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
   Theria; Eutheria; Primates; Haplorhini; Catarrhini; Hominidae.
   REFERENCE 1 (bases 1 to 1433)
      AUTHORS Binkert,C., Landwehr,J., Mary,J.L., Schwander,J. and Heinrich,G.
      TITLE   Cloning, sequence analysis and expression of a cDNA encoding a
15  novel insulin-like growth factor binding protein (IGFBP-2)
      JOURNAL EMBO J. 8, 2497-2502 (1989)
      STANDARD full automatic
   COMMENT   NCBI gi: 33009
   FEATURES
20  source          Location/Qualifiers
      1. .1433
      /organism="Homo sapiens"
      /dev_stage="fetal"
      /tissue_type="liver"
      misc_feature  1416. .1420
25  /note="pot. polyadenylation signal"
      polyA_site    1433
      /note="polyadenylation site"
      CDS           118. .1104
      /note="precursor polypeptide; (AA -39 to 289); NCBI gi:
30  33010."
      /codon_start=1
      /translation="MLPRVGC PALPLPPPPLLP LLLLLL LGASGGGGGARA EVLFR
CPPCTPERLAACGPPPVAPPAVA AVAGGARMPCAE LVREP GCGCCSVCARLEGEACG
VYTPRCGQLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGG
35  LVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGKHHLGLEEP
KKLRPPPARTPCQQLDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLQCK
MSLNGQRGECWCVPNTGKLIQGAPTIRGDPECHLFYNEQQEACGVHTQRMQ"
      (<400>21)
      CDS           118. .234
40  /note="signal peptide; (AA -39 to -1); NCBI gi: 33011."
      /codon_start=1
      /translation="MLPRVGC PALPLPPPPLLP LLLLLL LGASGGGGGARA"
      (<400>22)
      CDS           235. .1101
45  /note="mature IGFBP-2; (AA 1 to 289); NCBI gi: 33012."
      /codon_start=1
      /translation="EVLFRCPPCTPERLAACGPPPVAPPAVA AVAGGARMPCAE LV
EPGCGCCSVCARLEGEACGVYTPRCGQLRCYPHPGSELPLQALVMGEGTCEKRRDAE
YGASPEQVADNGDDHSEGG LVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVT
50  EQHRQMGKGKHHLGLEEPKKLRPPPARTPCQQLDQVLERISTMRLPDERGPLEHLY
SLHIPNCDKHGLYNLQCKMSLNGQRGECWCVPNTGKLIQGAPTIRGDPECHLFYNE
QQEACGVHTQRMQ" (<400>23)
   BASE COUNT  239 a    466 c    501 g    227 t
   ORIGIN
55

```

- 7 -

HSIGFBP2 Length: 1433 May 11, 1994 10:06 Type: N Check: 6232 ..

Figure 2 is a representation of the nucleotide sequence of IGFBP-3.

5
LOCUS HUMGFIBPA 2474 bp ss-mRNA PRI 15-JUN-1990
DEFINITION Human growth hormone-dependent insulin-like growth factor-binding protein mRNA, complete cds.
ACCESSION M31159
10 KEYWORDS insulin-like growth factor binding protein.
SOURCE Human plasma, cDNA to mRNA, clone BP-53.
ORGANISM Homo sapiens
Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria;
Eutheria; Primates; Haplorhini; Catarrhini; Hominidae.
15 REFERENCE 1 (bases 1 to 2474)
AUTHORS Wood,W.I., Cachianes,G., Henzel,W.J., Winslow,G.A., Spencer,S.A.,
Hellmiss,R., Martin,J.L. and Baxter,R.C.
TITLE Cloning and expression of the growth hormone-dependent insulin-like
growth factor-binding protein
20 JOURNAL Mol. Endocrinol. 2, 1176-1185 (1988)
STANDARD full automatic
COMMENT NCBI gi: 183115
FEATURES Location/Qualifiers
mRNA <1..2474
25 /note="GFIBP mRNA"
CDS 110..985
/gene="IGFBP1"
/note="insulin-like growth factor-binding protein; NCBI
gi: 183116."
30 /codon_start=1
/translation="MQRARPTLWAAALTLLVLLRGPPVARAGASSGGLGPVVRCEPCD
ARALAQCAPPPAVCAELVREPGCGCLTCALSEGQPCGIYTERCGSGLRCQSPDEAR
PLQALLDGRGLCVNASAVSRLRAYLLPAPPAPGNASESEEDRSAGSVESPSVSTHRV
SDPKFPHPLHSKIIIIKKGHAKDSQRYKVDYESQSTDTQNFSSSEKRETEYGPCRREME
35 DTLNHLKFLNVLSFRGVHIPNCDKKGIFYKKKQCRPSKGRKRGFPCWCVDKYGQPLPGYT
TKGKEDVHCYSMSQSK" (<400>24>)
source 1..2474
/organism="Homo sapiens"
BASE COUNT 597 a 646 c 651 g 580 t
40 ORIGIN

HUMGFIBPA Length: 2474 May 11, 1994 10:00 Type: N Check: 9946 ..

Figure 3 is a representation of the nucleotide sequence of IGF-1-receptor.

LOCUS HSIGFIRR 4989 bp RNA PRI 28-MAR-1991
DEFINITION Human mRNA for insulin-like growth factor I receptor
ACCESSION X04434 M24599
50 KEYWORDS glycoprotein; insulin receptor;
insulin-like growth factor I receptor; membrane glycoprotein;
receptor; tyrosine kinase.
SOURCE human

- 8 -

ORGANISM Homo sapiens
 Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
 Theria; Eutheria; Primates; Haplorhini; Catarrhini; Hominidae.

REFERENCE 1 (bases 1 to 4989)

5 AUTHORS Ullrich,A., Gray,A., Tam,A.W., Yang-Feng,T., Tsubokawa,M.,
 Collins,C., Henzel,W., Bon,T.L., Kathuria,S., Chen,E., Jakobs,S.,
 Francke,U., Ramachandran,J. and Fujita-Yamaguchi,Y.

TITLE Insulin-like growth factor I receptor primary structure: comparison
 10 with insulin receptor suggests structural dererminants that define
 functional specificity

JOURNAL EMBO J. 5, 2503-2512 (1986)

STANDARD full automatic

COMMENT NCBI gi: 33058

FEATURES Location/Qualifiers

15 source 1. .4989
 /organism="Homo sapiens"
 /tissue_type="placenta"
 /clone_lib="(lamda)gt10"
 /clone="(lambda)IGF-1-R.85, (lambda)IGF-1-R.76"

20 sig_peptide 32. .121
 mat_peptide 122. .4132
 /note="IGF-I receptor"

misc_feature 122. .2251
 /note="alpha-subunit (AA 1 - 710)"

25 misc_feature 182. .190
 /note="pot.N-linked glycosylation site (AA 21 - 23)"

misc_feature 335. .343
 /note="pot.N-linked glycostlation site (AA 72 - 74)"

misc_feature 434. .442
 30 /note="pot.N-linked glycostlation site (AA 105 - 107)"

misc_feature 761. .769
 /note="pot.N-linked glycostlation site (AA 214 - 216)"

misc_feature 971. .979
 /note="pot.N-linked glycostlation site (AA 284 - 286)"

35 misc_feature 1280. .1288
 /note="pot.N-linked glycostlation site (AA 387 - 389)"

misc_feature 1343. .1351
 /note="pot.N-linked glycosylation site (AA 408 - 410)"

misc_feature 1631. .1639
 40 /note="pot.N-linked glycostlation site (AA 504 - 506)"

misc_feature 1850. .1858
 /note="pot.N-linked glycosylation site (AA 577 - 579)"

misc_feature 1895. .1903
 /note="pot.N-linked glycosylation site (AA 592 - 594)"

45 misc_feature 1949. .1957
 /note="pot.N-linked glycosylation site (AA 610 - 612)"

misc_feature 2240. .2251
 /note="putative proreceptor processing site (AA 707 -
 710)"

50 misc_feature 2252. .4132
 /note="beta-subunit (AA 711 - 1337)"

misc_feature 2270. .2278
 /note="pot.N-linked glycosylation site (AA 717 - 719)"

misc_feature 2297. .2305
 55 /note="pot.N-linked glycosylation site (AA 726 - 728)"

misc_feature 2321. .2329
 /note="pot.N-linked glycosylation site (AA 734 - 736)"

- 9 -

```

    misc_feature      2729. .2737
                        /note="pot.N-linked glycosylation site (AA 870 - 872)"
    misc_feature      2768. .2776
                        /note="pot.N-linked glycosylation site (AA 883 - 885)"
5   misc_feature      2837. .2908
                        /note="transmembrane region (AA 906 - 929)"
    misc_feature      2918. .2926
                        /note="pot.N-linked glycosylation site (AA 933 - 935)"
    misc_feature      3047. .3049
10  misc_feature      3053. .3055
                        /note="pot.ATP binding site (AA 976)"
    misc_feature      3062. .3064
                        /note="pot.ATP binding site (AA 978)"
    misc_feature      3128. .3130
15  misc_feature      3128. .3130
                        /note="pot.ATP binding site (AA 981)"
    CDS                32. .4132
                        /product="IGF-I receptor"
                        /note="50 stops when translation attempted, frame 1, code
20  0"
BASE COUNT      1216 a   1371 c   1320 g   1082 t
ORIGIN

```

HSIGFIRR Length: 4989 May 11, 1994 12:10 Type: N Check: 133 ..

25

Figure 4A is a photographic representation of a Western ligand blot of HaCaT conditioned medium showing IGFBP-3 secreted in 24 hours after 7 day treatment with phosphorothioate oligonucleotides (BP3AS2, BP3AS3 and BP3S) at 0.5 μ M and 5 μ M;

30 * no oligonucleotide added.

Figure 4B is a graphical representation of a scanning imaging desitometry of Western ligand blot (Figure 4A), showing relative band intensities of IGFBP-3 and the 24kDa IGFBP-4 after treatment with phosphorothioate oligonucleotides;

35 * no oligonucleotide added.

Figure 5A is a photographic representation of a Western ligand blot of HaCaT conditioned medium showing IGFBP-3 secreted in 24 hours after 7 day treatment with phosphorothioate oligonucleotide BP3AS2 at 0.5 μ M compared with several control oligonucleotides at 0.5 μ M.

40 (a) oligonucleotide BP3AS2NS; (b) oligonucleotide BP3AS4; (c) oligonucleotide BP3AS4NS; and (untreated), no oligonucleotide added.

- 10 -

Figure 5B is a graphical representation of a scanning imaging densitometry of Western ligand blot (Figure 5A), showing relative band intensities of IGFBP-3 after treatment with phosphorothioate oligonucleotides as in Figure 5A, showing IGFBP-3 band intensities expressed as a percentage of the average band intensity from conditioned medium of cells not
5 treated with oligonucleotide.

Figure 6 is a graphical representation showing inhibition of IGF-I binding by antisense oligonucleotides to IGF-I receptor. IGFR.AS: antisense; IGFR.S: sense.

10 **Figure 7** is a graphical representation showing inhibition of IGFBP-3 production in culture medium following initial treatment with antisense oligonucleotides once daily over a 2 day period.

Figure 8 is a graphical representation showing optimization of IGFBP-3 antisense
15 oligonucleotide concentration as determined by relative IGFBP-3 concentration in culture medium.

Figure 9 is a diagrammatic representation of a map of IGF-1 Receptor mRNA and position of target ODNs.

20

Figure 10 is a photographic representation showing Lipid-mediated uptake of oligonucleotide in keratinocytes. HaCaT keratinocytes were incubated for 24 hours in medium (DMEM plus 10% v/v FCS) containing fluorescently labelled ODN (R451, 30 nM) and cytofectin GSV (2 μ g/ml). The cells were then transferred to ODN-free medium and
25 fluorescence microscopy (a) and phase contrast (b) images of the cells were obtained.

Figure 11 is a graphical representation of uptake (A) and toxicity (B) of ODN/lipid complexes in keratinocytes. Confluence HaCaT keratinocytes were incubated in DMEM containing fluorescently labelled ODN (R451) plus liposome over 120 hours, viewed using fluoresce
30 microscopy and trypan blue stained and counted.

- 11 -

Figure 12 is a graphical representation of an IGF-1 Receptor mRNA in ODN treated (30nM) HaCaT cells (2 μ g/ml GSV). HaCaT keratinocytes were treated for 96 hours with C-5 propynyl, dU, dC ODNs complexed with cytofectin GSV. Cells were treated with ODNs complementary to the human IGF-I receptor mRNA (27, 32, 74 and 78), 2 randomised sequence ODNs (R451) and R766), liposome alone (GSV) or were left untreated (UT). Total RNA was isolated then analysed for IGF-I receptor mRNA and GAPDH mRNA levels by RNase Protection and PhosphorImager quantitation.

(A) Electrophoretic analysis of IGF-I receptor and GAPDH mRNA fragments after RNase Protection. Molecular weight markers are shown on the right hand side. Full length probe is shown on the left hand side (G-probe and I-probe). GAPDH protected fragments (G) are seen at 316 bases and IGF-I receptor protected fragments (I) are seen at 276 bases.

(B) Relative level of IGF-I receptor mRNA following each treatment is shown.

Figure 13 is a graphical representation of an IGF-1 receptor mRNA in ODN treated (30nM) HaCaT cells (2 μ g/ml GSV). Summary of IGF-I receptor ODN screening data. HaCaT keratinocytes were treated for 96 hours with C-5 propynyl, dU, dC ODNs complexed with cytofectin GSV. Total RNA was isolated then analysed for IGF-I receptor mRNA and GAPDH mRNA levels by RNase protection and phosphorImager quantitation. Relative level of IGF-I receptor mRNA is shown after treatment with ODNs complementary to the human IGF-I receptor mRNA, 4 randomised sequence ODNs and liposome alone. (26-86=IGF-I receptor ODNs; R1, R4, R7 and R9 = randomised ODNs (R1=R121, R4=R451, R7=R766, R9=R961); GSV=liposome alone; UT=untreated). *indicates a significant difference in relative IGF-I receptor mRNA from GSV treated cells (n=4-10, p<0.05).

Figure 14 is a graphical representation of the effect of antisense oligonucleotides on IGF-1 receptor levels on the surface of keratinocytes. HaCaT cells were grown to confluence in 24-well plates in DMEM containing 10% v/v FCS. Oligodeoxynucleotide (ODN) and Cytofectin GSV (GSV, Glen Research) were mixed together in serum-free DMEM, incubated at room

- 12 -

temperature for 10 minutes before being diluted ten-fold in medium and placed on the cells. Cells were incubated for 72 hours with 30 nM random sequence or antisense ODN and 2 μ g/ml GSV or with GSV alone in DMEM containing 10% v/v FCS with solutions replaced every 24 hours. This was followed by incubation with ODN/GSV in serum-free DMEM for 5 48 hours. All incubations were performed at 37°C. Wells were washed twice with 1 ml cold PBS. Serum-free DMEM containing 10^{-10} M 125 I-IGF-I was added with or without the IGF-I analogue, des (1-3) IGF-I, at 10^{-10} M to 10^{-7} M. Cells were incubated at 4°C for 17 hours with gentle shaking then washed three times with 1 ml cold PBS and lysed in 250 μ l 0.5M NaOH/0.1% v/v Triton X-100 at room temperature for 4 hours. Specific binding of the 10 solubilised cell extract was measured using a γ counter.

Figure 15 is a graphical representation of the effect of antisense oligonucleotides on IGF-1 receptor levels on the surface of keratinocytes.

15 **Figure 16** is a photographic representation of H & E stained sections of (A) psoriatic skin biopsy prior to grafting and (B) 49 day old psoriatic skin graft using skin from the same donor.

Figure 17 is a photographic representation of uptake of oligonucleotide after intradermal 20 injection into psoriatic skin graft on a nude mouse. Psoriatic skin graft was intradermally injected with ODN (R451, 50 μ l, 10 μ M). The graft was removed and sectioned after 24 hours, then viewed using confocal microscopy.

25 **Figure 18(a)** is a photographic representation of Pregraft, Donor JH, Donor JH, PBS treated, 50 μ l, Donor JH, #50 treated, 50 μ l, 10 μ M.

Figure 18(b) is a photographic representation of Donor LB, pregraft, Donor LB, PBS treated (50 μ l), Donor LB, #74 treated (50 μ l, 10 μ M).

- 13 -

Figure 18(c) is a photographic representation of Donor PW, pregraft, Donor PW, R451 treated (50 μ l, 10 μ M), Donor LB, #74 treated (50 μ l, 10 μ M).

Figure 18(d) is a photographic representation of Donor GM, pregraft, Donor GB, R451
5 treated (50 μ l, 10 μ M), Donor GM, #27 treated (50 μ l, 10 μ M).

Figure 19(a) is a photographic representation showing Donor JH pregraft, Donor JH PBS treated 50 μ l, Donor JH #50 treated 50 μ l, 10 μ M.

10 Figure 19(b) is a photographic representation Donor LB pregraft, Donor LB PBS treated 50 μ l, Donor LB #74 treated 50 μ l, 10 μ M.

Figure 19(c) is a photographic representation showing Donor PW pregraft, Donor PW r451 treated 50 μ l, 10 μ M, Donor PW #74 treated 50 μ l, 10 μ M.

15

Figure 19(d) is a photographic representation showing Donor GM pregraft, Donor GM R451 treated 50 μ l, 10 μ M, Donor #27 treated 50 μ l, 10 μ M.

Figure 20 is a graphical representation showing suppression of psoriasis after treatment with
20 oligonucleotide (quantification). Oligonucleotide (50 μ l, 10 μ M) was injected every two days for 20 days, as were control treatments. Skin thickness was measured by removing the skin and using computer software (MCID analysis) to measure the exact thickness of each graft. N=3-4 for each treatment. *indicates a significant difference from the pregraft value (ANOVA, P<0.05)

25

Figure 21 is a photographic representation of α hKi-67 imunobiological binding.

Figure 22 is a photographic representation showing penetration of oligonucleotide into human skin after topical treatment. Fluorescently labelled oligonucleotide (10 μ M R451) was

- 14 -

applied topically after formulation with cytofectin GSV (10 $\mu\text{g/ml}$) and viewed using confocal microscopy.

Figure 23 is a photographical representation showing penetration of oligonucleotide into human skin after application of topical gel formation. Fluorescently labelled oligonucleotide (10 μM R451) was applied topically after complexing with cytofectin GSV (10 $\mu\text{g/ml}$) and formulation into 3% methylcellulose gel. Image was obtained using confocal microscopy.

Figure 24 is a graphical representation showing IGFBP-3 mRNA.

10

Figure 25(a) is a graphical representation showing IGFBP-3 mRNA in AON treated (100nM) HaCaT cells (2 $\mu\text{g/ml}$ GSV).

Figure 25(b) is a graphical representation showing IGFBP-3 mRNA levels of AON treated (100nm) HaCaT cells (2 $\mu\text{g/ml}$ GSV).

Figure 25(c) is a graphical representation showing IGFBP-3 mRNA in AON treated (30nM) HaCaT cells (2 $\mu\text{g/ml}$ GSV).

Figure 25(d) is a graphical representation showing IGFBP-3 mRNA in AON treated (30nM) HaCaT cells (2 $\mu\text{g/ml}$ GSV).

Figure 26(a) is a graphical representation showing IGFBP-3 mRNA in ODN treated (30nM) HaCaT cells (2 $\mu\text{g/ml}$). HaCaT keratinocytes were treated for 51 hours with C-5 propynl, dU, dC ODNs complexed with cytofectin GSV. Total RNA was isolated then analysed for IGFBP-3 mRNA and GAPDH mRNA levels by Northern analysis and phosphorimager quantitation. Relative level of IGFBP-3 mRNA is shown after treatment with ODNs complementary to the human IGFBP-3 mRNA, 4 randomised sequence ODNs and liposome alone. (1-24=IGFBP-3 ODNs; R1, R4, R7 and R9=randomised ODNs (R1=R121, R4=R451, R7=R766, R9 R961); GS=liposome alone; UT=untreated). *indicates a significant different in relative

30

- 15 -

IGFBP-3 mRNA from GSV treated cells (n= 5-8, $p < 0.01$), **indicates a significant difference in relative IGFBP-3 mRNA from GSV treated cells (n= 5-8, $p < 0.05$).

Figure 26(b) is a graphical representation showing IGFBP-3 mRNA in ODN treated (100nM) HaCaT cells (2 μ g/ml GSV). HaCaT keratinocytes were treated for 51 hours with C-5 propynl, dU, dC ODNs complexed with cytofectin GSV. Total RNA was isolated then analysed for IGFBP-3 mRNA and GAPDH mRNA levels by Northern analysis and phosphorimager quantitation. Relative level of IGFBP-3 mRNA is shown after treatment with ODNs complementary to the human IGFBP-3 mRNA, 4 randomised sequence ODNs and liposome alone. (1-24=IGFBP-3 ODNs; R1, R4, R7 and R9 = randomised ODNs (R1-R121, R4=R451, R7=R766, R9=R961), GS=liposome alone; UT=untreated). *indicates a significant difference in relative IGFBP-3 mRNA from GSV treated cells (n= 6-8, $p < 0.01$).

Figure 27 is a representation showing a reduction in IGF-I receptor mRNA in HaCaT cells following treatment with antisense oligonucleotides. Confluent HaCaT cells were treated every 24 h for 4 days with 2 μ g/ml GSV lipid alone (GSV) or complexed with 30 nM IGF-I receptor specific oligonucleotides (#26 to #86) or random sequence oligonucleotides (R121, R451 and R766). Total RNA was isolated and analysed for IGF-I receptor and GAPDH mRNA by RNase protection assay. (a). Representative RNase protection assay gel showing IGF-I receptor (*IGFR*) and GAPDH mRNA in untreated or treated HaCaT cells. In this example, a reduction in IGFR band intensity relative to GAPDH can be seen with AON #27 and #78, but not with #32, #74 or the controls (R4, R7, random oligonucleotides R451 and R766, respectively; G, GSV lipid; UT, untreated).

(b) Densitometric quantitation of IGF-I receptor mRNA (normalised to GAPDH mRNA) in HaCaT cells following treatment with IGF-I receptor specific oligonucleotides (solid black), random sequence oligonucleotides (horizontal striped bar) or GSV alone (shaded bar) compared to untreated cells (UT, vertical striped bar). Each oligonucleotide was assayed in duplicate in at least two separate experiments.

Results are presented as mean \pm SEM. A one-way ANOVA followed by Tukey's (Δ) test was performed; Δ indicates a significant difference between cells treated with IGF-I receptor specific AONs and all of the control treatments ($p < 0.05$). $n=4$ except for #27 and #32 ($n=6$), #28 and #68 ($n=3$), R766 ($n=9$), and R451, GSV and untreated ($n=10$).

5

Figure 28 is a representation showing a reduction in total cellular IGF-I receptor protein following antisense oligonucleotide treatment. Confluent HaCaT cells were treated every 24 h for 4 days with 2 μ g/ml GSV lipid alone (GSV) or complexed with 30 nM IGF-I receptor specific AONs (#27, #50 and #64) or the random sequence oligonucleotide, R451. Total cellular protein was isolated and analysed for IGF-I receptor by SDS PAGE followed by western blotting with an antibody specific for the human IGF-I receptor. (a) Duplicate treated cellular extracts showing the IGF-I receptor at the predicted size of 110 kD

(b) Densitometric quantitation of IGF-I receptor protein. Results are presented as mean \pm SEM of four different experiments each performed in duplicate. A one-way ANOVA followed by a Dunnett's test was performed; * indicates a significant difference from GSV treated cells ($p < 0.01$). GSV, GSV lipid alone; UT, untreated; R451, random sequence oligonucleotide; 64, 50, 27, IGF-I receptor-specific AONs.

Figure 29 is a representation showing a reduction in IGF-I receptor numbers on the keratinocyte cell surface after antisense oligonucleotide treatment. HaCaT cells were transfected with IGF-I receptor specific AONs #27 ($-\Delta-$), #50 ($-x-$), #64 ($-\blacksquare-$), a random sequence oligonucleotide R451 ($-o-$), or treated with GSV lipid alone ($-\square-$) every 24 h for four days (untreated cells, $-*-$). Competition binding assays using 125 I-IGF-I and the receptor-specific analogue, des(1-3)IGF-I, were performed (inset); plotted values are means \pm standard error. The mean values were then subjected to Scatchard analysis.

Figure 30 is a representation showing a reduction in keratinocyte cell number following antisense oligonucleotide treatment. HaCaT cells, initially at 40% confluence, were transfected with the IGF-I receptor specific AON #64, control sequences R451 and 6416, or

30

- 17 -

treated with GSV lipid alone every 24 h for 2 days (UT, untreated cells). Cell number was measured in the culture wells using a dye binding assay (Experimental protocol). Results are presented as mean \pm SD. A one-way ANOVA was performed, followed by a Tukey's multiple comparison test. ▲ indicates a significant difference between cells treated with AON #64 and all of the control treatments ($p < 0.001$).

Figure 31 is a representation showing a reversal of epidermal hyperplasia in psoriatic human skin grafts on nude mice following intradermal injection with antisense oligonucleotides

Grafted psoriasis lesions were injected with IGF-I receptor specific AONs, a random sequence oligonucleotide in PBS, or with PBS alone, every 2 days for 20 days, then analysed histologically. (a) Donor A graft treated with AON #50 showing epidermal thinning compared with pregraft and control (PBS) treated graft, and Donor B graft treated with AON #27 showing epidermal thinning compared with pregraft and control (R451) treated graft. E, epidermis; *Scale bar*, 400 μ m; all pictures are at the same magnification. (b) Mean epidermal cross-sectional area over the full width of grafts was determined by digital image analysis. Results are presented as mean \pm SEM. *Shaded bars*, control treatments: R451, random oligonucleotide sequence; *solid bars*, treatments with oligonucleotides that inhibited IGF-I receptor expression in vitro. * indicates a significant difference from the vehicle treated graft ($p < 0.01$, $n = 5-7$), ++ indicates a significant difference from the random sequence (R451) treated graft ($p < 0.01$, $n = 5-7$). (c) Parakeratosis (*arrow*) was absent in grafts treated with IGF-I receptor AONs (AON #50) but persisted in pregraft and control (PBS) treated graft. *Scale bar*, 100 μ m.

Figure 32 is a representation showing a reversal of epidermal hyperplasia correlates with reduced IGF-I receptor mRNA in grafted psoriasis lesions treated with antisense oligonucleotides (a) A psoriasis lesion prior to grafting, and after grafting and treatment with IGF-I receptor specific oligonucleotide #27 (AON #27) or random sequence (R451) was immunostained with antibodies to Ki67 to identify proliferating cells. Proliferating cells are indicated by a dark brown nucleus (arrows). *Scale bar*, 250 μ m; all pictures are at the same

- 18 -

magnification. (b) The same lesion prior to grafting and after oligonucleotide treatment as in (a) was subjected to in situ hybridisation with a ^{35}S -labeled cRNA probe complementary to the human IGF-I receptor mRNA. The presence of IGF-I receptor mRNA is indicated by silver grains (tiny black speckles), which are almost eliminated in the epidermis of the lesion
5 treated with the IGF-I receptor-specific oligonucleotide #27 (AON #27). Arrows indicate the basal layer of the epidermis with dermis underneath. *Scale bar, 50 μm .*

Figure 33 is a representation showing a reduction in IGF-I receptor mRNA in HaCaT keratinocytes following treatment with oligonucleotides. HaCaT cell monolayers grown to
10 90% confluence in DMEM containing 10% v/v fetal calf serum were treated with 24 h for two days with 2 $\mu\text{g}/\text{ml}$ GSV lipid alone (GSV) or complexed with 30 nM oligonucleotide. Total RNA was isolated and analysed for IGF-I receptor and GAPDH mRNA using a commercially available ribonuclease protection assay kit (RPAII, Ambicon Inc, Austin, Texas). Band intensity was quantified using ImageQuant software (Molecular Dynamics, Sunnyvale,
15 California).

Figure 34 is a representation showing a reduction in IGF-I receptor protein in HaCaT keratinocytes following treatment with oligonucleotides. HaCaT cell monolayers grown to 90% confluence in DMEM containing 10% v/v fetal calf serum were treated every 24 h for
20 four days with 2 $\mu\text{g}/\text{ml}$ GSV lipid alone (GSV) or complexed with 30 nM oligonucleotide. Cells were lysed in a buffer containing 50 mM HEPES, 150 mM NaCl, 10% v/v glycerol, 1% v/v Triton X-100 and 100 $\mu\text{g}/\text{ml}$ aprotinin on ice for 30 mins, then 30 μg of lysate was loaded onto a denaturing 7% w/v polyacrylamide gel followed by transfer onto an Immobilon-P membrane (Millipore, Bedford, Massachusetts). Membranes were incubated with the anti-
25 IGF-I receptor antibody C20 (Santa Cruz Biotechnology Inc., Santa Cruz, California, 25 ng/ml in 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 0.1% v/v Tween 20) for 1 h at room temperature and developed using the Vistra ECF western blotting kit (Amersham, Buckinghamshire, England). Band intensity was quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, California).

- 19 -

Figure 35 is a representation showing a reduction in HaCaT keratinocyte cell number following treatment with oligonucleotides. HaCaT cell monolayers grown to 40% confluence in DMEM containing 10% fetal calf serum were treated every 24 h for three days with 2 μ g/ml GSV lipid alone (GSV) or complexed with 15 nM oligonucleotide. Cell number was
5 measured every 24 h using the amido black dye binding assay [32].

- 20 -

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is predicated in part on the use of molecules and in particular genetic molecules and more particularly antisense molecules to down-regulate a growth factor, its
5 receptor and/or growth factor expression facilitating sequences.

Accordingly, one aspect of the present invention contemplates a method for ameliorating the effects of a medical disorder such as a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin or skin
10 capable of proliferation and/or inflammation or a cell otherwise involved in the said medical disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing a growth factor mediated cell proliferation and/or inflammation and/or other medical disorder.

15 Growth factor mediated cell proliferation and inflammation are also referred to as epidermal hyperplasias and these and other medical disorders may be mediated by any number of molecules such as but not limited to IGF-I, keratinocyte growth factor (KGF), transforming growth factor- α (TGF α), tumour necrosis factor- α (TNF α), interleukin-1, -4, -6 and 8 (IL-1, IL-4, IL-6 and IL-8, respectively), basic fibroblast growth factor (bFGF) or a combination
20 of one or more of the above. The present invention is particularly described and exemplified with reference to IGF-I and its receptor (IGF-I receptor) and to IGF-I facilitating molecules, IGFBPs, since targeting these molecules according to the methods contemplated herein provides the best results to date. This is done, however, with the understanding that the present invention extends to any growth factor or cytokine-like molecule, a receptor thereof
25 or a facilitating molecule like the IGFBPs involved in skin cell proliferation such as those molecules contemplated above and/or their receptors and/or facilitating molecules therefor.

According to this preferred embodiment, there is provided a method for ameliorating the effects of a medical disorder such as a proliferative and/or inflammatory skin disorder in a
30 mammal, said method comprising contacting the proliferating and/or inflamed skin or skin

- 21 -

capable of proliferation and/or inflammation or a cell otherwise involved with said medical disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation and/or inflammation and/or other medical disorder.

5

The present invention is particularly described by psoriasis as the proliferative skin disorder. However, the subject invention extends to a range of proliferative and/or inflammatory skin disorders or epidermal hyperplasias such as but not limited to psoriasis, ichthyosis, pityriasis rubra pilaris ("PRP"), seborrhoea, keloids, keratoses, neoplasias and scleroderma, warts,
10 benign growths and cancers of the skin. The present invention extends to a range of other disorders such as neovascularization conditions such as but not limited to hyperneovascularization such as neovascularization of the retina, lining of the brain, skin, hyperproliferation of the inside of blood vessels, kidney disease, atherosclerotic disease, hyperplasias of the gut epithelium or growth factor mediated malignancies such as IGF1-
15 mediated malignancies.

Furthermore, down-regulation of IGF-I receptor is useful as adjunctive therapy for epidermal hyperplasia. In accordance with this aspect of the present invention it is known that IGF-I receptor elicits separate intracellular signals which prevent apoptosis [19]. In keratinocytes,
20 IGF-I receptor activation has been shown to protect UV-irradiated cells from apoptosis [20]. In another cell type, a number of IGF-I receptors expressed by the cells correlated with tumorigenicity and apoptotic resistance [21]. Consequently, in accordance with the present invention, by inactivating IGF-I receptor on cells such as epidermal keratinocytes will achieve three important outcomes:

25

- (i) Acute epidermal hyperplasia following UV has been suggested to increase the risk of keratinocyte carcinogenic transformation [22]. By reducing IGF-I receptor expression in the epidermis, the incidence of epidermal hyperplasia following UV exposure is likely to be reduced leading to an overall acceleration in normalization of the lesion
30 and reduced carcinogenic risk.

- 22 -

- 5 (ii) Inhibition of anti-apoptotic action of IGF-I receptor will enhance the reversal of epidermal thickening and accelerate normalization of differentiation. Topical or injected IGF-I receptor antisense as adjunctive treatment will increase apoptosis in the epidermal layer thereby enhancing the reduction in acanthosis observed in UV treatments.
- 10 (iii) Survival of keratinocytes, ie. those which evade apoptosis is likely to occur when cells have damaged DNA. Such mutations may be in the tumor suppressor region. Consequently, the use of antisense therapy will result in less frequent selection of mutated keratinocytes and therefore reduced incidence of basal cell carcinomas and squamous.

According to this embodiment, there is provided a method for ameliorating the effects of a proliferative and/or inflammatory skin disorder such as psoriasis said method comprising
15 contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation with effective amounts of UV treatment and a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation and/or inflammation.

20 The UV treatment and nucleic acid molecule or its chemical analogue may be administered in any order or may be done simultaneously. This method is particularly useful in treating psoriasis by combination of UV and antisense therapy. Preferably the antisense therapy is directed to the IGF-I receptor.

25 In a preferred embodiment, the present invention is directed to a method for ameliorating the effects of psoriasis or other medical disorder, said method comprising contacting proliferating skin or skin capable of proliferation or cells associated with said disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation or ameliorating the medical disorder.

- 23 -

The present invention extends to any mammal such as but not limited to humans, livestock animals (e.g. horses, sheep, cows, goats, pigs, donkeys), laboratory test animals (e.g. rabbits, mice, guinea pigs), companion animals (e.g. cats, dogs) and captive wild animals. However, the instant invention is particularly directed to proliferative and/or inflammatory skin disorders such as psoriasis in humans as well as medical disorders contemplated above.

The aspects of the subject invention instantly contemplated are particularly directed to the topical application of one or more suitable nucleic acid molecules capable of inhibiting, reducing or otherwise interfering with IGF-mediated cell proliferation and/or inflammation. More particularly, the nucleic acid molecule targets IGF-I interaction with its receptor. Conveniently, therefore, the nucleic acid molecule is an antagonist of IGF-I interaction with its receptor. Most conveniently, the nucleic acid molecule antagonist is an antisense molecule to the IGF-I receptor, to IGF-I itself or to a molecule capable of facilitating IGF-I interaction with its receptor such as but not limited to an IGFBP.

15

Insofar as the invention relates to IGFBPs, the preferred molecules are IGFBP-2, -3, -4, -5 and -6. The most preferred molecules are IGFBP-2 and IGFBP-3.

The nucleotide sequences of IGFBP-2 and IGFBP-3 are set forth in Figures 1 (<400>1) and 2 (<400>2), respectively. According to a particularly preferred aspect of the present invention, there is provided a nucleic acid molecule comprising at least about ten nucleotides capable of hybridising to, forming a heteroduplex or otherwise interacting with an mRNA molecule directed from a gene corresponding to a genomic form of <400>1 and/or <400>2 and which thereby reduces or inhibits translation of said mRNA molecule. Preferably, the nucleic acid molecule is at least about 15 nucleotides in length and more preferably at least about 20-25 nucleotides in length. However, the instant invention extends to any length nucleic acid molecule including a molecule of 100-200 nucleotides in length to correspond to the full length of or near full length of the subject genes.

- 24 -

The nucleotide sequence of the antisense molecules may correspond exactly to a region or portion of <400>1 or <400>2 or may differ by one or more nucleotide substitutions, deletions and/or additions. It is a requirement, however, that the nucleic acid molecule interact with an mRNA molecule to thereby reduce its translation into active protein.

5

Examples of potential antisense molecules for IGFBP-2 and IGFBP-3 are those capable of interacting with sequences selected from the lists in Examples 6 and 7, respectively.

The nucleic acid molecules in the form of an antisense molecule may be linear or covalently
10 closed circular and single stranded or partially double stranded. A double stranded molecule may form a triplex with target mRNA or a target gene. The molecule may also be protected from, for example, nucleases, by any number of means such as using a nonionic backbone or a phosphorothioate linkage. A convenient nonionic backbone contemplated herein is ethylphosphotriester linkage or a 2'-O-methylribosyl derivative. A particularly useful
15 modification modifies the DNA backbone by introducing phosphorothioate internucleotide linkages. Alternatively or in addition to the pyrimidine bases are modified by inclusion of a C-5 propyne substitution which modification is proposed to enhance duplex stability [23]. The present invention extends to any chemical modification to the bases and/or RNA or DNA backbone. Reference to a "chemical analogue" of a nucleic acid molecule includes reference
20 to a modified base, nucleotide, nucleoside or phosphate backbone.

Examples of suitable oligonucleotide analogues are conveniently described in Ts'O *et al* [7]. Further suitable examples of oligonucleotide analogues and chemical modifications are described in references 25 to 31.

25

Alternatively, the antisense molecules of the present invention may target the IGF-I gene itself or its receptor or a multivalent antisense molecule may be constructed or separate molecules administered which target at least two or an IGFBP, IGF-I and/or IGF-I-receptor. Examples of suitable antisense molecules capable of targetting the IGF-I receptor are those capable of

- 25 -

interacting with sequences selected from the list in Example 8. One particularly useful antisense molecule is 5'- ATCTCTCCGCTTCCTTTC -3' (<400>10).

Other particularly useful antisense molecules are:

5 #27 UCCGGAGCCAGACUU

#64 CACAGUUGCUGCAAG

#78 UCUCCGCUUCCUUUC

#28 AGCCCCCACAGCGAG

#32 GCCUUGGAGAUGAGC

10 #40 UAACAGAGGUCAGCA

#42 GGAUCAGGGACCAGU

#46 CGGCAAGCUACACAG

#50 GGCAGGCAGGCACAC

15 Particularly useful molecules are selected from #27, #64 and #78. In a preferred embodiment these molecules comprise a C-5 propynyl dU, dC phosphorothioate modification.

A particularly preferred embodiment of the present invention contemplates a method of ameliorating the effects of psoriasis or other medical disorder, said method comprising
20 contacting proliferating skin or skin capable of proliferation or cells associated with said medical disorder with an effective amount of one or more nucleic acid molecules or chemical analogues thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation or ameliorating the medical disorder wherein said one or more molecules comprises a polynucleotide capable of interacting with mRNA directed from an IGF-I gene, an IGF-I
25 receptor gene or a gene encoding an IGFBP such as IGFBP-2 and/or IGFBP-3.

Preferably, the nucleic acid molecule are antisense molecules. Particularly useful antisense molecules are:

#27 UCCGGAGCCAGACUU

30 #64 CACAGUUGCUGCAAG

- 26 -

#78 UCUCCGCUUCCUUUC

#28 AGCCCCCACAGCGAG

#32 GCCUUGGAGAUGAGC

#40 UAACAGAGGUCAGCA

5 #42 GGAUCAGGGACCAGU

#46 CGGCAAGCUACACAG

#50 GGCAGGCAGGCACAC

Even more particularly useful molecules are selected from #27, #64 and #78.

10

In accordance with one aspect of the present invention the nucleic acid molecule is topically applied in aqueous solution or in conjunction with a cream, ointment, oil or other suitable carrier and/or diluent. A single application may be sufficient depending on the severity or exigencies of the condition although more commonly, multiple applications are required ranging from
15 hourly, multi-hourly, daily, multi-daily, weekly or monthly, or in some other suitable time interval. The treatment might comprise solely the application of the nucleic acid molecule or this may be applied in conjunction with other treatments for the skin proliferation and/or inflammatory disorder being treated or for other associated conditions including microbial infection, bleeding and the formation of a variety of rashes.

20

As an alternative to or in conjunction with antisense therapy, the subject invention extends to the nucleic acid molecule as, or incorporating, a ribozyme including a minizyme to, for example, IGF-I, its receptor or to molecules such as IGFBPs and in particular IGFBP-2 and -3. Ribozymes are synthetic nucleic acid molecules which possess highly specific endoribonuclease
25 activity. In particular, they comprise a hybridising region which is complementary in nucleotide sequence to at least part of a target RNA. Ribozymes are well described by Haseloff and Gerlach [8] and in International Patent Application No. WO 89/05852. The present invention extends to ribozymes which target mRNA specified by genes encoding IGF-I, its receptor or one or more IGFBPs such as IGFBP-2 and/or IGFBP-3.

30

- 27 -

According to this embodiment, there is provided in a particularly preferred aspect a ribozyme comprising a hybridising region and a catalytic region wherein the hybridising region is capable of hybridising to at least part of a target mRNA sequence transcribed from a genomic gene corresponding to (<400>1) or (<400>2) wherein said catalytic domain is capable of cleaving
5 said target mRNA sequence to reduce or inhibit IGF-I mediated cell proliferation and/or inflammation and/or other medical disorders.

Yet another aspect of the present invention contemplates co-suppression to reduce expression or to inhibit translation of an endogenous gene encoding, for example, IGF-I, its receptor, or
10 IGFBPs such as IGFBP-2 and/or -3. In co-suppression, a second copy of an endogenous gene or a substantially similar copy or analogue of an endogenous gene is introduced into a cell following topical administration. As with antisense molecules, nucleic acid molecules defining a ribozyme or nucleic acid molecules useful in co-suppression may first be protected such as by using a nonionic backbone.

15

The efficacy of the nucleic acid molecules of the present invention can be conveniently tested and screened using an *in vitro* system comprising a basal keratinocyte cell line. A particularly useful system comprises the HaCaT cell line described by Boukamp *et al* [9]. In one assay, IGF-I is added to an oligonucleotide treated HaCaT cell line. Alternatively, growth of
20 oligonucleotide treated HaCaT cells is observed on a feeder layer of irradiated 3T3 fibroblasts. Using such *in vitro* assays, it is observed that antisense oligonucleotides to IGFBP-3, for example, inhibit production of IGFBP-3 by HaCaT cells. Other suitable animal models include the nude mouse/human skin graft model (15; 16) and the "flaky skin" mouse model (17; 18). In the nude mouse model, microdermatome biopsies of psoriasis lesions are taken under
25 local anaesthetic from volunteers then transplanted to congenital athymic (nude) mice. These transplanted human skin grafts maintain the characteristic hyperproliferating epidermis for 6-8 weeks. They are an established model for testing the efficacy of topically applied therapies for psoriasis. In the "flaky skin" mouse model, the *fsn/fsn* mutation produces mice with skin resembling human psoriasis. This mouse, or another mutant mouse with a similar phenotype
30 is a further *in vivo* model to test the efficacy of topically applied therapies for psoriasis.

- 28 -

Another aspect of the present invention contemplates a pharmaceutical composition for topical administration which comprises a nucleic acid molecule capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation such as psoriasis and one or more pharmaceutically acceptable carriers and/or diluents. Preferably, the nucleic acid molecule is an antisense
5 molecule to IGF-I, the IGF-I receptor or an IGFBP such as IGFBP-2 and/or IGFBP-3 or comprises a ribozyme to one or more of these targets or is a molecule suitable for co-suppression of one or more of these targets. The composition may comprise a single species of a nucleic acid molecule capable of targeting one of IGF-I, its receptor or an IGFBP, such as IGFBP-2 or IGFBP-3 or may be a multi-valent molecule capable of targeting two or more of
10 IGF-I, its receptor or an IGFBP, such as IGFBP-2 and/or IGFBP-3.

The nucleic acid molecules may be administered in dispersions prepared in creams, ointments, oil or other suitable carrier and/or diluent such as glycerol, liquid polyethylene glycols and/or mixtures thereof. Under ordinary conditions of storage and use, these preparations may contain
15 a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for topical use include sterile aqueous solutions (where water soluble) or dispersions and powders for the extemporaneous preparation of topical solutions or dispersions. In all cases, the form is preferably sterile although this is not an absolute
20 requirement and is stable under the conditions of manufacture and storage. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of
25 dispersion and by the use of surfactants. The prevention of the action of microorganism can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.

- 29 -

Topical solutions are prepared by incorporating the nucleic acid molecule compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by where necessary filter sterilization.

- 5 The active agent may alternatively be administered by intravenous, subcutaneous, nasal drip, suppository, implant means amongst other suitable routes of administration including intraperitoneal, intramuscular, absorption through epithelial or mucocutaneous linings for example via nasal, oral, vaginal, rectal or gastrointestinal administration. Reference may conveniently be made to reference 24.

10

- As used herein "pharmaceutically acceptable carriers and/or diluents" include any and all solvents, dispersion media, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional
15 media or agent is incompatible with the active ingredient, use thereof in the pharmaceutical compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. Conveniently, the nucleic acid molecules of the present invention are stored in freeze-dried form and are reconstituted prior to use.

- 20 Yet another aspect of the present invention contemplates the use of a nucleic acid molecule in the manufacture of a medicament for the treatment of proliferative and/or inflammatory skin disorders or other medical disorders mediated by a growth factor. The proliferative and/or inflammatory skin disorder is generally psoriasis or other medical disorders as described above and the nucleic acid molecule targets IGF-I, the IGF-I receptor and/or an IGFBP such as IGFBP-
25 2 and/or IGFBP-3.

Still a further aspect of the present invention contemplates an agent comprising a nucleic acid molecule as hereinbefore defined useful in the treatment of proliferative and/or inflammatory skin disorders, such as psoriasis or other medical disorder..

30

- 30 -

The present invention further contemplates the use of the genetic molecules and in particular the antisense molecules to inhibit the anti-apoptotic activity of IGF-I receptor. Such a use is appropriate for the treatment of certain cancers and as adjunct therapy for epidermal hyperplasia such as in combination with UV treatment.

5

The present invention is further described by the following non-limiting Examples.

- 31 -

EXAMPLE 1

The differentiated human keratinocyte cell line, HaCaT [9] was used in the *in vitro* assay. Cells at passage numbers 33 to 36 were maintained as monolayer cultures in 5% v/v CO₂ at 37°C in Keratinocyte-SFM (Gibco) containing EGF and bovine pituitary extract as supplied. Media
5 containing foetal calf serum were avoided because of the high content of IGF-I binding proteins in serum.

Feeder layer plates of lethally irradiated 3T3 fibroblasts were prepared exactly as described by Rheinwald and Green [10].

10

EXAMPLE 2

Cells were grown to 4 days post confluence in 2cm² wells with daily medium changes of Keratinocyte-SFM, then the medium was changed to DMEM (Cytosystems, Australia), with the following additions: 25mM Hepes, 0.19% w/v, sodium bicarbonate, 0.03% w/v glutamine
15 (Sigma Chemical Co, USA), 50IU/ml penicillin and 50µg/ml streptomycin (Flow Laboratories). After 24 hours, IGF-I or tIGF-I was added to triplicate wells, at the concentrations indicated, in 0.5ml fresh DMEM containing 0.02% v/v bovine serum albumin (Sigma molecular biology grade) and incubated for a further 21 hours. [³H]-Thymidine (0.1µCi/well) was then added and the cells incubated for a further 3 hours. The medium was then aspirated and the cells washed
20 once with ice-cold PBS and twice with ice-cold 10% v/v TCA. The TCA-precipitated monolayers were then solubilized with 0.25M NaOH (200µl/well), transferred to scintillation vials and radioactivity determined by liquid scintillation counting (Pharmacia Wallac 1410 liquid scintillation counter).

25

EXAMPLE 3

HaCaT conditioned medium (250µl) was concentrated by adding 750µl cold ethanol, incubating at -20°C for 2 hours and centrifuging at 16,000g for 20 min at 4°C. The resulting pellet was air dried, resuspended thoroughly in non-reducing Laemmli sample buffer, heated to 90°C for 5 minutes and separated on 12% w/v SDS-PAGE according to the method of Laemmli (1970).
30 Separated proteins were electrophoretically transferred to nitrocellulose membrane (0.45mm, Schleicher and Schuell, Dassel, Germany) in a buffer containing 25mM Tris, 192mM glycine

- 32 -

and 20% v/v methanol. IGFBPs were then visualised by the procedure of Hossenlopp *et al* [11], using [¹²⁵I]-IGF-I, followed by autoradiography. Autoradiographs were scanned in a BioRad Model GS-670 Imaging Densitometer and band densities were determined using the Molecular Analyst program.

5

EXAMPLE 4

Phosphorothioate oligodeoxynucleotides were synthesised by Bresatec, Adelaide, South Australia, Australia. The following antisense sequences were used: BP3AS2, 5'- GCG CCC GCT GCA TGA CGC CTG CAA C -3' (<400>4), a 25mer complementary to the start codon
 10 region of the human IGFBP-3 mRNA; BP3AS3, 5'- CGG GCG GCT CAC CTG GAG CTG GCG -3' (<400>5), a 24mer complementary to the exon 1/intron 1 splice site; BP3AS4, 5'- AGG CGG CTG ACG GCA CTA -3' (<400>6), an 18mer complementary to a region of the coding sequence lacking RNA secondary structure and oligonucleotide-dimer formation (using the computer software "OLIGO for PC"). Since BP3AS4 was found to be ineffective at
 15 inhibiting IGFBP-3 synthesis, it was used as a control. The following additional control oligonucleotide sequences were used: BP3S, 5'- CAG GCG TCA TGC AGC GGG C -3' (<400>7), an 18mer sense control sequence equivalent to the start codon region; BP3AS2NS, 5'- CGG AGA TGC CGC ATG CCA GCG CAG G -3' (<400>8), a 25mer randomised sequence with the same GC content as BP3AS2; BP3AS4NS, 5'- GAC AGC GTC GGA GCG
 20 ATC -3' (<400>9), an 18mer randomised sequence with the same GC content as BP3AS4NS. Design of the oligonucleotides was based on the human IGFBP-3 cDNA sequence of Spratt *et al* [12].

Cells were grown to one day post confluence in 2cm² wells with daily medium changes of 0.5ml
 25 Keratinocyte-SFM, then subjected to daily medium changes of Keratinocyte-SFM for a further 4 days. Daily additions of 0.5ml fresh Keratinocyte-SFM were then continued for a further 7 days, except that at the time of medium addition, 5µl oligonucleotide in PBS was added to give the final concentrations indicated, then the wells were shaken to mix the oligonucleotide. After the final addition, cells were incubated for 24 hours and the medium collected for assay of
 30 IGFBPs. Cells were then counted after trypsinisation in a Coulter Industrial D Counter, Coulter Bedfordshire, UK. Cell numbers after oligonucleotide treatment differed by less than 10%.

- 33 -

EXAMPLE 5

HaCaT cells secrete mainly IGFBP-3 (>95%), with the only other IGFBP detectable in HaCaT conditioned medium being IGFBP-4 (<5%). The effect on IGFBP-3 and IGFBP-4 synthesis of antisense oligonucleotides at two concentrations, 5 μ M and 0.5 μ M, was tested. Two oligonucleotides were used, BP3AS2 and BP3AS3, directed against the start site and the intron 1/exon 1 splice site, respectively of the IGFBP-3 mRNA. As a control, a sense oligonucleotide corresponding to the start site was used. As shown in Figures 4A and 4B, all oligonucleotides at 5 μ M caused a significant reduction of IGFBP-3 synthesis compared with untreated cells, however, the two antisense oligonucleotides inhibited IGFBP-3 synthesis of approximately 50% compared to the sense control (Figure 4B). The antisense oligonucleotide directed to the start codon appeared to be more effective of the two, the difference being more apparent at the lower concentration of 0.5 μ M. The cells of IGFBP-4 secreted by the HaCaT cells make photographic reproduction of the bands on Western ligand blots difficult, however densitometry measurements provide adequate relative quantitation. This resulted in the significant observation that IGFBP-4 levels were unaffected by oligonucleotide addition to the cells, suggesting that the observed inhibitory effects on IGFBP-3 are specific.

To further investigate the inhibitory effects of the more effective of the two antisense oligonucleotides, BP3AS2, inhibition by this oligonucleotide at 0.5 μ M was compared with a number of control oligonucleotides, including one antisense oligonucleotide to IGFBP-3 that had proved to be ineffective at 0.5 μ M. As shown in Figures 5A and 5B, BP3AS2 was again inhibitory, resulting in levels of IGFBP-3 of approximately 50% of the most non-specifically inhibitory control oligonucleotide, the randomised equivalent of BP3AS2. The other control oligonucleotides caused no reduction in IGFBP-3 levels at 0.5 μ M, compared to untreated cells. Of possible significance is the fact that this control oligonucleotide, BP3AS2NS, like BP3AS2 itself, has the highest potential T_m of the three control oligonucleotides used in this experiment, enhancing the probability of non-specific base pairing with non-target mRNAs. However, the lack of inhibition of IGFBP-4 secretion by BP3AS2 suggests that this oligonucleotide is selective even compared with the most closely related protein likely to be present in this cell line.

- 34 -

EXAMPLE 6

Antisense oligonucleotides to IGFBP2 may be selected from molecules capable of interacting with one or more of the following sense oligonucleotides:

	ATTCGGGGCGAGGGA	CGCAGGGCCGTGCAC	CCGCGCCGCGCTGCC
5	TTCGGGGCGAGGGAG	GCAGGGCCGTGCACC	CGCGCCGCGCTGCCG
	TCGGGGCGAGGGAGG	CAGGGCCGTGCACCT	GCGCCGCGCTGCCGA
	CGGGGCGAGGGAGGA	AGGGCCGTGCACCTG	CGCCGCGCTGCCGAC
	GGGGCGAGGGAGGAG	GGGCCGTGCACCTGC	GCCGCGCTGCCGACC
	GGGCGAGGGAGGAGG	GGCCGTGCACCTGCC	CCGCGCTGCCGACCG
10	GGCGAGGGAGGAGGA	GCCGTGCACCTGCCG	CGCGCTGCCGACCGC
	GCGAGGGAGGAGGAA	CCGTGCACCTGCCCG	GCGCTGCCGACCGCC
	CGAGGGAGGAGGAAG	CGTGCACCTGCCCGC	CGCTGCCGACCGCCA
	GAGGGAGGAGGAAGA	GTGCACCTGCCCGCC	GCTGCCGACCGCCAG
	AGGGAGGAGGAAGAA	TGCACCTGCCCGCCC	CTGCCGACCGCCAGC
15	GGGAGGAGGAAGAAG	GCACCTGCCCGCCCG	TGCCGACCGCCAGCA
	GGAGGAGGAAGAAGC	CACCTGCCCGCCCGC	GCCGACCGCCAGCAT
	GAGGAGGAAGAAGCG	ACCTGCCCGCCCGCC	CCGACCGCCAGCATG
	AGGAGGAAGAAGCGG	CCTGCCCGCCCGCCC	CGACCGCCAGCATGC
	GGAGGAAGAAGCGGA	CTGCCCGCCCGCCCG	GACCGCCAGCATGCT
20	GAGGAAGAAGCGGAG	TGCCCGCCCGCCCGC	ACCGCCAGCATGCTG
	AGGAAGAAGCGGAGG	GCCCGCCCGCCCGCT	CCGCCAGCATGCTGC
	GGAAGAAGCGGAGGA	CCCGCCCGCCCGCTC	CGCCAGCATGCTGCC
	GAAGAAGCGGAGGAG	CCGCCCGCCCGCTCG	GCCAGCATGCTGCCG
	AAGAAGCGGAGGAGG	CGCCCGCCCGCTCGC	CCAGCATGCTGCCGA
25	AGAAGCGGAGGAGGC	GCCCGCCCGCTCGCT	CAGCATGCTGCCGAG
	GAAGCGGAGGAGGCG	CCCGCCCGCTCGCTC	AGCATGCTGCCGAGA
	AAGCGGAGGAGGCGG	CCGCCCGCTCGCTCG	GCATGCTGCCGAGAG
	AGCGGAGGAGGCGGC	CGCCCGCTCGCTCGC	CATGCTGCCGAGAGT
	GCGGAGGAGGCGGCT	GCCCGCTCGCTCGCT	ATGCTGCCGAGAGTG
30	CGGAGGAGGCGGCTC	CCCGCTCGCTCGCTC	TGCTGCCGAGAGTGG
	GGAGGAGGCGGCTCC	CCGCTCGCTCGCTCG	GCTGCCGAGAGTGGG
	GAGGAGGCGGCTCCC	CGCTCGCTCGCTCGC	CTGCCGAGAGTGGGC
	AGGAGGCGGCTCCCG	GCTCGCTCGCTCGCC	TGCCGAGAGTGGGCT
	GGAGGCGGCTCCCGC	CTCGCTCGCTCGCCC	GCCGAGAGTGGGCTG
35	GAGGCGGCTCCCGCT	TCGCTCGCTCGCCCG	CCGAGAGTGGGCTGC
	AGGCGGCTCCCGCTC	CGCTCGCTCGCCCGC	CGAGAGTGGGCTGCC
	GGCGGCTCCCGCTCG	GCTCGCTCGCCCGCC	GAGAGTGGGCTGCCC
	GCGGCTCCCGCTCGC	CTCGCTCGCCCGCCG	AGAGTGGGCTGCCCC
	CGGCTCCCGCTCGCA	TCGCTCGCCCGCCGC	GAGTGGGCTGCCCCG
40	GGCTCCCGCTCGCAG	CGCTCGCCCGCCGCG	AGTGGGCTGCCCCGC
	GCTCCCGCTCGCAGG	GCTCGCCCGCCGCGC	GTGGGCTGCCCCGCG
	CTCCCGCTCGCAGGG	CTCGCCCGCCGCGCC	TGGGCTGCCCCGCGC
	TCCCGCTCGCAGGGC	TCGCCCGCCGCGCCG	GGGCTGCCCCGCGCT
	CCCGCTCGCAGGGCC	CGCCCGCCGCGCCGC	GGCTGCCCCGCGCTG
45	CCGCTCGCAGGGCCG	GCCCGCCGCGCCGCG	GCTGCCCCGCGCTGC
	CGCTCGCAGGGCCGT	CCCGCCGCGCCGCGC	CTGCCCCGCGCTGCC
	GCTCGCAGGGCCGTG	CCGCCGCGCCGCGCT	TGCCCCGCGCTGCCG
	CTCGCAGGGCCGTGC	CGCCGCGCCGCGCTG	GCCCCGCGCTGCCGC
	TCGCAGGGCCGTGCA	GCCGCGCCGCGCTGC	CCCCGCGCTGCCGCT

- 35 -

CCCGCGCTGCCGCTG	CTGCTGCTACTGGGC	CTGTTCCGCTGCCCCG
CCGCGCTGCCGCTGC	TGCTGCTACTGGGCG	TGTTCCGCTGCCCCGC
CGCGCTGCCGCTGCC	GCTGCTACTGGGCGC	GTTCCGCTGCCCCGCC
GCGCTGCCGCTGCCG	CTGCTACTGGGCGCG	TTCCGCTGCCCCGCC
5 CGCTGCCGCTGCCGC	TGCTACTGGGCGCGA	TCCGCTGCCCCGCCCT
GCTGCCGCTGCCGCC	GCTACTGGGCGCGAG	CCGCTGCCCCGCCCTG
CTGCCGCTGCCGCCG	CTACTGGGCGCGAGT	CGCTGCCCGCCCTGC
TGCCGCTGCCGCCGC	TACTGGGCGCGAGTG	GCTGCCCGCCCTGCA
GCCGCTGCCGCCGCC	ACTGGGCGCGAGTGG	CTGCCCGCCCTGCAC
10 CCGCTGCCGCCGCCG	CTGGGCGCGAGTGGC	TGCCCGCCCTGCACA
CGCTGCCGCCGCCGC	TGGGCGCGAGTGGCG	GCCCGCCCTGCACAC
GCTGCCGCCGCCGCC	GGGCGCGAGTGGCGG	CCCGCCCTGCACACC
CTGCCGCCGCCGCCG	GGCGCGAGTGGCGGC	CCGCCCTGCACACCC
TGCCGCCGCCGCCGC	GCGCGAGTGGCGGCG	CGCCCTGCACACCCG
15 GCCGCCGCCGCCGCT	CGCGAGTGGCGGCGG	GCCCTGCACACCCGA
CCGCCGCCGCCGCTG	GCGAGTGGCGGCGGC	CCCTGCACACCCGAG
CGCCGCCGCCGCTGC	CGAGTGGCGGCGGCG	CCTGCACACCCGAGC
GCCGCCGCCGCTGCT	GAGTGGCGGCGGCGG	CTGCACACCCGAGCG
CCGCCGCCGCTGCTG	AGTGGCGGCGGCGGC	TGCACACCCGAGCGC
20 CGCCGCCGCTGCTGC	GTGGCGGCGGCGGCG	GCACACCCGAGCGCC
GCCGCCGCTGCTGCC	TGGCGGCGGCGGCGG	CACACCCGAGCGCCT
CCGCCGCTGCTGCCG	GGCGGCGGCGGCGGG	ACACCCGAGCGCCTG
CGCCGCTGCTGCCGC	GCGGCGGCGGCGGGG	CACCCGAGCGCCTGG
GCCGCTGCTGCCGCT	CGGCGGCGGCGGGGC	ACCCGAGCGCCTGGC
25 CCGCTGCTGCCGCTG	GGCGGCGGCGGGGCG	CCCGAGCGCCTGGCC
CGCTGCTGCCGCTGC	GCGGCGGCGGGGCGC	CCGAGCGCCTGGCCG
GCTGCTGCCGCTGCT	CGGCGGCGGGGCGCG	CGAGCGCCTGGCCGC
CTGCTGCCGCTGCTG	GGCGGCGGGGCGCGC	GAGCGCCTGGCCGCC
TGCTGCCGCTGCTGC	GCGGCGGGGCGCGCG	AGCGCCTGGCCGCCT
30 GCTGCCGCTGCTGCC	CGGCGGGGCGCGCGC	GCGCCTGGCCGCCTG
CTGCCGCTGCTGCCG	GGCGGGGCGCGCGCG	CGCCTGGCCGCCTGC
TGCCGCTGCTGCCGC	GCGGGGCGCGCGCGG	GCCTGGCCGCCTGCG
GCCGCTGCTGCCGCT	CGGGGCGCGCGCGGA	CCTGGCCGCCTGCGG
CCGCTGCTGCCGCTG	GGGGCGCGCGCGAG	CTGGCCGCCTGCGGG
35 CGCTGCTGCCGCTGC	GGGCGCGCGCGGAGG	TGGCCGCCTGCGGGC
GCTGCTGCCGCTGCT	GGCGCGCGCGGAGGT	GGCCGCCTGCGGGCC
CTGCTGCCGCTGCTG	GCGCGCGCGGAGGTG	GCCGCCTGCGGGCCC
TGCTGCCGCTGCTGC	CGCGCGCGGAGGTGC	CCGCCTGCGGGCCCC
GCTGCCGCTGCTGCT	GCGCGCGGAGGTGCT	CGCCTGCGGGCCCCC
40 CTGCCGCTGCTGCTG	CGCGCGGAGGTGCTG	GCCTGCGGGCCCCCG
TGCCGCTGCTGCTGC	GCGCGGAGGTGCTGT	CCTGCGGGCCCCCGC
GCCGCTGCTGCTGCT	CGCGGAGGTGCTGTT	CTGCGGGCCCCCGCC
CCGCTGCTGCTGCTG	GCGGAGGTGCTGTTCC	TGCGGGCCCCCGCCG
CGCTGCTGCTGCTGC	CGGAGGTGCTGTTCCG	GCGGGCCCCCGCCGG
45 GCTGCTGCTGCTGCT	GGAGGTGCTGTTCCG	CGGGCCCCCGCCGGT
CTGCTGCTGCTGCTA	GAGGTGCTGTTCCGC	GGGGCCCCCGCCGTT
TGCTGCTGCTGCTAC	AGGTGCTGTTCCGCT	GGCCCCCGCCGTTG
GCTGCTGCTGCTACT	GGTGCTGTTCCGCTG	GCCCCGCGCGTTGCG
CTGCTGCTGCTACTG	GTGCTGTTCCGCTGC	CCCCGCGCGTTGCGC
50 TGCTGCTGCTACTGG	TGCTGTTCCGCTGCC	CCCCGCGGTTGCGCC
GCTGCTGCTACTGGG	GCTGTTCCGCTGCC	CCCCGCGGTTGCGCC

- 36 -

	CCGCCGGTTGCGCCG	ATGCCATGCGCGGAG	TGCGCCCGGCTGGAG
	CGCCGGTTGCGCCGC	TGCCATGCGCGGAGC	GCGCCCGGCTGGAGG
	GCCGGTTGCGCCGCC	GCCATGCGCGGAGCT	CGCCCGGCTGGAGGG
	CCGGTTGCGCCGCCC	CCATGCGCGGAGCTC	GCCCGGCTGGAGGGC
5	CGGTTGCGCCGCCCC	CATGCGCGGAGCTCG	CCCGGCTGGAGGGCG
	GGTTGCGCCGCCCCG	ATGCGCGGAGCTCGT	CCGGCTGGAGGGCGA
	GTTGCGCCGCCCCGC	TGCGCGGAGCTCGTC	CGGCTGGAGGGCGAG
	TTGCGCCGCCCCGCC	GCGCGGAGCTCGTCC	GGCTGGAGGGCGAGG
	TGCGCCGCCCCGCCG	CGCGGAGCTCGTCCG	GCTGGAGGGCGAGGC
10	GCGCCGCCCCGCCGC	GCGGAGCTCGTCCGG	CTGGAGGGCGAGGCG
	CGCCGCCCCGCCGCG	CGGAGCTCGTCCGGG	TGGAGGGCGAGGCGT
	GCCGCCCCGCCGCGT	GGAGCTCGTCCGGGA	GGAGGGCGAGGCGTG
	CCGCCCCGCCGCGGTG	GAGCTCGTCCGGGAG	GAGGGCGAGGCGTGC
	CGCCCCGCCGCGGTGG	AGCTCGTCCGGGAGC	AGGGCGAGGCGTGCG
15	GCCCCGCCGCGGTGGC	GCTCGTCCGGGAGCC	GGGCGAGGCGTGCGG
	CCCGCCGCGGTGGCC	CTCGTCCGGGAGCCG	GGCGAGGCGTGCGGC
	CCGCCGCGGTGGCCG	TCGTCCGGGAGCCGG	GCGAGGCGTGCGGCG
	CGCCGCGGTGGCCGC	CGTCCGGGAGCCGGG	CGAGGCGTGCGGCGT
	GCCGCGGTGGCCGCA	GTCCGGGAGCCGGGC	GAGGCGTGCGGCGTC
20	CCGCGGTGGCCGCAG	TCCGGGAGCCGGGCT	AGGCGTGCGGCGTCT
	CGCGGTGGCCGCAGT	CCGGGAGCCGGGCTG	GGCGTGCGGCGTCTA
	GCGGTGGCCGCAGTG	CGGGAGCCGGGCTGC	GCGTGCGGCGTCTAC
	CGGTGGCCGCAGTGG	GGGAGCCGGGCTGCG	CGTGCGGCGTCTACA
	GGTGGCCGCAGTGGC	GGAGCCGGGCTGCGG	GTGCGGCGTCTACAC
25	GTGGCCGCAGTGGCC	GAGCCGGGCTGCGGC	TGCGGCGTCTACACC
	TGGCCGCAGTGGCCG	AGCCGGGCTGCGGCT	GCGGCGTCTACACCC
	GGCCGCAGTGGCCGG	GCCGGGCTGCGGCTG	CGGCGTCTACACCCC
	GCCGCAGTGGCCGGA	CCGGGCTGCGGCTGC	GGCGTCTACACCCCG
	CCGCAGTGGCCGGAG	CGGGCTGCGGCTGCT	GCGTCTACACCCCGC
30	CGCAGTGGCCGGAGG	GGGCTGCGGCTGCTG	CGTCTACACCCCGCG
	GCA GTGGCCGGAGGC	GGCTGCGGCTGCTGC	GTCTACACCCCGCGC
	CAGTGGCCGGAGGCG	GCTGCGGCTGCTGCT	TCTACACCCCGCGCT
	AGTGGCCGGAGGCGC	CTGCGGCTGCTGCTC	CTACACCCCGCGCTG
	GTGGCCGGAGGCGCC	TGCGGCTGCTGCTCG	TACACCCCGCGCTGC
35	TGGCCGGAGGCGCCC	GCGGCTGCTGCTCGG	ACACCCCGCGCTGCG
	GGCCGGAGGCGCCCG	CGGCTGCTGCTCGGT	CACCCCGCGCTGCGG
	GCCGGAGGCGCCCGC	GGCTGCTGCTCGGTG	ACCCCGCGCTGCGGC
	CCGGAGGCGCCCGCA	GCTGCTGCTCGGTGT	CCCCCGCGCTGCGGCC
	CGGAGGCGCCCGCAT	CTGCTGCTCGGTGTG	CCCGCGCTGCGGCCA
40	GGAGGCGCCCGCATG	TGCTGCTCGGTGTGC	CCCGCGCTGCGGCCAG
	GAGGCGCCCGCATGC	GCTGCTCGGTGTGCG	CGCGCTGCGGCCAGG
	AGGCGCCCGCATGCC	CTGCTCGGTGTGCGC	GCGCTGCGGCCAGGG
	GGCGCCCGCATGCCA	TGCTCGGTGTGCGCC	CGCTGCGGCCAGGGG
	GCGCCCGCATGCCAT	GCTCGGTGTGCGCCC	GCTGCGGCCAGGGGC
45	CGCCCGCATGCCATG	CTCGGTGTGCGCCCG	CTGCGGCCAGGGGCT
	GCCCGCATGCCATGC	TCGGTGTGCGCCCGG	TGCGGCCAGGGGCTG
	CCCGCATGCCATGCG	CGGTGTGCGCCCGGC	GCGGCCAGGGGCTGC
	CCGCATGCCATGCGC	GGTGTGCGCCCGGCT	CGGCCAGGGGCTGCG
	CGCATGCCATGCGCG	GTGTGCGCCCGGCTG	GGCCAGGGGCTGCGC
50	GCATGCCATGCGCGG	TGTGCGCCCGGCTGG	GCCAGGGGCTGCGCT
	CATGCCATGCGCGGA	GTGCGCCCGGCTGGA	CCAGGGGCTGCGCTG

- 37 -

CAGGGGCTGCGCTGC	CTGGTCATGGGCGAG	GCCAGCCCGGAGCAG
AGGGGCTGCGCTGCT	TGGTCATGGGCGAGG	CCAGCCCGGAGCAGG
GGGGCTGCGCTGCTA	GGTCATGGGCGAGGG	CAGCCCGGAGCAGGT
GGGCTGCGCTGCTAT	GTCATGGGCGAGGGC	AGCCCGGAGCAGGTT
5 GGCTGCGCTGCTATC	TCATGGGCGAGGGCA	GCCCGGAGCAGGTTG
GCTGCGCTGCTATCC	CATGGGCGAGGGCAC	CCCGGAGCAGGTTGC
CTGCGCTGCTATCCC	ATGGGCGAGGGCACT	CCGGAGCAGGTTGCAG
TGCGCTGCTATCCCC	TGGGCGAGGGCACTT	GGAGCAGGTTGCAGA
GCGCTGCTATCCCCA	GGGCGAGGGCACTTG	GAGCAGGTTGCAGAC
10 CGCTGCTATCCCCAC	GGCGAGGGCACTTGT	AGCAGGTTGCAGACA
GCTGCTATCCCCACC	GCGAGGGCACTTGTG	GCAGGTTGCAGACAA
CTGCTATCCCCACCC	CGAGGGCACTTGTGA	CAGGTTGCAGACAAT
TGCTATCCCCACCCG	GAGGGCACTTGTGAG	AGGTTGCAGACAATG
GCTATCCCCACCCGG	AGGGCACTTGTGAGA	GGTTGCAGACAATGG
15 CTATCCCCACCCGGG	GGGCACTTGTGAGAA	GTTGCAGACAATGGC
TATCCCCACCCGGGC	GGCACTTGTGAGAA	TTGCAGACAATGGCG
ATCCCCACCCGGGCT	GCACTTGTGAGAAAG	TGCAGACAATGGCGA
TCCCCACCCGGGCTC	CACTTGTGAGAAAGC	GCAGACAATGGCGAT
CCCCACCCGGGCTCC	ACTTGTGAGAAAGCG	CAGACAATGGCGATG
20 CCCACCCGGGCTCCG	CTTGTGAGAAAGCGC	AGACAATGGCGATGA
CCACCCGGGCTCCGA	TTGTGAGAAAGCGCC	GACAATGGCGATGAC
CACCCGGGCTCCGAG	TGTGAGAAAGCGCCG	ACAATGGCGATGACC
ACCCGGGCTCCGAGC	GTGAGAAAGCGCCGG	CAATGGCGATGACCA
CCCGGGCTCCGAGCT	TGAGAAAGCGCCGGA	AATGGCGATGACCAC
25 CCGGGCTCCGAGCTG	GAGAAAGCGCCGGAC	ATGGCGATGACCACT
CGGGCTCCGAGCTGC	AGAAGCGCCGGACG	TGGCGATGACCACTC
GGGCTCCGAGCTGCC	GAAGCGCCGGACGC	GGCGATGACCACTCA
GGCTCCGAGCTGCCC	AAGCGCCGGACGCC	GCGATGACCACTCAG
GCTCCGAGCTGCCCC	AGCGCCGGACGCCG	CGATGACCACTCAGA
30 CTCCGAGCTGCCCCT	GCGCCGGACGCCGA	GATGACCACTCAGAA
TCCGAGCTGCCCCTG	CGCCGGACGCCGAG	ATGACCACTCAGAAG
CCGAGCTGCCCCTG	GCCGGACGCCGAGT	TGACCACTCAGAAGG
CGAGCTGCCCCTGCA	CCGGACGCCGAGTA	GACCACTCAGAAGGA
GAGCTGCCCCTGAG	CGGGACGCCGAGTAT	ACCACTCAGAAGGAG
35 AGCTGCCCCTGAGG	GGGACGCCGAGTATG	CCACTCAGAAGGAGG
GCTGCCCCTGAGGC	GGACGCCGAGTATGG	CACTCAGAAGGAGGC
CTGCCCCTGAGGCG	GACGCCGAGTATGGC	ACTCAGAAGGAGGCC
TGCCCCTGAGGCGC	ACGCCGAGTATGGCG	CTCAGAAGGAGGCCT
GCCCCTGAGGCGCT	CGCCGAGTATGGCGC	TCAGAAGGAGGCCTG
40 CCCCTGAGGCGCTG	GCCGAGTATGGCGCC	CAGAAGGAGGCCTGG
CCCTGAGGCGCTGG	CCGAGTATGGCGCCA	AGAAGGAGGCCTGGT
CCTGAGGCGCTGGT	CGAGTATGGCGCCAG	GAAGGAGGCCTGGTG
CTGAGGCGCTGGTC	GAGTATGGCGCCAGC	AAGGAGGCCTGGTGG
TGAGGCGCTGGTCA	AGTATGGCGCCAGCC	AGGAGGCCTGGTGGG
45 GCAGGCGCTGGTCAT	GTATGGCGCCAGCCC	GGAGGCCTGGTGGAG
CAGGCGCTGGTCATG	TATGGCGCCAGCCCG	GAGGCCTGGTGGAGA
AGGCGCTGGTCATGG	ATGGCGCCAGCCCGG	AGGCCTGGTGGAGAA
GGCGCTGGTCATGGG	TGGCGCCAGCCCGGA	GGCCTGGTGGAGAAC
GCGCTGGTCATGGGC	GGCGCCAGCCCGGAG	GCCTGGTGGAGAAC
50 CGCTGGTCATGGGCG	GCGCCAGCCCGGAGC	CCTGGTGGAGAACCA
GCTGGTCATGGGCGA	CGCCAGCCCGGAGCA	

- 38 -

CTGGTGGAGAACCAC	AGTGCTGGCCGGAAG	CGGGAGAAGGTCACT
TGGTGGAGAACCACG	GTGCTGGCCGGAAGC	GGGAGAAGGTCACTG
GGTGGAGAACCACGT	TGCTGGCCGGAAGCC	GGAGAAGGTCACTGA
GTGGAGAACCACGTG	GCTGGCCGGAAGCCC	GAGAAGGTCACTGAG
5 TGGAGAACCACGTGG	CTGGCCGGAAGCCCC	AGAAGGTCACTGAGC
GGAGAACCACGTGGA	TGGCCGGAAGCCCCCT	GAAGGTCACTGAGCA
GAGAACCACGTGGAC	GGCCGGAAGCCCCCTC	AAGGTCACTGAGCAG
AGAACCACGTGGACA	GCCGGAAGCCCCCTCA	AGGTCACTGAGCAGC
GAACCACGTGGACAG	CCGGAAGCCCCCTCAA	GGTCACTGAGCAGCA
10 AACCACGTGGACAGC	CGGAAGCCCCCTCAAG	GTCACTGAGCAGCAC
ACCACGTGGACAGCA	GGAAGCCCCCTCAAGT	TCACTGAGCAGCACC
CCACGTGGACAGCAC	GAAGCCCCCTCAAGTC	CACTGAGCAGCACCG
CACGTGGACAGCACC	AAGCCCCCTCAAGTCG	ACTGAGCAGCACCGG
ACGTGGACAGCACCA	AGCCCCCTCAAGTCGG	CTGAGCAGCACCGGC
15 CGTGGACAGCACCAT	GCCCCCTCAAGTCGGG	TGAGCAGCACCGGCA
GTGGACAGCACCATG	CCCCCTCAAGTCGGGT	GAGCAGCACCGGCAG
TGGACAGCACCATGA	CCCTCAAGTCGGGTAT	AGCAGCACCGGCAGA
GGACAGCACCATGAA	CCTCAAGTCGGGTATG	GCAGCACCGGCAGAT
GACAGCACCATGAAC	CTCAAGTCGGGTATG	CAGCACCGGCAGATG
20 ACAGCACCATGAACA	TCAAGTCGGGTATGAA	AGCACCGGCAGATGG
CAGCACCATGAACAT	CAAGTCGGGTATGAA	GCACCGGCAGATGGG
AGCACCATGAACATG	AAGTCGGGTATGAAG	CACCGGCAGATGGGC
GCACCATGAACATGT	AGTCGGGTATGAAGG	ACCGGCAGATGGGCA
CACCATGAACATGTT	GTCCGGTATGAAGGA	CCGGCAGATGGGCAA
25 ACCATGAACATGTTG	TCCGGTATGAAGGAG	CGGCAGATGGGCAAG
CCATGAACATGTTGG	CGGTATGAAGGAGC	GGCAGATGGGCAAGG
CATGAACATGTTGGG	GGTATGAAGGAGCT	GCAGATGGGCAAGGG
ATGAACATGTTGGGC	GTATGAAGGAGCTG	CAGATGGGCAAGGGT
TGAACATGTTGGGCG	TATGAAGGAGCTGGC	AGATGGGCAAGGGTG
30 GAACATGTTGGGCGG	ATGAAGGAGCTGGCC	GATGGGCAAGGGTGG
AACATGTTGGGCGGG	TGAAGGAGCTGGCCG	ATGGGCAAGGGTGGC
CATGTTGGGCGGGG	GAAGGAGCTGGCCGT	TGGGCAAGGGTGGCA
ATGTTGGGCGGGGGA	AAGGAGCTGGCCGTG	GGGCAAGGGTGGCAA
35 TGTGGGCGGGGAG	AGGAGCTGGCCGTGT	GGCAAGGGTGGCAAG
GTTGGGCGGGGAGG	GGAGCTGGCCGTGTT	GCAAGGGTGGCAAGC
TTGGGCGGGGAGGC	GAGCTGGCCGTGTTT	CAAGGGTGGCAAGCA
TGGGCGGGGAGGCA	AGCTGGCCGTGTTCC	AAGGGTGGCAAGCAT
GGGCGGGGAGGCAG	GCTGGCCGTGTTCCG	AGGGTGGCAAGCATC
40 GGCGGGGAGGCAGT	CTGGCCGTGTTCCGG	GGGTGGCAAGCATCA
GCGGGGAGGCAGTG	TGGCCGTGTTCCGGG	GGTGGCAAGCATCAC
CGGGGAGGCAGTGC	GGCCGTGTTCCGGGA	GTGGCAAGCATCACC
GGGGGAGGCAGTGCT	GCCGTGTTCCGGGAG	TGGCAAGCATCACCT
GGGGAGGCAGTGCTG	CCGTGTTCCGGGAGA	GGCAAGCATCACCTT
45 GGGAGGCAGTGCTGG	CGTGTTCCGGGAGAA	GCAAGCATCACCTTG
GGAGGCAGTGCTGGC	GTGTTCCGGGAGAA	CAAGCATCACCTTGG
GAGGCAGTGCTGGCC	TGTTCCGGGAGAAAG	AAGCATCACCTTGGC
AGGCAGTGCTGGCCG	GTTCCGGGAGAAAGT	AGCATCACCTTGGCC
GGCAGTGCTGGCCGG	TTCCGGGAGAAAGTC	GCATCACCTTGGCCT
50 GCAGTGCTGGCCGGA	TCCGGGAGAAAGTCA	CATCACCTTGGCCTG
CAGTGCTGGCCGGAA	CCGGGAGAAAGTCAC	ATCACCTTGGCCTGG
		TCACCTTGGCCTGGA

- 39 -

5	CACCTTGGCCTGGAG ACCTTGGCCTGGAGG CCTTGGCCTGGAGGA CTTGGCCTGGAGGAG TTGGCCTGGAGGAGC TGGCCTGGAGGAGCC GGCCTGGAGGAGCCC GCCTGGAGGAGCCCA CCTGGAGGAGCCCAA	CCCTGCCAACAGGAA CCTGCCAACAGGAAC CTGCCAACAGGAACT TGCCAACAGGAACTG GCCAACAGGAACTGG CCAACAGGAACTGGA CAACAGGAACTGGAC AACAGGAACTGGACC ACAGGAACTGGACCA CAGGAACTGGACCAG AGGAACTGGACCAGG GGA ACTGGACCAGGT GAACTGGACCAGGTC AACTGGACCAGGTCC ACTGGACCAGGTCCCT CTGGACCAGGTCCCTG TGGACCAGGTCCCTGG GGACCAGGTCCCTGGA GACCAGGTCCCTGGAG ACCAGGTCCCTGGAGC CCAGGTCCCTGGAGCG CAGGTCCCTGGAGCGG AGGTCCCTGGAGCGGA GGTCCCTGGAGCGGAT GTCCTGGAGCGGATC TCCTGGAGCGGATCT CCTGGAGCGGATCTC CTGGAGCGGATCTCC TGGAGCGGATCTCCA GGAGCGGATCTCCAC GAGCGGATCTCCACC AGCGGATCTCCACCA GCGGATCTCCACCAT CGGATCTCCACCATG GGATCTCCACCATGC GATCTCCACCATGCG ATCTCCACCATGCGC TCTCCACCATGCGCC CTCCACCATGCGCCT TCCACCATGCGCCTT CCACCATGCGCCTTC CACCATGCGCCTTCC ACCATGCGCCTTCCG CCATGCGCCTTCCGG CATGCGCCTTCCGGA ATGCGCCTTCCGGAT TGCGCCTTCCGGATG GCGCCTTCCGGATGA CGCCTTCCGGATGAG GCCTTCCGGATGAGC CCTTCCGGATGAGCG	CTTCCGGATGAGCGG TTCCGGATGAGCGGG TCCGGATGAGCGGGG CCGGATGAGCGGGGC CGGATGAGCGGGGCC GGATGAGCGGGGCC GATGAGCGGGGCCCT ATGAGCGGGGCCCTC TGAGCGGGGCCCTCT GAGCGGGGCCCTCTG AGCGGGGCCCTCTGG GCGGGGCCCTCTGGA CGGGGCCCTCTGGAG GGGGCCCTCTGGAGC GGGCCCTCTGGAGCA GGCCCTCTGGAGCAC GCCCTCTGGAGCACC CCCTCTGGAGCACCT CCTCTGGAGCACCTC CTCTGGAGCACCTCT TCTGGAGCACCTCTA CTGGAGCACCTCTAC TGGAGCACCTCTACT GGAGCACCTCTACTC GAGCACCTCTACTCC AGCACCTCTACTCCC GCACCTCTACTCCCT CACCTCTACTCCCTG ACCTCTACTCCCTGC CCTCTACTCCCTGCA CTCTACTCCCTGCAC TCTACTCCCTGCACA CTACTCCCTGCACAT TACTCCCTGCACATC ACTCCCTGCACATCC CTCCCTGCACATCCC TCCCTGCACATCCCC CCCTGCACATCCCCA CCTGCACATCCCCAA CTGCACATCCCCAAC TGCACATCCCCAACT GCACATCCCCAACTG CACATCCCCAACTGT ACATCCCCAACTGTG CATCCCCAACTGTGA ATCCCCAACTGTGAC TCCCCAACTGTGACA CCCCAACTGTGACAA CCCAACTGTGACAAG CCA ACTGTGACAAGC CAACTGTGACAAGCA
10	CTGGAGGAGCCCAAG TGGAGGAGCCCAAGA GGAGGAGCCCAAGAA GAGGAGCCCAAGAAG AGGAGCCCAAGAAGC		
15	GGAGCCCAAGAAGCT GAGCCCAAGAAGCTG AGCCCAAGAAGCTGC GCCCAAGAAGCTGCG CCCAAGAAGCTGCGA		
20	CCAAGAAGCTGCGAC CAAGAAGCTGCGACC AAGAAGCTGCGACCA AGAAGCTGCGACCAC GAAGCTGCGACCACC		
25	AAGCTGCGACCACCC AGCTGCGACCACCCC GCTGCGACCACCCC CTGCGACCACCCCCT TGCAGCACCCCCTG		
30	GCGACCACCCCCTGC CGACCACCCCCTGCC GACCACCCCCTGCCA ACCACCCCCCTGCCAG CCACCCCCCTGCCAGG		
35	CACCCCCCTGCCAGGA ACCCCCCTGCCAGGAC CCCCCTGCCAGGACT CCCCTGCCAGGACTC CCCTGCCAGGACTCC		
40	CCTGCCAGGACTCCC CTGCCAGGACTCCCT TGCCAGGACTCCCTG GCCAGGACTCCCTGC CCAGGACTCCCTGCC		
45	CAGGACTCCCTGCCA AGGACTCCCTGCCAA GGACTCCCTGCCAAC GACTCCCTGCCAACA ACTCCCTGCCAACAG		
50	CTCCCTGCCAACAGG TCCCTGCCAACAGGA		

- 40 -

AACTGTGACAAGCAT	AACGGGCAGCGTGGG	ATCCAGGGAGCCCCC
ACTGTGACAAGCATG	ACGGGCAGCGTGGGG	TCCAGGGAGCCCCCA
CTGTGACAAGCATGG	CGGGCAGCGTGGGGA	CCAGGGAGCCCCCAC
TGTGACAAGCATGGC	GGGCAGCGTGGGGAG	CAGGGAGCCCCCACC
5 GTGACAAGCATGGCC	GGCAGCGTGGGGAGT	AGGGAGCCCCCACC
TGACAAGCATGGCCT	GCAGCGTGGGGAGTG	GGGAGCCCCCACCAT
GACAAGCATGGCCTG	CAGCGTGGGGAGTGC	GGAGCCCCCACCATC
ACAAGCATGGCCTGT	AGCGTGGGGAGTGCT	GAGCCCCCACCATCC
CAAGCATGGCCTGTA	GCGTGGGGAGTGCTG	AGCCCCCACCATCCG
10 AAGCATGGCCTGTAC	CGTGGGGAGTGCTGG	GCCCCCACCATCCGG
AGCATGGCCTGTACA	GTGGGGAGTGCTGGT	CCCCCACCATCCGGG
GCATGGCCTGTACAA	TGGGGAGTGCTGGTG	CCCCCACCATCCGGGG
CATGGCCTGTACAAC	GGGGAGTGCTGGTGT	CCCACCATCCGGGGG
ATGGCCTGTACAACC	GGGAGTGCTGGTGTG	CCACCATCCGGGGGG
15 TGGCCTGTACAACCT	GGAGTGCTGGTGTGT	CACCATCCGGGGGGA
GGCCTGTACAACCTC	GAGTGCTGGTGTGTG	ACCATCCGGGGGGAC
GCCTGTACAACCTCA	AGTGCTGGTGTGTGA	CCATCCGGGGGGACC
CCTGTACAACCTCAA	GTGCTGGTGTGTGAA	CATCCGGGGGGACCC
CTGTACAACCTCAAA	TGCTGGTGTGTGAAC	ATCCGGGGGGGACCCC
20 TGTACAACCTCAAAC	GCTGGTGTGTGAACC	TCCGGGGGGGACCCCG
GTACAACCTCAAACA	CTGGTGTGTGAACCC	CCGGGGGGGACCCCGA
TACAACCTCAAACAG	TGGTGTGTGAACCCC	CGGGGGGACCCCGAG
ACAACCTCAAACAGT	GGTGTGTGAACCCCA	GGGGGGACCCCGAGT
CAACCTCAAACAGTG	GTGTGTGAACCCCAA	GGGGGACCCCGAGTG
25 AACCTCAAACAGTGC	TGTGTGAACCCCAAC	GGGGACCCCGAGTGT
ACCTCAAACAGTGCA	GTGTGAACCCCAACA	GGGACCCCGAGTGTC
CCTCAAACAGTGCAA	TGTGAACCCCAACAC	GGACCCCGAGTGTCAT
CTCAAACAGTGCAAG	GTGAACCCCAACACC	GACCCCGAGTGTCATC
TCAAACAGTGCAAGA	TGAACCCCAACACCG	ACCCCGAGTGTCATC
30 CAAACAGTGCAAGAT	GAACCCCAACACCGG	CCCCGAGTGTCATCT
AAACAGTGCAAGATG	AACCCCAACACCGGG	CCCGAGTGTCATCTC
AACAGTGCAAGATGT	ACCCCAACACCGGGA	CCGAGTGTCATCTCT
ACAGTGCAAGATGTC	CCCCAACACCGGGAA	CGAGTGTCATCTCTT
CAGTGCAAGATGTCT	CCCAACACCGGGAAAG	GAGTGTCATCTCTTCT
35 AGTGCAAGATGTCTC	CCAACACCGGGAAAGC	AGTGTCATCTCTTCTA
GTGCAAGATGTCTCT	CAACACCGGGAAAGCT	GTGTCATCTCTTCTAC
TGCAAGATGTCTCTG	AACACCGGGAAAGCTG	GTCATCTCTTCTACAA
GCAAGATGTCTCTGA	ACACCGGGAAAGCTGA	TCATCTCTTCTACAA
CAAGATGTCTCTGAA	CACCGGGAAAGCTGAT	CATCTCTTCTACAAAT
40 AAGATGTCTCTGAAC	ACCGGGAAAGCTGATC	ATCTCTTCTACAAATG
AGATGTCTCTGAACG	CCGGGAAGCTGATCC	TCTCTTCTACAAATGA
GATGTCTCTGAACGG	CGGGAAGCTGATCCA	CTCTTCTACAAATGAG
ATGTCTCTGAACGGG	GGGAAGCTGATCCAG	TCTTCTACAAATGAGC
TGTCTCTGAACGGGC	GGAAGCTGATCCAGG	CTTCTACAAATGAGCA
45 GTCTCTGAACGGGCA	GAAGCTGATCCAGGG	TTCTACAAATGAGCAG
TCTCTGAACGGGCAG	AAGCTGATCCAGGGA	TCTACAAATGAGCAGC
CTCTGAACGGGCAGC	AGCTGATCCAGGGAG	CTACAAATGAGCAGCA
TCTGAACGGGCAGCG	GCTGATCCAGGGAGC	TACAATGAGCAGCAG
CTGAACGGGCAGCGT	CTGATCCAGGGAGCC	TACAATGAGCAGCAGG
50 TGAACGGGCAGCGTG	TGATCCAGGGAGCCC	ACAATGAGCAGCAGG
GAACGGGCAGCGTGG	GATCCAGGGAGCCCC	CAATGAGCAGCAGGA

- 41 -

AATGAGCAGCAGGAG	GCAGCCAGCCGGTGC	GCAGAAAACGGAGAG
ATGAGCAGCAGGAGG	CAGCCAGCCGGTGCC	CAGAAAACGGAGAGT
TGAGCAGCAGGAGGC	AGCCAGCCGGTGCCCT	AGAAAACGGAGAGTG
GAGCAGCAGGAGGCT	GCCAGCCGGTGCCCTG	GAAAACGGAGAGTGCT
5 AGCAGCAGGAGGCTT	CCAGCCGGTGCCCTGG	AAAACGGAGAGTGCTT
GCAGCAGGAGGCTTG	CAGCCGGTGCCCTGGC	AAACGGAGAGTGCTTG
CAGCAGGAGGCTTGCG	AGCCGGTGCCCTGGCG	AACGGAGAGTGCTTGG
AGCAGGAGGCTTGCGG	GCCGGTGCCCTGGCGC	ACGGAGAGTGCTTGGG
GCAGGAGGCTTGCGG	CCGGTGCCCTGGCGCC	CGGAGAGTGCTTGGG
10 CAGGAGGCTTGCGGG	CGGTGCCTGGCGCCC	GGAGAGTGCTTGGGT
AGGAGGCTTGCGGGG	GGTGCCTGGCGCCCC	GAGAGTGCTTGGGTG
GGAGGCTTGCGGGGT	GTGCCTGGCGCCCCCT	AGAGTGCTTGGGTGG
GAGGCTTGCGGGGTG	TGCCTGGCGCCCCCTG	GAGTGCTTGGGTGGT
AGGCTTGCGGGGTGC	GCCTGGCGCCCCCTGC	AGTGCTTGGGTGGTG
15 GGCTTGCGGGGTGCA	CCTGGCGCCCCCTGCC	GTGCTTGGGTGGTG
GCTTGCGGGGTGCAC	CTGGCGCCCCCTGCC	TGCTTGGGTGGTG
CTTGCGGGGTGCACA	TGGCGCCCCCTGCCCC	GCTTGGGTGGTG
TTGCGGGGTGCACAC	GGCGCCCCCTGCCCC	CTTGGGTGGTG
TGCGGGGTGCACACC	GCGCCCCCTGCCCC	TTGGGTGGTG
20 GCGGGGTGCACACCC	CGCCCCCTGCCCCCG	TGGGTGGTG
CGGGGTGCACACCCA	GCCCCCTGCCCCCGC	GGGTGGTG
GGGTGCACACCCAG	CCCCCTGCCCCCGCC	GGTGGTG
GGGTGCACACCCAGC	CCCTGCCCCCGCCC	GTGGTG
GGTGCACACCCAGCG	CCTGCCCCCGCCCC	TGGTG
25 GTGCACACCCAGCGG	CTGCCCCCGCCCCCT	GGTG
TGCACACCCAGCGGA	TGCCCCCGCCCCCTC	GTG
GCACACCCAGCGGAT	GCCCCCGCCCCCTCT	TGG
CACACCCAGCGGATG	CCCCCGCCCCCTCTC	TGGG
ACACCCAGCGGATGC	CCCCCGCCCCCTCTCC	TGGGG
30 CACCCAGCGGATGCA	CCCCGCCCCCTCTCCA	TGGGGT
ACCCAGCGGATGCAG	CCCGCCCCCTCTCCAA	TGGGGTG
CCCAGCGGATGCAGT	CCGCCCTCTCTCCAAA	TGGGGTGCT
CCAGCGGATGCAGTA	CGCCCCCTCTCCAAAC	TGGGGTGCTGGA
CAGCGGATGCAGTAG	GCCCCCTCTCCAAACA	TGGGGTGCTGGAG
35 AGCGGATGCAGTAGA	CCCCTCTCCAAACAC	GTGGGTGCTGGAGGA
GCGGATGCAGTAGAC	CCCTCTCCAAACACC	TGGGTGCTGGAGGA
CGGATGCAGTAGACC	CCTCTCCAAACACCG	TGGGTGCTGGAGGAT
GGATGCAGTAGACCG	CTCTCCAAACACCGG	GGGTGCTGGAGGATT
GATGCAGTAGACCGC	TCTCCAAACACCGGC	GGTGCTGGAGGATTT
40 ATGCAGTAGACCGCA	CTCCAAACACCGGCA	GTGCTGGAGGATTTT
TGCAGTAGACCGCAG	TCCAAACACCGGCAG	TGCTGGAGGATTTTC
GCAGTAGACCGCAGC	CCAAACACCGGCAGA	GCTGGAGGATTTTCC
CAGTAGACCGCAGCC	CAAACACCGGCAGAA	CTGGAGGATTTTCCA
AGTAGACCGCAGCCA	AAACACCGGCAGAAA	TGGAGGATTTTCCAG
45 GTAGACCGCAGCCAG	AACACCGGCAGAAAA	GGAGGATTTTCCAGT
TAGACCGCAGCCAGC	ACACCGGCAGAAAAAC	GAGGATTTTCCAGTT
AGACCGCAGCCAGCC	CACCGGCAGAAAAACG	AGGATTTTCCAGTTC
GACCGCAGCCAGCCG	ACCGGCAGAAAAACGG	GGATTTTCCAGTTCT
ACCGCAGCCAGCCGG	CCGGCAGAAAAACGGA	GATTTTCCAGTTCTG
50 CCGCAGCCAGCCGGT	CGGCAGAAAAACGGAG	ATTTTCCAGTTCTGA
CGCAGCCAGCCGGTG	GGCAGAAAACGGAGA	TTTTCCAGTTCTGAC
		TTTCCAGTTCTGACA
		TTCCAGTTCTGACAC
		TCCAGTTCTGACACA
		CCAGTTCTGACACAC
		CAGTTCTGACACACG
		AGTTCTGACACACGT
		GTTCTGACACACGTA
		TTCTGACACACGTAT
		TCTGACACACGTATT
		CTGACACACGTATTT

TGACACACGTAATTTA
 GACACACGTAATTTAT
 ACACACGTAATTTATA
 CACACGTAATTTATAT
 5 ACACGTAATTTATATT
 CACGTAATTTATATTT
 ACGTAATTTATATTTG
 CGTAATTTATATTTGG
 GTATTTATATTTGGG
 10 TATTTATATTTGGAA
 ATTTATATTTGGAAA
 TTTATATTTGGAAAG
 TTATATTTGGAAAGA
 TATATTTGGAAAGAG
 15 ATATTTGGAAAGAGA
 TATTTGGAAAGAGAC
 ATTTGGAAAGAGACC
 TTTGGAAAGAGACCA
 TTGGAAAGAGACCAG
 20 TGGAAAGAGACCAGC
 GGAAAGAGACCAGCA
 GAAAGAGACCAGCAC
 AAAGAGACCAGCACC
 AAGAGACCAGCACC
 25 AGAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 30 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 35 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 40 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 45 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 50 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC
 GAGACCAGCACC

CCGGGCCTCTCTCTTT
 CCGGCCTCTCTCTTC
 CGGCCTCTCTCTTCC
 GGCCTCTCTCTTCCC
 GCCTCTCTCTTCCCA
 CCTCTCTCTTCCAG
 CTCTCTCTTCCCAGC
 TCTCTCTTCCCAGCT
 CTCTCTTCCCAGCTC
 TCTCTTCCCAGCTGC
 CTCTTCCCAGCTGCA
 TCTTCCCAGCTGCAG
 CTTCCCAGCTGCAGA
 TTCCCAGCTGCAGAT
 TCCCAGCTGCAGATG
 CCCAGCTGCAGATGC
 CCAGCTGCAGATGCC
 CAGCTGCAGATGCCA
 AGCTGCAGATGCCAC
 GCTGCAGATGCCACA
 CTGCAGATGCCACAC
 TGCAGATGCCACACC
 GCAGATGCCACACCT
 CAGATGCCACACCTG
 AGATGCCACACCTGC
 GATGCCACACCTGCT
 ATGCCACACCTGCTC
 TGCCACACCTGCTCC
 GCCACACCTGCTCCT
 CCACACCTGCTCCTT
 CACACCTGCTCCTTC
 ACACCTGCTCCTTCT
 CACCTGCTCCTTCTT
 ACCTGCTCCTTCTTG
 CCTGCTCCTTCTTGC
 CTGCTCCTTCTTGCT
 TGCTCCTTCTTGCTT
 GCTCCTTCTTGCTTT
 CTCCTTCTTGCTTTC
 TCCTTCTTGCTTTCC
 CCTTCTTGCTTTCCC
 TTTCTTGCTTTCCCC
 TCTTGCTTTCCCCCG
 TCTTGCTTTCCCCGG
 TTGCTTTCCCCGGGG
 TGCTTTCCCCGGGGG
 GCTTTCCCCGGGGGA
 CTTTCCCCGGGGGAG
 TTTCCCCGGGGGAGG
 TTCCCCGGGGGAGGA

TCCCCGGGGGAGGAA
CCCCGGGGGAGGAAG
CCCCGGGGGAGGAAGG
CCGGGGGAGGAAGGG
CGGGGGAGGAAGGGG
GGGGGAGGAAGGGGG
GGGGAGGAAGGGGGT
GGGAGGAAGGGGGTT
GGAGGAAGGGGGTTT
GAGGAAGGGGGTTGT
AGGAAGGGGGTTGTG
GGAAGGGGGTTGTGG
GAAGGGGGTTGTGGT
AAGGGGGTTGTGGTC
AGGGGGTTGTGGTCG
GGGGGTTGTGGTCGG
GGGGTTGTGGTCGGG
GGGTTGTGGTCGGGG
GTTGTGGTCGGGGAG
TTGTGGTCGGGGAGC
TGTGGTCGGGGAGCT
GTGGTCGGGGAGCTG
TGGTCGGGGAGCTGG
GGTCGGGGAGCTGGG
GTCGGGGAGCTGGGG
TCGGGGAGCTGGGGT
CGGGGAGCTGGGGTA
GGGGAGCTGGGGTAC
GGGAGCTGGGGTACA
GGAGCTGGGGTACAG
GAGCTGGGGTACAGG
AGCTGGGGTACAGGT
GCTGGGGTACAGGTT
CTGGGGTACAGGTTT
TGGGGTACAGGTTTG
GGGGTACAGGTTTGG
GGGTACAGGTTTGGG
GGTACAGGTTTGGGG
GTACAGGTTTGGGGA
TACAGGTTTGGGGAG
ACAGGTTTGGGGAGG
CAGGTTTGGGGAGGG
AGGTTTGGGGAGCGG
GGTTTGGGGAGCGGG
GTTTGGGGAGGGGGA
TTTGGGGAGGGGGAA
TTGGGGAGGGGGAAAG
TGGGGAGGGGGGAAGA
GGGGAGGGGGGAAGAG
GGGAGGGGGGAAGAG

- 43 -

GGAGGGGGAAGAGAA	AGATTAAAGGAAGGA
GAGGGGGAAGAGAAA	GATTAAAGGAAGGAA
AGGGGGAAGAGAAAT	ATTAAAGGAAGGAAA
GGGGGAAGAGAAATT	TTAAAGGAAGGAAAA
5 GGGGAAGAGAAATTT	TAAAGGAAGGAAAAG
GGGAAGAGAAATTTT	AAAGGAAGGAAAAGT
GGAAGAGAAATTTTT	
GAAGAGAAATTTTTA	
AAGAGAAATTTTTAT	
10 AGAGAAATTTTTATT	
GAGAAATTTTTATTT	
AGAAATTTTTATTTT	
GAAATTTTTATTTTT	
AAATTTTTATTTTTG	
15 AATTTTTATTTTTGA	
ATTTTTATTTTTGAA	
TTTTTATTTTTGAAC	
TTTTATTTTTGAACC	
TTTATTTTTGAACCC	
20 TTATTTTTGAACCCC	
TATTTTTGAACCCCT	
ATTTTTGAACCCCTG	
TTTTTGAACCCCTGT	
TTTTGAACCCCTGTG	
25 TTTGAACCCCTGTGT	
TTGAACCCCTGTGTC	
TGAACCCCTGTGTCC	
GAACCCCTGTGTCCC	
AACCCCTGTGTCCCT	
30 ACCCCTGTGTCCCTT	
CCCCTGTGTCCCTTT	
CCCTGTGTCCCTTTT	
CCTGTGTCCCTTTTG	
CTGTGTCCCTTTTGC	
35 TGTGTCCCTTTTGCA	
GTGTCCCTTTTG CAT	
TGTCCCTTTTG CATA	
GTCCCTTTTG CATAA	
TCCCTTTTG CATAAG	
40 CCCTTTTG CATAAGA	
CCTTTGCATAAGAT	
CTTTTGCATAAGATT	
TTTTGCATAAGATTA	
TTTGCATAAGATTAA	
45 TTGCATAAGATTAAA	
TGCATAAGATTAAAG	
GCATAAGATTAAAGG	
CATAAGATTAAAGGA	
ATAAGATTAAAGGAA	
50 TAAGATTAAAGGAAG	
AAGATTAAAGGAAGG	

- 44 -

EXAMPLE 7

Antisense oligonucleotides to IGFBP3 may be selected from molecules capable of interacting

5 with one or more of the following sense oligonucleotides:

CTCAGCGCCCAGCCG	GCCGTGTA CTGTGCGC	GCAGCGTGCCCCGGT
TCAGCGCCCAGCCGC	CCGTGTA CTGTGCGCC	CAGCGTGCCCCGGTT
CAGCGCCCAGCCGCT	CGTGTA CTGTGCGCCC	AGCGTGCCCCGGTTG
10 AGCGCCCAGCCGCTT	GTGTA CTGTGCGCCCC	GCGTGCCCCGGTTGC
GCGCCCAGCCGCTTC	TGTA CTGTGCGCCCCA	CGTGCCCCGGTTGCA
CGCCCAGCCGCTTCC	GTACTGTGCGCCCCAT	GTGCCCCGGTTGCAG
GCCCAGCCGCTTCCT	TACTGTGCGCCCCATC	TGCCCCGGTTGCAGG
CCCAGCCGCTTCCTG	ACTGTGCGCCCCATCC	GCCCCGGTTGCAGGC
15 CCAGCCGCTTCCTGC	CTGTGCGCCCCATCCC	CCCCGGTTGCAGGCG
CAGCCGCTTCCTGCC	TGTGCGCCCCATCCCT	CCCGGTTGCAGGCGT
AGCCGCTTCCTGCCT	GTCGCCCCATCCCTG	CCGGTTGCAGGCGTC
GCCGCTTCCTGCCTG	TCGCCCCATCCCTGC	CGGTTGCAGGCGTCA
CCGCTTCCTGCCTGG	CGCCCCATCCCTGCG	GGTTGCAGGCGTCAT
20 CGCTTCCTGCCTGGA	GCCCCATCCCTGCGC	GTTGCAGGCGTCATG
GCTTCCTGCCTGGAT	CCCCATCCCTGCGCG	TTGCAGGCGTCATGC
CTTCCTGCCTGGATT	CCATCCCTGCGCGC	TGCAGGCGTCATGCA
TTCCTGCCTGGATTCC	CCATCCCTGCGCGCC	GCAGGCGTCATGCAG
TCCTGCCTGGATTCC	CATCCCTGCGCGCCC	CAGGCGTCATGCAGC
25 CCTGCCTGGATTCCA	ATCCCTGCGCGCCCA	AGGCGTCATGCAGCG
CTGCCTGGATTCCAC	TCCCTGCGCGCCAG	GGCGTCATGCAGCGG
TGCCTGGATTCCACA	CCCTGCGCGCCAGC	GCGTCATGCAGCGGG
GCCTGGATTCCACAG	CCTGCGCGCCAGCC	CGTCATGCAGCGGGC
CCTGGATTCCACAGC	CTGCGCGCCAGCCT	GTCATGCAGCGGGCG
30 CTGGATTCCACAGCT	TGCGCGCCAGCCTG	TCATGCAGCGGGCGC
TGGATTCCACAGCTT	GCGCGCCAGCCTGC	CATGCAGCGGGCGCG
GGATTCCACAGCTTC	CGCGCCAGCCTGCC	ATGCAGCGGGCGCGA
GATTCCACAGCTTCG	GCGCCAGCCTGCCA	TGCAGCGGGCGCGAC
ATTCCACAGCTTCGC	CGCCAGCCTGCCAA	GCAGCGGGCGCGACC
35 TTCCACAGCTTCGCG	GCCAGCCTGCCAAG	CAGCGGGCGCGACCC
TCCACAGCTTCGCGC	CCCAGCCTGCCAAGC	AGCGGGCGCGACCCA
CCACAGCTTCGCGCC	CCAGCCTGCCAAGCA	GCGGGCGCGACCCAC
CACAGCTTCGCGCCG	CAGCCTGCCAAGCAG	CGGGCGCGACCCACG
ACAGCTTCGCGCCGT	AGCCTGCCAAGCAGC	GGGCGCGACCCACGC
40 CAGCTTCGCGCCGTG	GCCTGCCAAGCAGCG	GGCGCGACCCACGCT
AGCTTCGCGCCGTGT	CCTGCCAAGCAGCGT	GCGCGACCCACGCTC
GCTTCGCGCCGTGTA	CTGCCAAGCAGCGTG	CGCGACCCACGCTCT
CTTCGCGCCGTGTAC	TGCCAAGCAGCGTGC	GCGACCCACGCTCTG
TTCGCGCCGTGTACT	GCCAAGCAGCGTGCC	CGACCCACGCTCTGG
45 TCGCGCCGTGTACTG	CCAAGCAGCGTGCCC	GACCCACGCTCTGGG
CGCGCCGTGTACTGT	CAAGCAGCGTGCCCC	ACCCACGCTCTGGGC
GCGCCGTGTACTGTC	AAGCAGCGTGCCCCG	CCCACGCTCTGGGCC
CGCCGTGTACTGTGC	AGCAGCGTGCCCCGG	CCACGCTCTGGGCCG

- 45 -

CACGCTCTGGGCCGCG	GGTGGCGCGGGCTGG	CGAGCCGTGCGACGC
ACGCTCTGGGCCGCT	GTGGCGCGGGCTGGC	GAGCCGTGCGACGCG
CGCTCTGGGCCGCTG	TGGCGCGGGCTGGCG	AGCCGTGCGACGCGC
GCTCTGGGCCGCTGC	GGCGCGGGCTGGCGC	GCCGTGCGACGCGCG
5 CTCTGGGCCGCTGCG	GCGCGGGCTGGCGCG	CCGTGCGACGCGCGT
TCTGGGCCGCTGCGC	CGCGGGCTGGCGCGA	CGTGCACGCGCGTG
CTGGGCCGCTGCGCT	GCGGGCTGGCGCGAG	GTGCGACGCGCGTGC
TGGGCCGCTGCGCTG	CGGGCTGGCGCGAGC	TGCGACGCGCGTGCA
GGGCCGCTGCGCTGA	GGGCTGGCGCGAGCT	GCGACGCGCGTGAC
10 GGCCGCTGCGCTGAC	GGCTGGCGCGAGCTC	CGACGCGCGTGCACT
GCCGCTGCGCTGACT	GCTGGCGCGAGCTCG	GACGCGCGTGCACTG
CCGCTGCGCTGACTC	CTGGCGCGAGCTCGG	ACGCGCGTGCACTGG
CGCTGCGCTGACTCT	TGGCGCGAGCTCGGG	CGCGCGTGCACTGGC
GCTGCGCTGACTCTG	GGCGCGAGCTCGGGG	GCGCGTGCACTGGCC
15 CTGCGCTGACTCTGC	GCGCGAGCTCGGGGG	CGCGTGCACTGGCCC
TGCGCTGACTCTGCT	CGCGAGCTCGGGGGG	GCGTGCACTGGCCCA
GCGCTGACTCTGCTG	GCGAGCTCGGGGGGCT	CGTGCACTGGCCCAAG
CGCTGACTCTGCTGG	CGAGCTCGGGGGGCTT	GTGCACTGGCCCAAGT
GCTGACTCTGCTGGT	GAGCTCGGGGGGCTTG	TGCACTGGCCCAAGTG
20 CTGACTCTGCTGGTG	AGCTCGGGGGGCTTGG	GCACTGGCCCAAGTGC
TGACTCTGCTGGTGCT	GCTCGGGGGGCTTGGG	CACTGGCCCAAGTGCG
GACTCTGCTGGTGCT	CTCGGGGGGCTTGGG	ACTGGCCCAAGTGCGC
ACTCTGCTGGTGCTG	TCGGGGGGGCTTGGGT	CTGGCCCAAGTGCGCG
CTCTGCTGGTGCTGC	CGGGGGGCTTGGGTCC	TGGCCCAAGTGCGCGC
25 TCTGCTGGTGCTGCT	GGGGGGGCTTGGGTCCC	GGCCCAAGTGCGCGCC
CTGCTGGTGCTGCTC	GGGGGCTTGGGTCCCC	GCCCAAGTGCGCGCCT
TGCTGGTGCTGCTCC	GGGGCTTGGGTCCCCG	CCCAGTGCGCGCCTC
GCTGGTGCTGCTCCG	GGGCTTGGGTCCCCGT	CCAGTGCGCGCCTCC
CTGGTGCTGCTCCGC	GGCTTGGGTCCCCGTG	CAGTGCGCGCCTCCG
30 TGGTGCTGCTCCGCG	GCTTGGGTCCCCGTGG	AGTGCGCGCCTCCGC
GGTGCTGCTCCGCGG	CTTGGGTCCCCGTGGT	GTGCGCGCCTCCGCC
GTGCTGCTCCGCGGG	TTGGGTCCCCGTGGTG	TGCGCGCCTCCGCCC
TGCTGCTCCGCGGGC	TGGGTCCCCGTGGTGC	GCGCGCCTCCGCCCG
GCTGCTCCGCGGGCC	GGGTCCCCGTGGTGCG	CGCGCCTCCGCCCGC
35 CTGCTCCGCGGGCCG	GGTCCCCGTGGTGCGC	GCGCCTCCGCCCGCC
TGCTCCGCGGGCCGC	GTCCCCGTGGTGCGCT	CGCCTCCGCCCGCCG
GCTCCGCGGGCCGCC	TCCCCGTGGTGCGCTG	GCCTCCGCCCGCCGT
CTCCGCGGGCCGCCG	CCCGTGGTGCGCTGC	CCTCCGCCCGCCGTG
TCCGCGGGCCGCCCG	CCGTGGTGCGCTGCG	CTCCGCCCGCCGTGT
40 CCGCGGGCCGCCCGGT	CGTGGTGCGCTGCGA	TCCGCCCGCCGTGTG
CGCGGGCCGCCCGTG	GTGGTGCGCTGCGAG	CCGCCCGCCGTGTGC
GCGGGCCGCCCGGTGG	TGGTGCGCTGCGAGC	CGCCCGCCGTGTGCG
CGGGCCGCCCGGTGGC	GGTGCGCTGCGAGCC	GCCCGCCGTGTGCGC
GGGCCCGCCCGGTGGCG	GTGCGCTGCGAGCCG	CCCGCCGTGTGCGCG
45 GGCCGCCCGGTGGCGC	TGCGCTGCGAGCCGT	CCGCCGTGTGCGCGG
GCCGCCCGGTGGCGCG	GCGCTGCGAGCCGTG	CGCCGTGTGCGCGGA
CCGCCCGGTGGCGCGG	CGCTGCGAGCCGTGC	GCCGTGTGCGCGGAG
CGCCCGGTGGCGCGGG	GCTGCGAGCCGTGCG	CCGTGTGCGCGGAGC
GCCGGTGGCGCGGGC	CTGCGAGCCGTGCGA	CGTGTGCGCGGAGCT
50 CCGGTGGCGCGGGCT	TGCGAGCCGTGCGAC	GTGTGCGCGGAGCTG
CGGTGGCGCGGGCTG	GCGAGCCGTGCGACG	TGTGCGCGGAGCTGG

- 46 -

GTGCGCGGAGCTGGT	ACTGAGCGAGGGCCA	CCTTCGCTGCCAGCC
TGCGCGGAGCTGGTG	CTGAGCGAGGGCCAG	CTTCGCTGCCAGCCG
GCGCGGAGCTGGTGC	TGAGCGAGGGCCAGC	TTCGCTGCCAGCCGT
CGCGGAGCTGGTGCG	GAGCGAGGGCCAGCC	TCGCTGCCAGCCGTC
5 GCGGAGCTGGTGCGC	AGCGAGGGCCAGCCG	CGCTGCCAGCCGTCG
CGGAGCTGGTGCGCG	GCGAGGGCCAGCCGT	GCTGCCAGCCGTCGC
GGAGCTGGTGCGCGA	CGAGGGCCAGCCGTG	CTGCCAGCCGTCGCC
GAGCTGGTGCGCGAG	GAGGGCCAGCCGTGC	TGCCAGCCGTCGCCC
AGCTGGTGCGCGAGC	AGGGCCAGCCGTGCG	GCCAGCCGTCGCCC
10 GCTGGTGCGCGAGCC	GGGCCAGCCGTGCGG	CCAGCCGTCGCCCCA
CTGGTGCGCGAGCCG	GGCCAGCCGTGCGGC	CAGCCGTCGCCCCGAC
TGGTGCGCGAGCCGG	GCCAGCCGTGCGGCA	AGCCGTCGCCCCGACG
GGTGCGCGAGCCGGG	CCAGCCGTGCGGCAT	GCCGTCGCCCCGACGA
GTGCGCGAGCCGGGC	CAGCCGTGCGGCATC	CCGTCGCCCCGACGAG
15 TGCGCGAGCCGGGCT	AGCCGTGCGGCATCT	CGTCGCCCCGACGAGG
GCGCGAGCCGGGCTG	GCCGTGCGGCATCTA	GTGCCCCGACGAGGC
CGCGAGCCGGGCTGC	CCGTGCGGCATCTAC	TCGCCCCGACGAGGCG
GCGAGCCGGGCTGCG	CGTGCGGCATCTACA	CGCCCCGACGAGGCGC
CGAGCCGGGCTGCGG	GTGCGGCATCTACAC	GCCCCGACGAGGCGCG
20 GAGCCGGGCTGCGGC	TGCGGCATCTACACC	CCCGACGAGGCGCGA
AGCCGGGCTGCGGCT	GCGGCATCTACACCG	CCGACGAGGCGCGAC
GCCGGGCTGCGGCTG	CGGCATCTACACCGA	CGACGAGGCGCGACC
CCGGGCTGCGGCTGC	GGCATCTACACCGAG	GACGAGGCGCGACCG
CGGGCTGCGGCTGCT	GCATCTACACCGAGC	ACGAGGCGCGACCGC
25 GGGCTGCGGCTGCTG	CATCTACACCGAGCG	CGAGGCGCGACCGCT
GGCTGCGGCTGCTGC	ATCTACACCGAGCGC	GAGGCGCGACCGCTG
GCTGCGGCTGCTGCC	TCTACACCGAGCGCT	AGGCGCGACCGCTGC
CTGCGGCTGCTGCCT	CTACACCGAGCGCTG	GGCGCGACCGCTGCA
TGCGGCTGCTGCCTG	TACACCGAGCGCTGT	GCGCGACCGCTGCAG
30 GCGGCTGCTGCCTGA	ACACCGAGCGCTGTG	CGCGACCGCTGCAGG
CGGCTGCTGCCTGAC	CACCGAGCGCTGTGG	GCGACCGCTGCAGGC
GGCTGCTGCCTGACG	ACCGAGCGCTGTGGC	CGACCGCTGCAGGCG
GCTGCTGCCTGACGT	CCGAGCGCTGTGGCT	GACCGCTGCAGGCGC
CTGCTGCCTGACGTG	CGAGCGCTGTGGCTC	ACCGCTGCAGGCGCT
35 TGCTGCCTGACGTGC	GAGCGCTGTGGCTCC	CCGCTGCAGGCGCTG
GCTGCCTGACGTGCG	AGCGCTGTGGCTCCG	CGCTGCAGGCGCTGC
CTGCCTGACGTGCGC	GCGCTGTGGCTCCGG	GCTGCAGGCGCTGCT
TGCCTGACGTGCGCA	CGCTGTGGCTCCGGC	CTGCAGGCGCTGCTG
GCCTGACGTGCGCAC	GCTGTGGCTCCGGCC	TGCAGGCGCTGCTGG
40 CCTGACGTGCGCACT	CTGTGGCTCCGGCCT	GCAGGCGCTGCTGGA
CTGACGTGCGCACTG	TGTGGCTCCGGCCTT	CAGGCGCTGCTGGAC
TGACGTGCGCACTGA	GTGGCTCCGGCCTTC	AGGCGCTGCTGGACG
GACGTGCGCACTGAG	TGGCTCCGGCCTTCG	GGCGCTGCTGGACGG
ACGTGCGCACTGAGC	GGCTCCGGCCTTCGC	GCGCTGCTGGACGGC
45 CGTGCGCACTGAGCG	GCTCCGGCCTTCGCT	CGCTGCTGGACGGCC
GTGCGCACTGAGCGA	CTCCGGCCTTCGCTG	GCTGCTGGACGGCCG
TGCGCACTGAGCGAG	TCCGGCCTTCGCTGC	CTGCTGGACGGCCGC
GCGCACTGAGCGAGG	CCGGCCTTCGCTGCC	TGCTGGACGGCCGCG
CGCACTGAGCGAGGG	CGGCCTTCGCTGCCA	GCTGGACGGCCGCGG
50 GCACTGAGCGAGGGC	GGCCTTCGCTGCCAG	CTGGACGGCCGCGGG
CACTGAGCGAGGGCC	GCCTTCGCTGCCAGC	TGGACGGCCGCGGGC

- 47 -

GGACGGCCGCGGGCT	CTACCTGCTGCCAGC	AGACCGCAGCGCCGG
GACGGCCGCGGGCTC	TACCTGCTGCCAGCG	GACCGCAGCGCCGGC
ACGGCCGCGGGCTCT	ACCTGCTGCCAGCGC	ACCGCAGCGCCGGCA
CGGCCGCGGGCTCTG	CCTGCTGCCAGCGCC	CCGCAGCGCCGGCAG
5 GGCCGCGGGCTCTGC	CTGCTGCCAGCGCCG	CGCAGCGCCGGCAGT
GCCGCGGGCTCTGCG	TGCTGCCAGCGCCGC	GCAGCGCCGGCAGTG
CCGCGGGCTCTGCGT	GCTGCCAGCGCCGCC	CAGCGCCGGCAGTGT
CGCGGGCTCTGCGTC	CTGCCAGCGCCGCCA	AGCGCCGGCAGTGTG
GCGGGCTCTGCGTCA	TGCCAGCGCCGCCAG	GCGCCGGCAGTGTGG
10 CGGGCTCTGCGTCAA	GCCAGCGCCGCCAGC	CGCCGGCAGTGTGGA
GGGCTCTGCGTCAAC	CCAGCGCCGCCAGCT	GCCGGCAGTGTGGAG
GGCTCTGCGTCAACG	CAGCGCCGCCAGCTC	CCGGCAGTGTGGAGA
GCTCTGCGTCAACGC	AGCGCCGCCAGCTCC	CGGCAGTGTGGAGAG
CTCTGCGTCAACGCT	GCGCCGCCAGCTCCA	GGCAGTGTGGAGAGC
15 TCTGCGTCAACGCTA	CGCCGCCAGCTCCAG	GCAGTGTGGAGAGCC
CTGCGTCAACGCTAG	GCCGCCAGCTCCAGG	CAGTGTGGAGAGCCC
TGCGTCAACGCTAGT	CCGCCAGCTCCAGGA	AGTGTGGAGAGCCCG
GCGTCAACGCTAGTG	CGCCAGCTCCAGGAA	GTGTGGAGAGCCCGT
CGTCAACGCTAGTGC	GCCAGCTCCAGGAAA	TGTGGAGAGCCCGTC
20 GTCAACGCTAGTGCC	CCAGCTCCAGGAAAT	GTGGAGAGCCCGTCC
TCAACGCTAGTGCCG	CAGCTCCAGGAAATG	TGGAGAGCCCGTCCG
CAACGCTAGTGCCGT	AGCTCCAGGAAATGC	GGAGAGCCCGTCCGT
AACGCTAGTGCCGTC	GCTCCAGGAAATGCT	GAGAGCCCGTCCGTC
ACGCTAGTGCCGTCA	CTCCAGGAAATGCTA	AGAGCCCGTCCGTCT
25 CGTAGTGCCGT CAG	TCCAGGAAATGCTAG	GAGCCCGTCCGTCTC
GCTAGTGCCGT CAGC	CCAGGAAATGCTAGT	AGCCCGTCCGTCTCC
CTAGTGCCGT CAGCC	CAGGAAATGCTAGTG	GCCCGTCCGTCTCCA
TAGTGCCGT CAGCCG	AGGAAATGCTAGTGA	CCGTCCGTCTCCAGC
AGTGCCGT CAGCCGC	GGAAATGCTAGTGAGT	CGTCCGTCTCCAGCA
30 GTGCCGT CAGCCGCC	GAAATGCTAGTGAGT	GTCCGTCTCCAGCAC
TGCCGT CAGCCGCCT	AAATGCTAGTGAGTC	TCCGTCTCCAGCACG
GCCGT CAGCCGCCTG	AATGCTAGTGAGTCG	CCGTCTCCAGCACGC
CCGT CAGCCGCCTGCG	ATGCTAGTGAGTCGG	CGTCTCCAGCACGCA
35 GT CAGCCGCCTGCGC	TGCTAGTGAGTCGGA	GTCTCCAGCACGCAC
TCAGCCGCCTGCGCG	GCTAGTGAGTCGGAG	TCTCCAGCACGCACC
CAGCCGCCTGCGCGC	CTAGTGAGTCGGAGG	CTCCAGCACGCACCG
AGCCGCCTGCGCGCC	TAGTGAGTCGGAGGA	TCCAGCACGCACCGG
GCCGCCTGCGCGCCT	AGTGAGTCGGAGGAA	CCAGCACGCACCGGG
40 CCGCCTGCGCGCCTA	GTGAGTCGGAGGAAG	CAGCACGCACCGGGT
CGCCTGCGCGCCTAC	TGAGTCGGAGGAAGA	AGCACGCACCGGGTG
GCCTGCGCGCCTACC	GAGTCGGAGGAAGAC	GCACGCACCGGGTGT
CCTGCGCGCCTACCT	AGTCGGAGGAAGACC	CACGCACCGGGTGTG
CTGCGCGCCTACCTG	GTCGGAGGAAGACCG	ACGCACCGGGTGTCT
45 TGCGCGCCTACCTGC	TCGGAGGAAGACCGC	CGCACCGGGTGTCTG
GCGCGCCTACCTGCT	CGGAGGAAGACCGCA	GCACCGGGTGTCTGA
CGCGCCTACCTGCTG	GGAGGAAGACCGCAG	CACCGGGTGTCTGAT
GCGCCTACCTGCTGC	GAGGAAGACCGCAGC	ACCGGGTGTCTGATC
CGCCTACCTGCTGCC	AGGAAGACCGCAGCG	CCGGGTGTCTGATCC
50 GCCTACCTGCTGCCA	GGAAGACCGCAGCGC	CGGGTGTCTGATCCC
CCTACCTGCTGCCAG	GAAGACCGCAGCGCC	GGGTGTCTGATCCCA
	AAGACCGCAGCGCCG	

- 48 -

GGTGTCTGATCCCAA	GAAAGGGCATGCTAA	GAGCACAGATACCCA
GTGTCTGATCCCAAG	AAAGGGCATGCTAAA	AGCACAGATACCCAG
TGTCTGATCCCAAGT	AAGGGCATGCTAAAG	GCACAGATACCCAGA
GTCTGATCCCAAGTT	AGGGCATGCTAAAGA	CACAGATACCCAGAA
5 TCTGATCCCAAGTTC	GGGCATGCTAAAGAC	ACAGATACCCAGAAC
CTGATCCCAAGTTCC	GGCATGCTAAAGACA	CAGATACCCAGAACT
TGATCCCAAGTTCCA	GCATGCTAAAGACAG	AGATACCCAGAACTT
GATCCCAAGTTCCAC	CATGCTAAAGACAGC	GATACCCAGAACTTC
ATCCCAAGTTCCACC	ATGCTAAAGACAGCC	ATACCCAGAACTTCT
10 TCCCAAGTTCCACCC	TGCTAAAGACAGCCA	TACCCAGAACTTCTC
CCCAAGTTCCACCCC	GCTAAAGACAGCCAG	ACCCAGAACTTCTCC
CCAAGTTCCACCCCC	CTAAAGACAGCCAGC	CCCAGAACTTCTCCT
CAAGTTCCACCCCCT	TAAAGACAGCCAGCG	CCAGAACTTCTCCTC
AAGTTCCACCCCCTC	AAAGACAGCCAGCGC	CAGAACTTCTCCTCC
15 AGTTCCACCCCCTCC	AAGACAGCCAGCGCT	AGAACTTCTCCTCCG
GTTCCACCCCCTCCA	AGACAGCCAGCGCTA	GAACTTCTCCTCCGA
TTCCACCCCCTCCAT	GACAGCCAGCGCTAC	AACTTCTCCTCCGAG
TCCACCCCCTCCATT	ACAGCCAGCGCTACA	ACTTCTCCTCCGAGT
CCACCCCCTCCATTC	CAGCCAGCGCTACAA	CTTCTCCTCCGAGTC
20 CACCCCCTCCATTCA	AGCCAGCGCTACAAA	TTCTCCTCCGAGTCC
ACCCCCTCCATTCAA	GCCAGCGCTACAAAG	TCTCCTCCGAGTCCA
CCCCCTCCATTCAAA	CCAGCGCTACAAAGT	CTCCTCCGAGTCCAA
CCCCTCCATTCAAAG	CAGCGCTACAAAGTT	TCCTCCGAGTCCAAG
CCCTCCATTCAAAGA	AGCGCTACAAAGTTG	CCTCCGAGTCCAAGC
25 CCTCCATTCAAAGAT	GCGCTACAAAGTTGA	CTCCGAGTCCAAGCG
CTCCATTCAAAGATA	CGCTACAAAGTTGAC	TCCGAGTCCAAGCGG
TCCATTCAAAGATAA	GCTACAAAGTTGACT	CCGAGTCCAAGCGGG
CCATTCAAAGATAAT	CTACAAAGTTGACTA	CGAGTCCAAGCGGGA
CATTCAAAGATAATC	TACAAAGTTGACTAC	GAGTCCAAGCGGGAG
30 ATTCAAAGATAATCA	ACAAAGTTGACTACG	AGTCCAAGCGGGAGA
TTCAAAGATAATCAT	CAAAGTTGACTACGA	GTCCAAGCGGGAGAC
TCAAAGATAATCATC	AAAGTTGACTACGAG	TCCAAGCGGGAGACA
CAAAGATAATCATCA	AAGTTGACTACGAGT	CCAAGCGGGAGACAG
AAAGATAATCATCAT	AGTTGACTACGAGTC	CAAGCGGGAGACAGA
35 AAGATAATCATCATC	GTTGACTACGAGTCT	AAGCGGGAGACAGAA
AGATAATCATCATCA	TTGACTACGAGTCTC	AGCGGGAGACAGAAT
GATAATCATCATCAA	TGACTACGAGTCTCA	GCGGGAGACAGAATA
ATAATCATCATCAAG	GACTACGAGTCTCAG	CGGGAGACAGAATAT
TAATCATCATCAAGA	ACTACGAGTCTCAGA	GGGAGACAGAATATG
40 AATCATCATCAAGAA	CTACGAGTCTCAGAG	GGAGACAGAATATGG
ATCATCATCAAGAAA	TACGAGTCTCAGAGC	GAGACAGAATATGGT
TCATCATCAAGAAAG	ACGAGTCTCAGAGCA	AGACAGAATATGGTC
CATCATCAAGAAAGG	CGAGTCTCAGAGCAC	GACAGAATATGGTCC
ATCATCAAGAAAGGG	GAGTCTCAGAGCACA	ACAGAATATGGTCCC
45 TCATCAAGAAAGGGC	AGTCTCAGAGCACAG	CAGAATATGGTCCCT
CATCAAGAAAGGGCA	GTCTCAGAGCACAGA	AGAATATGGTCCCTG
ATCAAGAAAGGGCAT	TCTCAGAGCACAGAT	GAATATGGTCCCTGC
TCAAGAAAGGGCATG	CTCAGAGCACAGATA	AATATGGTCCCTGCC
CAAGAAAGGGCATGC	TCAGAGCACAGATAC	ATATGGTCCCTGCCG
50 AAGAAAGGGCATGCT	CAGAGCACAGATACC	TATGGTCCCTGCCGT
AGAAAGGGCATGCTA	AGAGCACAGATACCC	ATGGTCCCTGCCGTA

- 49 -

	TGGTCCCTGCCGTAG	CAATGTGCTGAGTCC	ATTTTATAAGAAAAA
	GGTCCCTGCCGTAGA	AATGTGCTGAGTCCC	TTTTATAAGAAAAAG
	GTCCCTGCCGTAGAG	ATGTGCTGAGTCCCA	TTTATAAGAAAAAGC
	TCCCTGCCGTAGAGA	TGTGCTGAGTCCCAG	TTATAAGAAAAAGCA
5	CCCTGCCGTAGAGAA	GTGCTGAGTCCCAGG	TATAAGAAAAAGCAG
	CCTGCCGTAGAGAAA	TGCTGAGTCCCAGGG	ATAAGAAAAAGCAGT
	CTGCCGTAGAGAAAT	GCTGAGTCCCAGGGG	TAAGAAAAAGCAGTG
	TGCCGTAGAGAAATG	CTGAGTCCCAGGGGT	AAGAAAAAGCAGTGT
	GCCGTAGAGAAATGG	TGAGTCCCAGGGGTG	AGAAAAAGCAGTGTC
10	CCGTAGAGAAATGGA	GAGTCCCAGGGGTGT	GAAAAAGCAGTGTCG
	CGTAGAGAAATGGAA	AGTCCCAGGGGTGTA	AAAAAGCAGTGTCGC
	GTAGAGAAATGGAAG	GTCCCAGGGGTGTAC	AAAAGCAGTGTCGCC
	TAGAGAAATGGAAGA	TCCCAGGGGTGTACA	AAAGCAGTGTCGCCC
	AGAGAAATGGAAGAC	CCCAGGGGTGTACAC	AAGCAGTGTCGCCCT
15	GAGAAATGGAAGACA	CCAGGGGTGTACACA	AGCAGTGTCGCCCTT
	AGAAATGGAAGACAC	CAGGGGTGTACACAT	GCAGTGTCGCCCTTC
	GAAATGGAAGACACA	AGGGGTGTACACATT	CAGTGTCGCCCTTCC
	AAATGGAAGACACAC	GGGGTGTACACATT	AGTGTCGCCCTTCCA
	AATGGAAGACACACT	GGGTGTACACATTCC	GTGTCGCCCTTCCAA
20	ATGGAAGACACACTG	GGTGTACACATTCCC	TGTCGCCCTTCCAA
	TGGAAGACACACTGA	GTGTACACATTCCCA	GTGCGCCCTTCCAAAG
	GGAAGACACACTGAA	TGTACACATTCCCAA	TCGCCCTTCCAAAGG
	GAAGACACACTGAAT	GTACACATTCCCAAC	CGCCCTTCCAAAGGC
	AAGACACACTGAATC	TACACATTCCCAACT	GCCCTTCCAAAGGCA
25	AGACACACTGAATCA	ACACATTCCCAACTG	CCCTTCCAAAGGCAG
	GACACACTGAATCAC	CACATTCCCAACTGT	CCTTCCAAAGGCAGG
	ACACACTGAATCAC	ACATTCCCAACTGTG	CTTCCAAAGGCAGGA
	CACACTGAATCACCT	CATTCCCAACTGTGA	TTCCAAAGGCAGGAA
	ACACTGAATCACCTG	ATTCCCAACTGTGAC	TCCAAAGGCAGGAAG
30	CACTGAATCACCTGA	TTCCCAACTGTGACA	CCAAAGGCAGGAAGC
	ACTGAATCACCTGAA	TCCCAACTGTGACAA	CAAAGGCAGGAAGCG
	CTGAATCACCTGAAG	CCCAACTGTGACAAG	AAAGGCAGGAAGCGG
	TGAATCACCTGAAGT	CCAAGTGTGACAAGA	AAGGCAGGAAGCGGG
	GAATCACCTGAAGTT	CAAGTGTGACAAGAA	AGGCAGGAAGCGGGG
35	AATCACCTGAAGTTC	AACTGTGACAAGAA	GGCAGGAAGCGGGGCT
	ATCACCTGAAGTTCC	ACTGTGACAAGAAAG	GCAGGAAGCGGGGCT
	TCACCTGAAGTTCCT	CTGTGACAAGAAAGG	CAGGAAGCGGGGCTT
	CACCTGAAGTTCCTC	TGTGACAAGAAAGGA	AGGAAGCGGGGCTTC
	ACCTGAAGTTCCTCA	GTGACAAGAAAGGGAT	GGAAGCGGGGCTTCT
40	CCTGAAGTTCCTCAA	TGACAAGAAAGGGATT	GAAGCGGGGCTTCTG
	CTGAAGTTCCTCAAT	GACAAGAAAGGGATTT	AAGCGGGGCTTCTGC
	TGAAGTTCCTCAATG	ACAAGAAAGGGATTTT	AGCGGGGCTTCTGCT
	GAAGTTCCTCAATGT	CAAGAAAGGGATTTTA	GCGGGGCTTCTGCTG
	AAGTTCCTCAATGTG	AAGAAGGGATTTTATA	GGGGCTTCTGCTGGT
45	AGTTCCTCAATGTGC	GAAGGGATTTTATAA	GGGCTTCTGCTGGTG
	GTTTCCTCAATGTGCT	AAGGGATTTTATAAG	GGCTTCTGCTGGTGT
	TTCCTCAATGTGCTG	AGGGATTTTATAAGA	GCTTCTGCTGGTGTG
	TCCTCAATGTGCTGA	GGGATTTTATAAGAA	CTTCTGCTGGTGTGT
	CCTCAATGTGCTGAG	GGATTTTATAAGAAA	TTCTGCTGGTGTGTG
50	CTCAATGTGCTGAGT	GATTTTATAAGAAAA	TCTGCTGGTGTGTG
	TCAATGTGCTGAGTC		

- 50 -

CTGCTGGTGTGTGGA	GGGGAAGGAGGACGT	CGCAAGTTAATGTGG
TGCTGGTGTGTGGAT	GGGAAGGAGGACGTG	GCAAGTTAATGTGGA
GCTGGTGTGTGGATA	GGAAGGAGGACGTGC	CAAGTTAATGTGGAG
CTGGTGTGTGGATAA	GAAGGAGGACGTGCA	AAGTTAATGTGGAGC
5 TGGTGTGTGGATAAG	AAGGAGGACGTGCAC	AGTTAATGTGGAGCT
GGTGTGTGGATAAGT	AGGAGGACGTGCACT	GTTAATGTGGAGCTC
GTGTGTGGATAAGTA	GGAGGACGTGCACTG	TTAATGTGGAGCTCA
TGTGTGGATAAGTAT	GAGGACGTGCACTGC	TAATGTGGAGCTCAA
GTGTGGATAAGTATG	AGGACGTGCACTGCT	AATGTGGAGCTCAAA
10 TGTGGATAAGTATGG	GGACGTGCACTGCTA	ATGTGGAGCTCAAAT
GTGGATAAGTATGGG	GACGTGCACTGCTAC	TGTGGAGCTCAAATA
TGGATAAGTATGGGC	ACGTGCACTGCTACA	GTGGAGCTCAAATAT
GGATAAGTATGGGCA	CGTGCACTGCTACAG	TGGAGCTCAAATATG
GATAAGTATGGGCAG	GTGCACTGCTACAGC	GGAGCTCAAATATGC
15 ATAAGTATGGGCAGC	TGCACTGCTACAGCA	GAGCTCAAATATGCC
TAAGTATGGGCAGCC	GCCTGCTACAGCAT	AGCTCAAATATGCCT
AAGTATGGGCAGCCT	CACTGCTACAGCATG	GCTCAAATATGCCTT
AGTATGGGCAGCCTC	ACTGCTACAGCATGC	CTCAAATATGCCTTA
GTATGGGCAGCCTCT	CTGCTACAGCATGCA	TCAAATATGCCTTAT
20 TATGGGCAGCCTCTC	TGCTACAGCATGCAG	CAAATATGCCTTATT
ATGGGCAGCCTCTCC	GCTACAGCATGCAGA	AAATATGCCTTATTT
TGGGCAGCCTCTCCC	CTACAGCATGCAGAG	AATATGCCTTATTTT
GGGCAGCCTCTCCCA	TACAGCATGCAGAGC	ATATGCCTTATTTTG
GGCAGCCTCTCCAG	ACAGCATGCAGAGCA	TATGCCTTATTTTGC
25 GCAGCCTCTCCAGG	CAGCATGCAGAGCAA	ATGCCTTATTTTGCAC
CAGCCTCTCCAGGC	AGCATGCAGAGCAAG	TGCCTTATTTTGCAC
AGCCTCTCCAGGCT	GCATGCAGAGCAAGT	GCCTTATTTTGCACA
GCCTCTCCAGGCTA	CATGCAGAGCAAGTA	CCTTATTTTGCACAA
CCTCTCCAGGCTAC	ATGCAGAGCAAGTAG	CTTATTTTGCACAAA
30 CTCTCCAGGCTACA	TGCAGAGCAAGTAGA	TTATTTTGCACAAAA
TCTCCAGGCTACAC	GCAGAGCAAGTAGAC	TATTTTGCACAAAAG
CTCCAGGCTACACC	CAGAGCAAGTAGACG	ATTTTGCACAAAAGA
TCCCAGGCTACACCA	AGAGCAAGTAGACGC	TTTTGCACAAAAGAC
CCCAGGCTACACCAC	GAGCAAGTAGACGCC	TTTGCACAAAAGACT
35 CCAGGCTACACCACC	AGCAAGTAGACGCCT	TTGCACAAAAGACTG
CAGGCTACACCACCA	GCAAGTAGACGCCTG	TGCACAAAAGACTGC
AGGCTACACCACCAA	CAAGTAGACGCCTGC	GCACAAAAGACTGCC
GGCTACACCACCAAG	AAGTAGACGCCTGCC	CACAAAAGACTGCCA
GCTACACCACCAAGG	AGTAGACGCCTGCCG	ACAAAAGACTGCCAA
40 CTACACCACCAAGGG	GTAGACGCCTGCCGC	CAAAAGACTGCCAAG
TACACCACCAAGGGG	TAGACGCCTGCCGCA	AAAAGACTGCCAAGG
ACACCACCAAGGGGA	AGACGCCTGCCGCAA	AAAGACTGCCAAGGA
CACCACCAAGGGGAA	GACGCCTGCCGCAAG	AAGACTGCCAAGGAC
ACCACCAAGGGGAAG	ACGCCTGCCGCAAGT	AGACTGCCAAGGACA
45 CCACCAAGGGGAAGG	CGCCTGCCGCAAGTT	GACTGCCAAGGACAT
CACCAAGGGGAAGGA	GCCTGCCGCAAGTTA	ACTGCCAAGGACATG
ACCAAGGGGAAGGAG	CCTGCCGCAAGTTAA	CTGCCAAGGACATGA
CCAAGGGGAAGGAGG	CTGCCGCAAGTTAAT	TGCCAAGGACATGAC
CAAGGGGAAGGAGGA	TGCCGCAAGTTAATG	GCCAAGGACATGACC
50 AAGGGGAAGGAGGAC	GCCGCAAGTTAATGT	CCAAGGACATGACCA
AGGGGAAGGAGGACG	CCGCAAGTTAATGTG	CAAGGACATGACCAG

- 51 -

	AAGGACATGACCAGC	GTGAACTGATTTTTT	TATGGTTTCTTTGAA
	AGGACATGACCAGCA	TGAACTGATTTTTTT	ATGGTTTCTTTGAAT
	GGACATGACCAGCAG	GAAGTATTTTTTTTT	TGGTTTCTTTGAATG
	GACATGACCAGCAGC	AACTGATTTTTTTTA	GGTTTCTTTGAATGG
5	ACATGACCAGCAGCT	ACTGATTTTTTTTAA	GTTTCTTTGAATGGT
	CATGACCAGCAGCTG	CTGATTTTTTTTAAA	TTTCTTTGAATGGTA
	ATGACCAGCAGCTGG	TGATTTTTTTTAAAC	TTCTTTGAATGGTAA
	TGACCAGCAGCTGGC	GATTTTTTTTAAACC	TCTTTGAATGGTAAA
	GACCAGCAGCTGGCT	ATTTTTTTTAAACCA	CTTTGAATGGTAAAC
10	ACCAGCAGCTGGCTA	TTTTTTTTTAAACCAA	TTTGAATGGTAAACT
	CCAGCAGCTGGCTAC	TTTTTTTTTAAACCAA	TTGAATGGTAAACTT
	CAGCAGCTGGCTACA	TTTTTTTTTAAACCAA	TGAATGGTAAACTTG
	AGCAGCTGGCTACAG	TTTTTAAACCAAAGT	GAATGGTAAACTTGA
	GCAGCTGGCTACAGC	TTTTTAAACCAAAGTT	AATGGTAAACTTGAG
15	CAGCTGGCTACAGCC	TTTAAACCAAAGTTT	ATGGTAAACTTGAGC
	AGCTGGCTACAGCCT	TAAACCAAAGTTTA	TGGTAAACTTGAGCA
	GCTGGCTACAGCCTC	TAAACCAAAGTTTAG	GGTAAACTTGAGCAT
	CTGGCTACAGCCTCG	AAACCAAAGTTTAGA	GTAAACTTGAGCATC
	TGGCTACAGCCTCGA	AACCAAAGTTTAGAA	TAAACTTGAGCATCT
20	GGCTACAGCCTCGAT	ACCAAAGTTTAGAAA	AAACTTGAGCATCTT
	GCTACAGCCTCGATT	CCAAAGTTTAGAAAG	AACTTGAGCATCTTT
	CTACAGCCTCGATTT	CAAAGTTTAGAAAGA	ACTTGAGCATCTTTT
	TACAGCCTCGATTTA	AAAGTTTAGAAAGAG	CTTGAGCATCTTTTC
	ACAGCCTCGATTTAT	AAGTTTAGAAAGAGG	TTGAGCATCTTTTCA
25	CAGCCTCGATTTATA	AGTTTAGAAAGAGGT	TGAGCATCTTTTCAC
	AGCCTCGATTTATAT	GTTTAGAAAGAGGTT	GAGCATCTTTTCACT
	GCCTCGATTTATATT	TTTAGAAAGAGGTTT	AGCATCTTTTCACTT
	CCTCGATTTATATTT	TTAGAAAGAGGTTTT	GCATCTTTTCACTTT
	CTCGATTTATATTTT	TAGAAAGAGGTTTTT	CATCTTTTCACTTTC
30	TCGATTTATATTTCT	AGAAAGAGGTTTTTG	ATCTTTTCACTTTCC
	CGATTTATATTTCTG	GAAAGAGGTTTTTGA	TCTTTTCACTTTCCA
	GATTTATATTTCTGT	AAAGAGGTTTTTGAA	CTTTTCACTTTCCAG
	ATTTATATTTCTGTT	AAGAGGTTTTTGAAA	TTTTCACTTTCCAGT
	TTTATATTTCTGTTT	AGAGGTTTTTGAAAT	TTTCACTTTCCAGTA
35	TTATATTTCTGTTTG	GAGGTTTTTGAAATG	TTCACTTTCCAGTAG
	TATATTTCTGTTTGT	AGGTTTTTGAAATGC	TCACTTTCCAGTAGT
	ATATTTCTGTTTGTG	GGTTTTTGAAATGCC	CACTTTCCAGTAGTC
	TATTTCTGTTTGTGG	GTTTTTGAAATGCCT	ACTTTCCAGTAGTCA
	ATTTCTGTTTGTGGT	TTTTTGAAATGCCTA	CTTTCCAGTAGTCAG
40	TTTCTGTTTGTGGTG	TTTTGAAATGCCTAT	TTTCCAGTAGTCAGC
	TTCTGTTTGTGGTGA	TTTGAAATGCCTATG	TTCCAGTAGTCAGCA
	TCTGTTTGTGGTGAA	TTGAAATGCCTATGG	TCCAGTAGTCAGCAA
	CTGTTTGTGGTGAAAC	TGAAATGCCTATGGT	CCAGTAGTCAGCAAA
	TGTTTGTGGTGAACT	GAAATGCCTATGGTT	CAGTAGTCAGCAAAG
45	GTTTGTGGTGAACTG	AAATGCCTATGGTTT	AGTAGTCAGCAAAGA
	TTTGTGGTGAACTGA	AATGCCTATGGTTTC	GTAGTCAGCAAAGAG
	TTGTGGTGAACTGAT	ATGCCTATGGTTTCT	TAGTCAGCAAAGAGC
	TGTGGTGAACTGATT	TGCCTATGGTTTCTT	AGTCAGCAAAGAGCA
	GTGGTGAACTGATTT	GCCTATGGTTTCTTT	GTCAGCAAAGAGCAG
50	TGGTGAACTGATTTT	CCTATGGTTTCTTTG	TCAGCAAAGAGCAGT
	GGTGAACTGATTTTT	CTATGGTTTCTTTGA	CAGCAAAGAGCAGTT

- 52 -

AGCAAAGAGCAGTTT	ACTCGAGCACAGCAC	TTGGTCGAAGCGGCC
GCAAAGAGCAGTTTG	CTCGAGCACAGCACC	TGGTCGAAGCGGCCG
CAAAGAGCAGTTTGA	TCGAGCACAGCACCC	GGTCGAAGCGGCCGA
AAAGAGCAGTTTGAA	CGAGCACAGCACCCA	GTCGAAGCGGCCGAC
5 AAGAGCAGTTTGAAT	GAGCACAGCACCCAG	TCGAAGCGGCCGACC
AGAGCAGTTTGAATT	AGCACAGCACCCAGA	CGAAGCGGCCGACCA
GAGCAGTTTGAATTT	GCACAGCACCCAGAC	GAAGCGGCCGACCAC
AGCAGTTTGAATTTT	CACAGCACCCAGACT	AAGCGGCCGACCACT
GCAGTTTGAATTTTC	ACAGCACCCAGACTT	AGCGGCCGACCACTG
10 CAGTTTGAATTTTCT	CAGCACCCAGACTTC	GCGGCCGACCACTGA
AGTTTGAATTTTCTT	AGCACCCAGACTTCA	CGGCCGACCACTGAC
GTTTGAATTTTCTTG	GCACCCAGACTTCAT	GGCCGACCACTGACT
TTTGAATTTTCTTGT	CACCCAGACTTCATG	GCCGACCACTGACTT
TTGAATTTTCTTGTC	ACCCAGACTTCATGC	CCGACCACTGACTTT
15 TGAATTTTCTTGTCG	CCCAGACTTCATGCG	CGACCACTGACTTTG
GAATTTTCTTGTCGC	CCAGACTTCATGCGC	GACCACTGACTTTGT
AATTTTCTTGTCGCT	CAGACTTCATGCGCC	ACCACTGACTTTGTG
ATTTTCTTGTCGCTT	AGACTTCATGCGCCC	CCACTGACTTTGTGA
TTTTCTTGTCGCTTC	GACTTCATGCGCCCG	CACTGACTTTGTGAC
20 TTTCTTGTCGCTTCC	ACTTCATGCGCCCGT	ACTGACTTTGTGACT
TTCTTGTCGCTTCCT	CTTCATGCGCCCGTG	CTGACTTTGTGACTT
TCTTGTCGCTTCCTA	TTCATGCGCCCGTGG	TGACTTTGTGACTTA
CTTGTCGCTTCCTAT	TCATGCGCCCGTGGA	GACTTTGTGACTTAG
TTTGTCGCTTCCTATC	CATGCGCCCGTGGA	ACTTTGTGACTTAGG
25 TGTGCTTCCTATCA	ATGCGCCCGTGGAAT	CTTTGTGACTTAGGC
GTCGCTTCCTATCAA	TGCGCCCGTGGAATG	TTTGTGACTTAGGCG
TCGCTTCCTATCAAA	GCGCCCGTGGAATGC	TTGTGACTTAGGCGG
CGCTTCCTATCAAAA	CGCCCGTGGAATGCT	TGTGACTTAGGCGGC
GCTTCCTATCAAAAT	GCCCGTGGAATGCTC	GTGACTTAGGCGGCT
30 CTTCTATCAAAATA	CCCGTGGAATGCTCA	TGACTTAGGCGGCTG
TTCCTATCAAAATAT	CCGTGGAATGCTCAC	GACTTAGGCGGCTGT
TCCTATCAAAATATT	CGTGGAATGCTCACC	ACTTAGGCGGCTGTG
CCTATCAAAATATTC	GTGGAATGCTCACC	CTTAGGCGGCTGTGT
CTATCAAAATATTC	TGGAATGCTCACCAC	TTAGGCGGCTGTGTT
35 TATCAAAATATTCAG	GGAATGCTCACCACA	TAGGCGGCTGTGTTG
ATCAAAATATTCAGA	GAATGCTCACCACAT	AGGCGGCTGTGTTGC
TCAAAATATTCAGAG	AATGCTCACCACATG	GGCGGCTGTGTTGCC
CAAAATATTCAGAGA	ATGCTCACCACATGT	GCGGCTGTGTTGCCT
AAAATATTCAGAGAC	TGCTCACCACATGTT	CGGCTGTGTTGCCTA
40 AAATATTCAGAGACT	GCTCACCACATGTTG	GGCTGTGTTGCCTAT
AATATTCAGAGACTC	CTCACCACATGTTGG	GCTGTGTTGCCTATG
ATATTCAGAGACTCG	TCACCACATGTTGGT	CTGTGTTGCCTATGT
TATTCAGAGACTCGA	CACCACATGTTGGTC	TGTGTTGCCTATGTA
ATTCAGAGACTCGAG	ACCACATGTTGGTCG	GTGTTGCCTATGTAG
45 TTCAGAGACTCGAGC	CCACATGTTGGTCGA	TGTTGCCTATGTAGA
TCAGAGACTCGAGCA	CACATGTTGGTCGAA	GTTGCCTATGTAGAG
CAGAGACTCGAGCAC	ACATGTTGGTCGAAG	TTGCCTATGTAGAGA
AGAGACTCGAGCACA	CATGTTGGTCGAAGC	TGCCTATGTAGAGAA
GAGACTCGAGCACAG	ATGTTGGTCGAAGCG	GCCTATGTAGAGAAC
50 AGACTCGAGCACAGC	TGTTGGTCGAAGCGG	CCTATGTAGAGAAC
GACTCGAGCACAGCA	GTTGGTCGAAGCGGC	CTATGTAGAGAACAC

	TATGTAGAGAACACG	TATCGAGAATAGGAA	ATGCTCCTGGAGCTC
	ATGTAGAGAACACGC	ATCGAGAATAGGAAA	TGCTCCTGGAGCTCA
	TGTAGAGAACACGCT	TCGAGAATAGGAAAA	GCTCCTGGAGCTCAC
	GTAGAGAACACGCTT	CGAGAATAGGAAAAC	CTCCTGGAGCTCACA
5	TAGAGAACACGCTTC	GAGAATAGGAAAACC	TCCTGGAGCTCACAG
	AGAGAACACGCTTCA	AGAATAGGAAAACCT	CCTGGAGCTCACAGC
	GAGAACACGCTTCAC	GAATAGGAAAACCTT	CTGGAGCTCACAGCC
	AGAACACGCTTCACC	AATAGGAAAACCTTT	TGGAGCTCACAGCCT
	GAACACGCTTCACCC	ATAGGAAAACCTTTA	GGAGCTCACAGCCTT
10	AACACGCTTCACCCC	TAGGAAAACCTTTAA	GAGCTCACAGCCTTC
	ACACGCTTCACCCCC	AGGAAAACCTTTAAA	AGCTCACAGCCTTCT
	CACGCTTCACCCCCA	GGAAAACCTTTAAAC	GCTCACAGCCTTCTG
	ACGCTTCACCCCCAC	GAAAACCTTTAAACC	CTCACAGCCTTCTGT
	CGCTTCACCCCCACT	AAAACCTTTAAACCC	TCACAGCCTTCTGTG
15	GCTTCACCCCCACTC	AAACCTTTAAACCCC	CACAGCCTTCTGTGG
	CTTCACCCCCACTCC	AACCTTTAAACCCCG	ACAGCCTTCTGTGGT
	TTCACCCCCACTCCC	ACCTTTAAACCCCGG	CAGCCTTCTGTGGTG
	TCACCCCCACTCCCC	CCTTTAAACCCCGGT	AGCCTTCTGTGGTGT
	CACCCCCACTCCCCG	CTTTAAACCCCGGTC	GCCTTCTGTGGTGTG
20	ACCCCCACTCCCCGT	TTTAAACCCCGGTCA	CCTTCTGTGGTGTCA
	CCCCCACTCCCCGTA	TTAAACCCCGGTCA	CTTCTGTGGTGTCA
	CCCCACTCCCCGTAC	TAAACCCCGGTCA	TTCTGTGGTGTCA
	CCCACTCCCCGTACA	AAACCCCGGTCA	TCTGTGGTGTCA
	CCACTCCCCGTACAG	AACCCCGGTCA	CTGTGGTGTCA
25	CACTCCCCGTACAGT	ACCCCGGTCA	TGTGGTGTCA
	ACTCCCCGTACAGTG	CCCCGGTCA	GTGGTGTCA
	CTCCCCGTACAGTGC	CCCGGTCA	TGGTGTCA
	TCCCCGTACAGTGCG	CCGGTCA	GGTGTCA
	CCCGGTACAGTGCGC	CGGTCA	GTGTCA
30	CCCGTACAGTGCGCA	GGTCA	TGTCA
	CCGTACAGTGCGCAC	GTCA	GTCA
	CGTACAGTGCGCACA	TCATCCGGACATCCC	TCATTTCTGAAACA
	GTACAGTGCGCACAG	CATCCGGACATCCCA	CATTTCTGAAACAAG
	TACAGTGCGCACAGG	ATCCGGACATCCCAA	ATTTCTGAAACAAGG
35	ACAGTGCGCACAGGC	TCCGGACATCCCAAC	TTTCTGAAACAAGGG
	CAGTGCGCACAGGCT	CCGGACATCCCAACG	TTCTGAAACAAGGGC
	AGTGCGCACAGGCTT	CGGACATCCCAACGC	TCTGAAACAAGGGCG
	GTGCGCACAGGCTTT	GGACATCCCAACGCA	CTGAAACAAGGGCGT
	TGCGCACAGGCTTTA	GACATCCCAACGCAT	TGAAACAAGGGCGTG
40	GCGCACAGGCTTTAT	ACATCCCAACGCATG	GAAACAAGGGCGTGG
	CGCACAGGCTTTATC	CATCCCAACGCATGC	AAACAAGGGCGTGG
	GCACAGGCTTTATCG	ATCCCAACGCATGCT	AACAAGGGCGTGGAT
	CACAGGCTTTATCGA	TCCCAACGCATGCTC	ACAAGGGCGTGGATC
	ACAGGCTTTATCGAG	CCCAACGCATGCTCC	CAAGGGCGTGGATCC
45	CAGGCTTTATCGAGA	CCAACGCATGCTCCT	AAGGGCGTGGATCCC
	AGGCTTTATCGAGAA	CAACGCATGCTCCTG	AGGGCGTGGATCCCT
	GGCTTTATCGAGAAT	AACGCATGCTCCTGG	GGGCGTGGATCCCTC
	GCTTTATCGAGAATA	ACGCATGCTCCTGGA	GGCGTGGATCCCTCA
	CTTTATCGAGAATAG	CGCATGCTCCTGGAG	GCGTGGATCCCTCAA
50	TTTATCGAGAATAGG	GCATGCTCCTGGAGC	CGTGGATCCCTCAAC
	TTATCGAGAATAGGA	CATGCTCCTGGAGCT	GTGGATCCCTCAACC

- 54 -

	TGGATCCCTCAACCA	TTGGGGACTATTGGA	GTATCTAAGAATGTT
	GGATCCCTCAACCAA	TGGGGACTATTGGAG	TATCTAAGAATGTTT
	GATCCCTCAACCAAG	GGGGACTATTGGAGA	ATCTAAGAATGTTCT
	ATCCCTCAACCAAGA	GGGACTATTGGAGAA	TCTAAGAATGTTCTA
5	TCCCTCAACCAAGAA	GGACTATTGGAGAAA	CTAAGAATGTTCTAG
	CCCTCAACCAAGAAG	GACTATTGGAGAAAA	TAAGAATGTTCTAGG
	CCTCAACCAAGAAGA	ACTATTGGAGAAAAT	AAGAATGTTCTAGGG
	CTCAACCAAGAAGAA	CTATTGGAGAAAATA	AGAATGTTCTAGGGC
	TCAACCAAGAAGAAT	TATTGGAGAAAATAA	GAATGTTCTAGGGCA
10	CAACCAAGAAGAATG	ATTGGAGAAAATAAG	AATGTTCTAGGGCAC
	AACCAAGAAGAATGT	TTGGAGAAAATAAGG	ATGTTCTAGGGCACT
	ACCAAGAAGAATGTT	TGGAGAAAATAAGGT	TGTTCTAGGGCACTC
	CCAAGAAGAATGTTT	GGAGAAAATAAGGTG	GTTCTAGGGCACTCT
	CAAGAAGAATGTTTA	GAGAAAATAAGGTGG	TTCTAGGGCACTCTG
15	AAGAAGAATGTTTAT	AGAAAATAAGGTGGA	TCTAGGGCACTCTGG
	AGAAGAATGTTTATG	GAAAATAAGGTGGAG	CTAGGGCACTCTGGG
	GAAGAATGTTTATGT	AAAATAAGGTGGAGT	TAGGGCACTCTGGGA
	AAGAATGTTTATGTC	AAATAAGGTGGAGTC	AGGGCACTCTGGGAA
	AGAATGTTTATGTCT	AATAAGGTGGAGTCC	GGGCACTCTGGGAAC
20	GAATGTTTATGTCTT	ATAAGGTGGAGTCCT	GGCACTCTGGGAACC
	AATGTTTATGTCTTC	TAAGGTGGAGTCCTA	GCCTCTGGGAACCT
	ATGTTTATGTCTTCA	AAGGTGGAGTCCTAC	CACTCTGGGAACCTA
	TGTTTATGTCTTCAA	AGGTGGAGTCCTACT	ACTCTGGGAACCTAT
	GTTTATGTCTTCAAG	GGTGGAGTCCTACTT	CTCTGGGAACCTATA
25	TTTATGTCTTCAAGT	GTGGAGTCCTACTTG	TCTGGGAACCTATAA
	TTATGTCTTCAAGTG	TGGAGTCCTACTTGT	CTGGGAACCTATAAA
	TATGTCTTCAAGTGA	GGAGTCCTACTTGTT	TGGGAACCTATAAAG
	ATGTCTTCAAGTGAC	GAGTCCTACTTGTTT	GGGAACCTATAAAGG
	TGTCTTCAAGTGACC	AGTCCTACTTGTTTA	GGAACCTATAAAGGC
30	GTCTTCAAGTGACCT	GTCCTACTTGTTTAA	GAACCTATAAAGGCA
	TCTTCAAGTGACCTG	TCCTACTTGTTTAAA	AACCTATAAAGGCAG
	CTTCAAGTGACCTGT	CCTACTTGTTTAAAA	ACCTATAAAGGCAGG
	TTCAAGTGACCTGTA	TACTTGTTTAAAAAA	CCTATAAAGGCAGGT
	TCAAGTGACCTGTAC	TACTTGTTTAAAAAA	CTATAAAGGCAGGTA
35	CAAGTGACCTGTACT	ACTTGTTTAAAAAAT	TATAAAGGCAGGTAT
	AAGTGACCTGTACTG	CTTGTTTAAAAAATA	ATAAAGGCAGGTATT
	AGTGACCTGTACTGC	TTGTTTAAAAAATAT	TAAAGGCAGGTATTT
	GTGACCTGTACTGCT	TGTTTAAAAAATATG	AAAGGCAGGTATTTT
	TGACCTGTACTGCTT	GTTTAAAAAATATGT	AAGGCAGGTATTTTC
40	GACCTGTACTGCTTG	TTTAAAAAATATGTA	AGGCAGGTATTTTCG
	ACCTGTACTGCTTGG	TTAAAAAATATGTAT	AGGCAGGTATTTTCGG
	CCTGTACTGCTTGGG	TAAAAAATATGTATC	GCAGGTATTTTCGGG
	CTGTACTGCTTGGGG	AAAAAATATGTATCT	CAGGTATTTTCGGGCC
	TGTACTGCTTGGGGA	AAAAATATGTATCTA	AGGTATTTTCGGGCCC
45	GTAAGTCTTGGGGAC	AAAATATGTATCTAA	GGTATTTTCGGGCCCT
	TACTGCTTGGGGACT	AAATATGTATCTAAG	GTATTTTCGGGCCCTC
	ACTGCTTGGGGACTA	AATATGTATCTAAGA	TATTTTCGGGCCCTCC
	CTGCTTGGGGACTAT	ATATGTATCTAAGAA	ATTTTCGGGCCCTCCT
	TGCTTGGGGACTATT	TATGTATCTAAGAAT	TTTCGGGCCCTCCTC
50	GCTTGGGGACTATTG	ATGTATCTAAGAATG	TTTCGGGCCCTCCTCT
	CTTGGGGACTATTGG	TGTATCTAAGAATGT	TCGGGCCCTCCTCTT

- 55 -

CGGGCCCTCCTCTTC	CAGGATGGCTTTTGC	AGAGTCAGCCTCCAC
GGGCCCTCCTCTTCA	AGGATGGCTTTTGCT	GAGTCAGCCTCCACA
GGCCCTCCTCTTCAG	GGATGGCTTTTGCTG	AGTCAGCCTCCACAT
GCCCTCCTCTTCAGG	GATGGCTTTTGCTGC	GTCAGCCTCCACATT
5 CCCTCCTCTTCAGGA	ATGGCTTTTGCTGCG	TCAGCCTCCACATTC
CCTCCTCTTCAGGAA	TGGCTTTTGCTGCGG	CAGCCTCCACATTCA
CTCCTCTTCAGGAAT	GGCTTTTGCTGCGGC	AGCCTCCACATTCAG
TCCTCTTCAGGAATC	GCTTTTGCTGCGGCC	GCCTCCACATTCAGA
CCTCTTCAGGAATCT	CTTTTGCTGCGGCCC	CCTCCACATTCAGAG
10 CTCTTCAGGAATCTT	TTTGCTGCGGCCCC	CTCCACATTCAGAGG
TCTTCAGGAATCTTC	TTTGCTGCGGCCCCG	TCCACATTCAGAGGC
CTTCAGGAATCTTCC	TTGCTGCGGCCCCGT	CCACATTCAGAGGCA
TTCAGGAATCTTCCT	TGCTGCGGCCCCGTG	CACATTCAGAGGCAT
TCAGGAATCTTCCTG	GCTGCGGCCCCGTGG	ACATTCAGAGGCATC
15 CAGGAATCTTCCTGA	CTGCGGCCCCGTGGG	CATTCAGAGGCATCA
AGGAATCTTCCTGAA	TGCGGCCCCGTGGGG	ATTCAGAGGCATCAC
GGAATCTTCCTGAAG	GCGGCCCCGTGGGGT	TTCAGAGGCATCACAA
GAATCTTCCTGAAGA	CGGCCCCGTGGGGTA	TCAGAGGCATCACAA
AATCTTCCTGAAGAC	GGCCCCGTGGGGTAG	CAGAGGCATCACAAAG
20 ATCTTCCTGAAGACA	GCCCCGTGGGGTAGG	AGAGGCATCACAAAGT
TCTTCCTGAAGACAT	CCCCGTGGGGTAGGA	GAGGCATCACAAAGTA
CTTCCTGAAGACATG	CCCGTGGGGTAGGAG	AGGCATCACAAAGTAA
TTCCTGAAGACATGG	CCGTGGGGTAGGAGG	GGCATCACAAAGTAAT
TCCTGAAGACATGGC	CGTGGGGTAGGAGGG	GCATCACAAAGTAATG
25 CCTGAAGACATGGCC	GTGGGGTAGGAGGGA	CATCACAAAGTAATGG
CTGAAGACATGGCCC	TGGGGTAGGAGGGAC	ATCACAAAGTAATGGC
TGAAGACATGGCCCA	GGGGTAGGAGGGACA	TCACAAAGTAATGGCA
GAAGACATGGCCCA	GGGTAGGAGGGACAG	CACAAAGTAATGGCAC
AAGACATGGCCCA	GGTAGGAGGGACAGA	ACAAGTAATGGCACAA
30 AGACATGGCCCA	GATAGGAGGGACAGAG	CAAGTAATGGCACAA
GACATGGCCCA	TAGGAGGGACAGAGA	AAGTAATGGCACAA
ACATGGCCCA	AGGAGGGACAGAGAG	AGTAATGGCACAA
CATGGCCCA	GGAGGGACAGAGAGA	GTAATGGCACAA
ATGGCCCA	GAGGGACAGAGAGAC	TAATGGCACAA
35 TGGCCCA	AGGGACAGAGAGACG	AATGGCACAA
GGCCCA	GGGACAGAGAGACGG	ATGGCACAA
GCCCA	GGACAGAGAGACGGG	TGGCACAA
CCCAGT	GACAGAGAGACGGGA	GGCACAA
CCAGT	ACAGAGAGACGGGAG	GCACAA
40 CAGT	CAGAGAGACGGGAGA	CACAA
AGT	AGAGAGACGGGAGAG	ACA
GTC	GAGAGACGGGAGAGT	CA
TC	AGAGACGGGAGAGTC	CA
CGA	GAGACGGGAGAGTCA	CA
45 GA	AGACGGGAGAGTCAG	CA
AAG	GACGGGAGAGTCAGC	CA
AGG	ACGGGAGAGTCAGCC	CA
AGG	CGGGAGAGTCAGCCT	CA
GGC	GGGAGAGTCAGCCTC	CA
50 CCC	GGAGAGTCAGCCTCC	CA
CCAG	GAGAGTCAGCCTCCA	CA

- 56 -

	GATGACTGCAGAAAA	ATTTCTGAGGATAAG	TTTTGTCCTCCTTAG
	ATGACTGCAGAAAAT	TTTCTGAGGATAAGC	TTTGTCTCCTCCTTAGC
	TGACTGCAGAAAATA	TTCTGAGGATAAGCT	TTGTCTCCTCCTTAGCA
	GACTGCAGAAAATAG	TCTGAGGATAAGCTC	TGTCTCCTCCTTAGCAC
5	ACTGCAGAAAATAGT	CTGAGGATAAGCTCT	GTCTCCTCCTTAGCACA
	CTGCAGAAAATAGTG	TGAGGATAAGCTCTT	TCCTCCTTAGCACAA
	TGCAGAAAATAGTGT	GAGGATAAGCTCTTT	CCTCCTTAGCACAAT
	GCAGAAAATAGTGTT	AGGATAAGCTCTTTA	CTCCTTAGCACAATG
	CAGAAAATAGTGTTT	GGATAAGCTCTTTAA	TCCTTAGCACAATGT
10	AGAAAATAGTGTTTT	GATAAGCTCTTTAAA	CCTTAGCACAATGTA
	GAAAATAGTGTTTTG	ATAAGCTCTTTAAAG	CTTAGCACAATGTAA
	AAAATAGTGTTTTGT	TAAGCTCTTTAAAGG	TTAGCACAATGTAAA
	AAATAGTGTTTTGTA	AAGCTCTTTAAAGGC	TAGCACAATGTAAAA
	AATAGTGTTTTGTAG	AGCTCTTTAAAGGCA	AGCACAATGTAAAAA
15	ATAGTGTTTTGTAGT	GCTCTTTAAAGGCAA	GCACAATGTAAAAAA
	TAGTGTTTTGTAGTT	CTCTTTAAAGGCAAA	CACAATGTAAAAAAG
	AGTGTTTTGTAGTTC	TCTTTAAAGGCAAAG	ACAATGTAAAAAAGA
	GTGTTTTGTAGTTCA	CTTTAAAGGCAAAGC	CAATGTAAAAAAGAA
	TGTTTTGTAGTTCAA	TTTAAAGGCAAAGCT	AATGTAAAAAAGAAT
20	GTTTTGTAGTTCAAC	TAAAGGCAAAGCTT	ATGTAAAAAAGAATA
	TTTTGTAGTTCAACA	TAAAGGCAAAGCTTT	TGTAAAAAAGAATAG
	TTTGTAGTTCAACAA	AAAGGCAAAGCTTTA	GTAAAAAAGAATAGT
	TTGTAGTTCAACAAC	AAGGCAAAGCTTTAT	TAAAAAAGAATAGTA
	TGTAGTTCAACAAC	AGGCAAAGCTTTATT	AAAAAAGAATAGTAA
25	GTAGTTCAACAAC	GGCAAAGCTTTATTT	AAAAAGAATAGTAAT
	TAGTTCAACAAC	GCAAAGCTTTATTTT	AAAAGAATAGTAATA
	AGTTCAACAAC	CAAAGCTTTATTTTC	AAAGAATAGTAATAT
	GTTCAACAAC	AAAGCTTTATTTTCA	AAGAATAGTAATATC
	TTCAACAAC	AAGCTTTATTTTCAT	AGAATAGTAATATCA
30	TCAACAAC	AGCTTTATTTTCATC	GAATAGTAATATCAG
	CAACAAC	GCTTTATTTTCATCT	AATAGTAATATCAGA
	AACAAC	CTTTATTTTCATCTC	ATAGTAATATCAGAA
	ACAAC	TTTATTTTCATCTCT	TAGTAATATCAGAAC
	CAACTCAAGACGAAG	TTATTTTCATCTCTC	AGTAATATCAGAAC
35	AACTCAAGACGAAGC	TATTTTCATCTCTCA	GTAATATCAGAACAG
	ACTCAAGACGAAGCT	ATTTTCATCTCTCAT	TAATATCAGAACAGG
	CTCAAGACGAAGCTT	TTTTCATCTCTCATC	AATATCAGAACAGGA
	TCAAGACGAAGCTTA	TTTCATCTCTCATCT	ATATCAGAACAGGAA
	CAAGACGAAGCTTAT	TTCATCTCTCATCTT	TATCAGAACAGGAAG
40	AAGACGAAGCTTATT	TCATCTCTCATCTTT	ATCAGAACAGGAAGG
	AGACGAAGCTTATTT	CATCTCTCATCTTTT	TCAGAACAGGAAGGA
	GACGAAGCTTATTTTC	ATCTCTCATCTTTTG	CAGAACAGGAAGGAG
	ACGAAGCTTATTTCT	TCTCTCATCTTTTGT	AGAACAGGAAGGAGG
	CGAAGCTTATTTCTG	CTCTCATCTTTTGTC	GAACAGGAAGGAGGA
45	GAAGCTTATTTCTGA	TCTCATCTTTTGTC	AACAGGAAGGAGGAA
	AAGCTTATTTCTGAG	CTCATCTTTTGTCCT	ACAGGAAGGAGGAAT
	AGCTTATTTCTGAGG	TCATCTTTTGTCCTC	CAGGAAGGAGGAATG
	GCTTATTTCTGAGGA	CATCTTTTGTCCTCC	AGGAAGGAGGAATGG
	CTTATTTCTGAGGAT	ATCTTTTGTCCTCCT	GGAAGGAGGAATGGC
50	TTATTTCTGAGGATA	TCCTTTTGTCCTCCTT	GAAGGAGGAATGGCT
	TATTTCTGAGGATAA	CTTTTGTCCTCCTTA	AAGGAGGAATGGCTT

- 57 -

AGGAGGAATGGCTTG	GATTCACCCATGTTT	ATTCACACATATATG
GGAGGAATGGCTTGC	ATTCACCCATGTTTG	TTCACACATATATGC
GAGGAATGGCTTGCT	TTCACCCATGTTTGT	TCACACATATATGCA
AGGAATGGCTTGCTG	TCACCCATGTTTGTT	CACACATATATGCAG
5 GGAATGGCTTGCTGG	CACCCATGTTTGTTG	ACACATATATGCAGA
GAATGGCTTGCTGGG	ACCCATGTTTGTTGA	CACATATATGCAGAG
AATGGCTTGCTGGGG	CCCATGTTTGTTGAA	ACATATATGCAGAGA
ATGGCTTGCTGGGGA	CCATGTTTGTTGAAC	CATATATGCAGAGAA
TGGCTTGCTGGGGAG	CATGTTTGTTGAACT	ATATATGCAGAGAAG
10 GGCTTGCTGGGGAGC	ATGTTTGTTGAACTT	TATATGCAGAGAAGA
GCTTGCTGGGGAGCC	TGTTTGTTGAACTTA	ATATGCAGAGAAGAT
CTTGCTGGGGAGCCC	GTTTGTTGAACTTAG	TATGCAGAGAAGATA
TTGCTGGGGAGCCCA	TTTGTTGAACTTAGA	ATGCAGAGAAGATAT
TGCTGGGGAGCCCAT	TTGTTGAACTTAGAG	TGCAGAGAAGATATG
15 GCTGGGGAGCCCATC	TGTTGAACTTAGAGT	GCAGAGAAGATATGT
CTGGGGAGCCCATCC	GTTGAACTTAGAGTC	CAGAGAAGATATGTT
TGGGGAGCCCATCCA	TTGAACTTAGAGTCA	AGAGAAGATATGTTT
GGGGAGCCCATCCAG	TGAACTTAGAGTCAT	GAGAAGATATGTTCT
GGGAGCCCATCCAGG	GAACCTTAGAGTCATT	AGAAGATATGTTCTT
20 GGAGCCCATCCAGGA	AACCTTAGAGTCATT	GAAGATATGTTCTTG
GAGCCCATCCAGGAC	ACTTAGAGTCATTCT	AAGATATGTTCTTGT
AGCCCATCCAGGACA	CTTAGAGTCATTCTC	AGATATGTTCTTGTT
GCCCATCCAGGACAC	TTAGAGTCATTCTCA	GATATGTTCTTGTTA
CCCATCCAGGACACT	TAGAGTCATTCTCAT	ATATGTTCTTGTTAA
25 CCATCCAGGACACTG	AGAGTCATTCTCATG	TATGTTCTTGTTAAC
CATCCAGGACACTGG	GAGTCATTCTCATGC	ATGTTCTTGTTAACA
ATCCAGGACACTGGG	AGTCATTCTCATGCT	TGTTCTTGTTAACAT
TCCAGGACACTGGGA	GTCATTCTCATGCTT	GTTCTTGTTAACATT
CCAGGACACTGGGAG	TCATTCTCATGCTTT	TTCTTGTTAACATTG
30 CAGGACACTGGGAGC	CATTCTCATGCTTTT	TCTTGTTAACATTGT
AGGACACTGGGAGCA	ATTCTCATGCTTTTC	CTTGTTAACATTGTA
GGACACTGGGAGCAC	TTCTCATGCTTTTCT	TTGTTAACATTGTAT
GACACTGGGAGCACA	TCTCATGCTTTTCTT	TGTTAACATTGTATA
ACACTGGGAGCACAT	CTCATGCTTTTCTTT	GTTAACATTGTATAC
35 CACTGGGAGCACATA	TCATGCTTTTCTTTA	TTAACATTGTATACA
ACTGGGAGCACATAG	CATGCTTTTCTTTAT	TAACATTGTATACAA
CTGGGAGCACATAGA	ATGCTTTTCTTTATA	AACATTGTATACAAC
TGGGAGCACATAGAG	TGCTTTTCTTTATAA	ACATTGTATACAACA
GGGAGCACATAGAGA	GCTTTTCTTTATAAT	CATTGTATACAACAT
40 GGAGCACATAGAGAT	CTTTTCTTTATAATT	ATTGTATACAACATA
GAGCACATAGAGATT	TTTTCTTTATAATTC	TTGTATACAACATAG
AGCACATAGAGATTC	TTTCTTTATAAATCA	TGTATACAACATAGC
GCACATAGAGATTCA	TTCTTTATAAATCAC	GTATACAACATAGCC
CACATAGAGATTTCAC	TCTTTATAAATTCACA	TATACAACATAGCCC
45 ACATAGAGATTTCACC	CTTTATAAATTCACAC	ATACAACATAGCCCC
CATAGAGATTTCACCC	TTTATAAATTCACACA	TACAACATAGCCCCA
ATAGAGATTTCACCCA	TTATAAATTCACACAT	ACAACATAGCCCCAA
TAGAGATTTCACCCAT	TATAAATTCACACATA	CAACATAGCCCCAAA
AGAGATTTCACCCATG	ATAAATTCACACATAT	AACATAGCCCCAAAT
50 GAGATTTCACCCATGT	TAATTCACACATATA	ACATAGCCCCAAATA
AGATTTCACCCATGTT	AATTCACACATATAT	CATAGCCCCAAATAT

- 58 -

ATAGCCCCAAATATA	AGAGATGCTATATGA	CCCAGAGACTGGGCT
TAGCCCCAAATATAG	GAGATGCTATATGAT	CCAGAGACTGGGCTG
AGCCCCAAATATAGT	AGATGCTATATGATA	CAGAGACTGGGCTGC
GCCCCAAATATAGTA	GATGCTATATGATAC	AGAGACTGGGCTGCT
5 CCCCCAAATATAGTAA	ATGCTATATGATACA	GAGACTGGGCTGCTC
CCCCAAATATAGTAAG	TGCTATATGATACAA	AGACTGGGCTGCTCT
CCAAATATAGTAAGA	GCTATATGATACAAC	GACTGGGCTGCTCTC
CAAATATAGTAAGAT	CTATATGATACAAC	ACTGGGCTGCTCTCC
AAATATAGTAAGATC	TATATGATACAAC	CTGGGCTGCTCTCCC
10 AATATAGTAAGATCT	ATATGATACAAC	TGGGCTGCTCTCCCG
ATATAGTAAGATCTA	TATGATACAAC	GGGCTGCTCTCCCGG
TATAGTAAGATCTAT	ATGATACAAC	GGCTGCTCTCCCGGA
ATAGTAAGATCTATA	TGATACAAC	GCTGCTCTCCCGGAG
TAGTAAGATCTATAC	GATACAAC	CTGCTCTCCCGGAGG
15 AGTAAGATCTATACT	ATACAAC	TGCTCTCCCGGAGGC
GTAAGATCTATACTA	TACAAC	GCTCTCCCGGAGGCC
TAAGATCTATACTAG	ACAAC	CTCTCCCGGAGGCCA
AAGATCTATACTAGA	CAAC	TCTCCCGGAGGCCAA
AGATCTATACTAGAT	AACT	CTCCCGGAGGCCAAA
20 GATCTATACTAGATA	ACTGT	TCCCGGAGGCCAAAC
ATCTATACTAGATAA	CTGT	CCCGGAGGCCAAACC
TCTATACTAGATAAT	TGT	CCGGAGGCCAAACCC
CTATACTAGATAATC	GT	CGGAGGCCAAACCCA
TATACTAGATAATCC	TGG	GGAGGCCAAACCCAA
25 ATACTAGATAATCCT	GGC	GAGGCCAAACCCAAG
TACTAGATAATCCTA	CCAT	AGGCCAAACCCAAGA
ACTAGATAATCCTAG	CAT	GGCCAAACCCAAGAA
CTAGATAATCCTAGA	ATG	GCCAAACCCAAGAAG
TAGATAATCCTAGAT	ACT	CAAACCCAAGAAGG
30 AGATAATCCTAGATG	GACT	CAAACCCAAGAAGGT
GATAATCCTAGATGA	GACT	AAACCCAAGAAGGTC
ATAATCCTAGATGAA	ACT	AACCCAAGAAGGTCT
TAATCCTAGATGAAA	CTG	ACCCAAGAAGGTCTG
AATCCTAGATGAAAT	TG	CCAAGAAGGTCTGG
35 ATCCTAGATGAAATG	GAG	CCAAGAAGGTCTGGC
TCCTAGATGAAATGT	AGG	CAAGAAGGTCTGGCA
CCTAGATGAAATGTT	GAA	AAGAAGGTCTGGCAA
CTAGATGAAATGTTA	GAA	AGAAGGTCTGGCAAA
TAGATGAAATGTTAG	AA	GAAGGTCTGGCAAG
40 AGATGAAATGTTAGA	AAG	AAGGTCTGGCAAAGT
GATGAAATGTTAGAG	GAG	AGGTCTGGCAAAGTC
ATGAAATGTTAGAGA	GG	GGTCTGGCAAAGTCA
TGAAATGTTAGAGAT	GAG	GTCTGGCAAAGTCAG
GAAATGTTAGAGATG	AG	TCTGGCAAAGTCAGG
45 AAATGTTAGAGATGC	GCT	CTGGCAAAGTCAGGC
AATGTTAGAGATGCT	CT	TGGCAAAGTCAGGCT
ATGTTAGAGATGCTA	TC	GGCAAAGTCAGGCTC
TGTTAGAGATGCTAT	CAC	GCAAAGTCAGGCTCA
GTTAGAGATGCTATA	ACG	CAAAGTCAGGCTCAG
50 TTAGAGATGCTATAT	CGC	AAAGTCAGGCTCAGG
TAGAGATGCTATATG	CCC	AAGTCAGGCTCAGGG

- 59 -

AGTCAGGCTCAGGGA	GCTGCATAGAGCTCT	CCTATTAGCTTTTCT
GTCAGGCTCAGGGAG	CTGCATAGAGCTCTC	CTATTAGCTTTTCTT
TCAGGCTCAGGGAGA	TGCATAGAGCTCTCC	TATTAGCTTTTCTTT
CAGGCTCAGGGAGAC	GCATAGAGCTCTCCT	ATTAGCTTTTCTTTA
5 AGGCTCAGGGAGACT	CATAGAGCTCTCCTT	TTAGCTTTTCTTTAT
GGCTCAGGGAGACTC	ATAGAGCTCTCCTTG	TAGCTTTTCTTTATT
GCTCAGGGAGACTCT	TAGAGCTCTCCTTGA	AGCTTTTCTTTATTT
CTCAGGGAGACTCTG	AGAGCTCTCCTTGAA	GCTTTTCTTTATTTT
TCAGGGAGACTCTGC	GAGCTCTCCTTGAAA	CTTTTCTTTATTTT
10 CAGGGAGACTCTGCC	AGCTCTCCTTGAAAA	TTTTCTTTATTTT
AGGGAGACTCTGCCC	GCTCTCCTTGAAAAC	TTTCTTTATTTT
GGGAGACTCTGCCCT	CTCTCCTTGAAAACA	TTCTTTATTTT
GGAGACTCTGCCCTG	TCTCCTTGAAAACAG	TCTTTATTTT
GAGACTCTGCCCTGC	CTCCTTGAAAACAGA	CTTTATTTT
15 AGACTCTGCCCTGCT	TCCTTGAAAACAGAG	TTTATTTT
GACTCTGCCCTGCTG	CCTTGAAAACAGAGG	TTATTTT
ACTCTGCCCTGCTGC	CTTGAAAACAGAGGG	TATTTT
CTCTGCCCTGCTGCA	TTGAAAACAGAGGGG	ATTTT
TCTGCCCTGCTGCAG	TGAAAACAGAGGGGT	TTTTT
20 CTGCCCTGCTGCAGA	GAAAACAGAGGGGTCT	TTTTT
TGCCCTGCTGCAGAC	AAAACAGAGGGGTCT	TTTTT
GCCCTGCTGCAGACC	AAACAGAGGGGTCTC	TTTTT
CCCTGCTGCAGACCT	AACAGAGGGGTCTCA	TTTTT
CCTGCTGCAGACCTC	ACAGAGGGGTCTCAA	TTTTT
25 CTGCTGCAGACCTCG	CAGAGGGGTCTCAAG	TAACTTTT
TGCTGCAGACCTCGG	AGAGGGGTCTCAAGA	AACTTTTT
GCTGCAGACCTCGGT	GAGGGGTCTCAAGAC	ACTTTTT
CTGCAGACCTCGGTG	AGGGGTCTCAAGACA	CTTTTT
TGCAGACCTCGGTGT	GGGTCTCAAGACAT	TTTTT
30 GCAGACCTCGGTGTG	GGTCTCAAGACATT	TTTTT
CAGACCTCGGTGTGG	GGTCTCAAGACATT	TTTTT
AGACCTCGGTGTGGA	GTCTCAAGACATTCT	TTTTT
GACCTCGGTGTGGAC	TCTCAAGACATTCTG	TTTTT
ACCTCGGTGTGGACA	CTCAAGACATTCTGC	TTTTT
35 CCTCGGTGTGGACAC	TCAAGACATTCTGCC	TTTTT
CTCGGTGTGGACACA	CAAGACATTCTGCCT	TTTTT
TCGGTGTGGACACAC	AAGACATTCTGCCTA	TTTTT
CGGTGTGGACACACG	AGACATTCTGCCTAC	TTTTT
GGTGTGGACACACGC	GACATTCTGCCTACC	TTTTT
40 GTGTGGACACACGCT	ACATTCTGCCTACCT	TTTTT
TGTGGACACACGCTG	CATTCTGCCTACCTA	TTTTT
GTGGACACACGCTGC	ATTCTGCCTACCTAT	TTTTT
TGGACACACGCTGCA	TTCTGCCTACCTATT	TTTTT
GGACACACGCTGCAT	TCTGCCTACCTATTA	TTTTT
45 GACACACGCTGCATA	CTGCCTACCTATTAG	TTTTT
ACACACGCTGCATAG	TGCCTACCTATTAGC	TTTTT
CACACGCTGCATAGA	GCCTACCTATTAGCT	TTTTT
ACACGCTGCATAGAG	CCTACCTATTAGCTT	TTTTT
CACGCTGCATAGAGC	CTACCTATTAGCTTT	TTTTT
50 ACGCTGCATAGAGCT	TACCTATTAGCTTTT	TTTTT
CGCTGCATAGAGCTC	ACCTATTAGCTTTTC	TTTTT

- 60 -

GAGAAGTTTGTCTTG
 AGAAGTTTGTCTTGC
 GAAGTTTGTCTTGCA
 AAGTTTGTCTTGCAA
 5 AGTTTGTCTTGCAAT
 GTTTGTCTTGCAATG
 TTTGTCTTGCAATGT
 TTGTCTTGCAATGTA
 TGTCTTGCAATGTAT
 10 GTCTTGCAATGTATT
 TCTTGCAATGTATTT
 CTTGCAATGTATTTA
 TTGCAATGTATTTAT
 TGCAATGTATTTATA
 15 GCAATGTATTTATAA
 CAATGTATTTATAAA
 AATGTATTTATAAAT
 ATGTATTTATAAATA
 TGTATTTATAAATAG
 20 GTATTTATAAATAGT
 TATTTATAAATAGTA
 ATTTATAAATAGTAA
 TTTATAAATAGTAAA
 TTATAAATAGTAAAT
 25 TATAAATAGTAAATA
 ATAAATAGTAAATAA
 TAAATAGTAAATAAA
 AAATAGTAAATAAAG
 AATAGTAAATAAAGT
 30 ATAGTAAATAAAGTT
 TAGTAAATAAAGTTT
 AGTAAATAAAGTTTT
 GTAAATAAAGTTTTT
 TAAATAAAGTTTTTA
 35 AAATAAAGTTTTTAC
 AATAAAGTTTTTACC
 ATAAAGTTTTTACCA
 TAAAGTTTTTACCAT
 AAAGTTTTTACCATT
 40

EXAMPLE 8

Antisense oligonucleotides to IGF-I may be selected from molecules capable of interacting with one or more of the following sense oligonucleotides:

45

TTTTTTTTTTTTTTG
 TTTTTTTTTTTTTGA
 TTTTTTTTTTTTTGAG

TTTTTTTTTTTGAGA
 TTTTTTTTTTGAGAA
 TTTTTTTTTTGAGAAA

TTTTTTTTGAGAAAG
 TTTTTTTTGAGAAAGG
 TTTTTTTTGAGAAAGGG

- 61 -

TTTTTGAGAAAGGGA	GGAGGAGGGTCCCCG	CTCTCGCTCTGGCCG
TTTTTGAGAAAGGGAA	GAGGAGGGTCCCCGA	TCTCGCTCTGGCCGA
TTTGAGAAAGGGGAAT	AGGAGGGTCCCCGAC	CTCGCTCTGGCCGAC
TTGAGAAAGGGGAATT	GGAGGGTCCCCGACC	TCGCTCTGGCCGACG
5 TGAGAAAGGGGAATTT	GAGGGTCCCCGACCT	CGCTCTGGCCGACGA
GAGAAAGGGGAATTTTC	AGGGTCCCCGACCTC	GCTCTGGCCGACGAG
AGAAAGGGGAATTTCA	GGGTCCCCGACCTCG	CTCTGGCCGACGAGT
GAAAGGGGAATTTTCAT	GGTCCCCGACCTCGC	TCTGGCCGACGAGTG
AAAGGGGAATTTTCATC	GTCCCCGACCTCGCT	CTGGCCGACGAGTGG
10 AAGGGGAATTTTCATCC	TCCCCGACCTCGCTG	TGGCCGACGAGTGGG
AGGGGAATTTTCATCCC	CCCCGACCTCGCTGT	GGCCGACGAGTGGAG
GGGAATTTTCATCCCA	CCCGACCTCGCTGTG	GCCGACGAGTGGAGA
GGAATTTTCATCCCAA	CCGACCTCGCTGTGG	CCGACGAGTGGAGAA
GAATTTTCATCCCAAA	CGACCTCGCTGTGGG	CGACGAGTGGAGAAA
15 AATTTTCATCCCAAAT	GACCTCGCTGTGGGG	GACGAGTGGAGAAAT
ATTTTCATCCCAAATA	ACCTCGCTGTGGGGG	ACGAGTGGAGAAATC
TTTTCATCCCAAATAA	CCTCGCTGTGGGGGC	CGAGTGGAGAAATCT
TTCATCCCAAATAAAA	CTCGCTGTGGGGGCT	GAGTGGAGAAATCTG
TCATCCCAAATAAAAA	TCGCTGTGGGGGGCTC	AGTGGAGAAATCTGC
20 CATCCCAAATAAAAAG	CGCTGTGGGGGGCTCC	GTGGAGAAATCTGCG
ATCCCAAATAAAAAGG	GCTGTGGGGGGCTCCT	TGGAGAAATCTGCGG
TCCCAAATAAAAAGGA	CTGTGGGGGGCTCCTG	GGAGAAATCTGCGGG
CCCAAATAAAAAGGAA	TGTGGGGGGCTCCTGT	GAGAAATCTGCGGGC
CCAAATAAAAAGGAAT	GTGGGGGGCTCCTGTT	AGAAATCTGCGGGCC
25 CAAATAAAAAGGAATG	TGGGGGGCTCCTGTTT	GAAATCTGCGGGCCA
AAATAAAAAGGAATGA	GGGGGCTCCTGTTTC	AAATCTGCGGGCCAG
AATAAAAAGGAATGAA	GGGGCTCCTGTTTCT	AATCTGCGGGCCAGG
ATAAAAAGGAATGAAG	GGGCTCCTGTTTCTC	ATCTGCGGGCCAGGC
TAAAAGGAATGAAGT	GGCTCCTGTTTCTCT	TCTGCGGGCCAGGCA
30 AAAAGGAATGAAGTC	GCTCCTGTTTCTCTC	CTGCGGGCCAGGCAT
AAAGGAATGAAGTCT	CTCCTGTTTCTCTCC	TGCGGGCCAGGCATC
AAGGAATGAAGTCTG	TCCTGTTTCTCTCCG	GCGGGCCAGGCATCG
AGGAATGAAGTCTGG	CCTGTTTCTCTCCGC	CGGGCCAGGCATCGA
GGAATGAAGTCTGGC	CTGTTTCTCTCCGCC	GGCCAGGCATCGAC
35 GAATGAAGTCTGGCT	TGTTTCTCTCCGCCG	GGCCAGGCATCGACA
AATGAAGTCTGGCTC	GTTTCTCTCCGCCG	GCCAGGCATCGACAT
ATGAAGTCTGGCTCC	TTTCTCTCCGCCGCG	CCAGGCATCGACATC
TGAAGTCTGGCTCCG	TTCTCTCCGCCGCGC	CAGGCATCGACATCC
GAAGTCTGGCTCCGG	TCTCTCCGCCGCGCT	AGGCATCGACATCCG
40 AAGTCTGGCTCCGGA	CTCTCCGCCGCGCTC	GGCATCGACATCCGC
AGTCTGGCTCCGGAG	TCTCCGCCGCGCTCT	GCATCGACATCCGCA
GTCTGGCTCCGGAGG	CTCCGCCGCGCTCTC	CATCGACATCCGCAA
TCTGGCTCCGGAGGA	TCCGCCGCGCTCTCG	ATCGACATCCGCAAC
CTGGCTCCGGAGGAG	CCGCCGCGCTCTCGC	TCGACATCCGCAACG
45 TGGCTCCGGAGGAGG	CGCCGCGCTCTCGCT	CGACATCCGCAACGA
GGCTCCGGAGGAGGG	GCCGCGCTCTCGCTC	GACATCCGCAACGAC
GCTCCGGAGGAGGGT	CCGCGCTCTCGCTCT	ACATCCGCAACGACT
CTCCGGAGGAGGGTC	CGCGCTCTCGCTCTG	CATCCGCAACGACTA
TCCGGAGGAGGGTCC	GCGCTCTCGCTCTGG	ATCCGCAACGACTAT
50 CCGGAGGAGGGTCCC	CGCTCTCGCTCTGGC	TCCGCAACGACTATC
CGGAGGAGGGTCCCC	GCTCTCGCTCTGGCC	CCGCAACGACTATCA

- 62 -

CGCAACGACTATCAG	GGCTACCTCCACATC	CGCTTCCCCAAGCTC
GCAACGACTATCAGC	GCTACCTCCACATCC	GCTTCCCCAAGCTCA
CAACGACTATCAGCA	CTACCTCCACATCCT	CTTCCCCAAGCTCAC
AACGACTATCAGCAG	TACCTCCACATCCTG	TTCCCCAAGCTCACG
5 ACGACTATCAGCAGC	ACCTCCACATCCTGC	TCCCCAAGCTCACGG
CGACTATCAGCAGCT	CCTCCACATCCTGCT	CCCCAAGCTCACGGT
GACTATCAGCAGCTG	CTCCACATCCTGCTC	CCCAAGCTCACGGTC
ACTATCAGCAGCTGA	TCCACATCCTGCTCA	CCAAGCTCACGGTCA
CTATCAGCAGCTGAA	CCACATCCTGCTCAT	CAAGCTCACGGTCAT
10 TATCAGCAGCTGAAG	CACATCCTGCTCATC	AAGCTCACGGTCATT
ATCAGCAGCTGAAGC	ACATCCTGCTCATCT	AGCTCACGGTCATT
TCAGCAGCTGAAGCG	CATCCTGCTCATCTC	GCTCACGGTCATTAC
CAGCAGCTGAAGCGC	ATCCTGCTCATCTCC	CTCACGGTCATTACC
AGCAGCTGAAGCGCC	TCCTGCTCATCTCCA	TCACGGTCATTACCG
15 GCAGCTGAAGCGCCT	CCTGCTCATCTCCAA	CACGGTCATTACCGA
CAGCTGAAGCGCCTG	CTGCTCATCTCCAAG	ACGGTCATTACCGAG
AGCTGAAGCGCCTGG	TGCTCATCTCCAAGG	CGGTCATTACCGAGT
GCTGAAGCGCCTGGA	GCTCATCTCCAAGGC	GGTCATTACCGAGTA
CTGAAGCGCCTGGAG	CTCATCTCCAAGGCC	GTCATTACCGAGTAC
20 TGAAGCGCCTGGAGA	TCATCTCCAAGGCCG	TCATTACCGAGTACT
GAAGCGCCTGGAGAA	CATCTCCAAGGCCGA	CATTACCGAGTACTT
AAGCGCCTGGAGAAC	ATCTCCAAGGCCGAG	ATTACCGAGTACTTG
AGCGCCTGGAGAACT	TCTCCAAGGCCGAGG	TTACCGAGTACTTGC
GCGCCTGGAGAACTG	CTCCAAGGCCGAGGA	TACCGAGTACTTGCT
25 CGCCTGGAGAACTGC	TCCAAGGCCGAGGAC	ACCGAGTACTTGCTG
GCCTGGAGAACTGCA	CCAAGGCCGAGGACT	CCGAGTACTTGCTGC
CCTGGAGAACTGCAC	CAAGGCCGAGGACTA	CGAGTACTTGCTGCT
CTGGAGAACTGCACG	AAGGCCGAGGACTAC	GAGTACTTGCTGCTG
TGGAGAACTGCACGG	AGGCCGAGGACTACC	AGTACTTGCTGCTGT
30 GGAGAACTGCACGGT	GGCCGAGGACTACCG	GTACTTGCTGCTGTT
GAGAACTGCACGGTG	GCCGAGGACTACCGC	TACTTGCTGCTGTTT
AGAACTGCACGGTGA	CCGAGGACTACCGCA	ACTTGCTGCTGTTCC
GAACTGCACGGTGAT	CGAGGACTACCGCAG	CTTGCTGCTGTTCCG
AACTGCACGGTGATC	GAGGACTACCGCAGC	TTGCTGCTGTTCCGA
35 ACTGCACGGTGATCG	AGGACTACCGCAGCT	TGCTGCTGTTCCGAG
CTGCACGGTGATCGA	GGACTACCGCAGCTA	GCTGCTGTTCCGAGT
TGCACGGTGATCGAG	GACTACCGCAGCTAC	CTGCTGTTCCGAGTG
GCACGGTGATCGAGG	ACTACCGCAGCTACC	TGCTGTTCCGAGTGG
CACGGTGATCGAGGG	CTACCGCAGCTACCG	GCTGTTCCGAGTGGC
40 ACGGTGATCGAGGGC	TACCGCAGCTACCGC	CTGTTCCGAGTGGCT
CGGTGATCGAGGGCT	ACCGCAGCTACCGCT	TGTTCCGAGTGGCTG
GGTGATCGAGGGCTA	CCGCAGCTACCGCTT	GTTCCGAGTGGCTGG
GTGATCGAGGGCTAC	CGCAGCTACCGCTTC	TTCCGAGTGGCTGGC
TGATCGAGGGCTACC	GCAGCTACCGCTTCC	TCCGAGTGGCTGGCC
45 GATCGAGGGCTACCT	CAGCTACCGCTTCCC	CCGAGTGGCTGGCCT
ATCGAGGGCTACCTC	AGCTACCGCTTCCCC	CGAGTGGCTGGCCTC
TCGAGGGCTACCTCC	GCTACCGCTTCCCCA	GAGTGGCTGGCCTCG
CGAGGGCTACCTCCA	CTACCGCTTCCCCAA	AGTGGCTGGCCTCGA
GAGGGCTACCTCCAC	TACCGCTTCCCCAAG	GTGGCTGGCCTCGAG
50 AGGGCTACCTCCACA	ACCGCTTCCCCAAGC	TGGCTGGCCTCGAGA
GGGCTACCTCCACAT	CCGCTTCCCCAAGCT	GGCTGGCCTCGAGAG

GCTGGCCTCGAGAGC
CTGGCCTCGAGAGCC
TGGCCTCGAGAGCCT
GGCCTCGAGAGCCTC
5 GCCTCGAGAGCCTCG
CCTCGAGAGCCTCGG
CTCGAGAGCCTCGGA
TCGAGAGCCTCGGAG
CGAGAGCCTCGGAG
10 GAGAGCCTCGGAGAC
AGAGCCTCGGAGACC
GAGCCTCGGAGACCT
AGCCTCGGAGACCTC
GCCTCGGAGACCTCT
15 CCTCGGAGACCTCTT
CTCGGAGACCTCTTC
TCGGAGACCTCTTCC
CGGAGACCTCTTCCC
GGAGACCTCTTCCCC
20 GAGACCTCTTCCCCA
AGACCTCTTCCCCAA
GACCTCTTCCCCAAC
ACCTCTTCCCCAACC
CCTCTTCCCCAACCT
25 CTCTTCCCCAACCTC
TCTTCCCCAACCTCA
CTTCCCCAACCTCAC
TTCCCCAACCTCACG
TCCCCAACCTCACGG
30 CCCCACCTCACGGT
CCCAACCTCACGGTC
CCAACCTCACGGTCA
CAACCTCACGGTCAT
AACCTCACGGTCATC
35 ACCTCACGGTCATCC
CCTCACGGTCATCCG
CTCACGGTCATCCGC
TCACGGTCATCCGCG
CACGGTCATCCGCGG
40 ACGGTCATCCGCGGC
CGGTCATCCGCGGCT
GGTCATCCGCGGCTG
GTATCCGCGGCTGG
TCATCCGCGGCTGGA
45 CATCCGCGGCTGGAA
ATCCGCGGCTGGAAA
TCCGCGGCTGGAAAC
CCGCGGCTGGAAACT
CGCGGCTGGAAACTC
50 GCGGCTGGAAACTCT
CGGCTGGAAACTCTT

GGCTGGAAACTCTTCT
GCTGGAAACTCTTCT
CTGGAAACTCTTCTA
TGGAAACTCTTCTAC
GGAAACTCTTCTACA
GAAACTCTTCTACAA
AAACTCTTCTACAAC
AACTCTTCTACAAC
ACTCTTCTACAAC
CTCTTCTACAAC
TCTTCTACAAC
TTCTACAAC
TCTACAAC
CTACAAC
TACAAC
ACAAC
CAACTACGCCCTGGT
AACTACGCCCTGGT
ACTACGCCCTGGTCA
CTACGCCCTGGTCAT
TACGCCCTGGTCATC
ACGCCCTGGTCATCT
CGCCCTGGTCATCTT
GCCCTGGTCATCTTC
CCCTGGTCATCTTCG
CCTGGTCATCTTCGA
CTGGTCATCTTCGAG
TGGTCATCTTCGAGA
GGTCATCTTCGAGAT
GTCATCTTCGAGATG
TCATCTTCGAGATGA
CATCTTCGAGATGAC
ATCTTCGAGATGACC
TCTTCGAGATGACCA
CTTCGAGATGACCAA
TTCGAGATGACCAAT
TCGAGATGACCAATC
CGAGATGACCAATCT
GAGATGACCAATCTC
AGATGACCAATCTCA
GATGACCAATCTCAA
ATGACCAATCTCAAG
TGACCAATCTCAAGG
GACCAATCTCAAGGA
ACCAATCTCAAGGAT
CCAATCTCAAGGATA
CAATCTCAAGGATAT
AATCTCAAGGATATT
ATCTCAAGGATATTG
TCTCAAGGATATTGG

CTCAAGGATATTGGG
TCAAGGATATTGGGC
CAAGGATATTGGGCT
AAGGATATTGGGCTT
AGGATATTGGGCTTT
GGATATTGGGCTTTA
GATATTGGGCTTTAC
ATATTGGGCTTTACA
TATTGGGCTTTACAA
ATTGGGCTTTACAAC
TTGGGCTTTACAACC
TGGGCTTTACAACCT
GGGCTTTACAACCTG
GGCTTTACAACCTGA
GCTTTACAACCTGAG
CTTTACAACCTGAGG
TTTACAACCTGAGGA
TTACAACCTGAGGAA
TACAACCTGAGGAAC
ACAACCTGAGGAACA
CAACCTGAGGAACAT
AACCTGAGGAACATT
ACCTGAGGAACATTA
CCTGAGGAACATTAC
CTGAGGAACATTACT
TGAGGAACATTACTC
GAGGAACATTACTCG
AGGAACATTACTCGG
GGAACATTACTCGGG
GAACATTACTCGGGG
AACATTACTCGGGGG
ACATTACTCGGGGGG
CATTACTCGGGGGGC
ATTACTCGGGGGGCC
TTACTCGGGGGGCCA
TACTCGGGGGGCCAT
ACTCGGGGGGCCATC
CTCGGGGGGCCATCA
TCGGGGGGGCCATCAG
CGGGGGGCCATCAGG
GGGGGGGCCATCAGGA
GGGGGCCATCAGGAT
GGGGCCATCAGGATT
GGCCATCAGGATTG
GCCATCAGGATTGAG
CCATCAGGATTGAGA
CATCAGGATTGAGAA
ATCAGGATTGAGAAA
TCAGGATTGAGAAAA
CAGGATTGAGAAAAA

- 64 -

AGGATTGAGAAAAAT	CTGATCCTGGATGCG	AAGGAATGTGGGGAC
GGATTGAGAAAAATG	TGATCCTGGATGCGG	AGGAATGTGGGGACC
GATTGAGAAAAATGC	GATCCTGGATGCGGT	GGAATGTGGGGACCT
ATTGAGAAAAATGCT	ATCCTGGATGCGGTG	GAATGTGGGGACCTG
5 TTGAGAAAAATGCTG	TCCTGGATGCGGTGT	AATGTGGGGACCTGT
TGAGAAAAATGCTGA	CCTGGATGCGGTGTC	ATGTGGGGACCTGTG
GAGAAAAATGCTGAC	CTGGATGCGGTGTCC	TGTGGGGACCTGTGT
AGAAAAATGCTGACC	TGGATGCGGTGTCCA	GTGGGGACCTGTGTG
GAAAAATGCTGACCT	GGATGCGGTGTCCA	TGGGGACCTGTGTCC
10 AAAAAATGCTGACCTC	GATGCGGTGTCCAAT	GGGGACCTGTGTCCA
AAAATGCTGACCTCT	ATGCGGTGTCCAATA	GGGACCTGTGTCCAG
AAATGCTGACCTCTG	TGCGGTGTCCAATAA	GGACCTGTGTCCAGG
AATGCTGACCTCTGT	GCGGTGTCCAATAAC	GACCTGTGTCCAGGG
ATGCTGACCTCTGTT	CGGTGTCCAATAACT	ACCTGTGTCCAGGGA
15 TGCTGACCTCTGTTA	GGTGTCCAATAACTA	CCTGTGTCCAGGGAC
GCTGACCTCTGTTAC	GTGTCCAATAACTAC	CTGTGTCCAGGGACC
CTGACCTCTGTTACC	TGTCCAATAACTACA	TGTGTCCAGGGACCA
TGACCTCTGTTACCT	GTCCAATAACTACAT	GTGTCCAGGGACCAT
GACCTCTGTTACCTC	TCCAATAACTACATT	TGTCCAGGGACCATG
20 ACCTCTGTTACCTCT	CCAATAACTACATTG	GTCCAGGGACCATGG
CCTCTGTTACCTCTC	CAATAACTACATTGT	TCCAGGGACCATGGA
CTCTGTTACCTCTCC	AATAACTACATTGTG	CCAGGGACCATGGAG
TCTGTTACCTCTCCA	ATAACTACATTGTGG	CAGGGACCATGGAGG
CTGTTACCTCTCCAC	TAATACTACATTGTGGG	AGGGACCATGGAGGA
25 TGTTACCTCTCCACT	AACTACATTGTGGGG	GGGACCATGGAGGAG
GTTACCTCTCCACTG	ACTACATTGTGGGGA	GGACCATGGAGGAGA
TTACCTCTCCACTGT	CTACATTGTGGGGAA	GACCATGGAGGAGAA
TACCTCTCCACTGTG	TACATTGTGGGGAAT	ACCATGGAGGAGAAG
ACCTCTCCACTGTGG	ACATTGTGGGGAATA	CCATGGAGGAGAAGC
30 CCTCTCCACTGTGGA	CATTGTGGGGAATAA	CATGGAGGAGAAGCC
CTCTCCACTGTGGAC	ATTGTGGGGAATAAG	ATGGAGGAGAAGCCG
TCTCCACTGTGGACT	TTGTGGGGAATAAGC	TGGAGGAGAAGCCGA
CTCCACTGTGGACTG	TGTGGGGAATAAGCC	GGAGGAGAAGCCGAT
TCCACTGTGGACTGG	GTGGGGAATAAGCCC	GAGGAGAAGCCGATG
35 CCACTGTGGACTGGT	TGGGGAATAAGCCCC	AGGAGAAGCCGATGT
CACTGTGGACTGGTC	GGGGAATAAGCCCCC	GGAGAAGCCGATGTG
ACTGTGGACTGGTCC	GGGAATAAGCCCCCA	GAGAAGCCGATGTGT
CTGTGGACTGGTCCC	GGAATAAGCCCCCAA	AGAAGCCGATGTGTG
TGTGGACTGGTCCCT	GAATAAGCCCCCAAA	GAAGCCGATGTGTGA
40 GTGGACTGGTCCCTG	AATAAGCCCCCAAAG	AAGCCGATGTGTGAG
TGGACTGGTCCCTGA	ATAAGCCCCCAAAGG	AGCCGATGTGTGAGA
GGACTGGTCCCTGAT	TAAGCCCCCAAAGGA	GCCGATGTGTGAGAA
GACTGGTCCCTGATC	AAGCCCCCAAAGGAA	CCGATGTGTGAGAA
ACTGGTCCCTGATCC	AGCCCCCAAAGGAAT	CGATGTGTGAGAA
45 CTGGTCCCTGATCCT	GCCCCCAAAGGAATG	GATGTGTGAGAA
TGGTCCCTGATCCTG	CCCCCAAAGGAATGT	ATGTGTGAGAA
GGTCCCTGATCCTGG	CCCCAAAGGAATGTG	TGTGTGAGAA
GTCCCTGATCCTGGA	CCCAAAGGAATGTGG	GTGTGAGAA
TCCCTGATCCTGGAT	CCAAAGGAATGTGGG	TGTGAGAA
50 CCCTGATCCTGGATG	CAAAGGAATGTGGGG	GTGAGAA
CCTGATCCTGGATGC	AAAGGAATGTGGGGA	TGAGAA

- 65 -

	GAGAAGACCACCATC	CGCTGCCAGAAAATG	AACAATGAGTGCTGC
	AGAAGACCACCATCA	GCTGCCAGAAAATGT	ACAATGAGTGCTGCC
	GAAGACCACCATCAA	CTGCCAGAAAATGTG	CAATGAGTGCTGCCA
	AAGACCACCATCAAC	TGCCAGAAAATGTGC	AATGAGTGCTGCCAC
5	AGACCACCATCAACA	GCCAGAAAATGTGCC	ATGAGTGCTGCCACC
	GACCACCATCAACAA	CCAGAAAATGTGCCC	TGAGTGCTGCCACCC
	ACCACCATCAACAAT	CAGAAAATGTGCCCC	GAGTGCTGCCACCCC
	CCACCATCAACAATG	AGAAAATGTGCCCCA	AGTGCTGCCACCCCG
	CACCATCAACAATGA	GAAAATGTGCCCCAAG	GTGCTGCCACCCCGA
10	ACCATCAACAATGAG	AAAATGTGCCCCAAGC	TGCTGCCACCCCGAG
	CCATCAACAATGAGT	AAATGTGCCCCAAGCA	GCTGCCACCCCGAGT
	CATCAACAATGAGTA	AATGTGCCCCAAGCAC	CTGCCACCCCGAGTG
	ATCAACAATGAGTAC	ATGTGCCCCAAGCACG	TGCCACCCCGAGTGC
	TCAACAATGAGTACA	TGTGCCCCAAGCACGT	GCCACCCCGAGTGCC
15	CAACAATGAGTACAA	GTGCCCCAAGCACGTG	CCACCCCGAGTGCTT
	AACAATGAGTACAAC	TGCCCCAAGCACGTGT	CACCCCGAGTGCTTG
	ACAATGAGTACAAC	GCCCCAAGCACGTGTG	ACCCCGAGTGCTTGG
	CAATGAGTACAAC	CCCAAGCACGTGTGG	CCCCGAGTGCTTGGG
	AATGAGTACAAC	CCAAGCACGTGTGGG	CCCGAGTGCTTGGGC
20	ATGAGTACAAC	CAAGCACGTGTGGGA	CCGAGTGCTTGGGCA
	TGAGTACAAC	AAGCACGTGTGGGAA	CGAGTGCTTGGGCAG
	GAGTACAAC	AGCACGTGTGGGAAG	GAGTGCTTGGGCAGC
	AGTACAAC	GCACGTGTGGGAAGC	AGTGCTTGGGCAGCT
	GTACAAC	CACGTGTGGGAAGCG	GTGCTTGGGCAGCTG
25	TACAAC	ACGTGTGGGAAGCGG	TGCTTGGGCAGCTGC
	ACAAC	CGTGTGGGAAGCGGG	GCCTGGGCAGCTGCA
	CAAC	GTGTGGGAAGCGGGC	CCTGGGCAGCTGCAG
	AACT	TGTGGGAAGCGGGCG	CTGGGCAGCTGCAGC
	ACT	GTGGGAAGCGGGCGT	TGGGCAGCTGCAGCG
30	CTACCGCTGCTGGAC	TGGGAAGCGGGCGTG	GGGCAGCTGCAGCGC
	TACCGCTGCTGGACC	GGAAGCGGGCGTGCA	GGCAGCTGCAGCGCG
	ACCGCTGCTGGACCA	GGAAGCGGGCGTGCA	GCAGCTGCAGCGCGC
	CCGCTGCTGGACCACA	GAAGCGGGCGTGCA	CAGCTGCAGCGCGCC
35	GCTGCTGGACCACAA	AAGCGGGCGTGCA	AGCTGCAGCGCGCCT
	CTGCTGGACCACAAA	AGCGGGCGTGCA	GCTGCAGCGCGCCTG
	TGCTGGACCACAAAC	GCGGGCGTGCA	CTGCAGCGCGCCTGA
	GCTGGACCACAAACC	CGGGCGTGCA	TGCAGCGCGCCTGAC
	CTGGACCACAAACCG	GGGCGTGCA	GCAGCGCGCCTGACA
40	TGGACCACAAACCGC	GGCGTGCA	CAGCGCGCCTGACAA
	GGACCACAAACCGCT	GCGTGCA	AGCGCGCCTGACAAC
	GACCACAAACCGCTG	CGTGCA	GCGCGCCTGACAACG
	ACCACAAACCGCTGC	GTGCA	CGCGCCTGACAACGA
	CCACAAACCGCTGCC	TGC	GCGCCTGACAACGAC
45	CACAAACCGCTGCCA	GC	CGCCTGACAACGACA
	ACAAACCGCTGCCAG	CACCGAGAACAATGA	GCCTGACAACGACAC
	CAAACCGCTGCCAGA	ACCGAGAACAATGAG	CCTGACAACGACACG
	AAACCGCTGCCAGAA	CCGAGAACAATGAGT	CTGACAACGACACGG
	AACCGCTGCCAGAAA	CGAGAACAATGAGTG	TGACAACGACACGGC
50	ACCGCTGCCAGAAAA	GAGAACAATGAGTGC	GACAACGACACGGCC
	CCGCTGCCAGAAAAT	AGAACAATGAGTGCT	ACAACGACACGGCCT
		GAACAATGAGTGCTG	CAACGACACGGCCTG

- 66 -

AACGACACGGCCTGT	GTGCCTGCCTGCCCCG	GACCGTGACTTCTGCG
ACGACACGGCCTGTG	TGCCTGCCTGCCCCGC	ACCGTGACTTCTGCG
CGACACGGCCTGTGT	GCCTGCCTGCCCCGCC	CCGTGACTTCTGCGC
GACACGGCCTGTGTA	CCTGCCTGCCCCGCC	CGTGACTTCTGCGCC
5 ACACGGCCTGTGTAG	CTGCCTGCCCCGCCA	GTGACTTCTGCGCCA
CACGGCCTGTGTAGC	TGCCTGCCCCGCCAA	TGACTTCTGCGCCA
ACGGCCTGTGTAGCT	GCCTGCCCCGCCAAC	GACTTCTGCGCCAAC
CGGCCTGTGTAGCTT	CCTGCCCCGCCAACA	ACTTCTGCGCCAACA
GGCCTGTGTAGCTTG	CTGCCCCGCCAACAC	CTTCTGCGCCAACAT
10 GCCTGTGTAGCTTGC	TGCCCCGCCAACACC	TTCTGCGCCAACATC
CCTGTGTAGCTTGCC	GCCCCGCCAACACCT	TCTGCGCCAACATCC
CTGTGTAGCTTGCCG	CCGCCCAACACCTA	CTGCGCCAACATCCT
TGTGTAGCTTGCCGC	CCGCCCAACACCTAC	TGCGCCAACATCCTC
GTGTAGCTTGCCGCC	CGCCCAACACCTACA	GCGCCAACATCCTCA
15 TGTAGCTTGCCGCCA	GCCCAACACCTACAG	CGCCAACATCCTCAG
GTAGCTTGCCGCCAC	CCCAACACCTACAGG	GCCAACATCCTCAGC
TAGCTTGCCGCCACT	CCAACACCTACAGGT	CCAACATCCTCAGCG
AGCTTGCCGCCACTA	CAACACCTACAGGTT	CAACATCCTCAGCGC
GCTTGCCGCCACTAC	AACACCTACAGGTTT	AACATCCTCAGCGCC
20 CTTGCCGCCACTACT	ACACCTACAGGTTTG	ACATCCTCAGCGCCG
TTGCCGCCACTACTA	CACCTACAGGTTTGA	CATCCTCAGCGCCGA
TGCCGCCACTACTAC	ACCTACAGGTTTGAG	ATCCTCAGCGCCGAG
GCCGCCACTACTACT	CCTACAGGTTTGAGG	TCCTCAGCGCCGAGA
CCGCCACTACTACTA	CTACAGGTTTGAGGG	CCTCAGCGCCGAGAG
25 CGCCACTACTACTAT	TACAGGTTTGAGGGC	CTCAGCGCCGAGAGC
GCCACTACTACTATG	ACAGGTTTGAGGGCT	TCAGCGCCGAGAGCA
CCACTACTACTATGC	CAGGTTTGAGGGCTG	CAGCGCCGAGAGCAG
CACTACTACTATGCC	AGGTTTGAGGGCTGG	AGCGCCGAGAGCAGC
ACTACTACTATGCCG	GGTTTGAGGGCTGGC	GCGCCGAGAGCAGCG
30 CTACTACTATGCCGG	GTTTGAGGGCTGGCG	CGCCGAGAGCAGCGA
TACTACTATGCCGGT	TTTGAGGGCTGGCGC	GCCGAGAGCAGCGAC
ACTACTATGCCGGTG	TTGAGGGCTGGCGCT	CCGAGAGCAGCGACT
CTACTATGCCGGTGT	TGAGGGCTGGCGCTG	CGAGAGCAGCGACTC
TACTATGCCGGTGTG	GAGGGCTGGCGCTGT	GAGAGCAGCGACTCC
35 ACTATGCCGGTGTCT	AGGGCTGGCGCTGTG	AGAGCAGCGACTCCG
CTATGCCGGTGTCTG	GGGCTGGCGCTGTGT	GAGCAGCGACTCCGA
TATGCCGGTGTCTGT	GGCTGGCGCTGTGTG	AGCAGCGACTCCGAG
ATGCCGGTGTCTGTG	GCTGGCGCTGTGTGG	GCAGCGACTCCGAGG
TGCCGGTGTCTGTGT	CTGGCGCTGTGTGGA	CAGCGACTCCGAGGG
40 GCCGGTGTCTGTGTG	TGGCGCTGTGTGGAC	AGCGACTCCGAGGGG
CCGGTGTCTGTGTGC	GGCGCTGTGTGGACC	GCGACTCCGAGGGGT
CGGTGTCTGTGTGCC	GCGCTGTGTGGACCG	CGACTCCGAGGGGTT
GGTGTCTGTGTGCCT	CGCTGTGTGGACCGT	GACTCCGAGGGGTTT
GTGTCTGTGTGCCTG	GCTGTGTGGACCGTG	ACTCCGAGGGGTTTG
45 TGTCTGTGTGCCTGC	CTGTGTGGACCGTGA	CTCCGAGGGGTTTGT
GTCTGTGTGCCTGCC	TGTGTGGACCGTGAC	TCCGAGGGGTTTGTG
TCTGTGTGCCTGCCT	GTGTGGACCGTGACT	CCGAGGGGTTTGTGA
CTGTGTGCCTGCCTG	TGTGGACCGTGACTT	CGAGGGGTTTGTGAT
TGTGTGCCTGCCTGC	GTGGACCGTGACTTC	GAGGGGTTTGTGATC
50 GTGTGCCTGCCTGCC	TGGACCGTGACTTCT	AGGGGTTTGTGATCC
TGTGCCTGCCTGCCC	GGACCGTGACTTCTG	GGGGTTTGTGATCCA

- 67 -

GGGTTTGTGATCCAC	ATCCGCAACGGCAGC	CCGAAGGTCTGTGAG
GGTTTGTGATCCACG	TCCGCAACGGCAGCC	CGAAGGTCTGTGAGG
GTTTGTGATCCACGA	CCGCAACGGCAGCCA	GAAGGTCTGTGAGGA
TTTGTGATCCACGAC	CGCAACGGCAGCCAG	AAGGTCTGTGAGGAA
5 TTGTGATCCACGACG	GCAACGGCAGCCAGA	AGGTCTGTGAGGAAG
TGTGATCCACGACGG	CAACGGCAGCCAGAG	GGTCTGTGAGGAAGA
GTGATCCACGACGGC	AACGGCAGCCAGAGC	GTCTGTGAGGAAGAA
TGATCCACGACGGCG	ACGGCAGCCAGAGCA	TCTGTGAGGAAGAAA
GATCCACGACGGCGA	CGGCAGCCAGAGCAT	CTGTGAGGAAGAAAA
10 ATCCACGACGGCGAG	GGCAGCCAGAGCATG	TGTGAGGAAGAAAAG
TCCACGACGGCGAGT	GCAGCCAGAGCATGT	GTGAGGAAGAAAAGA
CCACGACGGCGAGTG	CAGCCAGAGCATGTA	TGAGGAAGAAAAGAA
CACGACGGCGAGTGC	AGCCAGAGCATGTAC	GAGGAAGAAAAGAAA
ACGACGGCGAGTGCA	GCCAGAGCATGTACT	AGGAAGAAAAGAAAA
15 CGACGGCGAGTGTCAT	CCAGAGCATGTACTG	GGAAGAAAAGAAAAC
GACGGCGAGTGTCATG	CAGAGCATGTACTGC	GAAGAAAAGAAAACA
ACGGCGAGTGTCATGC	AGAGCATGTACTGCA	AAGAAAAGAAAACAA
CGGCGAGTGTCATGCA	GAGCATGTACTGCAT	AGAAAAGAAAACAAA
GGCGAGTGTCATGCAG	AGCATGTACTGCATC	GAAAAGAAAACAAAG
20 GCGAGTGTCATGCAGG	GCATGTACTGCATCC	AAAAGAAAACAAAGA
CGAGTGTCATGCAGGA	CATGTACTGCATCCC	AAAGAAAACAAAGAC
GAGTGTCATGCAGGAG	ATGTACTGCATCCCT	AAGAAAACAAAGACC
AGTGTCATGCAGGAGT	TGTACTGCATCCCTT	AGAAAACAAAGACCA
GTGCATGCAGGAGTG	GTA TGTACTGCATCCCTTG	GAAAACAAAGACCAT
25 TGCATGCAGGAGTGC	TACTGCATCCCTTGT	AAAACAAAGACCATT
GCATGCAGGAGTGCC	ACTGCATCCCTTGTG	AAACAAAGACCATTG
CATGCAGGAGTGCCC	CTGCATCCCTTGTGA	AACAAAGACCATTGA
ATGCAGGAGTGCCCC	TGCATCCCTTGTGAA	ACAAAGACCATTGAT
TGCAGGAGTGCCCCCT	GCATCCCTTGTGAAG	CAAAGACCATTGATT
30 GCAGGAGTGCCCCCTC	CATCCCTTGTGAAGG	AAAGACCATTGATTCT
CAGGAGTGCCCCCTCG	ATCCCTTGTGAAGGT	AAGACCATTGATTCTG
AGGAGTGCCCCCTCGG	TCCCTTGTGAAGGTC	AGACCATTGATTCTGT
GGAGTGCCCCCTCGGG	CCCTTGTGAAGGTCC	GACCATTGATTCTGTT
GAGTGCCCCCTCGGGC	CCTTGTGAAGGTCTT	ACCATGATTCTGTTA
35 AGTGCCCCCTCGGGCT	CTTGTGAAGGTCTTG	CATTGATTCTGTTACT
GTGCCCCCTCGGGCTT	TTGTGAAGGTCTTGC	ATTGATTCTGTTACTT
TGCCCCCTCGGGCTTC	GTGAAGGTCTTGGCC	TTGATTCTGTTACTTC
GCCCCCTCGGGCTTCA	TGAAGGTCTTGGCCG	GATTCTGTTACTTCTG
CCCCCTCGGGCTTCAT	GAAGGTCTTGGCCG	ATTCTGTTACTTCTG
40 CCCTCGGGCTTCATC	AAGGTCTTGGCCGA	TTCTGTTACTTCTGC
CCTCGGGCTTCATCC	AGGTCTTGGCCGAA	TCTGTTACTTCTGCT
CTCGGGCTTCATCCG	GGTCTTGGCCGAAG	CTGTTACTTCTGCTC
TCGGGCTTCATCCGC	GTCTTGGCCGAAGG	TGTTACTTCTGCTCA
CGGGCTTCATCCGCA	TCCTTGGCCGAAGGT	GTTACTTCTGCTCAG
45 GGGCTTCATCCGCAA	CCTTGGCCGAAGGTC	TTACTTCTGCTCAGAT
GGCTTCATCCGCAAC	CTTGGCCGAAGGTCT	TACTTCTGCTCAGATG
GCTTCATCCGCAACG	TTGCCCCGAAGGTCTG	ACTTCTGCTCAGATG
CTTCATCCGCAACGG	TGCCCCGAAGGTCTGT	CTTCTGCTCAGATGC
TTCATCCGCAACGGC	GCCCCGAAGGTCTGTG	TTCTGCTCAGATGCT
50 TCATCCGCAACGGCA	CCCGAAGGTCTGTGA	
CATCCGCAACGGCAG		

- 68 -

TCTGCTCAGATGCTC	AACATCCGACGGGGG	CTCATCGAGGTGGTG
CTGCTCAGATGCTCC	ACATCCGACGGGGGA	TCATCGAGGTGGTGA
TGCTCAGATGCTCCA	CATCCGACGGGGGAA	CATCGAGGTGGTGAC
GCTCAGATGCTCCAA	ATCCGACGGGGGAAT	ATCGAGGTGGTGACG
5 CTCAGATGCTCCAAG	TCCGACGGGGGAATA	TCGAGGTGGTGACGG
TCAGATGCTCCAAGG	CCGACGGGGGAATAA	CGAGGTGGTGACGGG
CAGATGCTCCAAGGA	CGACGGGGGAATAAC	GAGGTGGTGACGGGC
AGATGCTCCAAGGAT	GACGGGGGAATAACA	AGGTGGTGACGGGCT
GATGCTCCAAGGATG	ACGGGGGAATAACAT	GGTGGTGACGGGCTA
10 ATGCTCCAAGGATGC	CGGGGAATAACATT	GTGGTGACGGGCTAC
TGCTCCAAGGATGCA	GGGGGAATAACATTG	TGGTGACGGGCTACG
GCTCCAAGGATGCAC	GGGAATAACATTGCT	GGTGACGGGCTACGT
CTCCAAGGATGCACC	GGAATAACATTGCTT	GTGACGGGCTACGTG
TCCAAGGATGCACCA	GAATAACATTGCTTC	TGACGGGCTACGTGA
15 CCAAGGATGCACCAT	AATAACATTGCTTCA	GACGGGCTACGTGAA
CAAGGATGCACCATC	ATAACATTGCTTCAG	ACGGGCTACGTGAAG
AAGGATGCACCATCT	TAACATTGCTTCAGA	CGGGCTACGTGAAGA
AGGATGCACCATCTT	AACATTGCTTCAGAG	GGGCTACGTGAAGAT
GGATGCACCATCTTC	ACATTGCTTCAGAGC	GGCTACGTGAAGATC
20 GATGCACCATCTTCA	CATTGCTTCAGAGCT	GCTACGTGAAGATCC
ATGCACCATCTTCAA	ATTGCTTCAGAGCTG	CTACGTGAAGATCCG
TGCACCATCTTCAAG	TTGCTTCAGAGCTGG	TACGTGAAGATCCGC
GCACCATCTTCAAGG	TGCTTCAGAGCTGGA	ACGTGAAGATCCGCC
CACCATCTTCAAGGG	GCTTCAGAGCTGGAG	CGTGAAGATCCGCCA
25 ACCATCTTCAAGGGC	CTTCAGAGCTGGAGA	GTGAAGATCCGCCAT
CCATCTTCAAGGGCA	TTCAGAGCTGGAGAA	TGAAGATCCGCCATT
CATCTTCAAGGGCAA	TCAGAGCTGGAGAAC	GAAGATCCGCCATTCT
ATCTTCAAGGGCAAT	CAGAGCTGGAGAACT	AAGATCCGCCATTCTC
TCTTCAAGGGCAATT	AGAGCTGGAGAACTT	AGATCCGCCATTCTCA
30 CTTCAAGGGCAATTT	GAGCTGGAGAACTTC	GATCCGCCATTCTCAT
TTCAAGGGCAATTTG	AGCTGGAGAACTTCA	ATCCGCCATTCTCATG
TCAAGGGCAATTTGC	GCTGGAGAACTTCAT	TCCGCCATTCTCATG
CAAGGGCAATTTGCT	CTGGAGAACTTCATG	CCGCCATTCTCATGCC
AAGGGCAATTTGCTC	TGGAGAACTTCATGG	CGCCATTCTCATGCC
35 AGGGCAATTTGCTCA	GGAGAACTTCATGGG	GCCATTCTCATGCCCT
GGGCAATTTGCTCAT	GAGAACTTCATGGGG	CCATTCTCATGCCCTT
GGCAATTTGCTCATT	AGAACTTCATGGGGC	CATTCTCATGCCCTTG
GCAATTTGCTCATTA	GAACCTTCATGGGGCT	ATTCTCATGCCCTTGG
CAATTTGCTCATTA	AACTTCATGGGGCTC	TTCTCATGCCCTTGGT
40 AATTTGCTCATTAAC	ACTTCATGGGGCTCA	TCTCATGCCCTTGGTC
ATTTGCTCATTAACA	CTTCATGGGGCTCAT	CTCATGCCCTTGGTCT
TTTGCTCATTAACAT	TTCATGGGGCTCATC	TCATGCCCTTGGTCTC
TTGCTCATTAACATC	TCATGGGGCTCATCG	CATGCCCTTGGTCTCC
TGCTCATTAACATCC	CATGGGGCTCATCGA	ATGCCCTTGGTCTCCT
45 GCTCATTAACATCCG	ATGGGGCTCATCGAG	TGCCTTGGTCTCCTT
CTCATTAACATCCGA	TGGGGCTCATCGAGG	GCCTTGGTCTCCTTG
TCATTAACATCCGAC	GGGGCTCATCGAGGT	CCTTGGTCTCCTTGT
CATTAACATCCGACG	GGGCTCATCGAGGTG	CTTGGTCTCCTTGTG
ATTAACATCCGACGG	GGCTCATCGAGGTGG	TTGGTCTCCTTGTCC
50 TTAACATCCGACGGG	GCTCATCGAGGTGGT	TGGTCTCCTTGTCTT
TAACATCCGACGGGG		

- 69 -

GTCTCCTTGTCTTC	CTAGAAGGGAATTAC	CTGTGGGACTGGGAC
TCTCCTTGTCTTCC	TAGAAGGGAATTACT	TGTGGGACTGGGACC
CTCCTTGTCTTCCT	AGAAGGGAATTACTC	GTGGGACTGGGACCA
TCCTTGTCTTCCTA	GAAGGGAATTACTCC	TGGGACTGGGACCAC
5 CCTTGTCTTCCTAA	AAGGGAATTACTCCT	GGGACTGGGACCACC
CTTGTCTTCCTAAA	AGGGAATTACTCCTT	GGACTGGGACCACCG
TTGTCTTCCTAAAA	GGGAATTACTCCTTC	GACTGGGACCACCGC
TGTCTTCCTAAAAA	GGAATTACTCCTTCT	ACTGGGACCACCGCA
GTCCTTCCTAAAAA	GAATTACTCCTTCTA	CTGGGACCACCGCAA
10 TCCTTCCTAAAAAAC	AATTACTCCTTCTAC	TGGGACCACCGCAAC
CCTTCCTAAAAAAC	ATTACTCCTTCTACG	GGGACCACCGCAACC
CTTCCTAAAAAACCT	TTACTCCTTCTACGT	GGACCACCGCAACCT
TTCTTCCTAAAAACCTT	TACTCCTTCTACGTC	GACCACCGCAACCTG
TCCTAAAAAACCTTC	ACTCCTTCTACGTCC	ACCACCGCAACCTGA
15 CCTAAAAAACCTTCG	CTCCTTCTACGTCTT	CCACCGCAACCTGAC
CTAAAAAACCTTCGC	TCCTTCTACGTCTTC	CACCGCAACCTGACC
TAAAAAACCTTCGCC	CCTTCTACGTCTTCG	ACCGCAACCTGACCA
AAAAAACCTTCGCCT	CTTCTACGTCTTCGA	CCGCAACCTGACCAT
AAAAACCTTCGCCTC	TTCTACGTCTTCGAC	CGCAACCTGACCATC
20 AAAACCTTCGCCTCA	TCTACGTCTTCGACA	GCAACCTGACCATCA
AAACCTTCGCCTCAT	CTACGTCTTCGACAA	CAACCTGACCATCAA
AACCTTCGCCTCATC	TACGTCTTCGACAAC	AACCTGACCATCAAA
ACCTTCGCCTCATCC	ACGTCTTCGACAACC	ACCTGACCATCAAAG
CCTTCGCCTCATCCT	CGTCTTCGACAACCA	CCTGACCATCAAAGC
25 CTTTCGCCTCATCCTA	GTCTTCGACAACCAG	CTGACCATCAAAGCA
TTTCGCCTCATCCTAG	TCCTTCGACAACCAGA	TGACCATCAAAGCAG
TCGCCTCATCCTAGG	CCTTCGACAACCAGAA	GACCATCAAAGCAGG
CGCCTCATCCTAGGA	CTCGACAACCAGAAC	ACCATCAAAGCAGGG
GCCTCATCCTAGGAG	TCGACAACCAGAACT	CCATCAAAGCAGGGA
30 CCTCATCCTAGGAGA	CGACAACCAGAACTT	CATCAAAGCAGGGAA
CTCATCCTAGGAGAG	GACAACCAGAACTTG	ATCAAAGCAGGGAAA
TCATCCTAGGAGAGG	ACAACCAGAACTTGC	TCAAAGCAGGGAAAA
CATCCTAGGAGAGGA	CAACCAGAACTTGCA	CAAAGCAGGGAAAAAT
ATCCTAGGAGAGGAG	AACCAGAACTTGCA	AAAGCAGGGAAAAATG
35 TCCTAGGAGAGGAGC	ACCAGAACTTGCA	AAGCAGGGAAAAATGT
CCTAGGAGAGGAGCA	CCAGAACTTGCA	AGCAGGGAAAAATGTA
CTAGGAGAGGAGCAG	CAGAACTTGCA	GCAGGGAAAAATGTAC
TAGGAGAGGAGCAGC	AGAACTTGCA	CAGGGAAAAATGTACT
AGGAGAGGAGCAGCT	GAACCTTGCA	AGGGAAAAATGTACTT
40 GGAGAGGAGCAGCTA	AACTTGCA	GGGAAAAATGTACTTT
GAGAGGAGCAGCTAG	ACTTGCA	GGAAAAATGTACTTTG
AGAGGAGCAGCTAGA	CTTGCA	GAAAAATGTACTTTGC
GAGGAGCAGCTAGAA	TTGCA	AAAATGTACTTTGCT
AGGAGCAGCTAGAAG	TGCA	AAATGTACTTTGCTT
45 GGAGCAGCTAGAAGG	GCAGCA	AATGTACTTTGCTTT
GAGCAGCTAGAAGGG	CAGCA	ATGTACTTTGCTTTC
AGCAGCTAGAAGGGA	AGCA	TGTACTTTGCTTTCA
GCAGCTAGAAGGGAA	GCA	GTACTTTGCTTTCAA
CAGCTAGAAGGGAAT	CA	TACTTTGCTTTCAAT
50 AGCTAGAAGGGAATT	AACTGTGGGACTGGG	ACTTTGCTTTCAATC
GCTAGAAGGGAATTA	ACTGTGGGACTGGGA	CTTTGCTTTCAATCC

- 70 -

TTTGCTTTCAATCCC	GTGACGGGGACTAAA	AACGGGGAGAGAGCC
TTGCTTTCAATCCCA	TGACGGGGACTAAAG	ACGGGGAGAGAGCCT
TGCTTTCAATCCCAA	GACGGGGACTAAAGG	CGGGGAGAGAGCCTC
GCTTTCAATCCCAAA	ACGGGGACTAAAGGG	GGGGAGAGAGCCTCC
5 CTTTCAATCCCAAAT	CGGGGACTAAAGGGC	GGGAGAGAGCCTCCT
TTTCAATCCCAAATT	GGGGACTAAAGGGCG	GGAGAGAGCCTCCTG
TTCAATCCCAAATTA	GGGACTAAAGGGCGC	GAGAGAGCCTCCTGT
TCAATCCCAAATTAT	GGACTAAAGGGCGCC	AGAGAGCCTCCTGTG
CAATCCCAAATTATG	GACTAAAGGGCGCCA	GAGAGCCTCCTGTGA
10 AATCCCAAATTATGT	ACTAAAGGGCGCCAA	AGAGCCTCCTGTGAA
ATCCCAAATTATGTG	CTAAAGGGCGCCAAA	GAGCCTCCTGTGAAA
TCCCAAATTATGTGT	TAAAGGGCGCCAAAG	AGCCTCCTGTGAAAG
CCCAAATTATGTGTT	AAAGGGCGCCAAAGC	GCCTCCTGTGAAAGT
CCAAATTATGTGTTT	AAGGGCGCCAAAGCA	CCTCCTGTGAAAGTG
15 CAAATTATGTGTTTC	AGGGCGCCAAAGCAA	CTCCTGTGAAAGTGA
AAATTATGTGTTTCC	GGGCGCCAAAGCAAA	TCCTGTGAAAGTGAC
AATTATGTGTTTCCG	GGCGCCAAAGCAAAG	CCTGTGAAAGTGACG
ATTATGTGTTTCCGA	GCGCCAAAGCAAAGG	CTGTGAAAGTGACGT
TTATGTGTTTCCGAA	CGCCAAAGCAAAGGG	TGTGAAAGTGACGTC
20 TATGTGTTTCCGAAA	GCCAAAGCAAAGGGG	GTGAAAGTGACGTCC
ATGTGTTTCCGAAAT	CCAAAGCAAAGGGGA	TGAAAGTGACGTCTT
TGTGTTTCCGAAATT	CAAAGCAAAGGGGAC	GAAAGTGACGTCTTG
GTGTTTCCGAAATTT	AAAGCAAAGGGGACA	AAAGTGACGTCTTGC
TGTTTCCGAAATTTA	AAGCAAAGGGGACAT	AAGTGACGTCTTGCA
25 GTTTCCGAAATTTAC	AGCAAAGGGGACATA	AGTGACGTCTTGCA
TTTCCGAAATTTACC	GCAAAGGGGACATAA	GTGACGTCTTGCA
TTCCGAAATTTACCG	CAAAGGGGACATAAA	TGACGTCTTGCA
TCCGAAATTTACCGC	AAAGGGGACATAAAC	GACGTCTTGCA
CCGAAATTTACCGCA	AAGGGGACATAAACA	ACGTCTTGCA
30 CGAAATTTACCGCAT	AGGGGACATAAACAC	CGTCTTGCA
GAAATTTACCGCATG	GGGGACATAAACACC	GTCTTGCA
AAATTTACCGCATGG	GGGACATAAACACCA	TCCTTGCA
AATTTACCGCATGGA	GGACATAAACACCAG	CCTTGCA
ATTTACCGCATGGAG	GACATAAACACCAGG	CTTGCA
35 TTTACCGCATGGAGG	ACATAAACACCAGGA	TGCA
TTACCGCATGGAGGA	CATAAACACCAGGAA	GCATTTACCTCCAC
TACCGCATGGAGGAA	ATAAACACCAGGAAC	CATTTACCTCCACC
ACCGCATGGAGGAAG	TAAACACCAGGAACA	ATTTACCTCCACC
CCGCATGGAGGAAGT	AAACACCAGGAACAA	TTTACCTCCACC
40 CGCATGGAGGAAGTG	AACACCAGGAACAAC	TTCACCTCCACC
GCATGGAGGAAGTGA	ACACCAGGAACAACG	TCACCTCCACC
CATGGAGGAAGTGAC	CACCAGGAACAACGG	CACCTCCACC
ATGGAGGAAGTGACG	ACCAGGAACAACGGG	ACCTCCACC
TGGAGGAAGTGACGG	CCAGGAACAACGGGG	CCTCCACC
45 GGAGGAAGTGACGGG	CAGGAACAACGGGGA	CTCCACC
GAGGAAGTGACGGGG	AGGAACAACGGGGAG	TCCACC
AGGAAGTGACGGGGA	GGAACAACGGGGAGA	CCACC
GGAAGTGACGGGGAC	GAACAACGGGGAGAG	CACC
GAAGTGACGGGGACT	AACAACGGGGAGAGA	ACC
50 AAGTGACGGGGACTA	ACAACGGGGAGAGAG	CCACC
AGTGACGGGGACTAA	CAACGGGGAGAGAGC	CACC

- 71 -

ACCACGTCGAAGAAT	GACTACAGGGATCTC	AAGAATGTCACAGAG
CCACGTCGAAGAATC	ACTACAGGGATCTCA	AGAATGTCACAGAGT
CACGTCGAAGAATCG	CTACAGGGATCTCAT	GAATGTCACAGAGTA
ACGTCGAAGAATCGC	TACAGGGATCTCATC	AATGTCACAGAGTAT
5 CGTCGAAGAATCGCA	ACAGGGATCTCATCA	ATGTCACAGAGTATG
GTCGAAGAATCGCAT	CAGGGATCTCATCAG	TGTCACAGAGTATGA
TCGAAGAATCGCATC	AGGGATCTCATCAGC	GTCACAGAGTATGAT
CGAAGAATCGCATCA	GGGATCTCATCAGCT	TCACAGAGTATGATG
GAAGAATCGCATCAT	GGATCTCATCAGCTT	CACAGAGTATGATGG
10 AAGAATCGCATCATC	GATCTCATCAGCTTC	ACAGAGTATGATGGG
AGAATCGCATCATCA	ATCTCATCAGCTTCA	CAGAGTATGATGGGC
GAATCGCATCATCAT	TCTCATCAGCTTCAC	AGAGTATGATGGGCA
AATCGCATCATCATA	CTCATCAGCTTCACC	GAGTATGATGGGCAG
ATCGCATCATCATAA	TCATCAGCTTCACCG	AGTATGATGGGCAGG
15 TCGCATCATCATAAC	CATCAGCTTCACCGT	GTATGATGGGCAGGA
CGCATCATCATAACC	ATCAGCTTCACCGTT	TATGATGGGCAGGAT
GCATCATCATAACCT	TCAGCTTCACCGTTT	ATGATGGGCAGGATG
CATCATCATAACCTG	CAGCTTCACCGTTTA	TGATGGGCAGGATGC
ATCATCATAACCTGG	AGCTTCACCGTTTAC	GATGGGCAGGATGCC
20 TCATCATAACCTGGC	GCTTCACCGTTTACT	ATGGGCAGGATGCCT
CATCATAACCTGGCA	CTTCACCGTTTACTA	TGGGCAGGATGCCTG
ATCATAACCTGGCAC	TTCACCGTTTACTAC	GGGCAGGATGCCTGC
TCATAACCTGGCACC	TCACCGTTTACTACA	GGCAGGATGCCTGCG
CATAACCTGGCACCG	CACCGTTTACTACAA	GCAGGATGCCTGCGG
25 ATAACCTGGCACCGG	ACCGTTTACTACAAG	CAGGATGCCTGCGGC
TAACCTGGCACCGGT	CCGTTTACTACAAGG	AGGATGCCTGCGGCT
AACCTGGCACCGGTA	CGTTTACTACAAGGA	GGATGCCTGCGGCTC
ACCTGGCACCGGTAC	GTTTACTACAAGGAA	GATGCCTGCGGCTCC
CCTGGCACCGGTACC	TTTACTACAAGGAAG	ATGCCTGCGGCTCCA
30 CTGGCACCGGTACCG	TACTACAAGGAAGC	TGCCTGCGGCTCCAA
TGGCACCGGTACCGG	TACTACAAGGAAGCA	GCCTGCGGCTCCAAC
GGCACCGGTACCGGC	ACTACAAGGAAGCAC	CCTGCGGCTCCAACA
GCACCGGTACCGGCC	CTACAAGGAAGCACC	CTGCGGCTCCAACAG
CACCGGTACCGGCCC	TACAAGGAAGCACCC	TGCGGCTCCAACAGC
35 ACCGGTACCGGCCCC	ACAAGGAAGCACCCCT	GCGGCTCCAACAGCT
CCGGTACCGGCCCCC	CAAGGAAGCACCCCTT	CGGCTCCAACAGCTG
CGGTACCGGCCCCCT	AAGGAAGCACCCCTT	GGCTCCAACAGCTGG
GGTACCGGCCCCCTG	AGGAAGCACCCCTTTA	GCTCCAACAGCTGGA
GTACCGGCCCCCTGA	GGAAGCACCCCTTTAA	CTCCAACAGCTGGA
40 TACCGGCCCCCTGAC	GAAGCACCCCTTTAAG	TCCAACAGCTGGAAC
ACCGGCCCCCTGACT	AAGCACCCCTTTAAGA	CCAACAGCTGGAACA
CCGGCCCCCTGACTA	AGCACCCCTTTAAGAA	CAACAGCTGGAACAT
CGGCCCCCTGACTAC	GCACCCCTTTAAGAAT	AACAGCTGGAACATG
GGCCCCCTGACTACA	CACCCCTTTAAGAATG	ACAGCTGGAACATGG
45 GCCCCCTGACTACAG	ACCCTTTAAGAATGT	CAGCTGGAACATGGT
CCCCCTGACTACAGG	CCCTTTAAGAATGTC	AGCTGGAACATGGTG
CCCCTGACTACAGGG	CCTTTAAGAATGTCA	GCTGGAACATGGTGG
CCCTGACTACAGGGA	CTTTAAGAATGTCAC	CTGGAACATGGTGG
CCTGACTACAGGGAT	TTTAAGAATGTCACA	TGGAACATGGTGGAC
50 CTGACTACAGGGATC	TTAAGAATGTCACAG	GGAACATGGTGGACG
TGACTACAGGGATCT	TAAGAATGTCACAGA	GAACATGGTGGACGT

- 72 -

AACATGGTGGACGTG	TTACTACATGGGCTG	GTGACCCTCACCATG
ACATGGTGGACGTGG	TACTACATGGGCTGA	TGACCCTCACCATGG
CATGGTGGACGTGGA	ACTACATGGGCTGAA	GACCCTCACCATGGT
ATGGTGGACGTGGAC	CTACATGGGCTGAAG	ACCCTCACCATGGTG
5 TGGTGGACGTGGACC	TACATGGGCTGAAGC	CCCTCACCATGGTGG
GGTGGACGTGGACCT	ACATGGGCTGAAGCC	CCTCACCATGGTGGG
GTGGACGTGGACCTC	CATGGGCTGAAGCCC	CTCACCATGGTGGAG
TGGACGTGGACCTCC	ATGGGCTGAAGCCCT	TCACCATGGTGGAGA
GGACGTGGACCTCCC	TGGGCTGAAGCCCTG	CACCATGGTGGAGAA
10 GACGTGGACCTCCCG	GGGCTGAAGCCCTGG	ACCATGGTGGAGAAC
ACGTGGACCTCCCGC	GGCTGAAGCCCTGGA	CCATGGTGGAGAACG
CGTGGACCTCCCGCC	GCTGAAGCCCTGGAC	CATGGTGGAGAACGA
GTGGACCTCCCGCCC	CTGAAGCCCTGGACT	ATGGTGGAGAACGAC
TGGACCTCCCGCCCA	TGAAGCCCTGGACTC	TGGTGGAGAACGACC
15 GGACCTCCCGCCCAA	GAAGCCCTGGACTCA	GGTGGAGAACGACCA
GACCTCCCGCCCAAC	AAGCCCTGGACTCAG	GTGGAGAACGACCAT
ACCTCCCGCCCAACA	AGCCCTGGACTCAGT	TGGAGAACGACCATA
CCTCCCGCCCAACAA	GCCCTGGACTCAGTA	GGAGAACGACCATAT
CTCCCGCCCAACAAG	CCCTGGACTCAGTAC	GAGAACGACCATATC
20 TCCCGCCCAACAAGG	CCTGGACTCAGTACG	AGAACGACCATATCC
CCCGCCCAACAAGGA	CTGGACTCAGTACGC	GAACGACCATATCCG
CCGCCCAACAAGGAC	TGGACTCAGTACGCC	AACGACCATATCCGT
CGCCCAACAAGGACG	GGA CT CAGTACGCCG	ACGACCATATCCGTG
GCCCAACAAGGACGT	GACTCAGTACGCCGT	CGACCATATCCGTGG
25 CCAACAAGGACGTG	ACTCAGTACGCCGTT	GACCATATCCGTGGG
CCAACAAGGACGTGG	CTCAGTACGCCGTTT	ACCATATCCGTGGGG
CAACAAGGACGTGGA	TCAGTACGCCGTTTA	CCATATCCGTGGGGC
AACAAGGACGTGGAG	CAGTACGCCGTTTAC	CATATCCGTGGGGCC
ACAAGGACGTGGAGC	AGTACGCCGTTTACG	ATATCCGTGGGGCCA
30 CAAGGACGTGGAGCC	GTACGCCGTTTACGT	TATCCGTGGGGCCAA
AAGGACGTGGAGCCC	TACGCCGTTTACGTC	ATCCGTGGGGCCAA
AGGACGTGGAGCCCG	ACGCCGTTTACGTCA	TCCGTGGGGCCAA
GGACGTGGAGCCCGG	CGCCGTTTACGTCAA	CCGTGGGGCCAAAG
GACGTGGAGCCCGGC	CCGTTTACGTCAAG	CGTGGGGCCAAAGAG
35 ACGTGGAGCCCGGCA	CCGTTTACGTCAAGG	GTGGGGCCAAAGAGTG
CGTGGAGCCCGGCAT	CGTTTACGTCAAGGC	TGGGGCCAAAGAGTGA
GTGGAGCCCGGCATC	GTTTACGTCAAGGCT	GGGGCCAAAGAGTGAG
TGGAGCCCGGCATCT	TTTACGTCAAGGCTG	GGGCAAGAGTGAGAT
GGAGCCCGGCATCTT	TTACGTCAAGGCTGT	GGCAAGAGTGAGATC
40 GAGCCCGGCATCTTA	TACGTCAAGGCTGTG	GCAAGAGTGAGATCT
AGCCCGGCATCTTAC	ACGTCAAGGCTGTGA	CCAAGAGTGAGATCT
GCCCGGCATCTTACT	CGTCAAGGCTGTGAC	CAAGAGTGAGATCTT
CCCGGCATCTTACTA	GTCAAGGCTGTGACC	AAGAGTGAGATCTTG
CCGGCATCTTACTAC	TCAAGGCTGTGACCC	AGAGTGAGATCTTGT
45 CGGCATCTTACTACA	CAAGGCTGTGACCCT	GAGTGAGATCTTGTA
GGCATCTTACTACAT	AAGGCTGTGACCCTC	AGTGAGATCTTGTA
GCATCTTACTACATG	AGGCTGTGACCCTCA	GTGAGATCTTGTA
CATCTTACTACATGG	GGCTGTGACCCTCAC	TGAGATCTTGTA
ATCTTACTACATGGG	GCTGTGACCCTCAC	GAGATCTTGTA
50 TCTTACTACATGGGC	CTGTGACCCTCACCA	AGATCTTGTA
CTTACTACATGGGCT	TGTGACCCTCACCAT	GATCTTGTA

- 73 -

ATCTTGACATTTCGC	CTTTCAGCATCGAAC	TCTCTGCCCCAACGGC
TCTTGACATTTCGCA	TTTCAGCATCGAACT	CTCTGCCCCAACGGCA
CTTGACATTTCGCAC	TTCAGCATCGAACTC	TCTGCCCCAACGGCAA
TTGTACATTTCGCACC	TCAGCATCGAACTCC	CTGCCCCAACGGCAAC
5 TGTACATTTCGCACCA	CAGCATCGAACTCCT	TGCCCCAACGGCAACC
GTACATTTCGCACCAA	AGCATCGAACTCCTC	GCCCCAACGGCAACCT
TACATTTCGCACCAAT	GCATCGAACTCCTCT	CCCCAACGGCAACCTG
ACATTTCGCACCAATG	CATCGAACTCCTCTT	CCAACGGCAACCTGA
CATTTCGCACCAATGC	ATCGAACTCCTCTTC	CAACGGCAACCTGAG
10 ATTTCGCACCAATGCT	TCGAACTCCTCTTCT	AACGGCAACCTGAGT
TTCGCACCAATGCTT	CGAACTCCTCTTCTC	ACGGCAACCTGAGTT
TCGCACCAATGCTTC	GAACTCCTCTTCTCA	CGGCAACCTGAGTTA
CGCACCAATGCTTCA	AACTCCTCTTCTCAG	GGCAACCTGAGTTAC
GCACCAATGCTTCAG	ACTCCTCTTCTCAGT	GCAACCTGAGTTACT
15 CACCAATGCTTCAGT	CTCCTCTTCTCAGTT	CAACCTGAGTTACTA
ACCAATGCTTCAGTT	TCCTCTTCTCAGTTA	AACCTGAGTTACTAC
CCAATGCTTCAGTTC	CCTCTTCTCAGTTAA	ACCTGAGTTACTACA
CAATGCTTCAGTTCC	CTCTTCTCAGTTAAT	CCTGAGTTACTACAT
AATGCTTCAGTTCCT	TCTTCTCAGTTAATC	CTGAGTTACTACATT
20 ATGCTTCAGTTCCTT	CTTCTCAGTTAATCG	TGAGTTACTACATTG
TGCTTCAGTTCCTTC	TTCTCAGTTAATCGT	GAGTTACTACATTGT
GCTTCAGTTCCTTCC	TCTCAGTTAATCGTG	AGTTACTACATTGTG
CTTCAGTTCCTTCCA	CTCAGTTAATCGTGA	GTTACTACATTGTGC
TTCAGTTCCTTCCAT	TCAGTTAATCGTGAA	TTACTACATTGTGCG
25 TCAGTTCCTTCCATT	CAGTTAATCGTGAAG	TACTACATTGTGCGC
CAGTTCCTTCCATTCC	AGTTAATCGTGAAGT	ACTACATTGTGCGCT
AGTTCCTTCCATTCC	GTTAATCGTGAAGTG	CTACATTGTGCGCTG
GTTCCCTTCCATTCCC	TTAATCGTGAAGTGG	TACATTGTGCGCTGG
TTCCTTCCATTCCCT	TAATCGTGAAGTGGA	ACATTGTGCGCTGGC
30 TCCTTCCATTCCCTT	AATCGTGAAGTGGA	CATTGTGCGCTGGCA
CCTTCCATTCCCTTG	ATCGTGAAGTGGAAC	ATTGTGCGCTGGCAG
CTTCCATTCCCTTGG	TCGTGAAGTGGAACC	TTGTGCGCTGGCAGC
TTCCATTCCCTTGGG	CGTGAAGTGGAACCC	TGTGCGCTGGCAGCG
TCCATTCCCTTGGAC	GTGAAGTGGAACCCT	GTGCGCTGGCAGCGG
35 CCATTCCCTTGGACG	TGAAGTGGAACCCTC	TGCGCTGGCAGCGGC
CATTCCCTTGGACGT	GAAGTGGAACCCTCC	GCGCTGGCAGCGGCA
ATTCCCTTGGACGTT	AAGTGGAACCCTCCC	CGCTGGCAGCGGCAG
TTCCCTTGGACGTTT	AGTGGAACCCTCCCT	GCTGGCAGCGGCAGC
TCCCTTGGACGTTCT	GTGGAACCCTCCCTC	CTGGCAGCGGCAGCC
40 CCCTTGGACGTTCTT	TGGAACCCTCCCTCT	TGGCAGCGGCAGCCT
CCTTGGACGTTCTTT	GGAACCCTCCCTCTC	GGCAGCGGCAGCCTC
CTTGGACGTTCTTTT	GAACCCTCCCTCTCT	GCAGCGGCAGCCTCA
TTGGACGTTCTTTCA	AACCCTCCCTCTCTG	CAGCGGCAGCCTCAG
TGGACGTTCTTTTCA	ACCCTCCCTCTCTGC	AGCGGCAGCCTCAGG
45 GGACGTTCTTTTCA	CCCTCCCTCTCTGCC	GCGGCAGCCTCAGGA
GACGTTCTTTTCA	CCTCCCTCTCTGCCC	CGGCAGCCTCAGGAC
ACGTTCTTTTCA	CTCCCTCTCTGCCCC	GGCAGCCTCAGGACG
CGTTCTTTTCA	TCCCTCTCTGCCCCA	GCAGCCTCAGGACGG
GTTCTTTTCA	CCCTCTCTGCCCCA	CAGCCTCAGGACGGC
50 TTCTTTTCA	CCTCTCTGCCCCAAC	AGCCTCAGGACGGCT
TTCTTTTCA	CTCTCTGCCCCAACG	GCCTCAGGACGGCTA

- 74 -

	CCTCAGGACGGCTAC	CCCATCAGGAAGTAT	AACCCCAAGACTGAG
	CTCAGGACGGCTACC	CCATCAGGAAGTATG	ACCCCAAGACTGAGG
	TCAGGACGGCTACCT	CATCAGGAAGTATGC	CCCCAAGACTGAGGT
	CAGGACGGCTACCTT	ATCAGGAAGTATGCC	CCCAAGACTGAGGTG
5	AGGACGGCTACCTTT	TCAGGAAGTATGCCG	CCAAGACTGAGGTGT
	GGACGGCTACCTTTA	CAGGAAGTATGCCGA	CAAGACTGAGGTGTG
	GACGGCTACCTTTAC	AGGAAGTATGCCGAC	AAGACTGAGGTGTGT
	ACGGCTACCTTTACC	GGAAGTATGCCGACG	AGACTGAGGTGTGTG
	CGGCTACCTTTACCG	GAAGTATGCCGACGG	GACTGAGGTGTGTGG
10	GGCTACCTTTACCGG	AAGTATGCCGACGGC	ACTGAGGTGTGTGGT
	GCTACCTTTACCGGC	AGTATGCCGACGGCA	CTGAGGTGTGTGGTG
	CTACCTTTACCGGCA	GTATGCCGACGGCAC	TGAGGTGTGTGGTGG
	TACCTTTACCGGCAC	TATGCCGACGGCACC	GAGGTGTGTGGTGGG
	ACCTTTACCGGCACA	ATGCCGACGGCACCA	AGGTGTGTGGTGGGG
15	CCTTTACCGGCACAA	TGCCGACGGCACCAT	GGTGTGTGGTGGGGA
	CTTTACCGGCACAAT	GCCGACGGCACCATC	GTGTGTGGTGGGGAG
	TTTACCGGCACAATT	CCGACGGCACCATCG	TGTGTGGTGGGGAGA
	TTACCGGCACAATTA	CGACGGCACCATCGA	GTGTGGTGGGGAGAA
	TACCGGCACAATTAC	GACGGCACCATCGAC	TGTGGTGGGGAGAAA
20	ACCGGCACAATTACT	ACGGCACCATCGACA	GTGGTGGGGAGAAAAG
	CCGGCACAATTACTG	CGGCACCATCGACAT	TGGTGGGGAGAAAAGG
	CGGCACAATTACTGC	GGCACCATCGACATT	GGTGGGGAGAAAAGGG
	GGCACAATTACTGCT	GCACCATCGACATTG	GTGGGGAGAAAAGGGC
	GCACAATTACTGCTC	CACCATCGACATTGA	TGGGGAGAAAAGGGCC
25	CACAATTACTGCTCC	ACCATCGACATTGAG	GGGGAGAAAAGGGCCT
	ACAATTACTGCTCCA	CCATCGACATTGAGG	GGGAGAAAAGGGCCTT
	CAATTACTGCTCCAA	CATCGACATTGAGGA	GGAGAAAAGGGCCTTG
	AATTACTGCTCCAAA	ATCGACATTGAGGAG	GAGAAAAGGGCCTTGC
	ATTACTGCTCCAAAG	TCGACATTGAGGAGG	AGAAAGGGCCTTGCT
30	TTACTGCTCCAAAGA	CGACATTGAGGAGGT	GAAAGGGCCTTGCTG
	TACTGCTCCAAAGAC	GACATTGAGGAGGTC	AAAGGGCCTTGCTGC
	ACTGCTCCAAAGACA	ACATTGAGGAGGTCA	AAGGGCCTTGCTGCG
	CTGCTCCAAAGACAA	CATTGAGGAGGTCAC	AGGGCCTTGCTGCGC
	TGCTCCAAAGACAAA	ATTGAGGAGGTCACA	GGGCCTTGCTGCGCC
35	GCTCCAAAGACAAAA	TTGAGGAGGTCACAG	GGCCTTGCTGCGCCT
	TCCAAAGACAAAAT	TGAGGAGGTCACAGA	GCCTTGCTGCGCCTG
	TCCAAAGACAAAATC	GAGGAGGTCACAGAG	CCTTGCTGCGCCTGC
	CCAAAGACAAAATCC	AGGAGGTCACAGAGA	CTTGCTGCGCCTGCC
	CAAAGACAAAATCCC	GGAGGTCACAGAGAA	TTGCTGCGCCTGCCC
40	AAAGACAAAATCCCC	GAGGTCACAGAGAAC	TGCTGCGCCTGCCCC
	AAGACAAAATCCCCA	AGGTCACAGAGAAC	GCTGCGCCTGCCCCA
	AGACAAAATCCCCAT	GGTCACAGAGAACCC	CTGCGCCTGCCCCAA
	GACAAAATCCCCATC	GTCACAGAGAACCCC	TGCGCCTGCCCCAAA
	ACAAAATCCCCATCA	TCACAGAGAACCCCA	GCGCCTGCCCCAAAA
45	CAAAATCCCCATCAG	CACAGAGAACCCCAA	CGCCTGCCCCAAAAAC
	AAAATCCCCATCAGG	ACAGAGAACCCCAAG	GCCTGCCCCAAAAACT
	AAATCCCCATCAGGA	CAGAGAACCCCAAGA	CCTGCCCCAAAACTG
	AATCCCCATCAGGAA	AGAGAACCCCAAGAC	CTGCCCCAAAACTGA
	ATCCCCATCAGGAAG	GAGAACCCCAAGACT	TGCCCCAAAACTGAA
50	TCCCCATCAGGAAGT	AGAACCCCAAGACTG	GCCCCAAAACTGAAG
	CCCCATCAGGAAGTA	GAACCCCAAGACTGA	CCCCAAAACTGAAGC

- 75 -

CCCAAACTGAAGCC	AAAGTCTTTGAGAAT	AGGAAGCGGAGAGAT
CCAAAACTGAAGCCG	AAGTCTTTGAGAATT	GGAAGCGGAGAGATG
CAAAACTGAAGCCGA	AGTCTTTGAGAATTT	GAAGCGGAGAGATGT
AAAACCTGAAGCCGAG	GTCTTTGAGAATTTTC	AAGCGGAGAGATGTC
5 AAACCTGAAGCCGAGA	TCTTTGAGAATTTCC	AGCGGAGAGATGTCA
AACTGAAGCCGAGAA	CTTTGAGAATTTCCCT	GCGGAGAGATGTCAT
ACTGAAGCCGAGAAG	TTTGAGAATTTCCCTG	CGGAGAGATGTCATG
CTGAAGCCGAGAAGC	TTGAGAATTTCCCTGC	GGAGAGATGTCATGC
TGAAGCCGAGAAGCA	TGAGAATTTCCCTGCA	GAGAGATGTCATGCA
10 GAAGCCGAGAAGCAG	GAGAATTTCCCTGCAC	AGAGATGTCATGCAA
AAGCCGAGAAGCAGG	AGAATTTCCCTGCACA	GAGATGTCATGCAAG
AGCCGAGAAGCAGGC	GAATTTCCCTGCACAA	AGATGTCATGCAAGT
GCCGAGAAGCAGGCC	AATTTCCCTGCACAAC	GATGTCATGCAAGTG
CCGAGAAGCAGGCCG	ATTTCCCTGCACAAC	ATGTCATGCAAGTGG
15 CGAGAAGCAGGCCGA	TTTCCCTGCACAAC	TGTCATGCAAGTGGC
GAGAAGCAGGCCGAG	TTCCTGCACAAC	GTCATGCAAGTGGCC
AGAAGCAGGCCGAGA	TCCTGCACAAC	TCATGCAAGTGGCCA
GAAGCAGGCCGAGAA	CCTGCACAAC	CATGCAAGTGGCCAA
AAGCAGGCCGAGAAG	CTGCACAAC	ATGCAAGTGGCCAAC
20 AGCAGGCCGAGAAGG	TGCACAAC	TGCAAGTGGCCAAAC
GCAGGCCGAGAAGGA	GCACAAC	GCAAGTGGCCAAAC
CAGGCCGAGAAGGAG	CACAAC	CAAGTGGCCAAAC
AGGCCGAGAAGGAGG	ACAAC	AAGTGGCCAAAC
GGCCGAGAAGGAGGA	CAAC	AGTGGCCAAAC
25 GCCGAGAAGGAGGAG	AACTCCATCTTCGT	GTGGCCAAAC
CCGAGAAGGAGGAGG	ACTCCATCTTCGTG	TGGCCAAAC
CGAGAAGGAGGAGGC	CTCCATCTTCGTGCC	GGCCAAAC
GAGAAGGAGGAGGCT	TCCATCTTCGTGCC	GCCAAAC
AGAAGGAGGAGGCTG	CCATCTTCGTGCC	CCAAC
30 GAAGGAGGAGGCTGA	CATCTTCGTGCC	CAAC
AAGGAGGAGGCTGAA	ATCTTCGTGCC	AAC
AGGAGGAGGCTGAAT	TCTTCGTGCC	AC
GGAGGAGGCTGAATA	CTTCGTGCC	CACC
GAGGAGGCTGAATAC	TTTCGTGCC	ACC
35 AGGAGGCTGAATACC	TCGTGCC	CC
GGAGGCTGAATACCG	CGTGCC	CAC
GAGGCTGAATACCGC	GTGCC	ACC
AGGCTGAATACCGCA	TGCC	AC
GGCTGAATACCGCAA	GCC	CA
40 GCTGAATACCGCAA	CCC	C
CTGAATACCGCAAAG	CC	C
TGAATACCGCAAAGT	C	C
GAATACCGCAAAGTC	AG	C
AATACCGCAAAGTCT	G	C
45 ATACCGCAAAGTCTT	AC	C
TACCGCAAAGTCTTT	C	C
ACCGCAAAGTCTTTG	CT	C
CCGCAAAGTCTTTGA	T	C
CGCAAAGTCTTTGAG	G	C
50 GCAAAGTCTTTGAGA	G	C
CAAAGTCTTTGAGAA	A	C

- 76 -

AGCAGGAACACCACG	CTGGAGACAGAGTAC	ACTGTCATTTCTAAC
GCAGGAACACCACGG	TGGAGACAGAGTACC	CTGTCATTTCTAAC
CAGGAACACCACGGC	GGAGACAGAGTACCC	TGTCATTTCTAACCT
AGGAACACCACGGCC	GAGACAGAGTACCCT	GTCATTTCTAACCTT
5 GGAACACCACGGCCG	AGACAGAGTACCCTT	TCATTTCTAACCTTC
GAACACCACGGCCGC	GACAGAGTACCCTTT	CATTTCTAACCTTCG
AACACCACGGCCGCA	ACAGAGTACCCTTTC	ATTTCTAACCTTCGG
ACACCACGGCCGCAG	CAGAGTACCCTTCT	TTTCTAACCTTCGGC
CACCACGGCCGCAGA	AGAGTACCCTTCTT	TTCTAACCTTCGGCC
10 ACCACGGCCGCAGAC	GAGTACCCTTCTTT	TCTAACCTTCGGCCT
CCACGGCCGCAGACA	AGTACCCTTCTTTG	CTAACCTTCGGCCTT
CACGGCCGCAGACAC	GTACCCTTCTTTGA	TAACCTTCGGCCTTT
ACGGCCGCAGACACC	TACCCTTCTTTGAG	AACCTTCGGCCTTTC
CGGCCGCAGACACCT	ACCCTTCTTTGAGA	ACCTTCGGCCTTTC
15 GGCCGCAGACACCTA	CCCTTCTTTGAGAG	CCTTCGGCCTTTCAC
GCCGCAGACACCTAC	CCTTCTTTGAGAGC	CTTCGGCCTTTCACA
CCGCAGACACCTACA	CTTCTTTGAGAGCA	TTTCGGCCTTTCACAT
CGCAGACACCTACAA	TTCTTTGAGAGCAG	TCGGCCTTTCACATT
GCAGACACCTACAAC	TTCTTTGAGAGCAGA	CGGCCTTTCACATTG
20 CAGACACCTACAACA	TCCTTTGAGAGCAGAG	GGCCTTTCACATTGT
AGACACCTACAACAT	CTTTGAGAGCAGAGT	GCCTTTCACATTGTA
GACACCTACAACATC	TTTGAGAGCAGAGTG	CCTTTCACATTGTAC
ACACCTACAACATCA	TTGAGAGCAGAGTGG	CTTTCACATTGTACC
CACCTACAACATCAC	TGAGAGCAGAGTGGA	TTTCACATTGTACCG
25 ACCTACAACATCACC	GAGAGCAGAGTGGAT	TTACATTGTACCGC
CCTACAACATCACCG	AGAGCAGAGTGGATA	TCACATTGTACCGCA
CTACAACATCACCGA	GAGCAGAGTGGATAA	CACATTGTACCGCAT
TACAACATCACCGAC	AGCAGAGTGGATAAC	ACATTGTACCGCATC
ACAACATCACCGACC	GCAGAGTGGATAACA	CATTGTACCGCATCG
30 CAACATCACCGACCC	CAGAGTGGATAACAA	ATTGTACCGCATCGA
AACATCACCGACCCG	AGAGTGGATAACAAG	TTGTACCGCATCGAT
ACATCACCGACCCGG	GAGTGGATAACAAGG	TGTACCGCATCGATA
CATCACCGACCCGGA	AGTGGATAACAAGGA	GTACCGCATCGATAT
ATCACCGACCCGGA	GTGGATAACAAGGAG	TACCGCATCGATATC
35 TCACCGACCCGGAAG	TGGATAACAAGGAGA	ACCGCATCGATATCC
CACCGACCCGGAAGA	GGATAACAAGGAGAG	CCGCATCGATATCCA
ACCGACCCGGAAGAG	GATAACAAGGAGAGA	CGCATCGATATCCAC
CCGACCCGGAAGAGC	ATAACAAGGAGAGAA	GCATCGATATCCACA
CGACCCGGAAGAGCT	TAACAAGGAGAGAAC	CATCGATATCCACAG
40 GACCCGGAAGAGCTG	AACAAGGAGAGAACT	ATCGATATCCACAGC
ACCCGGAAGAGCTGG	ACAAGGAGAGAACTG	TCGATATCCACAGCT
CCCGGAAGAGCTGGA	CAAGGAGAGAACTGT	CGATATCCACAGCTG
CCGGAAGAGCTGGAG	AAGGAGAGAACTGTC	GATATCCACAGCTGC
CGGAAGAGCTGGAGA	AGGAGAGAACTGTCA	ATATCCACAGCTGCA
45 GGAAGAGCTGGAGAC	GGAGAGAACTGTCAT	TATCCACAGCTGCAA
GAAGAGCTGGAGACA	GAGAGAACTGTCATT	ATCCACAGCTGCAAC
AAGAGCTGGAGACAG	AGAGAACTGTCATTT	TCCACAGCTGCAACC
AGAGCTGGAGACAGA	GAGAACTGTCATTTT	CCACAGCTGCAACCA
GAGCTGGAGACAGAG	AGAACTGTCATTTCT	CACAGCTGCAACCAC
50 AGCTGGAGACAGAGT	GAAGTGTATTTCTA	ACAGCTGCAACCACG
GCTGGAGACAGAGTA	AACTGTATTTCTAA	CAGCTGCAACCACGA

- 77 -

AGCTGCAACCACGAG	TTTGCAAGGACTATG	ACCTGGGAGCCAAGG
GCTGCAACCACGAGG	TTGCAAGGACTATGC	CCTGGGAGCCAAGGC
CTGCAACCACGAGGC	TGCAAGGACTATGCC	CTGGGAGCCAAGGCC
TGCAACCACGAGGCT	GCAAGGACTATGCCC	TGGGAGCCAAGGCCT
5 GCAACCACGAGGCTG	CAAGGACTATGCCCC	GGGAGCCAAGGCCTG
CAACCACGAGGCTGA	AAGGACTATGCCCGC	GGAGCCAAGGCCTGA
AACCACGAGGCTGAG	AGGACTATGCCCGCA	GAGCCAAGGCCTGAA
ACCACGAGGCTGAGA	GGACTATGCCCGCAG	AGCCAAGGCCTGAAA
CCACGAGGCTGAGAA	GACTATGCCCGCAGA	GCCAAGGCCTGAAAA
10 CACGAGGCTGAGAAG	ACTATGCCCGCAGAA	CCAAGGCCTGAAAAC
ACGAGGCTGAGAAGC	CTATGCCCGCAGAA	CAAGGCCTGAAAAC
CGAGGCTGAGAAGCT	TATGCCCGCAGAA	AAGGCCTGAAAAC
GAGGCTGAGAAGCTG	ATGCCCGCAGAA	AGGCCTGAAAAC
AGGCTGAGAAGCTGG	TGCCCGCAGAA	GGCCTGAAAAC
15 GGCTGAGAAGCTGGG	GCCCGCAGAA	GCCTGAAAAC
GCTGAGAAGCTGGGC	CCCGCAGAA	CCTGAAAAC
CTGAGAAGCTGGGCT	CCGCAGAA	CTGAAAAC
TGAGAAGCTGGGCTG	CGCAGAA	TGAAAAC
GAGAAGCTGGGCTGC	GCAGAA	GAAAAC
20 AGAAGCTGGGCTGCA	CAGAAG	AAAAC
GAAGCTGGGCTGCAG	AGAAG	AAAC
AAGCTGGGCTGCAGC	GAAG	AACT
AGCTGGGCTGCAGCG	AAG	ACT
GCTGGGCTGCAGCGC	AGG	CT
25 CTGGGCTGCAGCGCC	GAG	T
TGGGCTGCAGCGCCT	GAGC	CC
GGGCTGCAGCGCCTC	AGC	C
GGCTGCAGCGCCTCC	GC	AT
GCTGCAGCGCCTCCA	CAG	CT
30 CTGCAGCGCCTCCAA	AGAT	CT
TGCAGCGCCTCCAAC	GAT	CT
GCAGCGCCTCCAAC	AT	CT
CAGCGCCTCCAAC	TG	CT
AGCGCCTCCAAC	GAC	CT
35 GCGCCTCCAAC	GACAT	CT
CGCCTCCAAC	ACAT	CT
GCCTCCAAC	CATT	CT
CCTCCAAC	ATT	CT
CTCCAAC	TT	CT
40 TCCAAC	TC	CT
CCAAC	CT	CT
CAAC	CT	CT
AACT	CT	CT
ACT	CT	CT
45 CTT	CT	CT
TTC	CT	CT
TCG	CT	CT
CGT	CT	CT
GT	CT	CT
50 TCT	CT	CT
CTT	CT	CT

- 78 -

	GAGAATCCCAATGGA	GTTGAGGATCAGCGA	GGGGCCAAGCTAAAC
	AGAATCCCAATGGAT	TTGAGGATCAGCGAG	GGGCCAAGCTAAACC
	GAATCCCAATGGATT	TGAGGATCAGCGAGA	GGCCAAGCTAAACCG
	AATCCCAATGGATTG	GAGGATCAGCGAGAA	GCCAAGCTAAACCGG
5	ATCCCAATGGATTGA	AGGATCAGCGAGAAT	CCAAGCTAAACCGGC
	TCCCAATGGATTGAT	GGATCAGCGAGAATG	CAAGCTAAACCGGCT
	CCCAATGGATTGATT	GATCAGCGAGAATGT	AAGCTAAACCGGCTA
	CCAATGGATTGATTC	ATCAGCGAGAATGTG	AGCTAAACCGGCTAA
	CAATGGATTGATTCT	TCAGCGAGAATGTGT	GCTAAACCGGCTAAA
10	AATGGATTGATTCTA	CAGCGAGAATGTGTG	CTAAACCGGCTAAAC
	ATGGATTGATTCTAA	AGCGAGAATGTGTGT	TAAACCGGCTAAACC
	TGGATTGATTCTAAT	GCGAGAATGTGTGTC	AAACCGGCTAAACCC
	GGATTGATTCTAATG	CGAGAATGTGTGTCC	AACCGGCTAAACCCG
	GATTGATTCTAATGT	GAGAATGTGTGTCCA	ACCGGCTAAACCCGG
15	ATTGATTCTAATGTA	AGAATGTGTGTCCAG	CCGGCTAAACCCGGG
	TTGATTCTAATGTAT	GAATGTGTGTCCAGA	CGGCTAAACCCGGGG
	TGATTCTAATGTATG	AATGTGTGTCCAGAC	GGCTAAACCCGGGGA
	GATTCTAATGTATGA	ATGTGTGTCCAGACA	GCTAAACCCGGGGAA
	ATTCTAATGTATGAA	TGTGTGTCCAGACAG	CTAAACCCGGGGAAAC
20	TTCTAATGTATGAAA	GTGTGTCCAGACAGG	TAAACCCGGGGAACT
	TCTAATGTATGAAAT	TGTGTCCAGACAGGA	AAACCCGGGGAACTA
	CTAATGTATGAAATA	GTGTCCAGACAGGAA	AAACCCGGGGAACTAC
	TAATGTATGAAATAA	TGTCCAGACAGGAAT	ACCCGGGGAACTACA
	AATGTATGAAATAAA	GTCCAGACAGGAATA	CCCGGGGAACTACAC
25	ATGTATGAAATAAAA	TCCAGACAGGAATAC	CCGGGGAACTACACA
	TGTATGAAATAAAAT	CCAGACAGGAATACA	CGGGGAACTACACAG
	GTATGAAATAAAATA	CAGACAGGAATACAG	GGGGAACTACACAGC
	TATGAAATAAAATAC	AGACAGGAATACAGG	GGGAACTACACAGCC
	ATGAAATAAAATACG	GACAGGAATACAGGA	GGAACTACACAGCCC
30	TGAAATAAAATACGG	ACAGGAATACAGGAA	GAACTACACAGCCC
	GAAATAAAATACGGA	CAGGAATACAGGAAG	AACTACACAGCCCCG
	AAATAAAATACGGAT	AGGAATACAGGAAGT	ACTACACAGCCCCGA
	AATAAAATACGGATC	GGAATACAGGAAGTA	CTACACAGCCCCGAT
	ATAAAATACGGATCA	GAATACAGGAAGTAT	TACACAGCCCCGATT
35	TAAAATACGGATCAC	AAATACAGGAAGTATG	ACACAGCCCCGATT
	AAAATACGGATCACA	ATACAGGAAGTATGG	CACAGCCCCGATTCA
	AAATACGGATCACAA	TACAGGAAGTATGGA	ACAGCCCCGATTTCAG
	AATACGGATCACAA	ACAGGAAGTATGGAG	CAGCCCCGATTTCAGG
	ATACGGATCACAA	CAGGAAGTATGGAGG	AGCCCCGATTTCAGGC
40	TACGGATCACAA	AGGAAGTATGGAGGG	GCCCCGATTTCAGGCC
	ACGGATCACAA	GGAAGTATGGAGGGG	CCCCGATTTCAGGCCA
	CGGATCACAA	GAAGTATGGAGGGGC	CCGGATTTCAGGCCAC
	GGATCACAA	AAGTATGGAGGGGCC	CGGATTTCAGGCCACA
	GATCACAA	AGTATGGAGGGGCCA	GGATTTCAGGCCACAT
45	ATCACAA	GTATGGAGGGGCCAA	GATTTCAGGCCACATC
	TCACAAGTTGAGGAT	TATGGAGGGGCCAAG	ATTCAGGCCACATCT
	CACAAGTTGAGGATC	ATGGAGGGGCCAAGC	TTCAGGCCACATCTC
	ACAAGTTGAGGATCA	TGGAGGGGCCAAGCT	TCAGGCCACATCTCT
	CAAGTTGAGGATCAG	GGAGGGGCCAAGCTA	CAGGCCACATCTCTC
50	AAGTTGAGGATCAGC	GAGGGGCCAAGCTAA	AGGCCACATCTCTCT
	AGTTGAGGATCAGCG	AGGGGCCAAGCTAAA	GGCCACATCTCTCTC

	GCCACATCTCTCTCT	GTCCAGGCCAAAACA	CCCGTCGCTGTCCTG
	CCACATCTCTCTCTG	TCCAGGCCAAAACAG	CCGTCGCTGTCTGT
	CACATCTCTCTCTGG	CCAGGCCAAAACAGG	CGTCGCTGTCTGTG
	ACATCTCTCTCTGGG	CAGGCCAAAACAGGA	GTCGCTGTCTGTG
5	CATCTCTCTCTGGGA	AGGCCAAAACAGGAT	TCGCTGTCTGTG
	ATCTCTCTCTGGGAA	GGCCAAAACAGGATA	CGCTGTCTGTGTG
	TCTCTCTCTGGGAAT	GCCAAAACAGGATAT	GCTGTCTGTGTGATC
	CTCTCTCTGGGAATG	CCAAAACAGGATATG	CTGTCTGTGTGATCG
	TCTCTCTGGGAATGG	CAAAACAGGATATGA	TGTCTGTGTGTGATCGT
10	CTCTCTGGGAATGGG	AAAACAGGATATGAA	GTCTGTGTGTGATCGTG
	TCTCTGGGAATGGGT	AAACAGGATATGAAA	TCCTGTGTGTGATCGTGG
	CTCTGGGAATGGGTC	AACAGGATATGAAAA	CCTGTGTGTGATCGTGGG
	TCTGGGAATGGGTCG	ACAGGATATGAAAAC	CTGTGTGTGATCGTGGGA
	CTGGGAATGGGTCGT	CAGGATATGAAAAC	TGTGTGTGTGATCGTGGGAG
15	TGGGAATGGGTCGTG	AGGATATGAAAAC	GTTGTGTGTGATCGTGGGAGG
	GGGAATGGGTCGTGG	GGATATGAAAAC	TTGTGTGTGTGATCGTGGGAGGG
	GGAATGGGTCGTGGA	GATATGAAAAC	TGATGTGTGTGATCGTGGGAGGGT
	GAATGGGTCGTGGAC	ATATGAAAAC	GATGTGTGTGTGATCGTGGGAGGGTT
	AATGGGTCGTGGACA	TATGAAAAC	ATGTGTGTGTGATCGTGGGAGGGTTG
20	ATGGGTCGTGGACAG	ATGAAAAC	TCGTGTGTGTGATCGTGGGAGGGTTGG
	TGGGTCGTGGACAGA	TGAAAAC	CGTGTGTGTGTGATCGTGGGAGGGTTGGT
	GGGTCGTGGACAGAT	GAAAAC	GTGTGTGTGTGATCGTGGGAGGGTTGGTG
	GGTCGTGGACAGATC	AAAAC	TGGGAGGGTTGGTGAT
	GTCGTGGACAGATCC	AAAC	GGGAGGGTTGGTGATT
25	TCGTGGACAGATCCT	AACT	GAGGGTTGGTGATTAT
	CGTGGACAGATCCTG	ACT	AGGGTTGGTGATTATG
	GTGGACAGATCCTGT	CT	GGGTGGTGATTATGC
	TGGACAGATCCTGTG	TTCAT	GTTGGTGATTATGCTG
	GGACAGATCCTGTGT	TCAT	TTGGTGATTATGCTGT
30	GACAGATCCTGTGTT	CAT	GGTGATTATGCTGTAC
	ACAGATCCTGTGTTT	AT	TGATTATGCTGTACG
	CAGATCCTGTGTTCT	TCCAT	GATTATGCTGTACGCT
	AGATCCTGTGTTCTT	CCAT	ATTATGCTGTACGCTC
	GATCCTGTGTTCTTC	CAT	TTATGCTGTACGCTCT
35	ATCCTGTGTTCTTCT	CT	TATGCTGTACGCTCTT
	TCCTGTGTTCTTCTA	AT	ATGCTGTACGCTCTTC
	CCTGTGTTCTTCTAT	TCT	TGCTGTACGCTCTTCC
	CTGTGTTCTTCTATG	CTG	GCTGTACGCTCTTCCA
	TGTGTTCTTCTATGT	TGAT	CTGTACGCTCTTCCAT
40	GTGTTCTTCTATGTC	CAT	TGTACGCTCTTCCATA
	TGTTCTTCTATGTCC	AT	GTACGCTCTTCCATAG
	GTTCTTCTATGTCCA	TCAT	TACGCTCTTCCATAGA
	TTCTTCTATGTCCAG	CGCT	ACGCTCTTCCATAGAA
	TCTTCTATGTCCAGG	TCG	CGTCTTCCATAGAAA
45	CTTCTATGTCCAGGC	CGCT	GTCTTCCATAGAAAG
	TTCTATGTCCAGGCC	GCT	TCTTCCATAGAAAGA
	TCTATGTCCAGGCCA	CT	CTTCCATAGAAAGAG
	CTATGTCCAGGCCAA	TCT	
	TATGTCCAGGCCAAA	CTG	
50	ATGTCCAGGCCAAA	TG	
	TGTCCAGGCCAAAAC	CCCC	

- 80 -

TTCCATAGAAAGAGA	TCTGTGAACCCGGAG	TGGGAGGTGGCTCGG
TCCATAGAAAGAGAA	CTGTGAACCCGGAGT	GGGAGGTGGCTCGGG
CCATAGAAAGAGAAA	TGTGAACCCGGAGTA	GGAGGTGGCTCGGGA
CATAGAAAGAGAAAT	GTGAACCCGGAGTAC	GAGGTGGCTCGGGAG
5 ATAGAAAGAGAAATA	TGAACCCGGAGTACT	AGGTGGCTCGGGAGA
TAGAAAGAGAAATAA	GAACCCGGAGTACTT	GGTGGCTCGGGAGAA
AGAAAGAGAAATAAC	AACCCGGAGTACTTC	GTGGCTCGGGAGAAG
GAAAGAGAAATAACA	ACCCGGAGTACTTCA	TGGCTCGGGAGAAGA
AAAGAGAAATAACAG	CCCGGAGTACTTCAG	GGCTCGGGAGAAGAT
10 AAGAGAAATAACAGC	CCGGAGTACTTCAGC	GCTCGGGAGAAGATC
AGAGAAATAACAGCA	CGGAGTACTTCAGCG	CTCGGGAGAAGATCA
GAGAAATAACAGCAG	GGAGTACTTCAGCGC	TCGGGAGAAGATCAC
AGAAATAACAGCAGG	GAGTACTTCAGCGCT	CGGGAGAAGATCACC
GAAATAACAGCAGGC	AGTACTTCAGCGCTG	GGGAGAAGATCACCA
15 AAATAACAGCAGGCT	GTACTTCAGCGCTGC	GGAGAAGATCACCAT
AATAACAGCAGGCTG	TACTTCAGCGCTGCT	GAGAAGATCACCATG
ATAACAGCAGGCTGG	ACTTCAGCGCTGCTG	AGAAGATCACCATGA
TAACAGCAGGCTGGG	CTTCAGCGCTGCTGA	GAAGATCACCATGAG
AACAGCAGGCTGGGG	TTCAGCGCTGCTGAT	AAGATCACCATGAGC
20 ACAGCAGGCTGGGGA	TCAGCGCTGCTGATG	AGATCACCATGAGCC
CAGCAGGCTGGGGAA	CAGCGCTGCTGATGT	GATCACCATGAGCCG
AGCAGGCTGGGGAAAT	AGCGCTGCTGATGTG	ATCACCATGAGCCGG
GCAGGCTGGGGAAATG	GCGCTGCTGATGTGT	TCACCATGAGCCGGG
CAGGCTGGGGAAATGG	CGCTGCTGATGTGTA	CACCATGAGCCGGGA
25 AGGCTGGGGAAATGGA	GCTGCTGATGTGTAC	ACCATGAGCCGGGAA
GGCTGGGGAAATGGAG	CTGCTGATGTGTACG	CCATGAGCCGGGAAC
GCTGGGGAAATGGAGT	TGCTGATGTGTACGT	CATGAGCCGGGAACT
CTGGGGAAATGGAGTG	GCTGATGTGTACGTT	ATGAGCCGGGAACTT
TGGGGAAATGGAGTGC	CTGATGTGTACGTTT	TGAGCCGGGAACTTG
30 GGGGAATGGAGTGCT	TGATGTGTACGTTCC	GAGCCGGGAACTTGG
GGGAATGGAGTGCTG	GATGTGTACGTTCTT	AGCCGGGAACTTGGG
GGAATGGAGTGCTGT	ATGTGTACGTTCTTG	GCCGGGAACTTGGGC
GAATGGAGTGCTGTA	TGTGTACGTTCTTGAT	CCGGGAACTTGGGCA
AATGGAGTGCTGTAT	GTGTACGTTCTTGATG	CGGGAACTTGGGCAG
35 ATGGAGTGCTGTATG	GTACGTTCTTGATGA	GGGAACTTGGGCAGG
TGGAGTGCTGTATGC	TACGTTCTTGATGAG	GGAACTTGGGCAGGG
GGAGTGCTGTATGCC	ACGTTCTTGATGAGT	GAACTTGGGCAGGGG
GAGTGCTGTATGCCT	CGTTCTTGATGAGTG	AACTTGGGCAGGGGT
AGTGCTGTATGCCTC	GTTCTTGATGAGTGG	ACTTGGGCAGGGGTC
40 GTGCTGTATGCCTCT	TTCTTGATGAGTGGG	CTTGGGCAGGGGTCG
TGCTGTATGCCTCTG	TCCTGATGAGTGGGA	TTGGGCAGGGGTCGT
GCTGTATGCCTCTGT	CCTGATGAGTGGGAG	TGGGCAGGGGTCGTT
CTGTATGCCTCTGTG	CTGATGAGTGGGAGG	GGGCAGGGGTCGTTT
TGTATGCCTCTGTGA	TGATGAGTGGGAGGT	GGCAGGGGTCGTTTG
45 GTATGCCTCTGTGAA	GATGAGTGGGAGGTG	GCAGGGGTCGTTTGG
TATGCCTCTGTGAAC	ATGAGTGGGAGGTGG	CAGGGGTCGTTTGGG
ATGCCTCTGTGAACC	TGAGTGGGAGGTGGC	AGGGGTCGTTTGGGA
TGCCTCTGTGAACCC	GAGTGGGAGGTGGCT	GGGGTCGTTTGGGAT
GCCTCTGTGAACCCG	AGTGGGAGGTGGCTC	GGGTCTTTGGGATG
50 CCTCTGTGAACCCGG	GTGGGAGGTGGCTCG	GTCGTTTGGGATGGT
CTCTGTGAACCCGGA		

- 81 -

TCGTTTGGGATGGTC	CCTGAAACCAGAGTG	GAGAGGATTGAGTTT
CGTTTGGGATGGTCT	CTGAAACCAGAGTGG	AGAGGATTGAGTTTC
GTTTGGGATGGTCTA	TGAAACCAGAGTGGC	GAGGATTGAGTTTCT
TTTGGGATGGTCTAT	GAAACCAGAGTGGCC	AGGATTGAGTTTCTC
5 TTTGGGATGGTCTATG	AAACCAGAGTGGCCA	GGATTGAGTTTCTCA
TGGGATGGTCTATGA	AACCAGAGTGGCCAT	GATTGAGTTTCTCAA
GGGATGGTCTATGAA	ACCAGAGTGGCCATT	ATTGAGTTTCTCAAC
GGATGGTCTATGAAG	CCAGAGTGGCCATTA	TTGAGTTTCTCAACG
GATGGTCTATGAAGG	CAGAGTGGCCATTAA	TGAGTTTCTCAACGA
10 ATGGTCTATGAAGGA	AGAGTGGCCATTAAA	GAGTTTCTCAACGAA
TGGTCTATGAAGGAG	GAGTGGCCATTAAAA	AGTTTCTCAACGAAG
GGTCTATGAAGGAGT	AGTGGCCATTAAAAC	GTTTCTCAACGAAGC
GTCTATGAAGGAGTT	GTGGCCATTAAAACA	TTTCTCAACGAAGCT
TCTATGAAGGAGTTG	TGGCCATTAAAACAG	TTCTCAACGAAGCTT
15 CTATGAAGGAGTTGC	GGCCATTAAAACAGT	TCTCAACGAAGCTTC
TATGAAGGAGTTGCC	GCCATTAAAACAGTG	CTCAACGAAGCTTCT
ATGAAGGAGTTGCCA	CCATTAAAACAGTGA	TCAACGAAGCTTCTG
TGAAGGAGTTGCCAA	CATTAAAACAGTGAA	CAACGAAGCTTCTGT
GAAGGAGTTGCCAAG	ATTAAAACAGTGAAAC	AACGAAGCTTCTGTG
20 AAGGAGTTGCCAAGG	TATAAACAGTGAAACG	ACGAAGCTTCTGTGA
AGGAGTTGCCAAGGG	TAAAACAGTGAAACGA	CGAAGCTTCTGTGAT
GGAGTTGCCAAGGGT	AAAACAGTGAAACGAG	GAAGCTTCTGTGATG
GAGTTGCCAAGGGTG	AAACAGTGAAACGAGG	AAGCTTCTGTGATGA
AGTTGCCAAGGGTGT	AACAGTGAAACGAGGC	AGCTTCTGTGATGAA
25 GTTGCCAAGGGTGTG	ACAGTGAAACGAGGCC	GCTTCTGTGATGAAG
TTGCCAAGGGTGTGG	CAGTGAAACGAGGCCG	CTTCTGTGATGAAGG
TGCCAAGGGTGTGGT	AGTGAAACGAGGCCGC	TTCTGTGATGAAGGA
GCCAAGGGTGTGGTG	GTGAACGAGGCCGCA	TCTGTGATGAAGGAG
CCAAGGGTGTGGTGA	TGAACGAGGCCGCAA	CTGTGATGAAGGAGT
30 CAAGGGTGTGGTGAA	GAACGAGGCCGCAAG	TGTGATGAAGGAGTT
AAGGGTGTGGTGAAA	AACGAGGCCGCAAGC	GTGATGAAGGAGTTC
AGGGTGTGGTGAAAG	ACGAGGCCGCAAGCA	TGATGAAGGAGTTCA
GGGTGTGGTGAAAGA	CGAGGCCGCAAGCAT	GATGAAGGAGTTCAA
GGTGTGGTGAAAGAT	GAGGCCGCAAGCATG	ATGAAGGAGTTCAAT
35 GTGTGGTGAAAGATG	AGGCCGCAAGCATGC	TGAAGGAGTTCAATT
TGTGGTGAAAGATGA	GGCCGCAAGCATGCG	GAAGGAGTTCAATTG
TGGTGAAAGATGAA	CCGCAAGCATGCGT	AAGGAGTTCAATTGT
GGTGAAAGATGAACC	CGCAAGCATGCGTGA	AGGAGTTCAATTGTC
40 GTGAAAGATGAACCT	GCAAGCATGCGTGAG	GGAGTTCAATTGTCA
TGAAAGATGAACCTG	CAAGCATGCGTGAGA	GAGTTCAATTGTCCAC
GAAAGATGAACCTGA	AAGCATGCGTGAGAG	AGTTCAATTGTCCACC
AAAGATGAACCTGAA	AGCATGCGTGAGAGG	GTTCAATTGTCCACCA
AAGATGAACCTGAAA	GCATGCGTGAGAGGA	TTCAATTGTCCACCAT
45 AGATGAACCTGAAAC	CATGCGTGAGAGGAT	TCAATTGTCCACCATG
GATGAACCTGAAACC	ATGCGTGAGAGGATT	CAATTGTCCACCATGT
ATGAACCTGAAACCA	TGCGTGAGAGGATTG	AATTGTCCACCATGTG
TGAACCTGAAACCAG	GCGTGAGAGGATTGA	ATTGTCCACCATGTGG
GAACCTGAAACCAGA	CGTGAGAGGATTGAG	TTGTCCACCATGTGGT
50 AACCTGAAACCAGAG	GTGAGAGGATTGAGT	TGTCACCATGTGGTG
ACCTGAAACCAGAGT	TGAGAGGATTGAGTT	GTCACCATGTGGTGC
		TCACCATGTGGTGCG

- 82 -

CACCATGTGGTGCGA	GTCATCATGGAAGT	CTGAGGCCAGAAATG
ACCATGTGGTGCGAT	TCATCATGGAAGTGA	TGAGGCCAGAAATGG
CCATGTGGTGCGATT	CATCATGGAAGTGAT	GAGGCCAGAAATGGA
CATGTGGTGCGATTG	ATCATGGAAGTGATG	AGGCCAGAAATGGAG
5 ATGTGGTGCGATTGC	TCATGGAAGTGATGA	GGCCAGAAATGGAGA
TGTGGTGCGATTGCT	CATGGAAGTGATGAC	GCCAGAAATGGAGAA
GTGGTGCGATTGCTG	ATGGAAGTGATGACA	CCAGAAATGGAGAAT
TGGTGCGATTGCTGG	TGGAAGTGATGACAC	CAGAAATGGAGAATA
GGTGCGATTGCTGGG	GGAAGTGATGACACG	AGAAATGGAGAATAA
10 GTGCGATTGCTGGGT	GAAGTGATGACACGG	GAAATGGAGAATAAT
TGCGATTGCTGGGTG	AACTGATGACACGGG	AAATGGAGAATAATC
GCGATTGCTGGGTGT	ACTGATGACACGGGG	AATGGAGAATAATCC
CGATTGCTGGGTGTG	CTGATGACACGGGGC	ATGGAGAATAATCCA
GATTGCTGGGTGTGG	TGATGACACGGGGCG	TGGAGAATAATCCAG
15 ATTGCTGGGTGTGGT	GATGACACGGGGCGA	GGAGAATAATCCAGT
TTGCTGGGTGTGGTG	ATGACACGGGGCGAT	GAGAATAATCCAGTC
TGCTGGGTGTGGTGT	TGACACGGGGCGATC	AGAATAATCCAGTCC
GCTGGGTGTGGTGTC	GACACGGGGCGATCT	GAATAATCCAGTCCT
CTGGGTGTGGTGTC	ACACGGGGCGATCTC	AATAATCCAGTCCTA
20 TGGGTGTGGTGTC	CACGGGGCGATCTCA	ATAATCCAGTCCTAG
GGGTGTGGTGTC	ACGGGGCGATCTCAA	TAATCCAGTCCTAGC
GGTGTGGTGTC	CGGGGCGATCTCAAA	AATCCAGTCCTAGCA
GTGTGGTGTC	GGGGCGATCTCAAAA	ATCCAGTCCTAGCAC
TGTGGTGTC	GGGCGATCTCAAAAG	TCCAGTCCTAGCACC
25 GTGGTGTC	GGCGATCTCAAAAGT	CCAGTCCTAGCACCT
TGGTGTC	GCGATCTCAAAAGTT	CAGTCCTAGCACCTC
GGTGTC	CGATCTCAAAAGTTA	AGTCCTAGCACCTCC
GTGTC	GATCTCAAAAGTTAT	GTCTAGCACCTCCA
TGT	ATCTCAAAAGTTATC	TCCTAGCACCTCCAA
30 GT	TCTCAAAAGTTATCT	CCTAGCACCTCCAAG
T	CTCAAAAGTTATCTC	CTAGCACCTCCAAGC
T	TCAAAAGTTATCTCC	TAGCACCTCCAAGCC
T	CAAAAGTTATCTCCG	AGCACCTCCAAGCCT
35 A	AAAAGTTATCTCCGG	GCACCTCCAAGCCTG
A	AAAGTTATCTCCGGT	CACCTCCAAGCCTGA
A	AAGTTATCTCCGGTC	ACCTCCAAGCCTGAG
A	AGTTATCTCCGGTCT	CCTCCAAGCCTGAGC
40 G	GTTATCTCCGGTCTC	CTCCAAGCCTGAGCA
T	TTATCTCCGGTCTCT	TCCAAGCCTGAGCAA
T	TATCTCCGGTCTCTG	CCAAGCCTGAGCAAG
A	ATCTCCGGTCTCTGA	CAAGCCTGAGCAAGA
T	TCTCCGGTCTCTGAG	AAGCCTGAGCAAGAT
T	CTCCGGTCTCTGAGG	AGCCTGAGCAAGATG
T	TCCGGTCTCTGAGGC	GCCTGAGCAAGATGA
45 C	CCGGTCTCTGAGGCC	CCTGAGCAAGATGAT
C	CGGTCTCTGAGGCCA	CTGAGCAAGATGATT
C	GGTCTCTGAGGCCAG	TGAGCAAGATGATT
A	GTCTCTGAGGCCAGA	GAGCAAGATGATTCA
C	TCTCTGAGGCCAGAA	AGCAAGATGATTGAG
50 T	CTCTGAGGCCAGAAA	GCAAGATGATTGAG
G	TCTGAGGCCAGAAAT	CAAGATGATTGAGAT

- 83 -

AAGATGATTCAGATG	GCCAATAAGTTCGTG	GAAGATTTTCACAGTC
AGATGATTCAGATGG	CCAATAAGTTCGTCC	AAGATTTTCACAGTCA
GATGATTCAGATGGC	CAATAAGTTCGTCCA	AGATTTTCACAGTCAA
ATGATTCAGATGGCC	AATAAGTTCGTCCAC	GATTTTCACAGTCAAA
5 TGATTCAGATGGCCG	ATAAGTTCGTCCACA	ATTTTCACAGTCAAAA
GATTCAGATGGCCGG	TAAGTTCGTCCACAG	TTTCACAGTCAAAAT
ATTCAGATGGCCGGA	AAGTTCGTCCACAGA	TTTCACAGTCAAAATC
TTCAGATGGCCGGAG	AGTTCGTCCACAGAG	TCACAGTCAAAATCG
TCAGATGGCCGGAGA	GTTTCGTCCACAGAGA	CACAGTCAAAATCGG
10 CAGATGGCCGGAGAG	TTCGTCCACAGAGAC	ACAGTCAAAATCGGA
AGATGGCCGGAGAGA	TCGTCCACAGAGACC	CAGTCAAAATCGGAG
GATGGCCGGAGAGAT	CGTCCACAGAGACCT	AGTCAAAATCGGAGA
ATGGCCGGAGAGATT	GTCCACAGAGACCTT	GTCAAAATCGGAGAT
TGGCCGGAGAGATTG	TCCACAGAGACCTTG	TCAAAATCGGAGATT
15 GGCCGGAGAGATTGC	CCACAGAGACCTTGC	CAAAATCGGAGATTT
GCCGGAGAGATTGCA	CACAGAGACCTTGCT	AAAATCGGAGATTTT
CCGGAGAGATTGCAG	ACAGAGACCTTGCTG	AAATCGGAGATTTTG
CGGAGAGATTGCAGA	CAGAGACCTTGCTGC	AATCGGAGATTTTGG
GGAGAGATTGCAGAC	AGAGACCTTGCTGCC	ATCGGAGATTTTGGT
20 GAGAGATTGCAGACG	GAGACCTTGCTGCCC	TCGGAGATTTTGGTA
AGAGATTGCAGACGG	AGACCTTGCTGCCCC	CGGAGATTTTGGTAT
GAGATTGCAGACGGC	GACCTTGCTGCCCCG	GGAGATTTTGGTATG
AGATTGCAGACGGCA	ACCTTGCTGCCCCGA	GAGATTTTGGTATGA
GATTGCAGACGGCAT	CCTTGCTGCCCCGAA	AGATTTTGGTATGAC
25 ATTGCAGACGGCATG	CTTGCTGCCCCGAAT	GATTTTGGTATGACG
TTGCAGACGGCATGG	TTGCTGCCCCGAATT	ATTTTGGTATGACGC
TGCAGACGGCATGGC	TGCTGCCCCGAATTG	TTTTTGGTATGACCG
GCAGACGGCATGGCA	GCTGCCCCGAATTGC	TTTGGTATGACCGGA
CAGACGGCATGGCAT	CTGCCCGGAATTGCA	TTGGTATGACCGGAG
30 AGACGGCATGGCATA	TGCCCGGAATTGCAT	TGGTATGACCGGAGA
GACGGCATGGCATAC	GCCCGGAATTGCATG	GGTATGACCGGAGAT
ACGGCATGGCATACC	CCCGGAATTGCATGG	GTATGACCGGAGATA
CGGCATGGCATACCT	CCGGAATTGCATGGT	TATGACCGGAGATAT
GGCATGGCATACCTC	CGGAATTGCATGGTA	ATGACCGGAGATATC
35 GCATGGCATACCTCA	GGAATTGCATGGTAG	TGACCGGAGATATCT
CATGGCATACCTCAA	GAATTGCATGGTAGC	GACCGGAGATATCTA
ATGGCATACCTCAAC	AATTGCATGGTAGCC	ACCGGAGATATCTAT
TGGCATACCTCAACG	ATTGCATGGTAGCCG	CGCGGAGATATCTATG
GGCATACCTCAACGC	TTGCATGGTAGCCGA	GCGGAGATATCTATGA
40 GCATACCTCAACGCC	TGCATGGTAGCCGAA	CGAGATATCTATGAG
CATACCTCAACGCCA	GCATGGTAGCCGAAG	GAGATATCTATGAGA
ATACCTCAACGCCAA	CATGGTAGCCGAAGA	AGATATCTATGAGAC
TACCTCAACGCCAAT	ATGGTAGCCGAAGAT	GATATCTATGAGACA
ACCTCAACGCCAATA	TGGTAGCCGAAGATT	ATATCTATGAGACAG
45 CCTCAACGCCAATAA	GGTAGCCGAAGATTT	TATCTATGAGACAGA
CTCAACGCCAATAAG	GTAGCCGAAGATTTT	ATCTATGAGACAGAC
TCAACGCCAATAAGT	TAGCCGAAGATTTCA	TCTATGAGACAGACT
CAACGCCAATAAGTT	AGCCGAAGATTTTCA	CTATGAGACAGACTA
AACGCCAATAAGTTC	GCCGAAGATTTTACA	TATGAGACAGACTAT
50 ACGCCAATAAGTTCG	CCGAAGATTTTACAG	ATGAGACAGACTATT
CGCCAATAAGTTCGT	CGAAGATTTTACAGT	TGAGACAGACTATTA

- 84 -

5	GAGACAGACTATTAC AGACAGACTATTACC GACAGACTATTACCG ACAGACTATTACCGG CAGACTATTACCGGA AGACTATTACCGGAA GACTATTACCGGAAA ACTATTACCGGAAAG CTATTACCGGAAAGG TATTACCGGAAAGGA ATTACCGGAAAGGAG TTACCGGAAAGGAGG TACCGGAAAGGAGGC ACCGGAAAGGAGGCA CCGGAAAGGAGGCAA CGGAAAGGAGGCAAA GGAAAGGAGGCAAAG GAAAGGAGGCAAAGG AAAGGAGGCAAAGGG AAGGAGGCAAAGGGC AGGAGGCAAAGGGCT GGAGGCAAAGGGCTG GAGGCAAAGGGCTGC AGGCAAAGGGCTGCT GGCAAAGGGCTGCTG GCAAAGGGCTGCTGC CAAAGGGCTGCTGCC AAAGGGCTGCTGCCC AAGGGCTGCTGCCCC AGGGCTGCTGCCCCG GGGCTGCTGCCCCGT GGCTGCTGCCCCGTG GCTGCTGCCCCGTGC CTGCTGCCCCGTGCG TGCTGCCCCGTGCGCT GCTGCCCCGTGCGCTG CTGCCCCGTGCGCTGG TGCCCCGTGCGCTGGA GCCCCGTGCGCTGGAT CCCCGTGCGCTGGATG CCGTGCGCTGGATGT CGTGCGCTGGATGTC GTGCGCTGGATGTCT TGCGCTGGATGTCTC GCGCTGGATGTCTCC CGCTGGATGTCTCCT GCTGGATGTCTCCTG CTGGATGTCTCCTGA TGGATGTCTCCTGAG GGATGTCTCCTGAGT GATGTCTCCTGAGTC	ATGTCTCCTGAGTCC TGTCTCCTGAGTCCC GTCTCCTGAGTCCCT TCTCCTGAGTCCCTC CTCCTGAGTCCCTCA TCCTGAGTCCCTCAA CCTGAGTCCCTCAAG CTGAGTCCCTCAAGG TGAGTCCCTCAAGGA GAGTCCCTCAAGGAT AGTCCCTCAAGGATG GTCCCTCAAGGATGG TCCCTCAAGGATGGA CCCTCAAGGATGGAG CCTCAAGGATGGAGT CTCAAGGATGGAGTC TCAAGGATGGAGTCT CAAGGATGGAGTCTT AAGGATGGAGTCTTC AGGATGGAGTCTTCA GGATGGAGTCTTCAC GATGGAGTCTTCACC ATGGAGTCTTCACCA TGGAGTCTTCACCAC GGAGTCTTCACCCT GAGTCTTCACCCTT AGTCTTCACCCTTA GTCTTCACCCTTAC TCTTCACCCTTACT CTTCACCCTTACTC TTCACCCTTACTCG TCACCCTTACTCGG CACCCTTACTCGGA ACCCTTACTCGGAC CCCTTACTCGGACG CACTTACTCGGACGT ACTTACTCGGACGTC CTTACTCGGACGTCT TACTCGGACGTCTG TACTCGGACGTCTGG ACTCGGACGTCTGGT CTCGGACGTCTGGTC TCGGACGTCTGGTCC CGGACGTCTGGTCCT GGACGTCTGGTCCTT GACGTCTGGTCCTTC ACGTCTGGTCCTTCG CGTCTGGTCCTTCGG GTCTGGTCCTTCGGG TCTGGTCCTTCGGGG CTGGTCCTTCGGGGT	TGGTCCTTCGGGGTC GGTCCTTCGGGGTCG GTCCTTCGGGGTCGT TCCTTCGGGGTCGTC CCTTCGGGGTCGTCC CTTCGGGGTCGTCTC TTCGGGGTCGTCTCT TCGGGGTCGTCTCTC CGGGGTCGTCTCTG GGGGTCGTCTCTGG GGGTCGTCTCTGGG GGTCGTCTCTGGGA GTCGTCTCTGGGAG TCGTCTCTGGGAGA CGTCTCTGGGAGAT GTCCTCTGGGAGATC TCCTCTGGGAGATCG CCTCTGGGAGATCGC CTCTGGGAGATCGCC TCTGGGAGATCGCCA CTGGGAGATCGCCAC TGGGAGATCGCCACA GGGAGATCGCCACAC GGAGATCGCCACACT GAGATCGCCACACTG AGATCGCCACACTGG GATCGCCACACTGGC ATCGCCACACTGGCC TCGCCACACTGGCCG CGCCACACTGGCCGA GCCACACTGGCCGAG CCACACTGGCCGAGC CACACTGGCCGAGCA ACACTGGCCGAGCAG CACTGGCCGAGCAGC ACTGGCCGAGCAGCC CTGGCCGAGCAGCCC TGGCCGAGCAGCCCT GGCCGAGCAGCCCTA GCCGAGCAGCCCTAC CCGAGCAGCCCTACC CGAGCAGCCCTACCA GAGCAGCCCTACCAG AGCAGCCCTACCAGG GCAGCCCTACCAGGG CAGCCCTACCAGGGC AGCCCTACCAGGGCT GCCCTACCAGGGCTT CCCTACCAGGGCTTG CCTACCAGGGCTTGT CTACCAGGGCTTGTC
---	---	---	--

- 85 -

TACCAGGGCTTGTCC	CTTCTGGACAAGCCA	ATGTGCTGGCAGTAT
ACCAGGGCTTGTCCA	TTCTGGACAAGCCAG	TGTGCTGGCAGTATA
CCAGGGCTTGTCCAA	TCTGGACAAGCCAGA	GTGCTGGCAGTATAA
CAGGGCTTGTCCAAC	CTGGACAAGCCAGAC	TGCTGGCAGTATAAC
5 AGGGCTTGTCCAACG	TGGACAAGCCAGACA	GCTGGCAGTATAACC
GGGCTTGTCCAACGA	GGACAAGCCAGACAA	CTGGCAGTATAAACC
GGCTTGTCCAACGAG	GACAAGCCAGACAAC	TGGCAGTATAAACCC
GCTTGTCCAACGAGC	ACAAGCCAGACAAC	GGCAGTATAAACCCCA
CTTGTCCAACGAGCA	CAAGCCAGACAAC	GCAGTATAAACCCCAA
10 TTGTCCAACGAGCAA	AAGCCAGACAAC	CAGTATAAACCCCAAG
TGTCCAACGAGCAAG	AGCCAGACAAC	AGTATAAACCCCAAGA
GTCCAACGAGCAAGT	GCCAGACAAC	GTATAAACCCCAAGAT
TCCAACGAGCAAGTC	CCAGACAAC	TATAAACCCCAAGATG
CCAACGAGCAAGTCC	CAGACAAC	ATAAACCCCAAGATGA
15 CAACGAGCAAGTCCT	AGACAAC	TAACCCCAAGATGAG
AACGAGCAAGTCCTT	GACAAC	AACCCCAAGATGAGG
ACGAGCAAGTCCTTC	ACAAC	ACCCCAAGATGAGGC
CGAGCAAGTCCTTCG	CAAC	CCCCAAGATGAGGCC
GAGCAAGTCCTTCGC	CAAC	CCCAAGATGAGGCCT
20 AGCAAGTCCTTCGCT	CAAC	CCAAGATGAGGCCTT
GCAAGTCCTTCGCTT	CAAC	CAAGATGAGGCCTTC
CAAGTCCTTCGCTTC	CAAC	AAGATGAGGCCTTCC
AAGTCCTTCGCTTCG	CAAC	AGATGAGGCCTTCCT
AGTCCTTCGCTTCGT	CAAC	GATGAGGCCTTCCTT
25 GTCCTTCGCTTCGTC	CAAC	ATGAGGCCTTCCTTC
TCCTTCGCTTCGTCA	CAAC	TGAGGCCTTCCTTCC
CCTTCGCTTCGTCA	CAAC	GAGGCCTTCCTTCCT
CTTCGCTTCGTCA	CAAC	AGGCCTTCCTTCCTG
TTTCGCTTCGTCA	CAAC	GGCCTTCCTTCCTGG
30 TCGCTTCGTCA	CAAC	GCCTTCCTTCCTGGA
CGCTTCGTCA	CAAC	CCTTCCTTCCTGGAG
GCTTCGTCA	CAAC	CTTCCTTCCTGGAGA
CTTCGTCA	CAAC	TTCTTCCTTCCTGGAGAT
TTCGTCA	CAAC	TCCTTCCTTCCTGGAGATC
35 TCGTCATGGAGGGCG	CAAC	CCTTCCTTCCTGGAGATCA
CGTCATGGAGGGCGG	CAAC	CTTCCTTCCTGGAGATCAT
GTCATGGAGGGCGGC	CAAC	TTCTTCCTTCCTGGAGATCATC
TCATGGAGGGCGGCC	CAAC	TCCTTCCTTCCTGGAGATCATCA
CATGGAGGGCGGCCT	CAAC	CCTTCCTTCCTGGAGATCATCAG
40 ATGGAGGGCGGCCTT	CAAC	CTGGAGATCATCAGC
TGGAGGGCGGCCTTC	CAAC	TGGAGATCATCAGCA
GGAGGGCGGCCTTCT	CAAC	GGAGATCATCAGCAG
GAGGGCGGCCTTCTG	CAAC	GAGATCATCAGCAGC
AGGGCGGCCTTCTGG	CAAC	AGATCATCAGCAGCA
45 GGGCGGCCTTCTGGA	CAAC	GATCATCAGCAGCAT
GGCGGCCTTCTGGAC	CAAC	ATCATCAGCAGCATC
GCGGCCTTCTGGACA	CAAC	TCATCAGCAGCATCA
CGGCCTTCTGGACAA	CAAC	CATCAGCAGCATCAA
GGCCTTCTGGACAAG	CAAC	ATCAGCAGCATCAAA
50 GCCTTCTGGACAAGC	CAAC	TCAGCAGCATCAAG
CCTTCTGGACAAGCC	CAAC	CAGCAGCATCAAGA

- 86 -

AGCAGCATCAAAGAG	TACAGCGAGGAGAAC	GAGAACATGGAGAGC
GCAGCATCAAAGAGG	ACAGCGAGGAGAACA	AGAACATGGAGAGCG
CAGCATCAAAGAGGA	CAGCGAGGAGAACAA	GAACATGGAGAGCGT
AGCATCAAAGAGGAG	AGCGAGGAGAACAAG	AACATGGAGAGCGTC
5 GCATCAAAGAGGAGA	GCGAGGAGAACAAGC	ACATGGAGAGCGTCC
CATCAAAGAGGAGAT	CGAGGAGAACAAGCT	CATGGAGAGCGTCCC
ATCAAAGAGGAGATG	GAGGAGAACAAGCTG	ATGGAGAGCGTCCCC
TCAAAGAGGAGATGG	AGGAGAACAAGCTGC	TGGAGAGCGTCCCCC
CAAAGAGGAGATGGA	GGAGAACAAGCTGCC	GGAGAGCGTCCCCCT
10 AAAGAGGAGATGGAG	GAGAACAAGCTGCCC	GAGAGCGTCCCCCTG
AAGAGGAGATGGAGC	AGAACAAGCTGCCCCG	AGAGCGTCCCCCTGG
AGAGGAGATGGAGCC	GAACAAGCTGCCCCGA	GAGCGTCCCCCTGGA
GAGGAGATGGAGCCT	AACAAGCTGCCCCGAG	AGCGTCCCCCTGGAC
AGGAGATGGAGCCTG	ACAAGCTGCCCCGAGC	GCGTCCCCCTGGACC
15 GGAGATGGAGCCTGG	CAAGCTGCCCCGAGCC	CGTCCCCCTGGACCC
GAGATGGAGCCTGGC	AAGCTGCCCCGAGCCG	GTCCCCCTGGACCCC
AGATGGAGCCTGGCT	AGCTGCCCCGAGCCGG	TCCCCCTGGACCCCT
GATGGAGCCTGGCTT	GCTGCCCCGAGCCGGA	CCCCCTGGACCCCTC
ATGGAGCCTGGCTTC	CTGCCCCGAGCCGGAG	CCCCCTGGACCCCTCG
20 TGGAGCCTGGCTTCC	TGCCCCGAGCCGGAGG	CCCTGGACCCCTCGG
GGAGCCTGGCTTCCG	GCCCCGAGCCGGAGGA	CCTGGACCCCTCGGC
GAGCCTGGCTTCCGG	CCCGAGCCGGAGGAG	CTGGACCCCTCGGCC
AGCCTGGCTTCCGGG	CCGAGCCGGAGGAGC	TGGACCCCTCGGCCT
GCCTGGCTTCCGGGA	CGAGCCGGAGGAGCT	GGACCCCTCGGCCTC
25 CCTGGCTTCCGGGAG	GAGCCGGAGGAGCTG	GACCCCTCGGCCTCC
CTGGCTTCCGGGAGG	AGCCGGAGGAGCTGG	ACCCCTCGGCCTCCT
TGGCTTCCGGGAGGT	GCCGGAGGAGCTGGA	CCCCTCGGCCTCCTC
GGCTTCCGGGAGGTC	CCGGAGGAGCTGGAC	CCCTCGGCCTCCTCG
GCTTCCGGGAGGTCT	CGGAGGAGCTGGACC	CCTCGGCCTCCTCGT
30 CTTCCGGGAGGTCTC	GGAGGAGCTGGACCT	CTCGGCCTCCTCGTC
TTCCGGGAGGTCTCC	GAGGAGCTGGACCTG	TCGGCCTCCTCGTCC
TCCGGGAGGTCTCCT	AGGAGCTGGACCTGG	CGGCCTCCTCGTCCCT
CCGGGAGGTCTCCTT	GGAGCTGGACCTGGA	GGCCTCCTCGTCCCTC
35 CGGGAGGTCTCCTTC	GAGCTGGAGCTGGAG	GCCTCCTCGTCCCTCC
GGGAGGTCTCCTTCT	AGCTGGACCTGGAGC	CCTCCTCGTCCCTCCC
GGAGGTCTCCTTCTA	GCTGGACCTGGAGCC	CTCCTCGTCCCTCCCT
GAGGTCTCCTTCTAC	CTGGACCTGGAGCCA	TCCTCGTCCCTCCCTG
AGGTCTCCTTCTACT	TGGACCTGGAGCCAG	CCTCGTCCCTCCCTGC
GGTCTCCTTCTACTA	GGACCTGGAGCCAGA	CTCGTCCCTCCCTGCC
40 GTCTCCTTCTACTAC	GACCTGGAGCCAGAG	TCGTCCCTCCCTGCCA
TCTCCTTCTACTACA	ACCTGGAGCCAGAGA	CGTCCCTCCCTGCCAC
CTCCTTCTACTACAG	CCTGGAGCCAGAGAA	GTCCCTCCCTGCCACT
TCCTTCTACTACAGC	CTGGAGCCAGAGAAC	TCCTCCCTGCCACTG
CCTTCTACTACAGCG	TGGAGCCAGAGAAC	CCTCCCTGCCACTGC
45 CTTCTACTACAGCGA	GGAGCCAGAGAACAT	CTCCCTGCCACTGCC
TTCTACTACAGCGAG	GAGCCAGAGAACATG	TCCCTGCCACTGCCC
TCTACTACAGCGAGG	AGCCAGAGAACATGG	CCCTGCCACTGCCCC
CTACTACAGCGAGGA	GCCAGAGAACATGGA	CCTGCCACTGCCCCGA
TACTACAGCGAGGAG	CCAGAGAACATGGAG	CTGCCACTGCCCCGAC
50 ACTACAGCGAGGAGA	CAGAGAACATGGAGA	TGCCACTGCCCCGACA
CTACAGCGAGGAGAA	AGAGAACATGGAGAG	GCCACTGCCCCGACAG

- 87 -

CCACTGCCCCGACAGA	GGGGTGCTGGTCCTC	ATGAACGGGGGCGC
CACTGCCCCGACAGAC	GGGTGCTGGTCCTCC	TGAACGGGGGCGCA
ACTGCCCCGACAGACA	GGTGCTGGTCCTCCG	GAACGGGGGCGCAA
CTGCCCCGACAGACAC	GTGCTGGTCCTCCGC	AACGGGGGCGCAAG
5 TGCCCCGACAGACACT	TGCTGGTCCTCCGCG	ACGGGGGCGCAAGA
GCCCCGACAGACACTC	GCTGGTCCTCCGCGC	CGGGGGCGCAAGAA
CCCGACAGACACTCA	CTGGTCCTCCGCGCC	GGGGGCGCAAGAAC
CCGACAGACACTCAG	TGGTCCTCCGCGCCA	GGGGCGCAAGAACG
CGACAGACACTCAGG	GGTCCTCCGCGCCAG	GGGCCGCAAGAACGA
10 GACAGACACTCAGGA	GTCTCCGCGCCAGC	GGCCGCAAGAACGAG
ACAGACACTCAGGAC	TCCTCCGCGCCAGCT	GCCGCAAGAACGAGC
CAGACACTCAGGACA	CCTCCGCGCCAGCTT	CCGCAAGAACGAGCG
AGACACTCAGGACAC	CTCCGCGCCAGCTTC	CGCAAGAACGAGCGG
GACACTCAGGACACA	TCCGCGCCAGCTTCG	GCAAGAACGAGCGGG
15 ACACTCAGGACACAA	CCGCGCCAGCTTCGA	CAAGAACGAGCGGGC
CACTCAGGACACAAG	CGCGCCAGCTTCGAC	AAGAACGAGCGGGCC
ACTCAGGACACAAGG	GCGCCAGCTTCGACG	AGAACGAGCGGGCCT
CTCAGGACACAAGGC	CGCCAGCTTCGACGA	GAACGAGCGGGCCTT
TCAGGACACAAGGCC	GCCAGCTTCGACGAG	AACGAGCGGGCCTTG
20 CAGGACACAAGGCCG	CCAGCTTCGACGAGA	ACGAGCGGGCCTTGC
AGGACACAAGGCCGA	CAGCTTCGACGAGAG	CGAGCGGGCCTTGCC
GGACACAAGGCCGAG	AGCTTCGACGAGAGA	GAGCGGGCCTTGCCG
GACACAAGGCCGAGA	GCTTCGACGAGAGAC	AGCGGGCCTTGCCGC
ACACAAGGCCGAGAA	CTTCGACGAGAGACA	GCGGGCCTTGCCGCT
25 CACAAGGCCGAGAAC	TTCGACGAGAGACAG	CGGGCCTTGCCGCTG
ACAAGGCCGAGAACG	TCGACGAGAGACAGC	GGGCCTTGCCGCTGC
CAAGGCCGAGAACGG	CGACGAGAGACAGCC	GGCCTTGCCGCTGCC
AAGGCCGAGAACGGC	GACGAGAGACAGCCT	GCCTTGCCGCTGCCC
AGGCCGAGAACGGCC	ACGAGAGACAGCCTT	CCTTGCCGCTGCCCC
30 GGCCGAGAACGGCCC	CGAGAGACAGCCTTA	CTTGCCGCTGCCCCA
GCCGAGAACGGCCCC	GAGAGACAGCCTTAC	TTGCCGCTGCCCCAG
CCGAGAACGGCCCCG	AGAGACAGCCTTACG	TGCCGCTGCCCCAGT
CGAGAACGGCCCCCG	GAGACAGCCTTACGC	GCCGCTGCCCCAGTC
GAGAACGGCCCCCGG	AGACAGCCTTACGCC	CCGCTGCCCCAGTCT
35 AGAACGGCCCCGGCC	GACAGCCTTACGCCC	CGCTGCCCCAGTCTT
GAACGGCCCCCGGCC	ACAGCCTTACGCCCA	GCTGCCCCAGTCTTC
AACGGCCCCCGGCCCT	CAGCCTTACGCCCAC	CTGCCCCAGTCTTCG
ACGGCCCCCGGCCCTG	AGCCTTACGCCCACA	TGCCCCAGTCTTCGA
CGGCCCCCGGCCCTGG	GCCTTACGCCCACAT	GCCCCAGTCTTCGAC
40 GGCCCCGGGCCCTGGG	CCTTACGCCCACATG	CCCCAGTCTTCGACC
GCCCCGGGCCCTGGGG	CTTACGCCCACATGA	CCCAGTCTTCGACCT
CCCCGGGCCCTGGGGT	TTACGCCCACATGAA	CCAGTCTTCGACCTG
CCCGGCCCTGGGGTG	TACGCCCACATGAAC	CAGTCTTCGACCTGC
CCGGGCCCTGGGGTGC	ACGCCCACATGAACG	AGTCTTCGACCTGCT
45 CGGCCCTGGGGTGCT	CGCCCACATGAACGG	GTCTTCGACCTGCTG
GGCCCTGGGGTGCTG	GCCCACATGAACGGG	TCTTCGACCTGCTGA
GCCCTGGGGTGCTGG	CCCACATGAACGGGG	CTTCGACCTGCTGAT
CCCTGGGGTGCTGGT	CCACATGAACGGGGG	TTTCGACCTGCTGATC
CCTGGGGTGCTGGTC	CACATGAACGGGGGC	TCGACCTGCTGATCC
50 CTGGGGTGCTGGTCC	ACATGAACGGGGGCC	CGACCTGCTGATCCT
TGGGGTGCTGGTCCT	CATGAACGGGGGCCG	GACCTGCTGATCCTT

- 88 -

ACCTGCTGATCCTTG	GCGCAGCGGGGTGGG	TCCTGTACCTCAGTG
CCTGCTGATCCTTGG	CGCAGCGGGGTGGGG	CCTGTACCTCAGTGG
CTGCTGATCCTTGGA	GCAGCGGGGTGGGGG	CTGTACCTCAGTGGA
TGCTGATCCTTGAT	CAGCGGGGTGGGGGG	TGTACCTCAGTGGAT
5 GCTGATCCTTGATC	AGCGGGGTGGGGGGG	GTACCTCAGTGGATC
CTGATCCTTGATCC	GCGGGGTGGGGGGGG	TACCTCAGTGGATCT
TGATCCTTGATCCT	CGGGGTGGGGGGGGA	ACCTCAGTGGATCTT
GATCCTTGATCCTG	GGGGTGGGGGGGGAG	CCTCAGTGGATCTTC
ATCCTTGATCCTGA	GGGTGGGGGGGGAGA	CTCAGTGGATCTTCA
10 TCCTTGATCCTGAA	GGTGGGGGGGGAGAG	TCAGTGGATCTTCAG
CCTTGATCCTGAAT	GTGGGGGGGGAGAGA	CAGTGGATCTTCAGT
CTTGATCCTGAATC	TGGGGGGGGAGAGAG	AGTGGATCTTCAGTT
TTGGATCCTGAATCT	GGGGGGGGAGAGAGA	GTGGATCTTCAGTTC
TGGATCCTGAATCTG	GGGGGGGAGAGAGAG	TGGATCTTCAGTTCT
15 GGATCCTGAATCTGT	GGGGGGGAGAGAGAGT	GGATCTTCAGTTCTG
GATCCTGAATCTGTG	GGGGGAGAGAGAGT	GATCTTCAGTTCTGC
ATCCTGAATCTGTGC	GGGGAGAGAGAGTTT	ATCTTCAGTTCTGCC
TCCTGAATCTGTGCA	GGGAGAGAGAGTTTT	TCTTCAGTTCTGCCC
CCTGAATCTGTGCAA	GGAGAGAGAGTTTTA	CTTCAGTTCTGCCCT
20 CTGAATCTGTGCAAA	GAGAGAGAGTTTTAA	TTCAGTTCTGCCCTT
TGAATCTGTGCAAAC	AGAGAGAGTTTTAAC	TCAGTTCTGCCCTTG
GAATCTGTGCAAACA	GAGAGAGTTTTAACA	CAGTTCTGCCCTTGC
AATCTGTGCAAACAG	AGAGAGTTTTTAACAA	AGTTCTGCCCTTGCT
ATCTGTGCAAACAGT	GAGAGTTTTTAACAAT	GTTCTGCCCTTGCTG
25 TCTGTGCAAACAGTA	AGAGTTTTTAACAATC	TTCTGCCCTTGCTGC
CTGTGCAAACAGTAA	GAGTTTTTAACAATCC	TCTGCCCTTGCTGCC
TGTGCAAACAGTAAC	AGTTTTTAACAATCCA	CTGCCCTTGCTGCCC
GTGCAAACAGTAACG	GTTTTTAACAATCCAT	TGCCCTTGCTGCCCC
TGCAAACAGTAACGT	TTTTAACAATCCATT	GCCCTTGCTGCCCCG
30 GCAAACAGTAACGTG	TTTAACAATCCATT	CCCTTGCTGCCCCG
CAAACAGTAACGTGT	TTAACAATCCATTCA	CCTTGCTGCCCCGCG
AAACAGTAACGTGTG	TAACAATCCATTAC	CTTGCTGCCCCGCGG
AACAGTAACGTGTGC	ACAATCCATTACAA	TTGCTGCCCCGCGGA
ACAGTAACGTGTGCG	CAATCCATTACAAAG	TGCTGCCCCGCGGAG
35 CAGTAACGTGTGCGC	AATCCATTACAAAGC	GCTGCCCCGCGGAGA
AGTAACGTGTGCGCA	ATCCATTACAAAGCC	CTGCCCCGCGGAGAC
GTAACGTGTGCGCAC	TCCATTACAAAGCCT	TGCCCGCGGAGACA
TAACGTGTGCGCACG	CCATTACAAAGCCTC	GCCCGCGGAGACAG
AACGTGTGCGCACGC	CATTACAAAGCCTCC	CCCGCGGAGACAGC
40 ACGTGTGCGCACGCG	ATTACAAAGCCTCCT	CCGCGGAGACAGCT
CGTGTGCGCACGCGC	TTCACAAGCCTCCTG	CGCGGAGACAGCTT
GTGTGCGCACGCGCA	TCACAAGCCTCCTGT	GCGGAGACAGCTTC
TGTGCGCACGCGCAG	CACAAGCCTCCTGTA	CGGAGACAGCTTCT
GTGCGCACGCGCAGC	ACAAGCCTCCTGTAC	GGGAGACAGCTTCTC
45 TGCGCACGCGCAGCG	CAAGCCTCCTGTACC	GGAGACAGCTTCTCT
GCGCACGCGCAGCGG	AAGCCTCCTGTACCT	GAGACAGCTTCTCTG
CGCACGCGCAGCGGG	AGCCTCCTGTACCTC	AGACAGCTTCTCTGC
GCACGCGCAGCGGGG	GCCTCCTGTACCTCA	GACAGCTTCTCTGCA
CACGCGCAGCGGGGT	CCTCCTGTACCTCAG	ACAGCTTCTCTGCAG
50 ACGCGCAGCGGGGTG	CTCCTGTACCTCAGT	CAGCTTCTCTGCAGT
CGCGCAGCGGGGTGG		AGCTTCTCTGCAGTA

5	GCTTCTCTGCAGTAA CTTCTCTGCAGTAAA TTCTCTGCAGTAAAA TCTCTGCAGTAAAAC CTCTGCAGTAAAACA TCTGCAGTAAAACAC CTGCAGTAAAACACA TGCAGTAAAACACAT GCAGTAAAACACATT CAGTAAAACACATTT AGTAAAACACATTTG GTAAAACACATTTGG TAAAACACATTTGGG AAAACACATTTGGGA AAACACATTTGGGAT AACACATTTGGGATG ACACATTTGGGATGT CACATTTGGGATGTT ACATTTGGGATGTTT CATTTGGGATGTTCC ATTTGGGATGTTCCCT TTTGGGATGTTCCCTT TTGGGATGTTCCCTTT TGGGATGTTCCCTTTT GGGATGTTCCCTTTTT GGATGTTCCCTTTTTT GATGTTCCCTTTTTTC ATGTTCCCTTTTTTCA TGTTCCCTTTTTTCAA GTTCCCTTTTTTCAAT TTCCTTTTTTCAATA TCCTTTTTTCAATAT CCTTTTTTCAATATG CTTTTTTCAATATGC TTTTTTCAATATGCA TTTTTCAATATGCAA TTTTCAATATGCAAG TTTCAATATGCAAGC TTCAATATGCAAGCA TCAATATGCAAGCAG CAATATGCAAGCAGC AATATGCAAGCAGCT ATATGCAAGCAGCTT TATGCAAGCAGCTTT ATGCAAGCAGCTTTTT TGCAAGCAGCTTTTT GCAAGCAGCTTTTTA CAAGCAGCTTTTTAT AAGCAGCTTTTTATT AGCAGCTTTTTATT GCAGCTTTTTATTCC	CAGCTTTTTATTCCC AGCTTTTTATTCCCT GCTTTTTATTCCCTG CTTTTTATTCCCTGC TTTTTTATTCCCTGCC TTTTATTCCCTGCCC TTTATTCCCTGCCCA TTATTCCCTGCCCAA TATTCCCTGCCCAA ATTCCCTGCCCAAAC TCCCTGCCCAAACC TCCCTGCCCAAACCC CCCTGCCCAAACCCT CCTGCCCAAACCCTT CTGCCCAAACCCTTA TGCCCAAACCCTTAA GCCCAAACCCTTAAC CCCAAACCCTTAACT CCAAACCCTTAACTG CAAACCCTTAACTGA AAACCCTTAACTGAC AACCCTTAACTGACA ACCCTTAACTGACAT CCCTTAACTGACATG CCTTAACTGACATGG CTTAACTGACATGGG TTAACTGACATGGGC TAACTGACATGGGCC AACTGACATGGGCCT ACTGACATGGGCCTT CTGACATGGGCCTTT TGACATGGGCCTTTA GACATGGGCCTTTAA ACATGGGCCTTTAAG CATGGGCCTTTAAGA ATGGGCCTTTAAGAA TGGGCCTTTAAGAAC GGGCCTTTAAGAACC GGCCTTTAAGAACCCT GCCCTTTAAGAACCCT CCTTTAAGAACCCTTA CTTTAAGAACCCTTAA TTTAAGAACCCTTAAT TTAAGAACCCTTAATG TAAGAACCCTTAATGA AAGAACCCTTAATGAC AGAACCCTTAATGACA GAACCCTTAATGACAA AACCCTTAATGACAAC ACCTTAATGACAACA CCTTAATGACAACAC	CTTAATGACAACACT TTAATGACAACACTT TAATGACAACACTTA AATGACAACACTTAA ATGACAACACTTAAT TGACAACACTTAATA GACAACACTTAATAG ACAACACTTAATAGC CAACACTTAATAGCA AACACTTAATAGCAA ACACTTAATAGCAAC CACTTAATAGCAACA ACTTAATAGCAACAG CTTAATAGCAACAGA TTAATAGCAACAGAG TAATAGCAACAGAGC AATAGCAACAGAGCA ATAGCAACAGAGCAC TAGCAACAGAGCACT AGCAACAGAGCACTT GCAACAGAGCACTTG CAACAGAGCACTTGA AACAGAGCACTTGAG ACAGAGCACTTGAGA CAGAGCACTTGAGAA AGAGCACTTGAGAAC GAGCACTTGAGAAC AGCACTTGAGAACCA GCACCTGAGAACCA CACTTGAGAACCACT ACTTGAGAACCACTC CTTGAGAACCACTCT TTGAGAACCACTCTC TGAGAACCACTCTCC GAGAACCACTCTCCT AGAACCAGTCTCCTC GAACCAGTCTCCTCA AACCAGTCTCCTCAC ACCAGTCTCCTCACT CCAGTCTCCTCACTC CAGTCTCCTCACTCT AGTCTCCTCACTCTG GTCTCCTCACTCTGT TCTCCTCACTCTGTC CTCCTCACTCTGTCC TCCTCACTCTGTCCC CCTCACTCTGTCCCT CTCACTCTGTCCCTG TCACTCTGTCCCTGT CACTCTGTCCCTGTC ACTCTGTCCCTGTCC
---	---	---	---

- 90 -

CTCTGTCCCTGTCCT	AACGGAAAAATAATT	TGAGGAAGTGGCTGT
TCTGTCCCTGTCTT	ACGGAAAAATAATTG	GAGGAAGTGGCTGTC
CTGTCCCTGTCCTTC	CGGAAAAATAATTGC	AGGAAGTGGCTGTCC
TGTCCCTGTCCTTCC	GGAAAAATAATTGCC	GGAAGTGGCTGTCCC
5 GTCCCTGTCCTTCCC	GAAAAATAATTGCCA	GAAGTGGCTGTCCCT
TCCCTGTCCTTCCCT	AAAAATAATTGCCAC	AAGTGGCTGTCCCTG
CCCTGTCTTCCCTG	AAAATAATTGCCACA	AGTGGCTGTCCCTGT
CCTGTCTTCCCTGT	AAATAATTGCCACAA	GTGGCTGTCCCTGTG
CTGTCTTCCCTGTT	AATAATTGCCACAAG	TGGCTGTCCCTGTGG
10 TGTCTTCCCTGTTT	ATAATTGCCACAAGT	GGCTGTCCCTGTGGC
GTCCTTCCCTGTTCT	TAATTGCCACAAGTC	GCTGTCCCTGTGGCC
TCCTTCCCTGTTCTC	AATTGCCACAAGTCC	CTGTCCCTGTGGCCC
CCTTCCCTGTTCTCC	ATTGCCACAAGTCCA	TGTCCCTGTGGCCCC
CTTCCCTGTTCTCCC	TTGCCACAAGTCCAG	GTCCCTGTGGCCCCA
15 TCCCTGTTCTCTCCCT	TGCCACAAGTCCAGC	TCCCTGTGGCCCCAT
TCCCTGTTCTCCCTT	GCCACAAGTCCAGCT	CCCTGTGGCCCCATC
CCCTGTTCTCCCTTT	CCACAAGTCCAGCTG	CCTGTGGCCCCATCC
CCTGTTCTCCCTTTT	CACAAGTCCAGCTGG	CTGTGGCCCCATCCA
CTGTTCTCCCTTTTCT	ACAAGTCCAGCTGGG	TGTGGCCCCATCCAA
20 TGTCTCTCCCTTTCTC	CAAGTCCAGCTGGGA	GTGGCCCCATCCAAC
GTTCTCCCTTTCTCT	AAGTCCAGCTGGGAA	TGGCCCCATCCAACC
TTCTCCCTTTCTCTC	AGTCCAGCTGGGAAG	GGCCCCATCCAACCAC
TCTCCCTTTCTCTCT	GTCCAGCTGGGAAGC	GCCCCATCCAACCAC
CTCCCTTTCTCTCTC	TCCAGCTGGGAAGCC	CCCCATCCAACCACT
25 TCCCTTTCTCTCTCC	CCAGCTGGGAAGCCC	CCCATCCAACCACTG
CCCTTTCTCTCTCCT	CAGCTGGGAAGCCCT	CCATCCAACCACTGT
CCTTTCTCTCTCCTC	AGCTGGGAAGCCCTT	CATCCAACCACTGTA
CTTTCTCTCTCCTCT	GCTGGGAAGCCCTTT	ATCCAACCACTGTAC
TTTCTCTCTCCTCTC	CTGGGAAGCCCTTTT	TCCAACCACTGTACA
30 TTCTCTCTCCTCTCT	TGGGAAGCCCTTTT	CCAACCACTGTACAC
TCTCTCTCCTCTCTG	GGGAAGCCCTTTTAT	CAACCACTGTACACA
CTCTCTCCTCTCTGC	GGAAGCCCTTTTATC	AACCACTGTACACAC
TCTCTCCTCTCTGCT	GAAGCCCTTTTATCA	ACCACTGTACACACC
CTCTCCTCTCTGCTT	AAGCCCTTTTATCAG	CCACTGTACACACCC
35 TCTCCTCTCTGCTTC	AGCCCTTTTATCAGT	CACTGTACACACCCG
CTCCTCTCTGCTTCA	GCCCTTTTATCAGT	ACTGTACACACCCGC
TCCTCTCTGCTTTCAT	CCCTTTTATCAGTT	CTGTACACACCCGCC
CCTCTCTGCTTTCATA	CCTTTTATCAGTTT	TGTACACACCCGCCT
CTCTCTGCTTTCATAA	CTTTTATCAGTTTG	GTACACACCCGCCTG
40 TCTCTGCTTTCATAAC	TTTTTATCAGTTTGA	TACACACCCGCCTGA
CTCTGCTTTCATAACG	TTTTATCAGTTTGAG	ACACACCCGCCTGAC
TCTGCTTTCATAACGG	TTTATCAGTTTGAGG	CACACCCGCCTGACA
CTGCTTTCATAACGGA	TTATCAGTTTGAGGA	ACACCCGCCTGACAC
TGCTTTCATAACGGAA	TATCAGTTTGAGGAA	CACCCGCCTGACACC
45 GCTTTCATAACGGAAA	ATCAGTTTGAGGAAG	ACCCGCCTGACACCG
CTTTCATAACGGAAAA	TCAGTTTGAGGAAGT	CCCGCCTGACACCGT
TTCATAACGGAAAAA	CAGTTTGAGGAAGTG	CCGCCTGACACCGTG
TCATAACGGAAAAAT	AGTTTGAGGAAGTGG	CGCCTGACACCGTGG
CATAACGGAAAAATA	GTTTGAGGAAGTGGC	GCCTGACACCGTGGG
50 ATAACGGAAAAATAA	TTTGAGGAAGTGGCT	CCTGACACCGTGGGT
TAACGGAAAAATAAT	TTGAGGAAGTGGCTG	CTGACACCGTGGGTC

- 91 -

5	TGACACCGTGGGTCA GACACCGTGGGTCAT ACACCGTGGGTCATT CACCGTGGGTCATTA ACCGTGGGTCATTAC CCGTGGGTCATTACA CGTGGGTCATTACAA GTGGGTCATTACAAA TGGGTCATTACAAAA	TTATCTTTTACCTTT TATCTTTTACCTTTT ATCTTTTACCTTTCT TCTTTTACCTTTCTA CTTTTACCTTTCTAG TTTACCTTTTCTAGG TTCACCTTTTCTAGGG TCACCTTTTCTAGGGA CACCTTTTCTAGGGAC ACCTTTTCTAGGGACA CCTTTTCTAGGGACAT CTTTTCTAGGGACATG TTTCTAGGGACATGA TCTAGGGACATGAA CTAGGGACATGAAAT TAGGGACATGAAATT AGGGACATGAAATTT GGGACATGAAATTTA GGACATGAAATTTAC GACATGAAATTTACA ACATGAAATTTACAA CATGAAATTTACAAA ATGAAATTTACAAAG TGAAATTTACAAAGG GAAATTTACAAAGGG AAATTTACAAAGGGC AATTTACAAAGGGCC ATTTACAAAGGGCCA TTTACAAAGGGCCAT TTACAAAGGGCCATC TACAAAGGGCCATCG ACAAAGGGCCATCGT CAAAGGGCCATCGTT AAAGGGCCATCGTTC AAGGGCCATCGTTCA AGGGCCATCGTTCAT GGGCCATCGTTCATC GGCCATCGTTCATCC GCCATCGTTCATCCA CCATCGTTCATCCAA CATCGTTCATCCAAG ATCGTTCATCCAAGG TCGTTCATCCAAGGC CGTTCATCCAAGGCT GTTTCATCCAAGGCTG TTCATCCAAGGCTGT TCATCCAAGGCTGTT CATCCAAGGCTGTTA ATCCAAGGCTGTTAC TCCAAGGCTGTTACC	CCAAGGCTGTTACCA CAAGGCTGTTACCAT AAGGCTGTTACCAT AGGCTGTTACCATTT GGCTGTTACCATTTT GCTGTTACCATTTTA CTGTTACCATTTTAA TGTTACCATTTTAAAC GTTACCATTTTAAACG TTACCATTTTAAACGC TACCATTTTAAACGCT ACCATTTTAAACGCTG CCATTTTAAACGCTGC CATTTTAAACGCTGCC ATTTTAAACGCTGCCT TTTTTAAACGCTGCCTA TTTAAACGCTGCCTAA TTAAACGCTGCCTAAT TAACGCTGCCTAATTT AACGCTGCCTAATTTT ACGCTGCCTAATTTT CGCTGCCTAATTTTG GCTGCCTAATTTTGC CTGCCTAATTTTGCC TGCCCTAATTTTGCCA GCCTAATTTTGCCAA CCTAATTTTGCCAAA CTAATTTTGCCAAA TAATTTTGCCAAAAT AATTTTGCCAAAATC ATTTTGCCAAAATCC TTTTTGCCAAAATCCT TTTGCCAAAATCCTG TTGCCAAAATCCTGA TGCCAAAATCCTGAA GCCAAAATCCTGAAC CCAAAATCCTGAACT CAAAATCCTGAACTT AAAATCCTGAACTTT AAATCCTGAACTTTC AATCCTGAACTTTCT ATCCTGAACTTTCTC TCCTGAACTTTCTCC CCTGAACTTTCTCCC CTGAACTTTCTCCCT TGAACTTTCTCCCTC GAACCTTTCTCCCTCA AACTTTCTCCCTCAT ACTTTCTCCCTCATC CTTTCTCCCTCATCG TTTCTCCCTCATCGG
10	GGGTTCATTACAAAA GGTTCATTACAAAA GTCATTACAAAAAA TCATTACAAAAAAAC CATTACAAAAAAACA		
15	ATTACAAAAAAACAC TTACAAAAAAACACG TACAAAAAAACACGT ACAAAAAAACACGTG CAAAAAAAACACGTGG		
20	AAAAAAACACGTGGA AAAAAACACGTGGAG AAAAACACGTGGAGA AAAACACGTGGAGAT AAACACGTGGAGATG		
25	AACACGTGGAGATGG ACACGTGGAGATGGA CACGTGGAGATGGAA ACGTGGAGATGGAAA CGTGGAGATGGAAAT		
30	GTGGAGATGGAAATT TGGAGATGGAAATTT GGAGATGGAAATTTT GAGATGGAAATTTTT AGATGGAAATTTTTA		
35	GATGGAAATTTTTAC ATGGAAATTTTTACC TGGAAATTTTTACCT GGAAATTTTTACCTT GAAATTTTTACCTTT		
40	AAATTTTTACCTTTA AATTTTTACCTTTAT ATTTTTACCTTTATC TTTTTACCTTTATCT TTTTACCTTTATCTT		
45	TTTACCTTTATCTTT TTACCTTTATCTTTC TACCTTTATCTTTC ACCTTTATCTTTCAC CCTTTATCTTTCACC		
50	CTTTATCTTTCACCT TTTATCTTTCACCTT		

TTCTCCCTCATCGGC	GCATGGCAGCTGGTT	CCATCCGACTGCCCC
TCTCCCTCATCGGCC	CATGGCAGCTGGTTG	CATCCGACTGCCCCCT
CTCCCTCATCGGCCC	ATGGCAGCTGGTTGC	ATCCGACTGCCCCCTG
TCCCTCATCGGCCCCG	TGGCAGCTGGTTGCT	TCCGACTGCCCCCTGC
5 CCCTCATCGGCCCCG	GGCAGCTGGTTGCTC	CCGACTGCCCCCTGCT
CCTCATCGGCCCCGGC	GCAGCTGGTTGCTCC	CGACTGCCCCCTGCTG
CTCATCGGCCCCGGCG	CAGCTGGTTGCTCCA	GACTGCCCCCTGCTGT
TCATCGGCCCCGGCGC	AGCTGGTTGCTCCAT	ACTGCCCCCTGCTGTG
CATCGGCCCCGGCGCT	GCTGGTTGCTCCATT	CTGCCCCCTGCTGTGC
10 ATCGGCCCCGGCGCTG	CTGGTTGCTCCATTT	TGCCCCCTGCTGTGCT
TGGGCCCCGGCGCTGA	TGGTTGCTCCATTTG	GCCCCCTGCTGTGCTG
CGGCCCCGGCGCTGAT	GGTTGCTCCATTTGA	CCCCCTGCTGTGCTGC
GGCCCCGGCGCTGATT	GTTGCTCCATTTGAG	CCCTGCTGTGCTGCT
GCCCCGGCGCTGATTC	TTGCTCCATTTGAGA	CCTGCTGTGCTGCTC
15 CCCGGCGCTGATTCC	TGCTCCATTTGAGAG	CTGCTGTGCTGCTCA
CCGGCGCTGATTCCT	GCTCCATTTGAGAGA	TGCTGTGCTGCTCAA
CGGCGCTGATTCCTC	CTCCATTTGAGAGAC	GCTGTGCTGCTCAAG
GGCGCTGATTCCTCG	TCCATTTGAGAGACA	CTGTGCTGCTCAAGG
GCGCTGATTCCTCGT	CCATTTGAGAGACAC	TGTGCTGCTCAAGGC
20 CGCTGATTCCTCGTG	CATTTGAGAGACACG	GTGCTGCTCAAGGCC
GCTGATTCCTCGTGT	ATTTGAGAGACACGC	TGCTGCTCAAGGCCA
CTGATTCCTCGTGTC	TTTGAGAGACACGCT	GCTGCTCAAGGCCAC
TGATTCCTCGTGTC	TTGAGAGACACGCTG	CTGCTCAAGGCCACA
GATTCCTCGTGTCG	TGAGAGACACGCTGG	TGCTCAAGGCCACAG
25 ATTCCTCGTGTCGG	GAGAGACACGCTGGC	GCTCAAGGCCACAGG
TTCCTCGTGTCGGGA	AGAGACACGCTGGCG	CTCAAGGCCACAGGC
TCCTCGTGTCGGGAG	GAGACACGCTGGCGA	TCAAGGCCACAGGCA
CCTCGTGTCGGGAGG	AGACACGCTGGCGAC	CAAGGCCACAGGCAC
CTCGTGTCGGGAGGC	GACACGCTGGCGACA	AAGGCCACAGGCACA
30 TCGTGTCGGGAGGCA	ACACGCTGGCGACAC	AGGCCACAGGCACAC
CGTGTCGGGAGGCAT	CACGCTGGCGACACA	GGCCACAGGCACACA
GTGTCCGGAGGCATG	ACGCTGGCGACACAC	GCCACAGGCACACAG
GTCCGGAGGCATGG	CGTGGCGACACACT	CCACAGGCACACAGG
35 TCCGGAGGCATGGGT	GCTGGCGACACACTC	CACAGGCACACAGGT
CCGGAGGCATGGGTG	CTGGCGACACACTCC	ACAGGCACACAGGTC
CGGAGGCATGGGTGA	TGGCGACACACTCCG	CAGGCACACAGGTCT
GGAGGCATGGGTGAG	GGCGACACACTCCGT	AGGCACACAGGTCTC
GAGGCATGGGTGAGC	GCGACACACTCCGTC	GGCACACAGGTCTCA
40 AGGCATGGGTGAGCA	CGACACACTCCGTCC	GCACACAGGTCTCAT
GGCATGGGTGAGCAT	GACACACTCCGTCCA	CACACAGGTCTCATT
GCATGGGTGAGCATG	ACACACTCCGTCCAT	ACACAGGTCTCATTG
CATGGGTGAGCATGG	CACACTCCGTCCATC	CACAGGTCTCATTGC
ATGGGTGAGCATGGC	ACACTCCGTCCATCC	ACAGGTCTCATTGCT
45 TGGGTGAGCATGGCA	CACTCCGTCCATCCG	CAGGTCTCATTGCTT
GGGTGAGCATGGCAG	ACTCCGTCCATCCGA	AGGTCTCATTGCTTC
GGTGAGCATGGCAGC	CTCCGTCCATCCGAC	GGTCTCATTGCTTCT
GTGAGCATGGCAGCT	TCCGTCCATCCGACT	GTCTCATTGCTTCTG
TGAGCATGGCAGCTG	CCGTCCATCCGACTG	TCTCATTGCTTCTGA
50 GAGCATGGCAGCTGG	CGTCCATCCGACTGC	CTCATTGCTTCTGAC
AGCATGGCAGCTGGT	GTCCATCCGACTGCC	TCATTGCTTCTGACT
	TCCATCCGACTGCCC	CATTGCTTCTGACTA

- 93 -

ATTGCTTCTGACTAG	CTCTCAGTGAAGGTG
TTGCTTCTGACTAGA	TCTCAGTGAAGGTGG
TGCTTCTGACTAGAT	CTCAGTGAAGGTGGG
GCTTCTGACTAGATT	TCAGTGAAGGTGGGG
5 CTTCTGACTAGATTA	CAGTGAAGGTGGGGA
TTCTGACTAGATTAT	AGTGAAGGTGGGGAG
TCTGACTAGATTATT	GTGAAGGTGGGGAGA
CTGACTAGATTATTA	TGAAGGTGGGGAGAA
TGACTAGATTATTAT	GAAGGTGGGGAGAAG
10 GACTAGATTATTATT	AAGGTGGGGAGAAGC
ACTAGATTATTATTT	AGGTGGGGAGAAGCT
CTAGATTATTATTTG	GGTGGGGAGAAGCTG
TAGATTATTATTTGG	GTGGGGAGAAGCTGA
AGATTATTATTTGGG	TGGGGAGAAGCTGAA
15 GATTATTATTTGGGG	GGGGAGAAGCTGAAC
ATTATTATTTGGGGG	GGGAGAAGCTGAACC
TTATTATTTGGGGGA	GGAGAAGCTGAACCG
TATTATTTGGGGGAA	GAGAAGCTGAACCGG
ATTATTTGGGGGAAC	AGAAGCTGAACCGGC
20 TTATTTGGGGGAACT	
TATTTGGGGGAACTG	
ATTTGGGGGAACTGG	
TTTGGGGGAACTGGA	
TTGGGGGAACTGGAC	
25 TGGGGGAACTGGACA	
GGGGGAACTGGACAC	
GGGGAACTGGACACA	
GGGAACTGGACACAA	
GGAACCTGGACACAAT	
30 GAACTGGACACAATA	
AACTGGACACAATAG	
ACTGGACACAATAGG	
CTGGACACAATAGGT	
TGGACACAATAGGTC	
35 GGACACAATAGGTCT	
GACACAATAGGTCTT	
ACACAATAGGTCTTT	
CACAATAGGTCTTTC	
ACAATAGGTCTTTCT	
40 CAATAGGTCTTTCTC	
AATAGGTCTTTCTCT	
ATAGGTCTTTCTCTC	
TAGGTCTTTCTCTCA	
AGGTCTTTCTCTCAG	
45 GGTCTTTCTCTCAGT	
GTCTTTCTCTCAGTG	
TCTTTCTCTCAGTGA	
CTTTCTCTCAGTGAA	
TTTCTCTCAGTGAAG	
50 TTCTCTCAGTGAAGG	
TCTCTCAGTGAAGGT	

- 94 -

EXAMPLE 9

Sub-confluent HaCaT cells were treated as described above with phosphorothioate oligonucleotides IGFR.AS (antisense: 5'-ATCTCTCCGCTTCCTTTC-3'; (<400>10); ref 5 13) and IGFR.S (sense control: 5'-GAAAGGAAGCGGAGAGAT-3'; (<400>11); ref 13) IGF-I binding to the cell monolayers was then measured as ¹²⁵I-IGF-I.

EXAMPLE 10

The results of this experiment are shown in Figures 7 and 8.

10

HaCaT cells were initially plated in DMEM with 10% v/v serum, then AS oligo experiments were performed in complete "Keratinocyte-SFM" (Gibco) to exclude the influence of exogenous IGFBPs. Oligos were synthesised as phosphorothioate (nuclease-resistant) derivatives (Bresatec, South Australia) and were as follows: antisense: AS2, 5'-
15 GCGCCCGCTGCATGACGCCTGCAAC-3' (IGFBP-3 start codon); controls: AS2NS, 5'-CGGAGATGCCGCATGCCAGCGCAGG-3'; AS4, 5'-AGGCGGCTGACGGCACTA-3'; AS4NS, 5'-GACAGCGTCGGAGCGATC-3'; IGFRAS, 5'-ATCTCTCCGCTTCCTTTC-3'; IGFRS, 5'-GAAAGGAAGCGGAGAGAT-3'. Oligos to IGFBP-3 were based on the
20 published sequence of Spratt *et al* [12]. AS oligos were added to HaCaT monolayers in 0.5ml medium in 24-well plates at the concentrations and addition frequencies indicated. IGFBP-3 measured in cell-conditioned medium using a dot-blot assay, adapted from the Western ligand blot method of Hossenlopp *et al* [11], in which 100µl of conditioned medium was applied to nitrocellulose filters with a vacuum dot-blot apparatus. After drying the membranes at 37°C,
25 relative amounts of IGFBP are determined by ¹²⁵I-IGF-I-binding, autoradiography and computerised imaging densitometry. Triplicate wells (except in Figure 7, where duplicate wells were measured as shown) were analysed and corrected for changes in cell number per well. Relative cell number per well was determined using an amido black dye method, developed specifically for cultured monolayers of HaCaT cells [14]. Cell numbers differed
30 by less than 10% after treatment. For oligos to the IGF receptor, receptor quantitation in

- 95 -

intact HaCaT monolayers was by overnight incubation with ^{125}I -IGF-I (30,000cpm/well) at 4°C.

EXAMPLE 11

5 Experiments involving ribozymes are generally conducted as described in International Patent Application No. WO 89/05852 and in Haselhoff and Gerlach [8]. Ribozymes are constructed with a hybridising region which is complementary in nucleotide sequence to at least part of a target RNA which, in this case, encodes IGFBP-2. Activity of ribozymes is measurable on, for example, Northern blots or using animal models such as in the nude mouse model (15; 16)
10 or the "flaky skin" mouse model (17; 18).

EXAMPLE 12

The methods described in Example 11 are used for the screening of ribozymes which inhibit IGFBP-3 production. The activity of the ribozymes is determined as in Example 11.

15

EXAMPLE 13

The methods described in Example 11 are used for the screening of ribozymes which inhibit IGF-1 production. The activity of the ribozymes is determined as in Example 11.

20

EXAMPLE 14

The methods described in Example 11 are used for the screening of ribozymes which inhibit IGF-1 production. The activity of the ribozymes is determined as in Example 11.

EXAMPLE 15

25 Twenty-one antisense oligonucleotides targeted to mRNA sequences encoding the IGF-1 receptor, and four random oligonucleotides were synthesized. The antisense oligonucleotides are C5-propynyl-dU, dC 15mer phosphorothioate oligodeoxyribonucleotides. In these oligonucleotides, a phosphorothioate backbone replaces the phosphodiester backbone of naturally occurring DNA. The positions of the 21 sequence specific antisense
30 oligonucleotides relative to the IGF-1 receptor mRNA structure are shown in Figure 9.

- 96 -

EXAMPLE 16

Experiments were performed to determine the uptake of the antisense oligonucleotides of Example 15 into keratinocytes. Cells of the differentiated human keratinocyte cell line, HaCaT, were incubated for 24 hours in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (w/v) fetal calf serum (FCS) containing fluorescently labelled oligonucleotide (R451, a randomized sequence oligonucleotide, 30nM) and cytofectin GSV (2 μ g/ml, Glen Research, 44901 Falcon Place, Sterling, VA 20166, Cat. No. 70-3815-78). Cells were then transferred to oligonucleotide-free medium and fluorescence microscopy and phase contrast images of the cells were obtained. Figure 10 shows fluorescence microscopy (Panel A) and phase contrast (Panel B) images of uptake of fluorescently labelled oligonucleotide in the majority of cells in a HaCaT monolayer. The degree of uptake obtained with the cationic lipid cytofectin was far greater than the uptake obtained with the next best lipid tried, Tfx-50.

A further experiment was performed to assess the uptake and toxicity associated with the use of cytofectin GSV over five days. Confluent HaCaT keratinocytes were incubated in DMEM containing fluorescently labelled oligonucleotide R451 (30nM or 100 nM) plus cytofectin GSV (2 μ g/ml or 5 μ g/ml) over 120 hours, viewed by fluorescence microscopy, tryptan blue stained, and counted. The graphs in Figure 11 depict uptake (Panel A) and toxicity (Panel B). The proportion of cells containing oligonucleotide remained high over the 120 hour period. The combination of 30 nM oligonucleotide and 2 μ g/ml GSV provided optimal uptake and minimal toxicity.

EXAMPLE 17

The twenty-one oligonucleotides of Example 15 were then screened for their ability to inhibit IGF-I receptor mRNA levels in HaCaT cells, in accordance with the teachings herein. HaCaT cells were grown to 90% confluence in DMEM supplemented with 10% (v/v) FCS. Antisense oligonucleotides (30nM) were complexed with cytofectin GSV (2 μ g/ml) and added to the cells in the presence of serum. HaCaT keratinocytes were treated with the oligonucleotide/GSV complexes or randomized sequence oligonucleotides (R451, R766),

- 97 -

liposome alone (GSV), or were left untreated (UT). Duplicate treatments were performed. Repeat additions of the oligonucleotides/GSV complex were performed at 24, 48 and 76 hours following the first addition. Total RNA was isolated as per the RNazolB protocol (Biotecx Laboratories, Inc. 6023 South Loop East, Houston, TX 77033) 96 hours following the first
5 addition.

IGF-I receptor mRNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels were simultaneously determined by a ribonuclease (RNase) protection assay. The RNase Protection Assay kit, *in vitro* transcription kit, and IGF-I receptor and GAPDH DNA
10 templates were obtained from Ambion, Inc. (2130 Woodward St., Houston, TX 78744). The amount of IGF-I receptor mRNA in any given sample was expressed as the amount of IGF-I receptor mRNA relative to the amount of GAPDH mRNA. Each oligonucleotide was tested in at least two separate experiments.

15 Figure 12 depicts representative results of the screening process. Panel A shows an electrophoretic analysis of IGF-I receptor and GAPDH mRNA fragments after RNase protection. Molecular weight markers are shown on the right hand side. The full-length probe is shown on the left hand side; G-probe indicates the IGF-I receptor probe. GAPDH protected fragments (G) are seen at 316 bases and IGF-I protected fragments (I) are seen at
20 276 bases. Exhibit E, Panel B provides a graph indicating the relative level of IGF-I receptor mRNA following each treatment.

The results obtaining from the above screening assays are summarized in Figure 13. The graph depicts the relative level of IGF-I receptor mRNA after treatment with oligonucleotides
25 complementary to the human IGF-I receptor mRNA (26-86), four randomized sequence oligonucleotides (R1, R4, R7, R9), liposome alone (GSV), or no treatment (UT). Asterisks indicate a significant different in relative IGF-I receptor mRNA as compared to GSV treated cells (n=4-10, $p < 0.05$).

- 98 -

As demonstrated in Figure 13, treatment with eighteen of the twenty-one oligonucleotides resulted in a significant different in levels of IGF-I receptor mRNA relative to GSV treated cells. Three of the antisense oligonucleotides tested in the screening assay reduce IGF-I receptor mRNA to less than 35% of GSV-treated cells. These antisense oligonucleotides have the following sequences, presented in the 5' to 3' direction:

#27 UCCGGAGCCAGACUU

#64 CACAGUUGCUGCAAG

#78 UCUCCGCUUCCUUUC

10

As further demonstrated in Figure 13, six of the antisense oligonucleotides tested in the screening assay reduce IGF-I receptor mRNA to between 35 and 50% of GSV-treated cells. These antisense oligonucleotides have the following sequences, presented in the 5' to 3' direction:

15

#28 AGCCCCCACAGCGAG

#32 GCCUUGGAGAUGAGC

#40 UAACAGAGGUCAGCA

#42 GGAUCAGGGACCAGU

20 #46 CGGCAAGCUACACAG

#50 GGCAGGCAGGCACAC

EXAMPLE 19

Another experiment was performed demonstrating that antisense oligonucleotides targeted to genetic sequences encoding the IGF0I receptor and that reduce IGF-I receptor mRNA levels also inhibit the IGF-I receptor level on the surface of the treated cultured keratinocytes. HaCaT cells were grown to confluence in 24-well plates in DMEM containing 10% (v/v) FCS. Oligodeoxynucleotide and cytofectin GSV were mixed together in serum-free DMEM, and incubated at room temperature for 10 minutes before being diluted ten-fold in medium and placed on the cells. Cells were incubated for 72 hours with 30nM random sequence or

- 99 -

antisense oligonucleotide and 2 μ m/ml GSV, or with GSV alone in DMEM containing 10% (v/v) FCS with solutions replaced every 24 hours. This was followed by incubation with oligonucleotide/GSV in serum-free DMEM for 48 hours. All incubations were performed at 37°C. Cells were washed twice with 1ml cold PBS. Serum-free DMEM containing 10⁻⁷ M ¹²⁵I-IGF-I was added with or without the IGF-I analogue, des (1-3) IGF-I, at 10⁻¹¹ M to 10⁻⁷ M. Cells were incubated at 4°C for 17 hours with gentle shaking, then washed three times with 1ml cold PBS and lysed in 250 μ l 0.5M NaOH/0.1% (v/v) Triton X-100 at room temperature for 4 hours. Specific binding of the solubilised cell extract was measured using a gamma counter. As shown in Figure 14, treatment of HaCaT keratinocytes with oligonucleotide reduced cell surface IGF-I receptor levels to 30% of levels in untreated keratinocytes or in keratinocytes treated with liposome alone or a random oligonucleotide, R766. As shown in Figure 15, treatment with oligonucleotide #27 also significantly reduced cell surface IGF-I receptor levels relative to untreated keratinocytes or treatment with liposome alone or random nucleotide R451. As demonstrated in Example 17, oligonucleotides #64 and #27 reduce IGF-I receptor mRNA levels in cultured keratinocytes to less than 35% of GSV-treated cells. Accordingly, the ability of an oligonucleotide to reduce IGF-I receptor mRNA levels is correlated with its ability to reduce cell surface IGF-I receptor levels.

The forgoing Examples demonstrate that antisense oligonucleotides targeted to the IGF-I receptor can be delivered to human keratinocytes *in vitro*, can inhibit IGF-I receptor mRNA levels in human keratinocytes *in vitro*, and that inhibition of mRNA levels is correlated with reduction of cell surface IGF-I receptor levels.

EXAMPLE 19

Further experiments demonstrated the efficacy of antisense oligonucleotides targeted to the IGF-I receptor in an *in vivo* model of psoriasis. An animal model of psoriasis is the human psoriatic skin xenograft model. The skin used in this model contains the true disease state. In this model, reduction in epidermal thickness of psoriatic grafts in response to treatment is positively correlated with efficacy of treatment. Both normal and psoriatic human skin were

- 100 -

grated into a thymic (nude) mice in accordance with a thymic (nude) mice in accordance with the methods of Baker *et al* (1992) *Brit. J. Dermatol.* 126:105 and Nanney *et al* (1992) *J. Invest. Dermatol.* 92:296. Successful grafting was achieved, as demonstrated in Figure 16, which shows hemotoxylin and eosin (H&E) stained sections of a 49-day old psoriatic human skin graft (Panel B) compared to the histology of the skin graft prior to grafting (Panel A). The histological features of psoriasis present in the pregraft section (e.g., parakeratosis, acanthosis and pronounced rete ridges) are present in the grafts more than seven weeks post grafting.

- 10 Using the model, oligonucleotide uptake was measured in epidermal keratinocytes *in vivo* after intradermal injection. Fluorescently labelled oligonucleotide (R451, 50 μ l, 10 μ M injection) was intradermally injected into psoriatic and normal skin grafts on a thymic mice. Live confocal microscopy and fluorescence microscopy of fixed sections was then employed. Using both techniques, oligonucleotide was found to localize in the nucleus of over 90% of basal keratinocytes. Figure 17 shows the nuclear localization of oligonucleotide in psoriatic skin cells using conventional fluorescence microscopy of a graft that was removed and sectioned after 24 hours.

After establishing oligonucleotide uptake in the *in vivo* model, a small number of pilot experiments were performed to determine a schedule for treatment of grafted mice with antisense oligonucleotides targeted to genetic sequences encoding the IGF-I receptor. The treatment schedule was finalized as follows:

- 101 -

Graft Number	Treatment	Volume of Injection	ODN Concentration	Duration of Treatment
1-3	Vehicle (PBS)	50 μ l	-	20 days
4-6	RandomODN#R451	50 μ l	10 μ M	20 days
5 7-9	ODN#27	50 μ l	10 μ M	20 days
10-12	ODN#74	50 μ l	10 μ M	20 days
13-15	ODN#50	50 μ l	10 μ M	20 days

As determined above, oligonucleotide #27 (ODN #27) reduced IGF-I receptor mRNA *in vitro* to less than 35% of GSV-treated cells. Oligonucleotide #50 (ODN#50) reduced IGF-I receptor mRNA *in vitro* to between 35 and 50% of GSV-treated cells. Oligonucleotide #74 (ODN #74) was not inhibitory to IGF-I receptor mRNA *in vitro*. In the *in vivo* model, each mouse received two grafts. Random oligonucleotide or vehicle was injected intradermally in one graft and acted as a control. The second graft was injected with the targeted oligonucleotide. Each graft received an injection every second day for the duration of the treatment.

Histology of representative grafts from each treatment type are shown in Figures 18(a)-(d) and 19(a) - (d). Each sheet shows three images of H&E stained sections: the pregraft histology, the control treated graft, and the targeted oligonucleotide treated graft. Figures 18(a)-(d) are shown at 100x magnification; figures 19(a)-(d) are shown at 400x magnification. The total cross sectional area of epidermis of each graft was assessed using MCID analysis software. The pooled results from all of the treated grafts are shown in Figure 20.

25

As shown in Figures 18(a)-(d) and 19(a)-(d), the vehicle-treated (control) grafts were marginally thinner than the pregraft sections. The degree of regression in these experiments (ie., less than 10%) is not significant. A similar amount of marginal thinning

- 102 -

of epidermis compared to pregraft also occurred in pilot experiments in which psoriatic grafts were not injected, and thus it is unlikely that the vehicle itself has any effect. Histological features of psoriasis present in skin samples prior to grafting (clubbing of rete ridges, parakeratosis, acanthosis) were present in these grafts.

5

The random oligonucleotide treated grafts varied in epidermal thickness after 20 days of treatment. Grafts were either a similar thickness to the pregraft histology, or marginally thinner. Random oligonucleotide treated grafts were in each case significantly thicker than their targeted oligonucleotide treated pairs.

10

As shown in Figure 20, the targeted oligonucleotide treated grafts were significantly thinner than the pregraft sections and showed less parakeratosis and clubbing of rete ridges. Antisense oligonucleotides which were effective at reducing IGF-I receptor mRNA levels *in vitro* (#27 and #50) produced greater epidermal thinning than an

15 oligonucleotide which was not inhibitory to IGF-I receptor mRNA *in vitro* (#74).

Accordingly, there is a direct correlation between the ability of an oligonucleotide targeted to the IGF-I receptor to inhibit IGF-I receptor mRNA levels *in vitro* and the efficacy of the oligonucleotide as an anti-psoriasis agent in an *in vivo* model.

20

EXAMPLE 20

Another experiment demonstrated that treatment of psoriatic grafts with an oligonucleotide targeted to a genetic sequence encoding the IGF-I receptor results in inhibition of proliferation. Pregrafts from psoriatic patients, control grafts treated with R4541, and grafts treated with oligonucleotide #27 were obtained as described in Example 19. An

25 antibody to the cell cycle-specific nuclear antigen Ki67 was used to

immunohistochemically detect actively dividing cells and thereby assess proliferation. The α Ki67 antibody (DAKO, Glostrup, Denmark) recognizes the Ki67 antigen transiently expressed in nuclei of proliferating cells during late G₁, S, M and G₂ phases of the cycle and thus provides a marker for proliferation. Pregraft and graft sections were

30 immunohistochemically processed by standard methods using α Ki67 (according to the

- 103 -

manufacturer's instructions), peroxidase-conjugated anti-rabbit second stage antibody, and a chromogenic peroxidase substrate.

The results of this experiment are presented in Figure 21 as immunohistochemical sections at 100x magnification. The top panel of Figure 21 depicts a pregraft section obtained from a psoriatic patient. The epidermis is thicker than normal and nucleic are evident in the stratum corneum. Ki67 positive cells, appearing as brown dots, are evidence in the basal and suprabasal layers, and indicate actively proliferating cells. The control (R450-treated) graft in the bottom panel of Figure 21 also exhibits evidence of proliferation, including parakeratosis and Ki67-positive cells appearing as brown-staining nuclei. The center panel of Figure 21 exhibits the oligonucleotide #27-treated graft. This graft exhibits significantly reduced proliferation as evidenced by normal (thin) epidermis, lack of invaginations, and substantial loss of Ki67-positive cells.

These results indicate that treatment of human psoriatic grafts with an oligonucleotide targeted to mRNA encoding the IGF-I receptor results in inhibition of epidermal proliferation.

EXAMPLE 21

Topical formulations of complexes of oligonucleotides with cytofectin GSV in aqueous or methylcellulose gel formulations were prepared and assessed for uptake of the oligonucleotide by keratinocytes *in vivo*. The topical formulations contained oligonucleotides complexed with cytofectin GSV in an aqueous solution or methylcellulose carrier, as taught herein. With both aqueous and methylcellulose gel formulations, localization of oligonucleotide R451 to nuclei and cytoplasm of keratinocytes in normal human skin grafts on nude mice was observed. Figure 22 shows an image from confocal microscopy demonstrating oligonucleotide localization in the nuclei and cytoplasm of keratinocytes in normal human skin grafts after topical application of fluorescently labeled oligonucleotide (10 μ M R451) complexed with cytofectin GSV (10 μ g/ml). Figure 23 shows an image from confocal microscopy demonstrating that topical application of the

- 104 -

same oligonucleotide/GSV concentrations in a 3% (w/v) methylcellulose gel produced similar uptake in the target keratinocyte population. Using an aqueous formulation of oligonucleotide/GSV complexes, penetration of oligonucleotide into the viable epidermis was observed, whereas application of formulations of oligonucleotide complexed with
5 other cationic lipids resulted in localization of oligonucleotide in the stratum corneum.

EXAMPLE 22

Thirteen antisense oligonucleotides targeted to IGFBP-3 were synthesized. The antisense oligonucleotides are C5-propynyl-dU, Dc15 mer phosphorothioate
10 oligodeoxyribonucleotides. Figure 24 attached hereto is a schematic diagram indicating the position of the thirteen oligonucleotides relative to the IGFBP-3 mRNA structure.

These oligonucleotides were screened for their ability to inhibit IGFBP-3 mRNA levels of HaCaT cells in accordance with the teachings herein. HaCaT cells were grown to 90%
15 confluence in DMEM supplemented with 10% (v/v) FCS, then placed in complete keratinocyte serum free medium (KSFM, Gibco), which has a defined amount of EGF, for 24 hours. Oligonucleotides (30nM or 100nM) were complexed with GSV cytofectin (2 μ g/ml) and added to cells in complete KSFM to allow oligonucleotides to enter the nucleus before removal of EGF. Repeat additions were performed at three hours (in
20 serum free DMEM, which releases the EGF inhibition of IGFBP-3 mRNA) and again after another 24 hours. HaCaT cells were also treated with randomized sequence oligonucleotides (R121, R451, R766 and R961), liposome alone (GSV) or were left untreated (UT). Total RNA was isolated as described in Example 17, 24 hours after the last treatment. Total RNA (15 μ g) was analyzed by Northern analysis and
25 phosphorimager quantitation for IGFBP-3 and GAPDH mRNA. IGFBP-3 mRNA is expressed as the amount of IGFBP-3 mRNA relative to the amount of GAPDH mRNA.

Figures 25(a)-(d) provide graphs which depict results in this screening process. In these graphs, R1 and R12 refer to R121; R4, R4(0) and R45 refer to R451; R7, R7(0) and R76
30 refer to R766; and R9 and R96 refer to R961. The values were standardized to GSV-

- 105 -

treated cells, and data was pooled and statistically analyzed by ANOVA followed by Domet's test to compare each treatment to GSV-treated cells. The pooled data are presented as a bar graph in Figure 26. As demonstrated, at a concentration of 30nM, treatment of HaCaT cells with 8 of the 12 targeted oligonucleotides tested resulted in a statistically significant reduction in levels of IGFBP-3 mRNA relative to GSV-treated cells. At a concentration of 100nM, treatment with 9 of the 13 targeted oligonucleotides tested resulted in a statistically significant reduction in levels of IGFBP-3 mRNA relative to GSV-treated cells.

- 10 These experiments demonstrate that antisense oligonucleotides targeted to genetic sequences encoding IGFBP-3 can inhibit IGFBP-3 mRNA levels in human keratinocytes *in vitro*.

EXAMPLE 23

- 15 IGF-I receptor is a potent mitotic signalling molecule for keratinocytes and the human receptor elicits separate intracellular signals that prevent apoptosis (19). It is proposed in accordance with the present invention that inactivation of IGF-I receptors in epidermal keratinocytes will achieve three important outcomes in subsequent UV treatment of lesions:

20

- (i) Acute epidermal hyperplasia following UV has been suggested to increase the risk of keratinocyte carcinogenic transformation (22). By reducing IGF-I receptor expression in the epidermis, the incidence of epidermal hyperplasia following UV exposure is likely to be reduced leading to an overall acceleration in normalization of the lesion and reduced carcinogenic risk.

25

- (ii) Inhibition of anti-apoptotic action of IGF-I receptor will enhance the reversal of epidermal thickening and accelerate normalization of differentiation. Topical or injected IGF-I receptor antisense as adjunctive treatment will increase apoptosis in

- 106 -

the epidermal layer thereby enhancing the reduction in acanthosis observed in UV treatments.

- (iii) Survival of keratinocytes, ie. those which evade apoptosis is likely to occur when cells have damaged DNA. Such mutations may be in the tumor suppressor region. Consequently, the use of antisense therapy will result in less frequent selection of mutated keratinocytes and therefore reduced incidence of basal cell carcinomas and squamous.
- 10 Accordingly, antisense therapy, especially against IGF-I-receptor is useful in combination with UV therapy in the treatment of epidermal hyperplasia.

EXAMPLE 24

HaCaT cells were treated with antisense oligonucleotides directed to IGF-I receptor mRNA. Levels of IGF-I receptor mRNA were then monitored. In essence, confluent HaCaT cells were treated every 24 hours for four days with 2 μ g/ml GSV lipid alone (GSV) or complexed with 30 nM IGF-I receptor specific oligonucleotides (#26 to #86) or random sequence oligonucleotides (*R121*, *R451* and *R766*). Figure 27(a) is a photographic representation showing representative RNase protection assay gel showing IGF-I receptor (IGFR) and GAPDH mRNA in untreated or treated HaCaT cells. Figure 27(b) is a densitometric quantification of IGF-I receptor mRNA in a HaCaT cells following treatment with IGF-I receptor specific oligonucleotides (solid black) random sequence oligonucleotides (horizontal striped bar) or GSV alone (shaded bar) compared to untreated cells (UT, vertical striped bar).

25

EXAMPLE 25

In this example, reduction in total cellular IGF-I receptor protein was monitored following antisense oligonucleotide treatment. Confluence HaCaT cells were treated with 24 hours for 4 days with 2 μ g/ml GSV lipid alone (GSV) or complexed with 30 nM IGF-I receptor specific AONS (#27, #50 and #64) or the random sequence oligonucleotide, R451. Total

30

- 107 -

cellular protein was isolated and analysed for IGF-I receptor by SDS PAGE followed by western blotting with antibody specific for the human IGF-I receptor. Figure 28(a) shows duplicate treated cellular extracts following the IGF-I receptor at the predicted size of 110 kD. Figure 28(b) is a densitometric quantification of IGF-I receptor protein.

5

EXAMPLE 26

The reduction in IGF-I receptor numbers was determined on the keratinocyte cell surface after antisense oligonucleotide treatment. HaCaT cells were transfected with IGF-I receptor specific AONs #27, #50, #64, a random sequence oligonucleotides (R451) or following
10 treatment with GSV a lipid alone every 24 hours for 4 days. Competition binding assays using 125 I-IGF-I and the receptor-specific analogue, des(1-3)IGF-I were performed. Results are shown in Figure 29.

EXAMPLE 27

15 In this example, the apoptotic protecting effects of IGF-I receptor on keratinocyte cells was tested by following the reduction in keratino cell numbers following antisense oligonucleotide treatment. HaCaT cells, initially at 40% confluence, were transfected with the IGF-I receptor specific AON #64, control sequences R451 and 6414 or treated with GSV a lipid alone every 24 hours for 2 days. The cell number was measured in culture
20 wells using a dye binding assay. The results are presented in Figure 30. The results clearly confirm that the IGF-I receptor exhibits an anti-apoptotic effect. By reducing IGF-I receptor levels using antisense oligonucleotide treatment, the anti-apoptotic effect is interrupted and apoptosis results in the reduction in keratinocyte cell number. Results are shown in Figure 30.

25

EXAMPLE 28

This example shows a reversal of epidermal hyperplasia in psoriatic human skin grafts on nude mice following intradermal injection with antisense oligonucleotides. Grafted psoriasis lesions were injected with IGF-I receptor specific AONs, a random sequence
30 oligonucleotide in PBS, or with PBS alone, every 2 days for 20 days, then analysed

- 108 -

histologically. The results are shown in Figure 31. In Figure 31(a), donor A graft treated with AON #50 showing epidermal thinning compared with the pregraft and control (PBS) treated graft and donor graft treated with AON #27 showing epidermal thinning compared with pregraft and control (R451) treated graft. In Figure 31(b), the mean epidermal cross-sectional area over the full width of grafts is shown as determined by digital image analysis. The results show that epidermal hyperplasia is reversed following the intradermal injection of antisense oligonucleotides.

EXAMPLE 29

Figure 32 shows the reversal of epidermal hyperplasia correlating with reduced IGF-I receptor mRNA in grafted psoriasis lesions treated with antisense oligonucleotides. Figure 32(a) shows a psoriasis lesion prior to grafting and after grafting and treatment with IGF-I receptor specific oligonucleotide #27 (AON #27) or random sequence (R451) immunostained with antibodies to Ki67 to identify proliferating cells. Proliferating cells are indicated by a dark brown nucleus (arrows). Figure 32(b) shows the same lesion prior to grafting and after oligonucleotide treatment as in Figure 32(a) but subjected to *in situ* hybridisation with ³⁵S-labelled cRNA probe complementary to the human IGF-I receptor mRNA. The presence of IGF-I receptor mRNA is indicated by silver grains which are almost eliminated in the epidermis of the lesion treated with IGF-I receptor specific oligonucleotide # 27 (AON #27). This experiment shows that reversal of epidermal hyperplasia correlates with reduced IGF-I receptor mRNA in grafted psoriasis lesions treated with antisense oligonucleotides.

EXAMPLE 30

Figure 33 treatment with oligonucleotides. HaCaT cell monolayers were grown to 90% confluence in DMEM containing 10% fetal calf serum treated every 24 hours for two days with 2 µg/ml GSV lipid alone (GSV) or complexed with 30 nM oligonucleotide. Total RNA was isolated and analysed for IGF-I receptor and GAPDH mRNA using a commercially available ribonuclease protection assay kit. The results show a reduction in IGF-I receptor mRNA in the HaCaT keratinocyte cells.

- 109 -

EXAMPLE 31

Figure 34 treatment with oligonucleotides. HaCaT cell monolayers were grown to 90% confluence in DMEM containing 10% fetal calf serum treated every 24 hours for 4 days with 2 μ g/ml GSV lipid alone (GSV) or complexed with 30 nM oligonucleotide. Cells
5 were lysed in a buffer containing 50 mM HEPES, 150 mM NaCl, 10% v/v glycerol, 1 v/v Trison X-100 and 100 μ g/ml aprotinin on ice for 30 minutes, then 30 μ g of lysate was loaded onto a denaturing 7% w/v polyacrylamide gel followed by transfer onto an Immobilon-P membrane. Membranes were then incubated with anti-IGF-I receptor antibodies C20 (available from Santa Cruz Biotechnology Inc., Santa Cruz, California) for
10 1 hour at room temperature and developed using the Vistra ECF western blotting kit (Amersham). The results shown in Figure 34 confirm that IGF-I receptor protein is reduced in HaCaT keratinocytes following treatment with oligonucleotides.

EXAMPLE 32

15 This example shows a reduction in HaCaT keratinocyte cell number following treatment with oligonucleotides. The results are shown in Figure 35. HaCaT cell monolayers were grown at 40% confluence in DMEM containing 10% fetal calf serum treated every 24 hours for 3 days with 2 μ g/ml GSV lipid alone (GSV) or complexed with 15 nM oligonucleotide. Cell numbers were then measured every 24 hours using the amido black
20 dye binding assay [32]. Results show that HaCaT keratino cells decrease in number following treatment with oligonucleotides due to a reduction in the anti-apoptotic effect of the IGF-I receptor.

Those skilled in the art will appreciate that the invention described herein is susceptible to
25 variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

REFERENCES:

1. Sara V *Physiological Reviews* 70:591-614, 1990.
2. Rechler MM and Brown AL *Growth Regulation* 2:55-68, 1992.
3. Clemmons DR *Growth Regn* 2:80, 1992.
4. Oakes SR, KM Haynes, MJ Waters, AC Herington and GA Werther *J. Clin Endocrinol Metab* 73:1368-1373, 1992.
5. Camacho-Hubner C *et al. J Biol Chem* 267:11949-11956, 1992.
6. Neely KE *et al. J Inv Derm* 96:104, 1991.
7. Ts'O POP, Aurelian L, Chang E and Miller PS. Nonionic oligonucleotide analogs (Matagen TM) as anticodic agents in duplex and triplex formation. in "Antisense Strategies", Annals of the New York Academy of Sciences 660:159-177 (Baserga R and Denhardt DT, eds.), 1993.
8. Haseloff J and Gerlach L *Nature* 334:586-591, 1988.
9. Boukamp P, Petrussevska RT, Breitkreuz D, Hornung J, Markham A, Fusenig NE. *J Cell Biol* 106:761-771, 1988.
10. Rheinwald and Green *Cell* 6:331-344, 1975.
11. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. *Anal Biochem* 154:138-143, 1986.

- 111 -

12. Spratt SK, Tatsuno GP, Yamanaka MK, Ark BC, Detmer J, Mascarenhas D, Flynn J, Talkington-Verser C, Spencer EM. *Growth Factors* 3:63-72, 1990.
13. Pietrkowski, Z, Sell C, Lammers R, Ullrich A and Baserga R. *Mol. Cell. Biol.* 12: 3883-3889, 1992.
14. Schulz J, Dettlaff S, Fritzsche U, Harms U, Schiebel H, Derer W, Fusenig NE, Hulsén A and Böhm M. *J. Immunol. Meth.* 167:1-13, 1994.
15. Baker BS, Brent L, Valdimarsson H, Powles AV, Al-Imara L, Walker M and Fry L. *Brit. J. Dermatol* 126:105-110, 1992.
16. Nanney LB *et al* *J. Invest. Dermatol* 98:296-301, 1992.
17. Sundberg JP *et al* *Immunol. Investigations* 22:389-401, 1993.
18. Sundberg JP *et al* *J. Invest. Dermatol* 102:781-788, 1994.
19. O'Connor *et al* *Mol Cell Biol* 17:427-435, 1997.
20. Kuhn *et al* *Int J Cancer* 80:431-438, 1999.
21. Resnicoff *et al* *Cancer Res* 55:3739-3741, 1995.
22. Ouhtit *et al* *Am J Pathol* 156:201-207, 2000.
23. Froehler *et al* *Tetrahedron Lett* 34:1003-1006, 1992.
24. Gennaro (Ed) *Remington's Pharmaceutical Sciences* 18th Edition Mack Publishing Co., Easton PA USA, 1990.

- 112 -

25. Flanagan *et al* *Nat Biotechnol* **14**:1139-1145, 1996.
26. Flanagan *et al* *Nucleic Acids Res* **24**:2936-2941, 1996.
27. Flanagan *et al* *Mol Cell Biochem* **172**:213-225, 1997.
28. Gutierrez *et al* *Biochemistry* **36**:743-748, 1997.
29. Moulds *et al* *Biochemistry* **34**:5044-5053, 1995.
30. Wagner *et al* *Science* **260**:1510-1513, 1993.
31. Wagner *et al* *Nature* **372**:333-335, 1994.
32. Schultz *et al* *J Immunol Meth* **167**:1-13, 1994.

CLAIMS:

1. A method for ameliorating the effects of a medical disorder such as a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation or a cell otherwise involved with said medical disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing growth factor mediated cell proliferation and/or inflammation and/or other medical disorders.
2. A method according to claim 1 wherein cell proliferation and/or inflammation or other medical disorder is mediated by at least one of insulin-like growth factor I (IGF-I), keratinocyte growth factor (KGF), transforming growth factor- α (TGF α), tumour necrosis factor- α (TNF α), interleukin (IL) -1 (IL-1), IL-4, IL-6, IL-8 and/or basic fibroblast growth factor (bFGF).
3. A method according to claim 2 wherein cell proliferation and/or inflammation or other medical disorder is mediated by IGF-I.
4. A method according to claim 1 wherein the nucleic acid molecule inhibits or otherwise reduces IGF-I mediated cell proliferation and/or inflammation or other medical disorder.
5. A method according to claim 1 wherein the proliferative or inflammatory skin disorder is psoriasis, ichthyosis, pityriasis, rubra, pilaris, seborrhoea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths or cancers of the skin.
6. A method according to claim 5 wherein the skin condition is psoriasis.

- 114 -

7. A method according to claim 1 wherein the other medical disorder is a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease or hyperproliferation of the inside of blood vessels or any other hyperplasia.
8. A method according to claim 1 or 4 or 6 or 7 wherein the mammal is a human.
9. A method according to claim 1 or 4 or 6 or 7 wherein the nucleic acid molecule is capable of inhibiting, reducing or otherwise interfering with IGF-I-interaction with its receptor.
10. A method according to claim 9 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGF-I, IGF-I-receptor or an IGF binding protein (IGFBP).
11. A method according to claim 10 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGFBP-2, -3, -4, -5 or -6.
12. A method according to claim 11 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGFBP-2 or IGFBP-3.
13. A method according to claim 10 or 12 wherein the antisense molecule is at least about 15 nucleotides in length and is capable of interacting with at least one sequence selected from the list set forth in Example 6 or Example 7 or Example 8.
14. A method according to claim 12 wherein the antisense molecule comprises the nucleotide sequence:

5'-ATCTCTCCGCTTCCTTTC-3' (<400>10)

- 115 -

15. A method according to claim 12 wherein the antisense molecule is selected from the following:

UCCGGAGCCAGACUU (<400>12)

CACAGUUGCUGCAAG (<400>13)

UCUCCGCUUCCUUUC (<400>14)

AGCCCCACAGCGAG (<400>15)

GCCUUGGAGAUGAGC (<400>16)

UAACAGAGGUCAGCA (<400>17)

GGAUCAGGGACCAGU (<400>18)

CGGCAAGCUACACAG (<400>19)

GGCAGGCAGGCACAC (<400>20)

16. A method according to claim 15 wherein the antisense molecule in <400>12, <400>13 or <400>14.
17. A method according to claim 15 wherein the antisense molecule in <400>12.
18. A nucleic acid molecule comprising at least about 10 nucleotides capable of hybridising to or forming a heteroduplex or otherwise interacting with a complementary form of <400>12 to <400>20 inclusive.
19. A nucleic acid molecule comprising at least about 15 nucleotides capable of hybridising to or form a heteroduplex or otherwise interacting with a complementary form of <400>12 to <400>14 inclusive.
20. A method of ameliorating the effects of psoriasis or other medical disorder, said method comprising contacting proliferating skin or skin capable of proliferation or cell otherwise associated with said medical disorder with an effective amount of one or more nucleic acid molecules or chemical analogues thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation other medical disorder

- 116 -

- wherein said one or more molecules comprises a polynucleotide capable of interacting with mRNA directed from an IGF-I gene, an IGF-I receptor gene or a gene encoding an IGFBP.
21. A method according to claim 20 wherein the IGFBP is IGFBP-2 or IGFBP-3.
 22. A method according to claim 20 or 21 wherein the mammal is a human.
 23. A method according to claim 22 wherein the nucleic acid molecule is capable of interacting with a nucleotide sequence selected from the list set forth in <400>12 to <400>14 inclusive.
 24. A method according to claim 23 wherein the nucleic acid molecule comprises the nucleotide sequence selected from <400>12 to <400>14.
 25. A composition comprising a nucleic acid molecule capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation or other medical disorder said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.
 26. A composition according to claim 25 wherein the nucleic acid molecule is antisense molecule to a gene encoding IGF-I, IGF-I-receptor or an IGFBP.
 27. A composition according to claim 26 wherein the nucleic acid molecule is selected from <400>12 to <400>20 inclusive.
 28. A composition according to claim 26 selected from <400>12 to <400>14 inclusive.
 29. A method for ameliorating the effects of a proliferative and/or inflammatory skin disorder such as psoriasis said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation with effective amounts of UV treatment and a nucleic acid molecule or chemical

- 117 -

analogue thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation and/or inflammation.

30. A method according to claim 29 wherein the proliferative or inflammatory skin disorder is psoriasis, ichthyosis, pityriasis, rubra, pilaris, seborrhoea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths or cancers of the skin.
31. A method according to claim 30 wherein the proliferative or inflammatory skin disorder is psoriasis.
32. A method according to claim 29 or 30 or 31 wherein the nucleic acid molecule is capable of inhibiting, reducing or otherwise interfering with IGF-I-interaction with its receptor.
33. A method according to claim 32 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGF-I, IGF-I-receptor or an IGF binding protein (IGFBP).
34. A method according to claim 33 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGFBP-2, -3, -4, -5 or -6.
35. A method according to claim 34 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGFBP-2 or IGFBP-3.
36. A method according to claim 33 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGF-I receptor.
37. A method according to any one of claims 29 to 36 wherein the antisense molecule is at least about 15 nucleotides in length and is capable of interacting with at least one sequence selected from the list set forth in Example 6 or Example 7 or Example 8.

- 118 -

38. A method according to claim 37 wherein the antisense molecule comprises the nucleotide sequence:

5'-ATCTCTCCGCTTCCTTTC-3' (<400>10)

39. A method according to claim 37 wherein the antisense molecule is selected from the following:

UCCGGAGCCAGACUU (<400>12)

CACAGUUGCUGCAAG (<400>13)

UCUCCGCUUCCUUUC (<400>14)

AGCCCCACAGCGAG (<400>15)

GCCUUGGAGAUGAGC (<400>16)

UAACAGAGGUCAGCA (<400>17)

GGAUCAGGGACCAGU (<400>18)

CGGCAAGCUACACAG (<400>19)

GGCAGGCAGGCACAC (<400>20)

40. A method according to claim 39 wherein the antisense molecule in <400>12, <400>13 or <400>14.
41. A method according to claim 40 wherein the antisense molecule in <400>12.
42. A method according to claim 39 wherein the UV treatment occurs simultaneously with or following contact with the nucleic acid molecule or its chemical analogue.
43. Use of an antisense molecule directed to the gene encoding IGF-I receptor or its mRNA as adjunct therapy in combination with UV treatment to reduce proliferation and/or inflammation of keratinocyte cells.
44. Use according to claim 43 in the treatment of psoriasis.

1/65




Figure 1

Substitute Sheet
(Rule 26) RO/AU

2/65

1 ATTCGGGGCG AGGGAGGAGG AAGAAGCGGA GGAGGCGGCT CCCGCTCGCA
51 GGGCCGTGCA CCTGCCCGCC CGCCCGCTCG CTGCTCGCC CGCCGCGCCG
101 CGCTGCCGAC CGCCAGCATG CTGCCGAGAG TGGGCTGCC CGCGCTGCCG
151 CTGCCGCCGC CGCCGCTGCT GCCGCTGCTG CCGCTGCTGC TGCTGCTACT
201 GGGCGCGAGT GGGCGCGGCG GCGGGGCGCG CGCGGAGGTG CTGTTCCGCT
251 GCCCGCCCTG CACACCCGAG CGCCTGGCCG CCTGCGGGCC CCCGCCGGTT
301 GCGCCGCCCG CCGCGGTGGC CGCAGTGGCC GGAGGCGCCC GCATGCCATG
351 CGCGGAGCTC GTCCGGGAGC CGGGCTGCGG CTGCTGCTCG GTGTGCGCCC
401 GGCTGGAGGG CGAGGCGTGC GGCGTCTACA CCCCGCGCTG CGGCCAGGGG
451 CTGCGCTGCT ATCCCCACCC GGGCTCCGAG CTGCCCCCTGC AGGCGCTGGT
501 CATGGGCGAG GGCAC TTGTG AGAAGCGCCG GGACGCCGAG TATGGCGCCA
551 GCCCGGAGCA GGTTCAGAC AATGGCGATG ACCACTCAGA AGGAGGCCCTG
601 GTGGAGAACC ACGTGGACAG CACCATGAAC ATGTTGGCG GGGAGGCAG
651 TGCTGGCCGG AAGCCCCCTCA AGTCGGGTAT GAAGGAGCTG GCCGTGTTCC
701 GGGAGAAGGT CACTGAGCAG CACCGGCAGA TGGGCAAGGG TGGCAAGCAT

Figure 1(ii)

3/65

751 CACCTTGGCC TGGAGGAGCC CAAGAAGCTG CGACCACCCC CTGCCAGGAC
801 TCCCTGCCAA CAGGAACTGG ACCAGGTCCT GGAGCGGATC TCCACCATGC
851 GCCTTCCGGA TGAGCGGGGC CCTCTGGAGC ACCTCTACTC CCTGCACATC
901 CCCAACTGTG ACAAGCATGG CCTGTACAAC CTCAAAACAGT GCAAGATGTC
951 TCTGAACGGG CAGCGTGGG AGTGCTGGTG TGTGAACCCC AACACCGGA
1001 AGCTGATCCA GAGAGCCCC ACCATCCGG GGGACCCCGA GTGTCATCTC
1051 TTCTACAATG AGCAGCAGGA GGCTTGCGG GTGCACACCC AGCGGATGCA
1101 GTAGACCGCA GCCAGCCGGT GCCTGGCGCC CCTGCCCCCC GCCCTCTCC
1151 AAACACCGGC AGAAAACGGA GAGTGCTTGG GTGGTGGGTG CTGGAGGATT
1201 TTCCAGTTCT GACACACGTA TTTATATTG GAAAGAGACC AGCACCGAGC
1251 TCGGCACCTC CCCGGCCTCT CTCTTCCCAG CTGCAGATGC CACACCTGCT
1301 CCTTCTTGCT TTCCCCGGGG GAGGAAGGG GTTGTGGTCG GGGAGCTGGG
1351 GTACAGGTTT GGGGAGGGG AAGAGAAATT TTTATTTTG AACCCCTGTG
1401 TCCCTTTTGC ATAAGATTAA AGGAAGGAAA AGT

Figure 1(ii)

4/65




Figure 2
Substitute Sheet
(Rule 26) RO/AU

51/65

1 CTCAGCGCCC AGCCGCTTCC TGCCTGGATT CCACAGCTTC GCGCCGTGTA
51 CTGTGCGCCC ATCCCTGCGC GCCCAGCCTG CCAAGCAGCG TGCCCCGGTT
101 GCAGGCGTCA TGCAGCGGC GCGACCCACG CTCTGGGCCG CTGCGCTGAC
151 TCTGCTGGTG CTGCTCCGG GCGCGCCGGT GCGCGGGCT GCGCGAGCT
201 CGGGGGGCTT GGGTCCCCTG GTGCGCTGCG AGCCGTGCGA CGCGCGTGCA
251 CTGGCCAGT GCGCGCCTCC GCCCGCCGTG TCGCGGAGC TGGTGCGCGA
301 GCCGGGCTGC GGCTGCTGCC TGACGTGCGC ACTGAGCGAG GGCCAGCCGT
351 GCGGCATCTA CACCGAGCGC TGTGGCTCCG GCCTTCGCTG CCAGCCGTCG
401 CCCGACGAGG CGCGACCCTG GCAGGCGCTG CTGGACGGCC GCGGGCTCTG
451 CGTCAACGCT AGTGCCGTCA GCCGCCCTGCG CGCCTACCTG CTGCCAGCGC
501 CGCCAGCTCC AGGAAATGCT AGTGAGTCGG AGGAAGACCG CAGCGCCGGC
551 AGTGTGGAGA GCCCGTCCGT CTCAGCACG CACCGGGTGT CTGATCCCAA
601 GTTCCACCCC CTCCATTCAA AGATAATCAT CATCAAGAAA GGGCATGCTA
651 AAGACAGCCA GCGCTACAAA GTTGACTACG AGTCTCAGAG CACAGATACC
701 CAGAACTTCT CCTCCGAGTC CAAGCGGGAG ACAGAATATG GTCCCTGCCG

Figure 2(i)

6/65

751 TAGAGAAATG GAAGACACAC TGAATCACCT GAAGTTCCCTC AATGTGCTGA
801 GTCCCAGGGG TGTACACATT CCCAACTGTG ACAAGAAGGG ATTTTATAAG
851 AAAAAGCAGT GTCGCCCTTC CAAAGGCAGG AAGCGGGGCT TCTGCTGGTG
901 TGTGGATAAG TATGGGCAGC CTCTCCCAGG CTACACCACC AAGGGGAAGG
951 AGGACGTGCA CTGCTACAGC ATGCAGAGCA AGTAGACGCC TGCCGCAAGT
1001 TAATGTGGAG CTCAAATATG CCTTATTTTG CACAAAAGAC TGCCAAGGAC
1051 ATGACCAGCA GCTGGCTACA GCCTCGATT TATATTCTGT TTGTGGTGAA
1101 CTGATTTTTT TTAAACCAAA GTTTAGAAAG AGGTTTTTGA AATGCCTATG
1151 GTTTCCTTGA ATGGTAAACT TGAGCATCTT TTCACTTTCC AGTAGTCAGC
1201 AAAGAGCAGT TTGAAATTTT TTGTCGCTTC CTATCAAAAT ATTCAGAGAC
1251 TCGAGCACAG CACCCAGACT TCATGCGCCC GTGGAATGCT CACCACATGT
1301 TGGTCGAAGC GGCCGACCAC TGACTTTGTG ACTTAGGCGG CTGTGTTGCC
1351 TATGTAGAGA ACACGCTTCA CCCCACCTCC CCGTACAGTG CGCACAGGCT
1401 TTATCGAGAA TAGGAAAACC TTAAACCCC GTTCATCCGG ACATCCCAAC
1451 GCATGCTCCT GGAGCTCACA GCCTTCTGTG GTGTCAATTC TGAAACAAGG

Figure 2(ii)

7/65

1501 GCGTGGATCC CTCAACCAAG AAGAATGTTT ATGTCTTCAA GTGACCTGTA
1551 CTGCTTGGGG ACTATTGGAG AAAATAAGGT GGAGTCCCTAC TTGTTTAAAA
1601 AATATGTATC TAAGAATGTT CTAGGGCACT CTGGGAACCT ATAAAGGCAG
1651 GTATTTTCGG CCTCTCTCTT CAGGAATCTT CCTGAAGACA TGGCCCAGTC
1701 GAAGGCCCAG GATGGCTTTT GCTGCGGCCC CGTGGGGTAG GAGGGACAGA
1751 GAGACGGGAG AGTCAGCCTC CACATTGAGA GGCATCACAA GTAAATGGCAC
1801 AATTCTTCGG ATGACTGCAG AAAATAGTGT TTTGTAGTTC AACAACTCAA
1851 GACGAAGCTT ATTTCTGAGG ATAAGCTCTT TAAAGGCCAA GCTTTATTTT
1901 CATCTCTCAT CTTTGTGCTT CTTAGCACA ATGTAAAAA GAATAGTAAT
1951 ATCAGAACAG GAAGGAGGAA TGGCTTGCTG GGGAGCCCAT CCAGGACACT
2001 GGGAGCACAT AGAGATTAC CCATGTTGT TGAACCTAGA GTCATTCTCA
2051 TGCTTTTCTT TATAATTAC ACATATATGC AGAGAAGATA TGTCTTGT
2101 AACATTGTAT ACAACATAGC CCCAAATATA GTAAGATCTA TACTAGATAA
2151 TCCTAGATGA AATGTTAGAG ATGCTATATG ATACAACTGT GGCCATGACT
2201 GAGGAAAGGA GCTCACGCC AGAGACTGGG CTGCTCTCCC GGAGGCCAAA

Figure 2(iii)

8/65

2251 CCCAAGAAGG TCTGGCAAAG TCAGGCTCAG GGAGACTCTG CCCTGCTGCA
2301 GACCTCGGTG TGGACACACG CTGCATAGAG CTCCTCCTTGA AACACAGAGG
2351 GTCICAAGAC ATTCTGCCTA CCTATTAGCT TTCTCTTTATT TTTTAACTT
2401 TTTGGGGGGA AAAGTATTTT TGAGAAAGTTT GTCCTGCAAT GTATTATATA
2451 ATAGTAAATA AAGTTTTTAC CATT

9/65

(i)
(ii)
(iii)
(iv)
(v)
(vi)
(vii)

Figure 3
Substitute Sheet
(Rule 26) RO/AU

10/65

Figure 3(i)

11/65

```

751 CTGGGCAGCT GCAGCGCGCC TGACAACGAC ACGGCCCTGTG TAGCTTGCCG
801 CCACTACTAC TATGCCGGTG TCTGTGTGCC TGCCTGCCCG CCCAACACCT
851 ACAGGTTTGA GGGCTGGCGC TGTGTGGACC GTGACTTCTG CGCCAACATC
901 CTCAGCGCCG AGAGCAGCGA CTCGAGGGG TTTGTGATCC ACGACGGCGA
951 GTGCATGCAG GAGTGCCCTT CCGGCTTCAT CCGCAACGGC AGCCAGAGCA
1001 TGTACTGCAT CCTTGTGAA GGTCCCTTGCC CGAAGGTCTG TGAGGAAGAA
1051 AAGAAACAA AGACCATTGA TTCTGTTACT TCTGCTCAGA TGCTCCAAGG
1101 ATGCACCATC TTCAAGGCA ATTTGCTCAT TAACATCCGA CGGGGAATA
1151 ACATTGCTTC AGAGCTGGAG AACTTCATGG GGCTCATCGA GGTGGTGACG
1201 GGCTACGTGA AGATCCGCCA TTCTCATGCC TTGGTCTCCT TGTCCTTCCT
1251 AAAAACCTT CGCCTCATCC TAGGAGAGGA GCAGCTAGAA GGAATTACT
1301 CCTTCTACGT CCTCGACAAC CAGAACTTGC AGCAACTGTG GGACTGGGAC
1351 CACCGCAACC TGACCATCAA AGCAGGGAAA ATGTACTTTG CTTTCAATCC
1401 CAAATTATGT GTTTCCGAAA TTTACCGCAT GGAGGAAGTG ACGGGGACTA
1451 AAGGGCGCCA AAGCAAAGGG GACATAAACA CCAGGAACAA CGGGGAGAGA

```

Figure 3(ii)

12/65

1501 GCCTCCTGTG AAAGTGACGT CCTGCATTTC ACCTCCACCA CCACGTCGAA
1551 GAATCGCATC ATCATAACCT GGCACCGGTA CCGGCCCCCT GACTACAGGG
1601 ATCTCATCAG CTTCAACCGTT TACTACAAGG AAGCACCCCTT TAAGAATGTC
1651 ACAGAGTATG ATGGGCAGGA TGCCTGCGGC TCCAACAGCT GGAACATGGT
1701 GGACGTGGAC CTCCTCGCCA ACAAGGACGT GGAGCCCGC ATCTTACTAC
1751 ATGGGCTGAA GCCCTGGACT CAGTACGCCG TTACGTCAA GGCTGTGACC
1801 CTCACCATGG TGGAGAACGA CCATATCCGT GGGGCCAAGA GTGAGATCTT
1851 GTACATTCGC ACCAATGCTT CAGTTCCTTC CATTCCTCTG GACGTTCTTT
1901 CAGCATCGAA CTCCTCTTCT CAGTTAATCG TGAAGTGGAA CCTCCCCTCT
1951 CTGCCCCAAG GCAACCTGAG TTAATAATT GTGCGCTGGC AGCGGCAGCC
2001 TCAGGACGGC TACCTTTACC GGCACAATTA CTGCTCCAAA GACAAAATCC
2051 CCATCAGGAA GTATGCCGAC GGCACCATCG ACATTGAGGA GGTACACAGAG
2101 AACCCCAAGA CTGAGGTGTG TGGTGGGAG AAAGGGCCTT GCTGCGCCTG
2151 CCCCAAAACT GAAGCCGAGA AGCAGGCCGA GAAGGAGGAG GCTGAATACC
2201 GCAAAGTCTT TGAGAAATTTC CTGCACAACT CCATCTTCTG GCCCAGACCT

Figure 3(iii)

13/65

2251 GAAAGGAAGC GGAGAGATGT CATGCAAGTG GCCAACACCA CCATGTCCAG
2301 CCGAAGCAGG AACACCACGG CCGCAGACAC CTACAACATC ACCGACCCGG
2351 AAGAGCTGGA GACAGAGTAC CCTTTCCTTG AGAGCAGAGT GGATAACAAG
2401 GAGAGAACTG TCATTTCTAA CCTTCGGCCT TTCACATTGT ACCGCATCGA
2451 TATCCACAGC TGCAACCACG AGGCTGAGAA GCTGGGCTGC AGCGCCTCCA
2501 ACTTCGTCTT TGCAAGGACT ATGCCCGCAG AAGGAGCAGA TGACATTCCCT
2551 GGGCCAGTGA CCTGGGAGCC AAGGCCCTGAA AACTCCATCT TTTTAAAGTG
2601 GCCGGAACCT GAGAAATCCCA ATGGATTGAT TCTAATGTAT GAAATAAAAT
2651 ACGGATCACA AGTTGAGGAT CAGCGAGAAT GTGTGTCCAG ACAGGAATAC
2701 AGGAAGTATG GAGGGGCCAA GCTAAACCCG CTAAACCCGG GGAACCTACAC
2751 AGCCCGGATT CAGGCCACAT CTCTCTCTGG GAATGGGTCTG TGGACAGATC
2801 CTGTGTTCTT CTATGTCCAG GCCAAACACAG GATATGAAA CTTCATCCAT
2851 CTGATCATCG CTCGTGCCCGT CGCTGTCCCTG TTGATCGTGG GAGGGTTGGT
2901 GATTATGCTG TACGTCTTCC ATAGAAAGAG AAATAACAGC AGGCTGGGGA
2951 ATGGAGTGCT GTATGCCTCT GTGAACCCCG AGTACTTCAG CGCTGCTGAT

Figure 3(iv)

14/65

3001 GTGTACGTTC CTGATGAGTG GGAGGTGGCT CGGGAGAAGA TCACCATGAG
3051 CCGGGAACCTT GGCAGGGGT CGTTTGGGAT GGCTATGAA GGAGTTGCCA
3101 AGGGTGTGGT GAAAGATGAA CCTGAAACCA GAGTGGCCAT TAAACAGTG
3151 AACGAGGCCG CAAGCATGCG TGAGAGGATT GAGTTTCTCA ACGAAGCTTC
3201 TGTGATGAAG GAGTTCAATT GTCACCATGT GTGCGATTG CTGGGTGTGG
3251 TGTCCCAAGG CCAGCCAACA CTGGTCATCA TGGAACTGAT GACACGGGC
3301 GATCTCAAA GTTATCTCCG GTCTCTGAGG CCAGAAATGG AGAATAATCC
3351 AGTCCTAGCA CCTCCAAGCC TGAGCAAGAT GATTCAGATG GCCGGAGAGA
3401 TTGCAGACGG CATGGCATACTCTCAACGCCA ATAAGTTCTGT CCACAGAGAC
3451 CTTGCTGCCC GGAATTGCAT GGTAGCCGAA GATTTCACAG TCAAATCGG
3501 AGATTTTGGT ATGACGCGAG ATATCTATGA GACAGACTAT TACCGGAAAG
3551 GAGGCAAAGG GCTGCTGCCC GTGCGCTGGA TGTCCTCTGA GTCCCTCAAG
3601 GATGGAGTCT TCACCACTTA CTCGGACGTC TGGTCCCTCG GGTCTCTCCT
3651 CTGGGAGATC GCCACACTGG CCGAGCAGCC CTACCAGGGC TTGTCCAACG
3701 AGCAAGTCCT TCGCTTCGTC ATGGAGGGCG GCCTTCTGGA CAAGCCAGAC

Figure 3(v)

15/65

3751 AACTGTCCCTG ACATGCTGTT TGAAC TGATG CGCATGTGCT GGCAGTATAA
3801 CCCCAAGATG AGGCCCTTCCT TCCTGGAGAT CATCAGCAGC ATCAAAGAGG
3851 AGATGGAGCC TGGCTTCCGG GAGGTCTCCT TCTACTACAG CGAGGAGAAC
3901 AAGCTGCCCG AGCCGGAGGA GCTGGACCTG GAGCCAGAGA ACATGGAGAG
3951 CGTCCCCCTG GACCCCTCGG CCTCCTCGTC CTCCCTGCCA CTGCCCGACA
4001 GACACTCAGG ACACAAGGCC GAGAACGGCC CCGGCCCTGG GGTGCTGGTC
4051 CTCCGCGCCA GCTTCGACGA GAGACAGCCT TACGCCACA TGAACGGGGG
4101 CCGCAAGAAC GAGCGGCCT TGCCGCTGCC CCAGTCTTCG ACCTGCTGAT
4151 CCTTGGATCC TGAATCTGTG CAAACAGTAA CGTGTGCGCA CGCGCAGCGG
4201 GGTGGGGGG GAGAGAGAGT TTAAACAATC CATTCACAAG CCTCCTGTAC
4251 CTCAGTGGAT CTTCAGTTCT GCCCTTGCTG CCCGCGGGAG ACAGCTTCTC
4301 TGCAGTAAA CACATTGGG ATGTTCCCTT TTTCAATATG CAAGCAGCTT
4351 TTTATTCCCT GCCCAAACCC TTAAGTACA TGGGCCCTTA AGAACCTTAA
4401 TGACAACACT TAATAGCAAC AGAGCACTG AGAACCACTC TCCTCACTCT
4451 GTCCCCTGTCC TTCCCCTGTT TCCCTTTCTC TCTCCTCTCT GCTTCATAAC

Figure 3(vi)

16/65

4501 GGAAAAATAA TTGCCACAAG TCCAGCTGGG AAGCCCTTTT TATCAGTTTG
4551 AGGAAGTGGC TGTCCCTGTG GCCCATCCA ACCACTGTAC ACACCCGCCT
4601 GACACCGTGG GTCATTACAA AAAAACACGT GGAGATGGAA ATTTTACCT
4651 TTATCTTTCA CCTTCTAGG GACATGAAAT TTACAAAGGG CCATCGTTCA
4701 TCCAAGGCTG TTACCATTTT AACGCTGCCT AATTTGCCA AAATCCTGAA
4751 CTTTCTCCCT CATCGGCCCG GCGCTGATTC CTCGTGTCCG GAGGCATGGG
4801 TGAGCATGGC AGCTGGTTGC TCCATTGAG AGACACGCTG GCGACACACT
4851 CCGTCCATCC GACTGCCCCCT GCTGTGCTGC TCAAGGCCAC AGGCACACAG
4901 GTCTCATTGC TTCTGACTAG ATTATTATT GGGGGAAGT GACACAATAG
4951 GTCTTCTCT CAGTGAAGGT GGGGAGAAGC TGAACCGGC

Substitute Sheet
(Rule 26) RO/AU

Figure 3 (vii)

17/65

BP3AS2	BP3AS3	BP3S
5 μ M 0.5 μ M	5 μ M 0.5 μ M	5 μ M *
[[[



*no oligo

Figure 4a




Figure 4b




Figure 5a

20/65




Figure 5b

21/65




Figure 6

22/65






Figure 7

23/65

Optimization of IGFBP-3 AS oligo concentration**Figure 8**Substitute Sheet
(Rule 26) RO/AU

Map of IGF-I Receptor mRNA and position of target ODNs




- Position of the 21 tested ODNs (|)
- mRNA transcript lengths = 7Kb and 11Kb
- coding sequence 46-4149


Figure 9

25/65

Lipid-mediated uptake of oligonucleotide in keratinocytes



B



A

Figure 10

26/65

Uptake (A) and toxicity (B) of ODN/ lipid complexes in keratinocytes






Figure 11

Substitute Sheet
(Rule 26) RO/AU

27/65

**IGF-I Receptor mRNA in ODN
treated (30nM) HaCaT cells (2 μ g/ml GSV)**

A**B****Figure 12**

Substitute Sheet
(Rule 26) RO/AU

28/65

**IGF-I receptor mRNA in ODN treated (30nM)
HaCaT cells (2µg/ml GSV)**




Figure 13

29/65

**Effect of antisense oligonucleotides on IGF-1
receptor levels on the surface of keratinocytes:**
Competition Assay - 125 I IGF-1 vs Des 1-3 IGF-1




Figure 14
Substitute Sheet
(Rule 26) RO/AU

30/65

**Effect of antisense oligonucleotides on IGF-1
receptor levels on the surface of keratinocytes:
Competition Assay - 125 I IGF-1 vs Des 1-3 IGF-1**




Figure 15

Substitute Sheet
(Rule 26) RO/AU

31/65

H&E stained sections of (A) psoriatic skin biopsy prior to grafting and
(B) 49 day old psoriatic skin graft using skin from same donor

**A****B**

Figure 16

32/65

Uptake of oligonucleotide after intradermal injection
into psoriatic skin graft on a nude mouse




Figure 17

33/65

Pregraft, Donor JH



Donor JH, PBS treated (50 μ l)



Donor JH, #50 treated (50 μ l, 10 μ M)




Figure 18a

34/65

Donor LB, pregraft



Donor LB, PBS treated (50 μ l)



Donor LB, #74 treated (50 μ l, 10 μ M)



Figure 18b

35/65

Donor PW, pregraft



Donor PW, R451 treated (50 μ l, 10 μ M)



Donor LB, #74 treated (50 μ l, 10 μ M)




Figure 18c

36/65

Donor GM, pregraft



Donor GM, R451 treated (50 μ l, 10 μ M)



Donor GM, #27 treated (50 μ l, 10 μ M)




Figure 18d


37/65



Donor JH Pregraft



Donor JH PBS treated 50ul



Donor JH # 50 treated 50ul, 10uM

Figure 19a

38/65



Donor LB Pregraft



Donor LB PBS treated 50ul



Donor LB # 74 treated 50ul, 10uM

Figure 19b
Substitute Sheet
(Rule 26) RO/AU

39/65



Donor PW Pregraft




Donor PW R451 treated 50ul, 10um



Donor PW # 74 treated 50ul, 10uM

Figure 19c
Substitute Sheet
(Rule 26) RO/AU

40/65



Donor GM Pregraft



Donor GM R451 treated 50ul, 10um



Donor GM # 27 treated 50ul, 10uM

Figure 19d
Substitute Sheet
(Rule 26) RO/AU

41/65




Figure 20

42/65

α hKi-67



Pregraft
GM



Oligo 27



Oligo R451

Figure 21
Substitute Sheet
(Rule 26) RO/AU

43/65

**Penetration of oligonucleotide into
human skin after topical treatment**




Figure 22

Substitute Sheet
(Rule 26) RO/AU

44/65

Penetration of oligonucleotide into human
skin after topical gel formulation





Figure 23
Substitute Sheet
(Rule 26) RO/AU


IGFBP-3 mRNA



- Position of the 13 tested ODNs (I)
- mRNA transcript length = 2.5 Kb
- coding sequence 133-1009

Figure 24

IGFBP-3 mRNA in AON treated (100nM) HaCaT cells (2ug/ml GSV)



Treatment

Figure 25a

47/65

IGFBP-3 mRNA levels in AON treated (100nM) HaCaT cells (2ug/ml GSV)




Figure 25b

IGFBP-3 mRNA in AON treated (30nM) HaCaT cells (2ug/ml GSV)




Figure 25c

49/65

IGFBP-3 mRNA in AON treated (30nM) HaCaT cells (2µg/ml GSV)




Figure 25d

50/65




Figure 26a

51/65

IGFBP-3 mRNA in ODN treated (100nM) HaCaT cells (2µg/ml GSV)




Figure 26b

52/65




Figure 27a

53/65




Figure 27 b

54/65




Figure 28a

55/65




Figure 28b

56/65




Figure 29

57/65




Figure 30

58/65

DONOR B



pregraft



AON #27



R451

DONOR A



pregraft



AON #50



PBS

Figure 31a

59/65




Figure 31b

60/65

pregraft



AON #50



PBS



Figure 31c

Substitute Sheet
(Rule 26) RO/AU


61/65



pregraft



AON #27




R451

Figure 32a

62/65

pregraft



AON #27



R451




Figure 32b

Substitute Sheet
(Rule 26) RO/AU

63/65




Figure 33

64/65




Figure 34

65/65

Amido black assay - 3 x 24h
treatments (15nM ODN, 2ug/ml GSV)




Figure 35

- 1 -

SEQUENCE LISTING

<110> MURDOCH CHILDREN'S RESEARCH INSTITUTE

<120> A METHOD FOR THE PROPHYLAXIS AND/OR TREATMENT OF
MEDICAL DISORDERS

<130> 2288267/EJH

<140> INTERNATIONAL

<141> 2000-06-21

<150> 60/140345

<151> 1999-06-21

<160> 24

<170> PatentIn Ver. 2.1

<210> 1

<211> 1433

<212> DNA

<213> synthetic construct

<400> 1

```
attcggggcg agggaggagg aagaagcgga ggaggcggct cccgctcgca gggccgtgca 60
cctgccccgc cgcccgctcg ctgctcgcc cgccgcgcc cgctgccgac cgccagcatg 120
ctgccgagag tgggctgccc cgcgctgcc ctgccgcgc cgccgctgct gccgctgctg 180
ccgctgctgc tgetgctact gggcgcgagt ggcggcggcg gcggggcgcg cgcgagggtg 240
ctgttccgct gcccgccctg cacacccgag cgcctggccg cctgcgggcc cccgccggtt 300
gcgcgcgccg ccgcggtggc cgcagtggcc ggaggcgccc gcatgccatg cgcggagctc 360
gtccgggagc cgggctgcgg ctgctgctcg gtgtgcgcc ggctggaggg cgaggcgtgc 420
ggcgtctaca ccccgcgctg cggccagggg ctgcgctgct atccccaccc gggctccgag 480
ctgcccctgc aggcgctggt catgggcgag ggcacttgtg agaagcgccg ggacgccgag 540
tatggcgcca gcccgagca ggttcagac aatggcgatg accactcaga aggaggcctg 600
gtggagaacc acgtggacag caccatgaac atgttgggcg ggggaggcag tgctggccgg 660
aagcccctca agtcgggtat gaaggagctg gccgtgttcc gggagaaggc cactgagcag 720
caccggcaga tgggcaaggg tggcaagcat caccttggcc tggaggagcc caagaagctg 780
cgaccacccc ctgccaggac tccctgccaa caggaaactgg accaggtcct ggagcggatc 840
tccacccatgc gccttccgga tgagcggggc cctctggagc acctctactc cctgcacatc 900
```

- 2 -

cccaactgtg acaagcatgg cctgtacaac ctcaaacagt gcaagatgtc tctgaacggg 960
cagcgtgggg agtgctggtg tgtgaacccc aacaccggga agctgatcca gggagccccc 1020
accatccggg gggaccccgga gtgtcatctc ttctacaatg agcagcagga ggcttgccgg 1080
gtgcacaccc agcggatgca gtagaccgca gccagccggt gcctggcgcc cctgcccccc 1140
gcccctctcc aaacaccggc agaaaacgga gagtgtcttg gtggtgggtg ctggaggatt 1200
ttccagttct gacacacgta tttatatattg gaaagagacc agcaccgagc tcggcacctc 1260
cccggcctct ctcttcccag ctgcagatgc cacacctgct ccttcttgct tccccgggg 1320
gaggaagggg gttgtggtcg gggagctggg gtacaggttt ggggaggggg aagagaaatt 1380
tttatTTTTG aaccctgtg tcccttttgc ataagattaa aggaaggaaa agt 1433

<210> 2

<211> 2474

<212> DNA

<213> synthetic construct

<400> 2

ctcagcgccc agccgcttcc tgcctggatt ccacagcttc gcgccgtgta ctgtcgcccc 60
atccctgcgc gccagcctg ccaagcagcg tgccccgggt gcagcgctca tgcagcgggc 120
gcgacccacg ctctggggcg ctgcgctgac tctgtggtg ctgctccgcg ggccgcgggt 180
ggcgcgggct ggcgcgagct cggggggctt ggggtcccggt gtgcgctgcg agccgtgcga 240
cgcgcgctga ctggcccagt gcgcgcctcc gcccgccgtg tgcgcggagc tgggtgcgca 300
gccgggctgc ggctgtgccc tgacgtgcgc actgagcgag ggccagccgt gcggcatcta 360
caccgagcgc tgtggctccg gccttcgctg ccagccgtcg cccgacgagg cgcgaccgct 420
gcagggcgtg ctggacggcc gcgggctctg cgtcaacgct agtgccgtca gccgcctgcg 480
cgctacctg ctgccagcgc cgccagctcc aggaatatgt agtgagtcgg aggaagaccg 540
cagcgccggc agtgtggaga gcccgctcgt ctccagcacg caccgggtgt ctgatcccaa 600
gttccacccc ctccattcaa agataatcat catcaagaaa gggcatgcta aagacagcca 660
gcgctacaaa gttgactacg agtctcagag cacagatacc cagaacttct cctccgagtc 720
caagcgggag acagaatatg gtccctgccg tagagaaatg gaagacacac tgaatcacct 780
gaagttcctc aatgtgctga gtcccagggg tgtacacatt cccaactgtg acaagaaggg 840
atTTTtataag aaaaagcagt gtcgcccttc caaaggcagg aagcggggct tctgtggtg 900
tgtggataag tatgggcagc ctctcccagg ctacaccacc aaggggaagg aggacgtgca 960
ctgctacagc atgcagagca agtagacgcc tgccgcaagt taatgtggag ctcaaatatg 1020
ccttattttg cacaaaagac tgccaaggac atgaccagca gctggctaca gcctcgattt 1080
atattttctgt ttgtggtgaa ctgatttttt ttaaaccaaa gtttagaaag aggtttttga 1140
aatgcctatg gtttctttga atggtaaact tgagcatctt ttcactttcc agtagtcagc 1200
aaagagcagt ttgaattttc ttgtcgcttc ctatcaaaat attcagagac tcgagcacag 1260
caccagact tcatgcgccc gtggaatgct caccacatgt tggtcgaagc ggccgaccac 1320
tgactttgtg acttaggcgg ctgtgttgcc tatgtagaga acacgcttca ccccaactcc 1380
ccgtacagtg cgcacaggct ttatcgagaa taggaaaacc tttaaacccc ggcatccgg 1440

- 3 -

```

acatcccaac gcatgctcct ggagctcaca gccttctgtg gtgtcatttc tgaaacaagg 1500
gcgtggatcc ctcaaccaag aagaatgttt atgtcttcaa gtgacctgta ctgcttgggg 1560
actattggag aaaataaggt ggagtcctac ttgtttaaaa aatatgtatc taagaatgtt 1620
ctagggcact ctgggaacct ataaaggcag gtatttcggg ccctcctctt caggaatctt 1680
cctgaagaca tggccagctc gaaggcccag gatggctttt gctgcggccc cgtggggtag 1740
gagggacaga gagacgggag agtcagcctc cacattcaga ggcatcacia gtaatggcac 1800
aattcttcgg atgactgcag aaaatagtgt tttgtagttc aacaactcaa gacgaagctt 1860
atctctgagg ataagctctt taaaggcaaa gctttatttt catctctcat cttttgtcct 1920
ccttagcaca atgtaaaaaa gaatagtaat atcagaacag gaaggaggaa tggcttgctg 1980
gggagcccat ccaggacact gggagcacat agagattcac ccatgtttgt tgaacttaga 2040
gtcattctca tgcttttctt tataattcac acatatatgc agagaagata tgttcttggt 2100
aacattgtat acaacatagc cccaaatata gtaagatcta tactagataa tcctagatga 2160
aatgttagag atgctatatg atacaactgt ggccatgact gaggaaagga gctcacgccc 2220
agagactggg ctgctctccc ggaggccaaa cccaagaagg tctggcaaag tcaggctcag 2280
ggagactctg ccctgctgca gacctcgggtg tggacacacg ctgcatagag ctctccttga 2340
aaacagaggg gtctcaagac attctgccta cctattagct tttctttatt tttttaactt 2400
tttgggggga aaagtatttt tgagaagttt gtcttgcaat gtatttataa atagtaaata 2460
aagtttttac catt 2474

```

<210> 3

<211> 4989

<212> DNA

<213> synthetic construct

<400> 3

```

tttttttttt ttttgagaaa gggaatttca tcccaaataa aaggaatgaa gtctggctcc 60
ggaggagggt ccccgacctc gctgtggggg ctctgttttc tctccgccgc gctctcgctc 120
tggccgacga gtggagaaat ctgcgggcca ggcatcgaca tccgcaacga ctatcagcag 180
ctgaagcgcc tggagaactg cacggtgatc gagggctacc tccacatcct gctcatctcc 240
aaggccgagg actaccgcag ctaccgcttc cccaagctca cggtcattac cgagtacttg 300
ctgctgttcc gagtggctgg cctcgagagc ctcgagacc tcttcccaa cctcacgggc 360
atccgcggct ggaaactctt ctacaactac gccctggtca tcttcgagat gaccaatctc 420
aaggatattg ggcttttcaa cctgaggaac attactcggg gggccatcag gattgagaaa 480
aatgctgacc tctgttacct ctccactgtg gactgggtccc tgatcctgga tgcggtgtcc 540
aataactaca ttgtggggaa taagccccc aaggaatgtg gggacctgtg tccagggacc 600
atggaggaga agccgatgtg tgagaagacc accatcaaca atgagtacaa ctaccgctgc 660
tggaccacaa accgctgcc aaaaatgtgc ccaagcacgt gtgggaagcg ggcgtgcacc 720
gagaacaatg agtcttgcca ccccgagtgc ctgggcagct gcagcgcgcc tgacaacgac 780
acggcctgtg tagcttgccg ccaactactac tatgccggtg tctgtgtgcc tgcctgcccg 840
cccaacacct acaggtttga gggctggcgc tgtgtggacc gtgacttctg cgccaacatc 900

```

- 4 -

ctgagcgccg agagcagcga ctccgagggg tttgtgatcc acgacggcga gtgcatgcag 960
 gaggccccct cgggcttcat ccgcaacggc agccagagca tgtactgcat cccttgtgaa 1020
 ggtccttgcc cgaaggtctg tgaggaagaa aagaaaacaa agaccattga ttctgttact 1080
 tctgctcaga tgctccaagg atgcaccatc ttcaagggca atttgctcat taacatccga 1140
 cgggggaata acattgcttc agagctggag aacttcatgg ggctcatcga ggtggtgacg 1200
 ggctacgtga agatccgcca ttctcatgcc ttggtctcct tgccttcctt aaaaaacctt 1260
 cgcctcatcc taggagagga gcagctagaa ggggaattact ccttctacgt cctcgacaac 1320
 cagaacttgc agcaactgtg ggactgggac caccgcaacc tgaccatcaa agcagggaaa 1380
 atgtactttg ctttcaatcc caaattatgt gtttccgaaa tttaccgcat ggaggaagtg 1440
 acggggacta aagggcgcca aagcaaaggg gacataaaca ccaggaacaa cggggagaga 1500
 gcctcctgtg aaagtgcgt cctgcatttc acctccacca ccacgtcgaa gaatcgcatc 1560
 atcataacct ggaccggta ccggccccct gactacaggg atctcatcag cttcaccgtt 1620
 tactacaagg aagcaccctt taagaatgtc acagagtatg atgggcagga tgcctgcggc 1680
 tccaacagct ggaacatggt ggacgtggac ctcccggcca acaaggacgt ggagcccggc 1740
 atcttactac atgggctgaa gccctggact cagtacggcg tttacgtcaa ggctgtgacc 1800
 ctcccatgg tggagaacga ccataccgt gggggccaaga gtgagatcct gtacattcgc 1860
 accaatgctt cagttccttc cattcccttg gacgttcttt cagcatcgaa ctctcttct 1920
 cagttaatcg tgaagtggaa cctccctct ctgcccacg gcaacctgag ttactacatt 1980
 gtgcgctggc agcggcagcc tcaggacggc tacctttacc ggcacaatta ctgctccaaa 2040
 gacaaaatcc ccatcaggaa gtatgccgac ggaccatcg acattgagga ggtcacagag 2100
 aacccaaga ctgaggtgtg tgggtgggag aaagggcctt gctgcgcctg ccccaaaact 2160
 gaagccgaga agcaggccga gaaggaggag gctgaatacc gcaaagtctt tgagaatttc 2220
 ctgcacaact ccatcttcgt gccagacct gaaaggaagc ggagagatgt catgcaagt 2280
 gccaacacca ccatgtccag ccgaagcagg aacaccacgg ccgcagacac ctacaacatc 2340
 accgaccgg aagagctgga gacagagtac cctttctttg agagcagagt ggataacaag 2400
 gagagaactg tcatctctaa ccttcggcct ttacattgt accgcatcga tatccacagc 2460
 tgcaaccacg aggctgagaa gctgggctgc agcgctcca acttcgtctt tgcaaggact 2520
 atgcccgag aaggagcaga tgacattcct gggccagtga cctgggagcc aaggcctgaa 2580
 aactccatct ttttaaagtg gccggaacct gagaatccca atggattgat tctaattgat 2640
 gaaataaaat acggatcaca agttgaggat cagcgagaat gtgtgtccag acaggaatac 2700
 aggaagtatg gaggggcca gctaaaccgg ctaaaccggg ggaactacac agcccgatt 2760
 caggccacat ctctctctgg gaatgggtcg tggacagatc ctgtgttctt ctatgtccag 2820
 gccaaaacag gatatgaaaa cttcatccat ctgatcatcg ctctgccgt cgctgtcctg 2880
 ttgatcgtgg gaggttggt gattatgctg tacgtcttcc atagaaagag aaataacagc 2940
 aggtggggga atggagtgt gtatgcctct gtgaaccgg agtacttcag cgctgctgat 3000
 gtgtacgttc ctgatgagt ggaggtggct cgggagaaga tcaccatgag ccgggaactt 3060
 gggcaggggt cgtttgggat ggtctatgaa ggagttgcca aggtgtggt gaaagatgaa 3120
 cctgaaacca gagtggccat taaaacagt aacgaggccg caagcatgcg tgagaggatt 3180
 gagtttctca acgaagcttc tgtgatgaag gagttcaatt gtcaccatgt ggtgcgattg 3240
 ctgggtgtgg tgtccaagg ccagccaaca ctggctatca tggaaactgat gacacggggc 3300
 gatctcaaaa gttatctccg gtctctgagg ccagaaatgg agaataatcc agtcctagca 3360

- 5 -

```

cctccaagcc tgagcaagat gattcagatg gccggagaga ttgcagacgg catggcatac 3420
ctcaacgcca ataagttcgt ccacagagac cttgctgccc ggaattgcat ggtagccgaa 3480
gatttcacag tcaaaatcgg agatttttgt atgacgcgag atatctatga gacagactat 3540
taccggaaaag gaggcaaagg gctgctgccc gtgcgctgga tgtctcctga gtccctcaag 3600
gatggagtct tcaccactta ctccgacgtc tggtccttcg gggtcgtcct ctgggagatc 3660
gccacactgg ccgagcagcc ctaccagggc ttgtccaacg agcaagtcct tcgcttcgtc 3720
atggaggggcg gccttctgga caagccagac aactgtcctg acatgctgtt tgaactgatg 3780
cgcatgtgct ggcagtataa cccaagatg aggccttcct tcctggagat catcagcagc 3840
atcaaagagg agatggagcc tggcttcggg gaggtctcct tctactacag cgaggagaac 3900
aagctgcccc agccggagga gctggacctg gagccagaga acatggagag cgtccccctg 3960
gacccctcgg cctcctcgtc ctccctgcca ctgccgaca gacactcagg acacaaggcc 4020
gagaacggcc ccggccctgg ggtgctggtc ctccgcgcca gcttcgacga gagacagcct 4080
tacgcccaca tgaacggggg ccgcaagaac gagcgggcct tgccgctgcc ccagtcttcg 4140
acctgctgat ccttggatcc tgaatctgtg caaacagtaa cgtgtgcgca cgcgcagcgg 4200
gggtggggggg gagagagagt ttaacaatc cattcacaag cctcctgtac ctcagtggat 4260
cttcagttct gcccttgctg ccgcgaggag acagcttctc tgcagtaaaa cacatttggg 4320
atgttccttt tttcaatatg caagcagctt tttattccct gcccaaacc ttaactgaca 4380
tgggccttta agaaccttaa tgacaacact taatagcaac agagcacttg agaaccagtc 4440
tcctcactct gtccctgtcc ttccctgttc tccctttctc tctcctctct gcttcataac 4500
ggaaaaataa ttgccacaag tccagctggg aagccctttt tatcagtttg aggaagtggc 4560
tgtccctgtg gccccatcca accactgtac acaccgcct gacaccgtgg gtcattacaa 4620
aaaaacacgt ggagatggaa atttttacct ttatctttca cttttctagg gacatgaaat 4680
ttacaaaggg ccatcgttca tccaaggctg ttaccatttt aacgctgcct aattttgcca 4740
aaatcctgaa cttttctcct catcgccccg gcgctgattc ctctgtgtccg gaggcatggg 4800
tgagcatggc agctgggtgc tccatttgag agacacgctg gcgacacact ccgtccatcc 4860
gactgcccct gctgtgctgc tcaaggccac aggcacacag gtctcattgc ttctgactag 4920
attattattt gggggaactg gacacaatag gtctttctct cagtgaaggt ggggagaagc 4980
tgaaccggc

```

<210> 4

<211> 25

<212> DNA

<213> synthetic construct

<400> 4

gcgcccgtg catgacgcct gcaac

25

<210> 5

<211> 24

- 6 -

<212> DNA

<213> synthetic construct

<400> 5

cgggcggctc acctggagct ggcg

24

<210> 6

<211> 18

<212> DNA

<213> synthetic construct

<400> 6

aggcggctga cggcacta

18

<210> 7

<211> 19

<212> DNA

<213> synthetic construct

<400> 7

caggcgatcat gcagcgggc

19

<210> 8

<211> 25

<212> DNA

<213> synthetic construct

<400> 8

cggagatgcc gcatgccagc gcagg

25

<210> 9

<211> 18

<212> DNA

<213> synthetic construct

<400> 9

gacagcgctcg gagcgatc

18

- 7 -

<210> 10
<211> 18
<212> DNA
<213> synthetic construct

<400> 10
atctctccgc ttcctttc 18

<210> 11
<211> 18
<212> DNA
<213> synthetic construct

<400> 11
gaaaggaagc ggagagat 18

<210> 12
<211> 12
<212> DNA
<213> synthetic construct

<400> 12
ccggagccag ac 12

<210> 13
<211> 12
<212> DNA
<213> synthetic construct

<400> 13
cacaggcgca ag 12

<210> 14
<211> 8
<212> DNA
<213> synthetic construct

- 8 -

<400> 14

cccgcgcc

8

<210> 15

<211> 15

<212> DNA

<213> synthetic construct

<400> 15

agccccaca gcgag

15

<210> 16

<211> 12

<212> DNA

<213> synthetic construct

<400> 16

gccggagaga gc

12

<210> 17

<211> 13

<212> DNA

<213> synthetic construct

<400> 17

aacagaggca gca

13

<210> 18

<211> 13

<212> DNA

<213> synthetic construct

<400> 18

ggacaggac cag

13

<210> 19

- 9 -

<211> 14

<212> DNA

<213> synthetic construct

<400> 19

cggcaagcac acag

14

<210> 20

<211> 15

<212> DNA

<213> synthetic construct

<400> 20

ggcaggcagg cacac

15

<210> 21

<211> 328

<212> PRT

<213> human

<400> 21

Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu Pro Pro Pro Pro

1

5

10

15

Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu Gly Ala Ser Gly

20

25

30

Gly Gly Gly Gly Ala Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys

35

40

45

Thr Pro Glu Arg Leu Ala Ala Cys Gly Pro Pro Pro Val Ala Pro Pro

50

55

60

Ala Ala Val Ala Ala Val Ala Gly Gly Ala Arg Met Pro Cys Ala Glu

65

70

75

80

Leu Val Arg Glu Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg Leu

85

90

95

- 10 -

Glu Gly Glu Ala Cys Gly Val Tyr Thr Pro Arg Cys Gly Gln Gly Leu
 100 105 110

Arg Cys Tyr Pro His Pro Gly Ser Glu Leu Pro Leu Gln Ala Leu Val
 115 120 125

Met Gly Glu Gly Thr Cys Glu Lys Arg Arg Asp Ala Glu Tyr Gly Ala
 130 135 140

Ser Pro Glu Gln Val Ala Asp Asn Gly Asp Asp His Ser Glu Gly Gly
 145 150 155 160

Leu Val Glu Asn His Val Asp Ser Thr Met Asn Met Leu Gly Gly Gly
 165 170 175

Gly Ser Ala Gly Arg Lys Pro Leu Lys Ser Gly Met Lys Glu Leu Ala
 180 185 190

Val Phe Arg Glu Lys Val Thr Glu Gln His Arg Gln Met Gly Lys Gly
 195 200 205

Gly Lys His His Leu Gly Leu Glu Glu Pro Lys Lys Leu Arg Pro Pro
 210 215 220

Pro Ala Arg Thr Pro Cys Gln Gln Glu Leu Asp Gln Val Leu Glu Arg
 225 230 235 240

Ile Ser Thr Met Arg Leu Pro Asp Glu Arg Gly Pro Leu Glu His Leu
 245 250 255

Tyr Ser Leu His Ile Pro Asn Cys Asp Lys His Gly Leu Tyr Asn Leu
 260 265 270

Lys Gln Cys Lys Met Ser Leu Asn Gly Gln Arg Gly Glu Cys Trp Cys
 275 280 285

Val Asn Pro Asn Thr Gly Lys Leu Ile Gln Gly Ala Pro Thr Ile Arg
 290 295 300

Gly Asp Pro Glu Cys His Leu Phe Tyr Asn Glu Gln Gln Glu Ala Cys
 305 310 315 320

- 11 -

Gly Val His Thr Gln Arg Met Gln
325

<210> 22

<211> 39

<212> PRT

<213> human

<400> 22

Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu Pro Pro Pro Pro
1 5 10 15

Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu Leu Gly Ala Ser Gly
20 25 30

Gly Gly Gly Gly Ala Arg Ala
35

<210> 23

<211> 289

<212> PRT

<213> human

<400> 23

Glu Val Leu Phe Arg Cys Pro Pro Cys Thr Pro Glu Arg Leu Ala Ala
1 5 10 15

Cys Gly Pro Pro Pro Val Ala Pro Pro Ala Ala Val Ala Ala Val Ala
20 25 30

Gly Gly Ala Arg Met Pro Cys Ala Glu Leu Val Arg Glu Pro Gly Cys
35 40 45

Gly Cys Cys Ser Val Cys Ala Arg Leu Glu Gly Glu Ala Cys Gly Val
50 55 60

Tyr Thr Pro Arg Cys Gly Gln Gly Leu Arg Cys Tyr Pro His Pro Gly
65 70 75 80

- 12 -

Ser Glu Leu Pro Leu Gln Ala Leu Val Met Gly Glu Gly Thr Cys Glu
85 90 95

Lys Arg Arg Asp Ala Glu Tyr Gly Ala Ser Pro Glu Gln Val Ala Asp
100 105 110

Asn Gly Asp Asp His Ser Glu Gly Gly Leu Val Glu Asn His Val Asp
115 120 125

Ser Thr Met Asn Met Leu Gly Gly Gly Gly Ser Ala Gly Arg Lys Pro
130 135 140

Leu Lys Ser Gly Met Lys Glu Leu Ala Val Phe Arg Glu Lys Val Thr
145 150 155 160

Glu Gln His Arg Gln Met Gly Lys Gly Gly Lys His His Leu Gly Leu
165 170 175

Glu Glu Pro Lys Lys Leu Arg Pro Pro Pro Ala Arg Thr Pro Cys Gln
180 185 190

Gln Glu Leu Asp Gln Val Leu Glu Arg Ile Ser Thr Met Arg Leu Pro
195 200 205

Asp Glu Arg Gly Pro Leu Glu His Leu Tyr Ser Leu His Ile Pro Asn
210 215 220

Cys Asp Lys His Gly Leu Tyr Asn Leu Lys Gln Cys Lys Met Ser Leu
225 230 235 240

Asn Gly Gln Arg Gly Glu Cys Trp Cys Val Asn Pro Asn Thr Gly Lys
245 250 255

Leu Ile Gln Gly Ala Pro Thr Ile Arg Gly Asp Pro Glu Cys His Leu
260 265 270

Phe Tyr Asn Glu Gln Gln Glu Ala Cys Gly Val His Thr Gln Arg Met
275 280 285

Gln

- 13 -

<210> 24

<211> 291

<212> PRT

<213> human

<400> 24

Met Gln Arg Ala Arg Pro Thr Leu Trp Ala Ala Ala Leu Thr Leu Leu
 1 5 10 15

Val Leu Leu Arg Gly Pro Pro Val Ala Arg Ala Gly Ala Ser Ser Gly
 20 25 30

Gly Leu Gly Pro Val Val Arg Cys Glu Pro Cys Asp Ala Arg Ala Leu
 35 40 45

Ala Gln Cys Ala Pro Pro Pro Ala Val Cys Ala Glu Leu Val Arg Glu
 50 55 60

Pro Gly Cys Gly Cys Cys Leu Thr Cys Ala Leu Ser Glu Gly Gln Pro
 65 70 75 80

Cys Gly Ile Tyr Thr Glu Arg Cys Gly Ser Gly Leu Arg Cys Gln Pro
 85 90 95

Ser Pro Asp Glu Ala Arg Pro Leu Gln Ala Leu Leu Asp Gly Arg Gly
 100 105 110

Leu Cys Val Asn Ala Ser Ala Val Ser Arg Leu Arg Ala Tyr Leu Leu
 115 120 125

Pro Ala Pro Pro Ala Pro Gly Asn Ala Ser Glu Ser Glu Glu Asp Arg
 130 135 140

Ser Ala Gly Ser Val Glu Ser Pro Ser Val Ser Ser Thr His Arg Val
 145 150 155 160

Ser Asp Pro Lys Phe His Pro Leu His Ser Lys Ile Ile Ile Ile Lys
 165 170 175

Lys Gly His Ala Lys Asp Ser Gln Arg Tyr Lys Val Asp Tyr Glu Ser

- 14 -

180	185	190
Gln Ser Thr Asp Thr Gln Asn Phe Ser Ser Glu Ser Lys Arg Glu Thr		
195	200	205
Glu Tyr Gly Pro Cys Arg Arg Glu Met Glu Asp Thr Leu Asn His Leu		
210	215	220
Lys Phe Leu Asn Val Leu Ser Pro Arg Gly Val His Ile Pro Asn Cys		
225	230	235
240		
Asp Lys Lys Gly Phe Tyr Lys Lys Lys Gln Cys Arg Pro Ser Lys Gly		
245	250	255
Arg Lys Arg Gly Phe Cys Trp Cys Val Asp Lys Tyr Gly Gln Pro Leu		
260	265	270
Pro Gly Tyr Thr Thr Lys Gly Lys Glu Asp Val His Cys Tyr Ser Met		
275	280	285
Gln Ser Lys		
290		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 00/00693

A. CLASSIFICATION OF SUBJECT MATTERInt Cl⁷: A61K 38/30; 17/06; 17/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Derwent WPAT IGF-1, IGFBP, Insulin Like Growth Factor/Binding Pair.**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AU 77314/94,A (688793) (Celtrix Pharmaceuticals, Inc.) 30 March 1995.	1-9, 20-22, 25, 29-37
X	AU 28753/95,A (692278) (Royal Children's Hospital Research Foundation, Australia.) 25 January 1996.	1-13, 20-23, 29-36
X	Wraight, Christopher J. et al., Expression of insulin-like growth factor binding protein-3 (IGFBP-3) J. Invest. Dermatol. (1997), 108(4), 452-456.	1-13,20-23,29-36

☒ Further documents are listed in the continuation of Box C☐ See patent family annex

* Special categories of cited documents:

"A" Document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
24 August 2000

Date of mailing of the international search report

- 4 OCT 2000

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200
WODEN ACT 2606 AUSTRALIA
E-mail address: pct@ipaustalia.gov.au
Facsimile No.: (02) 6285 3929

Authorized officer

A. WILCOX
Telephone No.: (02) 6283 2243

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 00/00693

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Jeschke, Marc G.; Barrow, Robert E.; Hawkins, Hal K.; Chrysopoula, Mina S. T.; Perez-Polo, J. Regina; Herdon, David, N. Effect of Multiple gene transfers of insulin like growth factor I complementary DNA gene constructs in rats after thermal injury. Arch. Surg. (1999), 134(10), 1137-1141.	1-13,20-23,29-36
X	WO 96/01636 (Royal Childrens Hospital Research Foundation) 25 January 1996.	1-13
X	WO 96/33216 (Pharmacia AB) 24 October 1996.	1-13

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 00/00693

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1,2,5-8 have been partially searched.
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

The specification provides support for methods and compositions which inhibit IGF-1 mediated cell proliferation and/or inflammation. There is no basis in the specification for methods and compositions derived from an invention for the treatment of cell proliferation and/or inflammation mediated by factors other than IGF-1.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
The claims are directed to methods and compositions which inhibit IGF-1 mediated cell proliferation and/or inflammation. The broader claims include cell proliferation and/or inflammation mediated by keratinocyte growth factor (KGF), TGF- α , TNF- α , IL-1, IL-2, IL-6, IL-8 and/or basic fibroblast growth factor (bFGF). Claims 1,2 and 5-8 are considered to include multiple inventions.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.